Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION
Document Type and Number:
WIPO Patent Application WO/2020/041169
Kind Code:
A2
Abstract:
Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

Inventors:
BARBAY J KENT (US)
CHAI WENYING (US)
HIRST GAVIN C (US)
KREUTTER KEVIN D (US)
KUMMER DAVID A (US)
MCCLURE KELLY J (US)
NISHIMURA RACHEL T (US)
SHIH AMY Y (US)
VENABLE JENNIFER D (US)
VENKATESAN HARIHARAN (US)
WEI JIANMEI (US)
Application Number:
US2019/047015
Publication Date:
February 27, 2020
Filing Date:
August 19, 2019
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
JANSSEN PHARMACEUTICA NV (BE)
BARBAY J KENT (US)
International Classes:
C07D417/10; A61K31/554; C07D417/14; C07D419/10; C07D419/14; C07D471/04; C07D487/04; C07D513/04; C07D513/14; C07D515/04; C07D515/14
Foreign References:
Other References:
MIMOTO, T. ET AL., BRAIN RESEARCH., vol. 1446, 2012, pages 109 - 118
ALEKSUNES, L.M. ET AL., J. PHARMACOL. EXP. THER., vol. 333, no. 1, 2010, pages 140 - 151
CHIN, M.P. ET AL., AM. J. NEPHROL., vol. 39, 2014, pages 499 - 508
SHELTON, L. M. ET AL., KIDNEY INTERNATIONAL, vol. 84, 2013, pages 1090 - 1095
NITURE, S. K. ET AL., FREE RADIC. BIOL. MED., vol. 66, 2014, pages 36 - 44
HOWDEN, R., OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2013, pages 1 - 10
JIANG, S. ET AL., EXPERT OPINION ON THERAPEUTIC TARGETS, vol. 20, 2016, pages 1413 - 1424
DAVIES, T.G. ET AL., J. MED. CHEM., vol. 59, 2016, pages 3991 - 4006
BOUTTEN, A. ET AL., TRENDS MOL. MED., no. 17, 2011, pages 363 - 371
CHO, H-Y. ET AL., TOXICOL. APPL. PHARMACOL., vol. 244, 2010, pages 43 - 56
ADENUGA, D. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 403, no. 3-4, 2010, pages 452 - 456
IIZUKA, T. ET AL., GENES TO CELLS, vol. 10, no. 12, 2005, pages 1113 - 1125
CRACOWSKI, J-L. ET AL., AM. J. GASTROENTEROL., vol. 97, 2002, pages 99 - 103
HATSUGAI, M. ET AL., J. GASTROENTEROL., vol. 45, 2010, pages 488 - 500
REZAIE, A. ET AL., DIG. DIS. SCI., vol. 52, 2007, pages 2015 - 2021
KRUIDENIER, L. ET AL., ALIMENT PHARMACOL. THER., vol. 16, 2002, pages 1997 - 2015
CATARZI, S. ET AL., INFLAMM. BOWEL DIS., vol. 17, 2011, pages 1674 - 84
KHOR, B. ET AL., NATURE, vol. 474, no. 7351, 2011, pages 307 - 317
ARISAWA, T. ET AL., HEPATO-GASTROENTEROLOGY, vol. 55, 2008, pages 394 - 397
COPE, G. F. ET AL., HUMAN TOXICOL., vol. 6, 1987, pages 189 - 193
ONYIAH, J. C. ET AL., GUT MICROBES, vol. 5, no. 2, 2014, pages 220 - 224
KHOR, T. O. ET AL., CANCER RES., vol. 66, no. 24, 2006, pages 11580 - 11584
ONYIAH, J. C. ET AL., GASTROENTEROLOGY, vol. 144, 2013, pages 789 - 798
LU, M. C. ET AL., NATURE, SCI REP., vol. 6, 2016, pages 26585
JIANG, Z-Y. ET AL., J. MED. CHEM., vol. 58, no. 16, 2015, pages 6410 - 6421
ALMENIER, H. A. ET AL., FRONTEIRS IN BIOSCIENCE, vol. E4, 2012, pages 1335 - 1344
KADAM, D. P. ET AL., IND. J. CLIN. BIOCHEM., vol. 25, no. 4, 2010, pages 388 - 392
SCHIMEL, A. M. ET AL., AM. J. PATHOL., vol. 178, 2011, pages 2032 - 2043
BITAR, M. S. ET AL., INVEST. OPHTHALMOL. VISUAL SCI, vol. 53, no. 9, 2012, pages 5806 - 5813
ABED, D. A. ET AL., ACTA PHARMACEUTICA SINICA B, vol. 5, no. 4, 2015, pages 285 - 299
BITAR, M. S. ET AL., AM. J. PHSIOL. ENDOCRINOL. METAB., vol. 301, no. 6, 2011, pages E1119 - 1129
ROCHETTE, L. ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1840, no. 9, 2014, pages 2709 - 2729
BHAKKIYALAKSHMI, E. ET AL., PHARMACOL. RESEARCH, vol. 91, 2015, pages 104 - 114
HOUSTIS, N. ET AL., NATURE, vol. 440, no. 7086, 2006, pages 944 - 948
KWEIDER,N. ET AL., ANNALS OF ANATOMY, vol. 196, 2014, pages 268 - 277
LISK, C. ET AL., FREE RADICAL BIOLOGY AND MEDICINE, vol. 63, 2013, pages 264 - 273
SCHAFER, M. ET AL., GENES AND DEVELOPMENT, vol. 24, no. 10, 2010, pages 1045
KIM, J.-H. ET AL., J. CLIN. INVESTIGATION, vol. 124, 2014, pages 730 - 741
SHIMOZONO, R. ET AL., MOL. PHARMACOL., vol. 84, 2013, pages 62 - 70
CHOWDRY, S. ET AL., FREE RADICAL BIOLOGY AND MEDICINE, vol. 48, 2010, pages 357 - 371
S.M. BERGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19, XP002675560, doi:10.1002/jps.2600660104
"Handbook of Pharmaceutical Salts, Properties, Selection, and Use", 2002, WILEY-VCH AND VHCA
Attorney, Agent or Firm:
SHIRTZ, Joseph F. et al. (US)
Download PDF:
Claims:
What is claimed is:

1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof

wherein

X is CH or N;

Q is CH or N;

M is CH or N;

wherein

when X is N, each of Q and M is CH;

when Q is N, each of X and M is CH; and

when M is N, each of X and Q are CH;

R15 is CH3 or Cl;

R13 is H, F or C1-C4alkyl;

R14 is H, F or C1-C4alkyl;

HetA is selected from the group consisting of

wherein

R1 is selected from the group consisting of C3-C4cycloalkyl, C1-C4alkyl and C1-C4alkyl monosubstituted with cyclopropyl or cyclobutyl;

R2 is selected from the group consisting of H, C1-C4alkyl and C1-C4perhaloalkyl; R3 is H or C1-C4alkyl;

R4 is selected from the group consisting of C1-C4alkyl, C1-C4perhaloalkyl and

C3-C4cycloalkyl;

R7 is H or C1-C4alkyl;

R8 is C1-C4alkyl;

R9 is C1-C4alkyl;

R10 is selected from the group consisting of H, -OC3-C4cycloalkyl and

-OC1-C4perhaloalkyl;

HetB is selected from the group consisting of

wherein

Z is selected from the group consisting of O, CH2, NH and N(CH3);

T is CH or N;

Y is CH or N;

W is CH or N;

V is O or N(CH3);

R16 is H or F;

R17 is H or F;

n is 0, 1 or 2;

R18 is selected from the group consisting of H, -CN, halo, C(O)NH2, C1-C4alkyl and C1- C4perhaloalkyl;

R19 is selected from the group consisting of H; CN; halo; C(O)NH2; N(R38)C1-C6alkyl; C1-C4alkyl; C1-C4perhaloalkyl; ; OC1-C6alkyl;

OC1-C6alkyl substituted with one or two substituents selected from the group consisting of -OH, -OCH3, -O(CH2)3OH, -N(R36)R37, C1-C4alkyl,

and

-N(R38)C1-C6alkyl substituted with one or two substituents selected from the group consisting of OH, -OCH3, -N(R36)R37, C1-C4alkyl ,

C1-C4alkyl monosubstituted with a substituent selected from the group consisting of -C(O)NHCH2CH2OH, -C(O)NHCH2CH2OCH2CH2NH2, C(O)NH2 and OH; R20 is H or C1-C4alkyl;

R21 is selected from the group consisting of H, -CN, halo, C1-C4alkyl and C1- C4perhaloalkyl;

R22 and R23 are taken together with the carbon to which they are attached to form (a) the moiety , wherein R is selected from the group consisting of CH2, NR38 and O, m is 0 or 1, and p is 0 or 1; or (b) the moiety

R22’ is selected from the group consisting of H, C1-C4alkyl and C3-C4cycloalkyl, and R23’ is selected from the group consisting of H, C1-C4alkyl and C3-C4cycloalkyl;

R24 is selected from the group consisting of H; CN; halo; C(O)NH2;

C(O)(NH)C3-C4cycloalkyl; N(R38)C1-C6alkyl; C1-C4alkyl; C1-C4perhaloalkyl;

OH

OC1-C6alkyl;

OC1-C6alkyl substituted with one or two substituents selected from the group consisting of -OH, -OCH3, -O(CH2)3OH, -N(R36)R37, C1-C4alkyl; and

-N(R38)C1-C6alkyl substituted with one or two substituents selected from the group consisting of OH, -OCH3, -N(R36)R37, C1-C4alkyl, ,

and

and

C1-C4alkyl monosubstituted with a substituent selected from the group consisting of -C(O)NHCH2CH2OH, -C(O)NHCH2CH2OCH2CH2NH2, C(O)NH2 and OH; R25 is selected from the group consisting of H; CN; halo; C(O)NH2;

N(R38)C1-C6alkyl; C1-C4alkyl; C1-C4perhaloalkyl; ; OC1-C6alkyl;

OC1-C6alkyl substituted with one or two substituents selected from the group consisting of -OH, -OCH3, -O(CH2)3OH, -N(R36)R37, C1-C4alkyl, and

-N(R38)C1-C6alkyl substituted with one or two substituents selected from the group consisting of OH, -OCH3, -N(R36)R37, C1-C4alkyl, and and

C1-C4alkyl monosubstituted with a substituent selected from the group consisting of -C(O)NHCH2CH2OH, -C(O)NHCH2CH2OCH2CH2NH2, C(O)NH2 and OH; R26 is selected from the group consisting of H, -CN, halo, C1-C4alkyl and C1- C4perhaloalkyl;

R27 is H or C1-C4alkyl;

R36 and R37 are independently selected from the group consisting of H and C1-C4alkyl; R38 is H or C1-C4alkyl;

provided that when HetA is then HetB is not

2. A compound as claimed in claim 1, wherein HetA is

3. A compound as claimed in claim 1, wherein HetA is

4. A compound as claimed in claim 1, wherein HetA is

R1 is C1-C4alkyl, R10 is H and R2 is C1-C4alkyl.

5. A compound as claimed in claim 1, wherein HetA is R1 is C1-C4alkyl, R10 is H and R2 is CH3.

6. A compound as claimed in claim 1, wherein HetA is

R1 is C1-C2alkyl, R10 is H and R2 is CH3. 7. A compound as claimed in claim 1, wherein HetA is

R1 is CH 0

2CH3, R1 is H and R2 is CH3. 8. A compound as claimed in claim 1, wherein HetA is

R1 is CH 2

3, R10 is H and R is CH3.

9. A compound as claimed in claim 1, wherein HetA is

10. A compound as claimed in claim 1, wherein HetA is and R4 is C1-C4alkyl or C1-C4perhaloalkyl. 11. A compound as claimed in claim 1, wherein HetA is

and R4 is C1-C4perhaloalkyl.

12. A compound as claimed in claim 1, wherein HetA is

and R4 is C1-C2perhaloalkyl.

13. A compound as claimed in claim 1, wherein HetA is

and R4 is CF3.

14. A compound as claimed in claim 1, wherein HetA is

R4 is C1-C4perhaloalkyl, R3 is C1-C4alkyl and R7 is H.

15. A compound as claimed in claim 1, wherein HetA is R4 is C1-C2perhaloalkyl, R3 is C1-C4alkyl and R7 is H.

16. A compound as claimed in claim 1, wherein HetA is R4 is C1-C2perhaloalkyl, R3 is C1-C2alkyl and R7 is H. 17. A compound as claimed in claim 1, wherein HetA is R4 is C1-C2perhaloalkyl, R3 is CH3 and R7 is H.

18. A compound as claimed in claim 1, wherein HetA is R4 is CF3, R3 is CH3 and R7 is H.

19. A compound as claimed in claim 1, wherein X is N.

20. A compound as claimed in claim 1, wherein X is CH.

21. A compound as claimed in claim 1, wherein R15 is CH3.

22. A compound as claimed in claim 1, wherein R15 is Cl.

23. A compound as claimed in claim 1, wherein R13 is CH3.

24. A compound as claimed in claim 1, wherein R13 is CH 4

3 and R1 is H.

25. A compound as claimed in claim 1, wherein R13 is CH3 and R14 is CH3.

26. A compound as claimed in claim 1, wherein R13 is H and R14 is H.

27. A compound as claimed in claim 1, wherein HetA is R4 is CF3, R3 is CH3, R7 is H and X is N.

28. A compound as claimed in claim 1, wherein HetA is R4 is CF3, R3 is CH3, R7 is H, X is N and R15 is CH3.

29. A compound as claimed in claim 1, wherein HetA is , R4 is CF3, R3 is CH3, R7 is H, X is N, R15 is CH3, R13 is H and R14 is H.

30. A compound as claimed in claim 1, wherein HetA is R4 is CF3, R3 is CH 15

3, R7 is H, X is N, R is CH 13

3, R is CH3 and R14 is

CH3. 31. A compound as claimed in claim 1, wherein HetA is

7

R4 is CF 3

3, R is CH3, R7 is H and X is CH.

32. A compound as claimed in claim 1, wherein HetA is

R4 is CF3, R3 is CH3, R7 is H, X is CH, and R15 is Cl.

33. A compound as claimed in claim 1, wherein HetA is

, R1 is CH2CH3, R10 is H, R2 is CH3 and X is N.

34. A compound as claimed in claim 1, wherein HetA is

R1 is CH 10

2CH3, R is H, R2 is CH3 , X is N, R15 is CH3., R13 is H and R14 is H.

35. A compound as claimed in claim 1, wherein HetA is R1 is CH2CH3, R10 is H, R2 is CH3 , X is N and R15 is Cl.

36. A compound as claimed in claim 1, wherein HetA is R1 is CH2CH 0

3, R1 is H, R2 is CH3, X is CH, R15 is CH3, R13 is H and R14

is H.

37. A compound as claimed in claim 1, wherein HetA is R1 is CH2CH 10

3, R is H, R2 is CH3, X is CH and R15 is Cl.

38. A compound as claimed in claim 1, wherein HetB is selected from the group consisting of

39. A compound as claimed in claim 1, wherein HetB is selected from the group consisting of

. 40. A compound as claimed in claim 1, wherein HetB is . 41. A compound as claimed in claim 1, wherein HetB is . 42. A compound as claimed in claim 1, wherein HetB is

. 43. A compound as claimed in claim 1, wherein HetB is

44. A compound as claimed in claim 1, wherein HetB is

, R22 and R23 are taken together with the carbon to which they are attached to form the moiety , wherein R is CH2 or O, m is 0 or 1, and p is 0 or 1.

45. A compound as claimed in claim 1, wherein HetB is

, R22 and R23 are taken together with the carbon to which they are attached to form the moiety wherein R is O, m is 0 or 1, and p is 0 or 1.

46. A compound as claimed in claim 1, wherein HetB is , R22 and R23 are taken together with the carbon to which they are attached to

form the moiety wherein R is O, m is 1, and p is 1. 47. A compound as claimed in claim 1, wherein HetB is

, R22 and R23 are taken together with the carbon to which they are attached to

form the moiety wherein R is O, m is 1, p is 1, R13 is C1-C4alkyl, and R14 is C1- C4alkyl. 48. A compound as claimed in claim 1, wherein HetB is

R22 and R23 are taken together with the carbon to which they are attached to

form the moiety wherein R is O, m is 1, p is 1, R13 is CH3, and R14 is CH3.

49. A compound as claimed in claim 1, wherein HetA is HetB is ,R4 is CF3, R3 is CH3, R7 is H, X is CH, R15 is

CH3, R22 and R23 are taken together with the carbon to which they are attached to form the

moiety wherein R is O, m is 1, p is 1, R13 is CH3, and R14 is CH3.

50. A compound as claimed in claim 1, wherein

HetA is HetB is ,R4 is CHF 3

2, R is CH3, R7 is H, X is CH, Q is CH, M is CH, W is N, R24 is H, R21 is CH3, R15 is CH3, R13 is CH3, R14 is CH3, and R22 and R23 are taken together with the carbon to which they are attached to form the moiety

51. A compound as claimed in claim 1, wherein

HetA is HetB is ,R4 is CF 3

3, R is CH3, R7 is H, X is CH, R15 is CH 22

3, R and R23 are taken together with the carbon to which they are attached to form the

moiety wherein R is O, m is 1, p is 1, R13 is CH 14

3, R is CH3 and R24 is OC2-C4alkyl or OC2-C4alkyl is substituted with

52. A compound as claimed in claim 1, wherein

HetA is HetB is , R4 is cyclopropyl, R3 is CH 7

3, R is H, X is

CH, Q is CH, M is CH, R15 is CH3, R22 and R23 are taken together with the carbon to which they

are attached to form the moiety wherein R is O, m is 1, p is 1, R13 is CH3, and R14 is CH

3. 53. A compound as claimed in claim 1, wherein

HetA i HetB is , R1 is CH 2

2CH3, R is CH3, R10 is H, X is CH, Q is CH, M is N, R15 is CH3, R22 and R23 are taken together with the carbon to which they are

attached to form the moiety , wherein R is O, m is 1, p is 1, R13 is CH3, and R14 is CH3.

54. A compound as claimed in claim 1, wherein

HetA is HetB is R1 is cyclopropyl, R2 is CH3, R10 is H, X is

CH, Q is CH, M is N, R15 is CH 2

3, R2 and R23 are taken together with the carbon to which they are attached to form the moiety wherein R is O, m is 1, p is 1, R13 is CH3, and R14 is CH3. 55. A compound as claimed in claim 1, wherein R1 is C1-C4alkyl that is substituted with one of cyclopropyl and cyclobutyl. 56. A compound as claimed in claim 1, wherein R18 is OC1-C4alkyl substituted with one of -OH, -N(R36)R37 and

57. A compound as claimed in claim 1, wherein R18 is NHC1-C4alkyl substituted with one of OH and CH3. 58. A compound as claimed in claim 1, wherein R18 is C1-C4alkyl is substituted with one of C(O)NHCH2CH2OH and OH. 59. A compound as claimed in claim 1, wherein R24 is OC1-C4alkyl substituted with one of -OH, -N(R36)R37 and

60. A compound as claimed in claim 1, wherein R24 is NHC1-C4alkyl substituted with one of OH and CH3. 61. A compound as claimed in claim 1, wherein R24 is C1-C4alkyl is substituted with one of C(O)NHCH2CH2OH and OH.

62. A compound as claimed in claim 1, wherein R25 is OC1-C4alkyl substituted with one of -OH, -N(R36)R37 and

63. A compound as claimed in claim 1, wherein R25 is NHC1-C4alkyl substituted with one of OH and CH3. 64. A compound as claimed in claim 1, wherein R25 is C1-C4alkyl is substituted with one of C(O)NHCH2CH2OH and OH. 65. A compound selected from the group consisting of

3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5-dioxido- 7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)- 3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)- 3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid; (*S)-3-(3-((1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3- (((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3- (((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3- (((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2- dimethylpropanoic acid;

(*S)- 3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(R)- 3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid; 2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)- 2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)- 2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)- 3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)- 3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5-dioxido- 7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)- 3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)- 3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid

(*S)-3-(3-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid; (*S)-3-(4-Methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-((3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid ;

(*S)-3-(3-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(6-((3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(6-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid; (*S) 2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl-2,2’-dimethyl-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S) 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl-2,2’-dimethyl-3-(8- methy-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R) 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl-2,2’-dimethyl-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(R/S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(R/S)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(R/S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6-methyl-5- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6-methyl-5- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6-methyl-5- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-(difluoromethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((R- 5,5-dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)- 4-methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3- ((R-5,5-dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid; 3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1’,1’- dioxidospiro[oxetane-3,3’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3- ((R-5,5-dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1’,1’- dioxidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]oxathiazepin-2’(3’H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1’,1’- dioxidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]oxathiazepin-2’(3’H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(4-(Difluoromethyl-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R-5,5-dioxido- 7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(4-(Difluoromethyl-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R-5,5- dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R) 3-(4-(Difluoromethyl-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R-5,5- dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1’,1’- dioxidospiro[benzo[b][1,4,5]oxathiazepin-4,3’-oxetan]-2,(3H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-((5’- methyl-1’,1’-dioxido-5’H-spiro[cyclopropane-1,4’-pyrido[2,3-f][1,2,5]thiadiazepin]-2’(3’H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1’,1’- dioxidospiro[benzo[b][1,4,5]oxathiazepin-4,3’-oxetan]-2,(3H)-yl)methyl)-4- methylphenyl)propanoic acid; (*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1’,1’- dioxidospiro[benzo[b][1,4,5]oxathiazepin-4,3’-oxetan]-2,(3H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3- ((5’-methyl-1’,1’-dioxido-5’H-spiro[cyclopropane-1,4’-pyrido[2,3-f][1,2,5]thiadiazepin]- 2’(3’H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3- ((5’-methyl-1’,1’-dioxido-5’H-spiro[cyclopropane-1,4’-pyrido[2,3-f][1,2,5]thiadiazepin]- 2’(3’H)-yl)methyl)phenyl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3- (((*R)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3- (((*R)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3- (((*R)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

3-(4-Chloro-3-(((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2’,3’- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-(((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Chloro-3-(((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(4-Chloro-3-((1’,1’-dioxoidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid; (*R)-3-(4-Chloro-3-((1’,1’-dioxoidospiro[oxetane-3,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-((1’,1’-dioxoidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

3-(4-Chloro-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Chloro-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(4-Chloro-3-(((*S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Chloro-3-(((*S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-(((*S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(4-Chloro-3-((1’,1’-dioxoidospiro[benzo[b]]oxethiazepine-4,3’-oxetan]-2(3H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Chloro-3-((1’,1’-dioxoidospiro[benzo[b]]oxethiazepine-4,3’-oxetan]-2(3H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid; (*S)-3-(4-Chloro-3-((1’,1’-dioxoidospiro[benzo[b]]oxethiazepine-4,3’-oxetan]-2(3H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((8-Fluoro-1,1-dioxidospiro[benzo[b][1,4,5]oxathiazepin]-4,1’-cyclopropan]- 2(3H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8-Fluoro-1,1-dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3’-oxetan]-2(3H)- yl)methyl]-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-((7’-Chloro-1’,1’-dioxidospiro(cyclopropane-1.4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((7’-((2-Hydroxyethyl)amino-1’,1’-dioxidospiro[cyclopropane-1.4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridinn-7-yl)propanoic acid;

(*S)-3-(3-((7’-((2-Hydroxypropyl)amino-1’,1’-dioxidospiro[cyclopropane-1.4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridinn-7-yl)propanoic acid;

(*S)-3-(3-((7’-Hydroxy-1’,1’-dioxidospiro[cyclopropane-1,4’-pyrido[2,3,- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(4-Cyano-3-((8’-methyl-1’,1’-dioxidospiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]trizolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Cyano-3-((8’-methyl-1’,1’-dioxidospiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]trizolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Cyano-3-((8’-methyl-1’,1’-dioxidospiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]trizolo[4,3-a]pyridine-7-yl)propanoic acid; (*S)-3-(3-((7’-((3-Methoxypropyl)amino)-1’,1’-dioxidospiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(-3-((7’-((3-Hydroxypropyl)(methyl)amino)-1’,1’-dioxidospiro[cyclopropane- 1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(-3-((7’-((3-Methoxypropoxy)-1’,1’-dioxidospiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(-3-((7’-((3-Hydroxyethyl)(methyl)amino)-1’,1’-dioxidospiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Methyl-((7’-((2-morpholinoethyl)amino)-1’,1’-dioxidospiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((1’,1’-Dioxido-7’-((2-(piperidin-1-yl)ethyl)amino)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((7’-(Butylamino)-1’,1’-dioxidospiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(3-((7’-((3-Hydroxypropyl)amino)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((7’-((3-Hydroxypropyl)amino)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(3-((7’-((3-Hydroxypropyl)amino)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid; 3-(3-((7’-(((R)-4-Hydroxybutan-2-yl)amino)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(3-((7’-(((S)-4-Hydroxybutan-2-yl)amino)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((7’-(((R)-4-Hydroxybutan-2-yl)amino)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(3-((7’-(((R)-4-Hydroxybutan-2-yl)amino)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(((S)-4-Hydroxybutan-2-yl)amino)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(3-((7’-(((S)-4-Hydroxybutan-2-yl)amino)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(((S)-4-Hydroxybutan-2-yl)amino)-8’-methyl-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(((R)-3-Hydroxy-3-methylbutan-2-yl)amino)-8’-methyl-1’,1’-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid; (*R)-3-(3-((7’-(((1s,3S)-3-Hydroxycyclobutyl)amino)-8’-methyl-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido3-(3-((7’-(((*S)-4-hydroxybutan-2- yl)amino)-8’-methyl-1’,1’-dioxido-7’-(2-(piperidin-1-yl)ethoxy)-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-3-(3-((7’-(((*S)-4-hydroxybutan- 2-yl)amino)-8’-methyl-1’,1’-dioxido-7’-(2-(piperidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(3-((7’-(3-((2-Hydroxyethyl)amino)-3-oxopropyl)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2’,3’- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2-methyl-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(3*R)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2’,3’- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2-methyl-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(3*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2’,3’- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2-methyl-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(5,8-Dimethyl-3)-(trifluoromethyl)-[1,2,4-triazolo[4,3-a]pyridine-7-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)-2-methylpropanoic acid; (3*R)-3-(5,8-Dimethyl-3)-(trifluoromethyl)-[1,2,4-triazolo[4,3-a]pyridine-7-yl)-3-(3- (((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)-2-methylpropanoic acid;

(3*S)-3-(5,8-Dimethyl-3)-(trifluoromethyl)-[1,2,4-triazolo[4,3-a]pyridine-7-yl)-3-(3- (((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)-2-methylpropanoic acid;

(R/S)-3-(3-(((*S)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((*S)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((*R)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((*R)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid; (*R)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-[3-[(5,5-Dioxo-7a,8,9,10-tetrahydro-7H-pyrrolo[2,1-d][1,2,5]benzothiadiazepin-6- yl)methyl]-4-methyl-phenyl]-3-(1-ethyl-4-methyl-benzotriazol-5-yl)propanoic acid;

(*R)-3-[3-[(5,5-Dioxo-7a,8,9,10-tetrahydro-7H-pyrrolo[2,1-d][1,2,5]benzothiadiazepin- 6-yl)methyl]-4-methyl-phenyl]-3-(1-ethyl-4-methyl-benzotriazol-5-yl)propanoic acid;

(R/S)-3-[3-[(4,4-Dimethyl-1,1-dioxo-3H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl]- 4-methyl-phenyl]-3-(1-ethyl-4-methyl-benzotriazol-5-yl)propanoic acid;

(R/S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid; (*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin- 2-yl)methyl)-4-methylphenyl)-3-(3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid; (*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3- (((*R)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3- (((*R)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3- (((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3- (((R)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(6-(((R)-4-ethyl-1,1- dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-5-methylpyridin-2- yl)propanoic acid; (*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(6-(((R)-4-ethyl-1,1- dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-5-methylpyridin-2- yl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(6-(((R)-4-ethyl-1,1- dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-5-methylpyridin-2- yl)propanoic acid;

(R/S)-3-(4-Methyl-3-(((*S)-9-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-Methyl-3-(((S)-9-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(4-Methyl-3-(((*S)-9-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(4-Methyl-3-(((*R)-9-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-Methyl-3-(((*R)-9-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(4-Methyl-3-(((*R)-9-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(4-Methyl-3-((5'-methyl-1',1'-dioxido-5'H-spiro[cyclopropane-1,4'-pyrido[2,3- f][1,2,5]thiadiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-Methyl-3-((5'-methyl-1',1'-dioxido-5'H-spiro[cyclopropane-1,4'-pyrido[2,3- f][1,2,5]thiadiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(t*rifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(4-Methyl-3-((5'-methyl-1',1'-dioxido-5'H-spiro[cyclopropane-1,4'-pyrido[2,3- f][1,2,5]thiadiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-Methyl-3-(((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(4-Methyl-3-(((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(3*S)-3-(3-((3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-4-Ethyl-8-methyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3- b][1,4,5]oxathiazepin-2-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-3-(3-((8'-Chloro-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-3-Cyano-5,5-dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4- d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-3-Chloro-5,5-dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4- d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-3-(trifluoromethyl)-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-3-(trifluoromethyl)-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8'-Cyano-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8'-Carbamoyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-2-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-2-Carbamoyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-2-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-3-(3-(((*R)-2-Carbamoyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((S)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((R)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-Methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5-dioxido- 7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5-dioxido- 7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5-dioxido- 7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)-yl)methyl)-4- methylphenyl)propanoic acid; (*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)-yl)methyl)-4- methylphenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-benzo[f]pyrido[2,1-d][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-(((*S)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-(((*S)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-(((*S)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-(((*R)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-(((*R)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-(((*R)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-((5'- methyl-1',1'-dioxido-5'H-spiro[cyclopropane-1,4'-pyrido[2,3-f][1,2,5]thiadiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid; (*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-((5'- methyl-1',1'-dioxido-5'H-spiro[cyclopropane-1,4'-pyrido[2,3-f][1,2,5]thiadiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-((5'- methyl-1',1'-dioxido-5'H-spiro[cyclopropane-1,4'-pyrido[2,3-f][1,2,5]thiadiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((8'-fluoro-1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

(R/S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*S)- 5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*S)- 5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(R/S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)- 5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid; (*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)- 5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)- 5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(R/S)-3-(6-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(6-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(6-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)propanoic acid;

(*S)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)propanoic acid; (*R)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)propanoic acid;

3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-4-ethyl-1,1- dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-4- ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-4- ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid;

3-(3-(((S)-5,5--Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*S)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; 3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin- 7-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin- 2-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin- 2-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)-4-methylphenyl)-3-(3-ethyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-ethyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-ethyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-ethyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-ethyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-ethyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid; (*S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

3-(3-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)-yl)methyl)-4- methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1,1-dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9-tetrahydro-6H-azeto[2,1-d]pyrido[2,3- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9-tetrahydro-6H-azeto[2,1-d]pyrido[2,3- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9-tetrahydro-6H-azeto[2,1-d]pyrido[2,3- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9-tetrahydro-6H-azeto[2,1-d]pyrido[2,3- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(6-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(6-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(6-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-benzo[f]pyrido[2,1- d][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-benzo[f]pyrido[2,1- d][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

3-(6-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid; (*S)-3-(6-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(6-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(4-methyl-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-methyl-3-(((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8'-Fluoro-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((3-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(5- methyl-6-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3- (5-methyl-6-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl- 3-(5-methyl-6-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-2,2-dimethyl-3-(4-methyl-3-((8'- methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-2,2-dimethyl-3-(4-methyl-3-((8'- methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid; (*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxidospiro[piperidine-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1',1'-Dioxidospiro[piperidine-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxidospiro[azetidine-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1',1'-Dioxidospiro[azetidine-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[piperidine-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[piperidine-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((7'-(3-((2-(2-Aminoethoxy)ethyl)amino)-3-oxopropyl)-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-((7'-(3-((2-(2-aminoethoxy)ethyl)amino)-3-oxopropyl)-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-2,2-dimethyl-3-(4-methyl-3-((8'- methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-dimethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidine-1-yl)-ethoxy)2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-dimethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(piperidine-1-yl)-ethoxy)2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-dimethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(piperidine-1-yl)-ethoxy)2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-dimethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(piperidine-1-yl)-ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-dimethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(piperidine-1-yl)-ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-dimethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin-1-yl)-ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-dimethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin-1-yl)-ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’-(3’H)-yl)methyl)phenyl)propanoic acid; (*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(3-((7’-(2-(4,4-Difluoropiperidin-1-yl)ethoxy)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a][pyridine-7- yl)propanoic acid;

(*R)-3-(3-((7’-(((1R,3R)-3-Hydroxycyclobutyl)amino)-8’-methyl-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-7’-(((R-1-morpholinopropan-2-yl)amino)- 1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-7’-(((S-1-morpholinopropan-2-yl)amino)- 1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-7’-(((1-morpholinopropan-2-yl)amino)- 1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-7’-((2-morpholinoethyl)amino)-1’,1’- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-7’-((2-morpholinoethyl)amino)-1’,1’- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(((S)-1-(pyrrolidine-1- yl)propan-2-yl)amino)-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(3-((1’,1’-Dioxido-7’-(2-(piperazin-1-yl)ethoxy)-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a][pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-(8’-methyl-1’,1’-dioxido-7’-(2-(piperidin-4-yl)ethoxy)- 2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a][pyridine-7- yl)propanoic acid; (*S)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin-1- yl)ethoxy)-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a][pyridine-7-yl)propanoic acid;

(*S)-3-(3-1’,1’-Dioxido-7’-(2-(piperidin-1-yl)ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a][pyridine-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(piperidin-1- yl)ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin-1- yl)ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(piperidin-1-yl)ethoxy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)propanoic acid;

3-(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-((1-piperidin-1- yl)propan-2-yl)amino)-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-((7’-(2-(4-Methoxypiperidin-1-yl)ethoxy)-8’-methyl-1’,1’- dioxidospiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(piperidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(((S)-1-piperidin-1- yl)propan-2-yl)amino)spiro[cyclopropane-1,4’-pyrido [2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-1',1'-Dioxido-4,5-dihydro-2H-spiro[furan-3,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-1',1'-Dioxido-4,5-dihydro-2H-spiro[furan-3,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-(((*S)-8'-methyl-1',1'-dioxido-4,5-dihydro-2H- spiro[furan-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-(((*R)-8'-methyl-1',1'-dioxido-4,5-dihydro-2H- spiro[furan-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*S)-1',1'-Dioxido-4,5-dihydro-2H-spiro[furan-3,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-1',1'-Dioxido-4,5-dihydro-2H-spiro[furan-3,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-2,2-Dimethyl-3-(4-methyl-3-(((*S)-8'-methyl-1',1'-dioxido-4,5-dihydro-2H- spiro[furan-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-(((*R)-8'-methyl-1',1'-dioxido-4,5-dihydro-2H- spiro[furan-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid; (R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*S)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*S)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-2,2-dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran- 4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-2,2-dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran- 4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8'-fluoro-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8-fluoro-1,1-dioxido-2',3',5',6'-tetrahydrospiro[benzo[b][1,4,5]oxathiazepine- 4,4'-pyran]-2(3H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(3S*)-3-(3-((8-fluoro-1,1-dioxido-2',3',5',6'- tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4'-pyran]-2(3H)-yl)methyl)-4-methylphenyl)-2- methyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(6-((8-fluoro-1,1-dioxido- 2',3',5',6'-tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4'-pyran]-2(3H)-yl)methyl)-5- methylpyridin-2-yl)propanoic acid;

(*S)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(6-((8-fluoro-1,1-dioxido- 2',3',5',6'-tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4'-pyran]-2(3H)-yl)methyl)-5- methylpyridin-2-yl)propanoic acid;

(*R)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(6-((8-fluoro-1,1-dioxido- 2',3',5',6'-tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4'-pyran]-2(3H)-yl)methyl)-5- methylpyridin-2-yl)propanoic acid; (*S)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4-methyl-3- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4-methyl-3- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(S)-3-(7-(difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(R*)-3-(7-(difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(S*)-3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(R*)-3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid; (*S)-3-(3-((4,4-dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin- 2-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((4,4-dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin- 2-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-difluoro-3-(3-((8-fluoro-1,1-dioxido-2',3',5',6'- tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4'-pyran]-2(3H)-yl)methyl)-4-methylphenyl)-3- (8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((R)-5,5-dioxido-7a,8,9,10- tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((R)-5,5-dioxido-7a,8,9,10- tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((R)-5,5-dioxido-7a,8,9,10- tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((S)-5,5-dioxido-7a,8,9,10- tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((S)-5,5-dioxido-7a,8,9,10- tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((S)-5,5-dioxido-7a,8,9,10- tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid; 3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((S)-5,5-dioxido-7,7a,8,9,10,11- hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((*S)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((*S)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((*R)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((*R)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((*R)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid; (*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-((10,10-Difluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-10,10-Difluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-10,10-difluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid ;

(*R)-3-(3-(((*S)-10,10-Difluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-10,10-Difluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*R)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*R)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*R)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid; 3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*S)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*S)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*S)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((R)-4-ethyl- 1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((R)-4- ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((R)-4- ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid; (*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3-(((*S)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3- (((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3- (((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

3-(6-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)-yl)methyl)-5- methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-((1,1-dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)- yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin- 7-yl)propanoic acid;

(*R)-3-(6-((1,1-dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)- yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin- 7-yl)propanoic acid;

3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(5-methyl-6-(((*S)- 3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(5-methyl-6- (((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(5-methyl-6- (((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)pyridin-2-yl)propanoic acid; 3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(5-methyl-6-(((*R)- 3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(5-methyl-6- (((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(5-methyl-6- (((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)pyridin-2-yl)propanoic acid;

3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin- 7-yl)propanoic acid;

(*S)-3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin- 7-yl)propanoic acid;

(*R)-3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin- 7-yl)propanoic acid;

3-(6-(((*S)-3-Fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-(((*S)-3-Fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*S)-3-Fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3-(((*S)- 3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)phenyl)propanoic acid; (*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3- (((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3- (((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3-(((*R)- 3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3- (((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3- (((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

3-(6-(((*S)-3-Fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-2-methyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(3*S)-3-(6-(((S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-2-methyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(3*R)-3-(6-(((*S)-3-Fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-2-methyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(6-((8'-Fluoro-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-((8'-Fluoro-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(6-((8'-Fluoro-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*S)-3- fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*R)-3- fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(3*S)-3-(8-Ethyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2-methyl-3-(4- methyl-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

(3*S)-2-Methyl-3-(4-methyl-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro- 6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(3*S)-3-(8-Ethyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2-methyl-3-(4- methyl-3-(((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

(*S)-3-(8-Ethyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3- (((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

(*S)-3-(8-Ethyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3- (((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

3-(6-((3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-(((*S)-3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-3-(6-(((*R)-3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*S)-3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*R)-3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((8-fluoro-1,1- dioxido-2',3',5',6'-tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4'-pyran]-2(3H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((8-fluoro- 1,1-dioxido-2',3',5',6'-tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4'-pyran]-2(3H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((8-fluoro- 1,1-dioxido-2',3',5',6'-tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4'-pyran]-2(3H)- yl)methyl)-4-methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((8'-fluoro-1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((8'-fluoro- 1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((8'-fluoro- 1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-((8'-Chloro-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid; (*S)-3-(3-((8'-Chloro-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((8'-Chloro-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((8'-fluoro-1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((8'-fluoro- 1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((8'-fluoro- 1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3-((8'- methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(4-Methyl-3-((7'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((*R)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-3-(3-(((*R)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((S)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((S)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((S)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(2*S,3*R)-2-Methyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(2*R,3*R)-2-Methyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanamide;

(*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanamide;

(*R)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanamide; 3-(3-((8'-Carbamoyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8'-Carbamoyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((8'-Carbamoyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(2S,3*R)-3-(3-(Trifluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2-methylpropanoic acid;

(*S)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(5-methyl-6- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(5-methyl-6- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(R/S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid; (*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3-yl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(6-methyl-5- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3-yl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(6-methyl-5- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)pyridin-3-yl)propanoic acid;

(R/S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(R/S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (R/S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (6-methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (6-methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (6-methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(R/S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3-(4- methyl-3-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

3-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((7'-methoxy- 1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid; (*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((7'- methoxy-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((7'- methoxy-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

(R/S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (6-methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (6-methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (6-methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(R/S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid; (*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(5-methyl-4- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(5-methyl-4- ((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-((7’-(2-(3-fluoroazetidin-1-yl)ethoxy)-8’-methyl-1’,1’- dioxidospiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-2,2-dimethyl-3-(4-methyl-3-((8’-methyl-7’-(2-morpholinoethoxy)-1’,1’- dioxidospiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phenyl)-3- (8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((1’,1’-dioxido-7’-(2-(pyrrolidine-1-yl)ethoxy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((7’-(3-amino-3-oxopropyl)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S) 2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-((1-(piperidin-1- yl)propan-2-yl)oxy)-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]- 2’,(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid; (*S) 2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(((*R)-1-(piperidin-1- yl)propan-2-yl)oxy)-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]- 2’,(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S) 2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(((*S)-1-(piperidin-1- yl)propan-2-yl)oxy)-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]- 2’,(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(((*R)-1-(piperidin-1- yl)propan-2-yl)amino)-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(2-(Azetidin-1-yl)ethoxy)-8’-methyl-1’,1’-dioxidospiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((7’-(3-Cyclobutylamino-3-oxopropyl)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(2-Hydroxyethoxy)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((7'-(3-(3-Hydroxypropoxy)propoxy)-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-((7'-(3-(3-Hydroxypropoxy)propoxy)-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid; (*R)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1- yl)ethoxy)-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(6-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin- 2-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(6-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin- 2-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(5-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin- 3-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(5-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin- 3-yl)-2,2-dimethylpropanoic acid;

(*S)-2,2-dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxidospiro[oxetane-3,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((1’,1’-dioxidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-3-(3-((1’,1’- dioxidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxido-7'-(((S)-1-(piperidin-1-yl)propan-2- yl)amino)spiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6- methyl-5-((8’-methyl-1’,1’-dioxidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]]oxathiazepin]- 2’(3’H)-yl)methyl)pyridine-3-yl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6- methyl-5-((8’-methyl-1’,1’-dioxidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]]oxathiazepin]- 2’(3’H)-yl)methyl)pyridine-3-yl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6- methyl-5-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidine-1-yl)ethoxy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]]oxathiazepin]-2’(3’H)-yl)methyl)pyridine-3-yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid; (*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6- methyl-5-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidine-1-yl)ethoxy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]]oxathiazepin]-2’(3’H)-yl)methyl)pyridine-3-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid; (*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid; (*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1',1'- dioxidospiro[piperidine-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1',1'- dioxidospiro[piperidine-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[piperidine-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[piperidine-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1',1'- dioxidospiro[piperidine-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[piperidine-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(5-(((*R)-3-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-6-methylpyridin-3-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(5-(((*S)-3-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-6-methylpyridin-3-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-3-(5-(((*R)-3-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-6-methylpyridin-3-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(5-(((*S)-3-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-6-methylpyridin-3-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-2,2-dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1- yl)ethoxy)spiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxido-7'-(((S)-1-(piperidin-1-yl)propan-2- yl)amino)spiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxido-7'-(((S)-1-(piperidin-1-yl)propan-2- yl)amino)spiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-((7’-(2-(4-fluoropiperidin-1-yl)ethoxy)-8’-methyl-1’,1’- dioxidospiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(2-(4-fluoropiperidin-1-yl)ethoxy)-8’-methyl-1’,1’- dioxidospiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(5-methyl-4- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)pyridin-2-yl)propanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. 66. A compound as claimed in claim 65 wherein the compound is selected from the group consisting of

(*S)-3-(3-((1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)- 3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(4-Methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. 67. A compound as claimed in claim 65 wherein the compound is selected from the group consisting of

(*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)- 3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(4-Methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. 68. A compound as claimed in claim 65 wherein the compound is selected from the group consisting of

(*S)-3-(3-((1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-Methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. 69. A compound as claimed in claim 65 wherein the compound is selected from the group consisting of (*S)-33-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(4-Methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. 70. A compound as claimed in claim 65 wherein the compound is selected from the group consisting of

(*S)- 2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)- 3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(4-Methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. 71. A compound as claimed in claim 65 wherein the compound is selected from the group consisting of (*S)-3-(3-((1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)- 3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(4-Methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. 72. A compound as claimed in claim 65 wherein the compound is selected from the group consisting of

(*S)-3-(3-((1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)- 3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. 73. A compound as claimed in claim 65 wherein the compound is

(*S)-3-(3-((1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts thereof.

74. A compound as claimed in claim 65 wherein the compound is

(*S)- 3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid; and

pharmaceutically acceptable salts thereof. 75. A compound as claimed in claim 65 wherein the compound is

(*S)- 2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts thereof. 76. A compound as claimed in claim 65 wherein the compound is

(*S)-3-(4-Methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts thereof. 77. A compound as claimed in claim 65 wherein the compound is

(*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts thereof. 78. A compound as claimed in claim 65 wherein the compound is selected from the group consisting of

(*S)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S) 2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid; 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl-2,2’-dimethyl-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S) 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl-2,2’-dimethyl-3-(8- methy-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R) 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl-2,2’-dimethyl-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(R/S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(R/S)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid; (*S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(R/S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6-methyl-5- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6-methyl-5- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6-methyl-5- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. 79. A compound as claimed in claim 65 wherein the compound is selected from the group consisting of

(*S)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (R/S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S) 2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl-2,2’-dimethyl-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid; (*S) 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl-2,2’-dimethyl-3-(8- methy-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R) 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl-2,2’-dimethyl-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. 80. A compound as claimed in claim 65 wherein the compound is selected from the group consisting of

2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S) 2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl-2,2’-dimethyl-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S) 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl-2,2’-dimethyl-3-(8- methy-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R) 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl-2,2’-dimethyl-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid; and

pharmaceutically acceptable salts, and combinations thereof.

81. A compound as claimed in claim 65 wherein the compound is selected from the group consisting of

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

(*S) 2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. 82. A compound as claimed in claim 65 wherein the compound is

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid; and

pharmaceutically acceptable salts thereof. 83. A compound as claimed in claim 65 wherein the compound is (*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid; and

pharmaceutically acceptable salts thereof. 84. A compound as claimed in claim 65 wherein the compound is

(*S) 2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid; and

pharmaceutically acceptable salts thereof. 85. A compound as claimed in claim 65 wherein the compound is

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid; and

pharmaceutically acceptable salts thereof. 86. A compound as claimed in claim 65 wherein the compound is

(*S)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts thereof. 87. A compound as claimed in claim 65 wherein the compound is

(*S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid; and

pharmaceutically acceptable salts thereof. 88. A compound as claimed in claim 65 wherein the compound is (*R)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4-methyl-3- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid; and

pharmaceutically acceptable salts thereof. 89. A compound as claimed in claim 65 wherein the compound is

(*S)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid; and

pharmaceutically acceptable salts thereof. 90. A compound as claimed in claim 65 wherein the compound is

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid; and

pharmaceutically acceptable salts thereof. 91. A compound as claimed in claim 65 wherein the compound is

(*R)-3-(3-(((*S)-1',1'-Dioxido-4,5-dihydro-2H-spiro[furan-3,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts thereof. 92. A compound as claimed in claim 65 wherein the compound is

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid; and

pharmaceutically acceptable salts thereof.

93. A compound as claimed in claim 65 wherein the compound is (*S)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin-1- yl)ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid; and

pharmaceutically acceptable salts thereof. 94. A compound as claimed in claim 65 wherein the compound is

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-2,2-dimethyl- 3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)propanoic acid; and

pharmaceutically acceptable salts thereof. 95. A compound as claimed in claim 65 wherein the compound is

(*S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(5-methyl-4- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)pyridin-2-yl)propanoic acid; and

pharmaceutically acceptable salts thereof. 96. A compound as claimed in claim 65 wherein the compound is

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid; and

pharmaceutically acceptable salts thereof. 97. A compound as claimed in claim 65 wherein the compound is selected from the group consisting of

(*R)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4-methyl-3- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid; (*S)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(((*S)-1',1'-Dioxido-4,5-dihydro-2H-spiro[furan-3,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin-1- yl)ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(5-methyl-4- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid; and

pharmaceutically acceptable salts thereof. 98. A pharmaceutical composition for treating a subject suffering from or diagnosed with a disease, disorder, or medical condition associated with the KEAP1-Nrf2 interaction, comprising an effective amount of at least one compound as claimed in claim 1.

99. A pharmaceutical composition for treating a subject suffering from or diagnosed with a disease, disorder, or medical condition associated with the KEAP1-Nrf2 interaction, comprising an effective amount of at least one compound or a pharmaceutically acceptable salt thereof selected from the group consisting of

3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5-dioxido- 7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)- 3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)- 3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-((1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid; (*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3- (((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3- (((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3- (((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2- dimethylpropanoic acid;

(*S)- 3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(R)- 3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)- 2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)- 2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)- 3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)- 3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5-dioxido- 7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)- 3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)- 3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid

(*S)-3-(3-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(4-Methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-((3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(3-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid ;

(*S)-3-(3-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(6-((3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S) 2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid; 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl-2,2’-dimethyl-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S) 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl-2,2’-dimethyl-3-(8- methy-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R) 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl-2,2’-dimethyl-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(R/S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(R/S)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid; (*S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(R/S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6-methyl-5- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6-methyl-5- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6-methyl-5- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-(difluoromethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((R- 5,5-dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)- 4-methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3- ((R-5,5-dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1’,1’- dioxidospiro[oxetane-3,3’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3- ((R-5,5-dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid; (*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1’,1’- dioxidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]oxathiazepin-2’(3’H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1’,1’- dioxidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]oxathiazepin-2’(3’H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(4-(Difluoromethyl-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R-5,5-dioxido- 7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(4-(Difluoromethyl-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R-5,5- dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R) 3-(4-(Difluoromethyl-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R-5,5- dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1’,1’- dioxidospiro[benzo[b][1,4,5]oxathiazepin-4,3’-oxetan]-2,(3H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-((5’- methyl-1’,1’-dioxido-5’H-spiro[cyclopropane-1,4’-pyrido[2,3-f][1,2,5]thiadiazepin]-2’(3’H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1’,1’- dioxidospiro[benzo[b][1,4,5]oxathiazepin-4,3’-oxetan]-2,(3H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1’,1’- dioxidospiro[benzo[b][1,4,5]oxathiazepin-4,3’-oxetan]-2,(3H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3- ((5’-methyl-1’,1’-dioxido-5’H-spiro[cyclopropane-1,4’-pyrido[2,3-f][1,2,5]thiadiazepin]- 2’(3’H)-yl)methyl)phenyl)propanoic acid; (*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3- ((5’-methyl-1’,1’-dioxido-5’H-spiro[cyclopropane-1,4’-pyrido[2,3-f][1,2,5]thiadiazepin]- 2’(3’H)-yl)methyl)phenyl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3- (((*R)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3- (((*R)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3- (((*R)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

3-(4-Chloro-3-(((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2’,3’- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-(((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Chloro-3-(((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(4-Chloro-3-((1’,1’-dioxoidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(4-Chloro-3-((1’,1’-dioxoidospiro[oxetane-3,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-((1’,1’-dioxoidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid; 3-(4-Chloro-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Chloro-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(4-Chloro-3-(((*S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Chloro-3-(((*S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-(((*S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(4-Chloro-3-((1’,1’-dioxoidospiro[benzo[b]]oxethiazepine-4,3’-oxetan]-2(3H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Chloro-3-((1’,1’-dioxoidospiro[benzo[b]]oxethiazepine-4,3’-oxetan]-2(3H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-((1’,1’-dioxoidospiro[benzo[b]]oxethiazepine-4,3’-oxetan]-2(3H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((8-Fluoro-1,1-dioxidospiro[benzo[b][1,4,5]oxathiazepin]-4,1’-cyclopropan]- 2(3H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid; (*S)-3-(3-((8-Fluoro-1,1-dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3’-oxetan]-2(3H)- yl)methyl]-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-((7’-Chloro-1’,1’-dioxidospiro(cyclopropane-1.4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((7’-((2-Hydroxyethyl)amino-1’,1’-dioxidospiro[cyclopropane-1.4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridinn-7-yl)propanoic acid;

(*S)-3-(3-((7’-((2-Hydroxypropyl)amino-1’,1’-dioxidospiro[cyclopropane-1.4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridinn-7-yl)propanoic acid;

(*S)-3-(3-((7’-Hydroxy-1’,1’-dioxidospiro[cyclopropane-1,4’-pyrido[2,3,- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(4-Cyano-3-((8’-methyl-1’,1’-dioxidospiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]trizolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Cyano-3-((8’-methyl-1’,1’-dioxidospiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]trizolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Cyano-3-((8’-methyl-1’,1’-dioxidospiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]trizolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((7’-((3-Methoxypropyl)amino)-1’,1’-dioxidospiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(-3-((7’-((3-Hydroxypropyl)(methyl)amino)-1’,1’-dioxidospiro[cyclopropane- 1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid; (*S)-3-(-3-((7’-((3-Methoxypropoxy)-1’,1’-dioxidospiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(-3-((7’-((3-Hydroxyethyl)(methyl)amino)-1’,1’-dioxidospiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Methyl-((7’-((2-morpholinoethyl)amino)-1’,1’-dioxidospiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((1’,1’-Dioxido-7’-((2-(piperidin-1-yl)ethyl)amino)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((7’-(Butylamino)-1’,1’-dioxidospiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(3-((7’-((3-Hydroxypropyl)amino)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((7’-((3-Hydroxypropyl)amino)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(3-((7’-((3-Hydroxypropyl)amino)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(3-((7’-(((R)-4-Hydroxybutan-2-yl)amino)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(3-((7’-(((S)-4-Hydroxybutan-2-yl)amino)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid; (*S)-3-(3-((7’-(((R)-4-Hydroxybutan-2-yl)amino)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(3-((7’-(((R)-4-Hydroxybutan-2-yl)amino)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(((S)-4-Hydroxybutan-2-yl)amino)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(3-((7’-(((S)-4-Hydroxybutan-2-yl)amino)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(((S)-4-Hydroxybutan-2-yl)amino)-8’-methyl-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(((R)-3-Hydroxy-3-methylbutan-2-yl)amino)-8’-methyl-1’,1’-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-((7’-(((1s,3S)-3-Hydroxycyclobutyl)amino)-8’-methyl-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido3-(3-((7’-(((*S)-4-hydroxybutan-2- yl)amino)-8’-methyl-1’,1’-dioxido-7’-(2-(piperidin-1-yl)ethoxy)-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-3-(3-((7’-(((*S)-4-hydroxybutan- 2-yl)amino)-8’-methyl-1’,1’-dioxido-7’-(2-(piperidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(3-((7’-(3-((2-Hydroxyethyl)amino)-3-oxopropyl)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2’,3’- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2-methyl-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(3*R)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2’,3’- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2-methyl-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(3*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2’,3’- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2-methyl-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(5,8-Dimethyl-3)-(trifluoromethyl)-[1,2,4-triazolo[4,3-a]pyridine-7-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)-2-methylpropanoic acid;

(3*R)-3-(5,8-Dimethyl-3)-(trifluoromethyl)-[1,2,4-triazolo[4,3-a]pyridine-7-yl)-3-(3- (((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)-2-methylpropanoic acid;

(3*S)-3-(5,8-Dimethyl-3)-(trifluoromethyl)-[1,2,4-triazolo[4,3-a]pyridine-7-yl)-3-(3- (((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)-2-methylpropanoic acid; (R/S)-3-(3-(((*S)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((*S)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((*R)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((*R)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid; (*S)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-[3-[(5,5-Dioxo-7a,8,9,10-tetrahydro-7H-pyrrolo[2,1-d][1,2,5]benzothiadiazepin-6- yl)methyl]-4-methyl-phenyl]-3-(1-ethyl-4-methyl-benzotriazol-5-yl)propanoic acid;

(*R)-3-[3-[(5,5-Dioxo-7a,8,9,10-tetrahydro-7H-pyrrolo[2,1-d][1,2,5]benzothiadiazepin- 6-yl)methyl]-4-methyl-phenyl]-3-(1-ethyl-4-methyl-benzotriazol-5-yl)propanoic acid;

(R/S)-3-[3-[(4,4-Dimethyl-1,1-dioxo-3H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl]- 4-methyl-phenyl]-3-(1-ethyl-4-methyl-benzotriazol-5-yl)propanoic acid;

(R/S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid; (*S)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin- 2-yl)methyl)-4-methylphenyl)-3-(3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid; (R/S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3- (((*R)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3- (((*R)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3- (((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3- (((R)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(6-(((R)-4-ethyl-1,1- dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-5-methylpyridin-2- yl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(6-(((R)-4-ethyl-1,1- dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-5-methylpyridin-2- yl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(6-(((R)-4-ethyl-1,1- dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-5-methylpyridin-2- yl)propanoic acid; (R/S)-3-(4-Methyl-3-(((*S)-9-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-Methyl-3-(((S)-9-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(4-Methyl-3-(((*S)-9-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(4-Methyl-3-(((*R)-9-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-Methyl-3-(((*R)-9-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(4-Methyl-3-(((*R)-9-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(4-Methyl-3-((5'-methyl-1',1'-dioxido-5'H-spiro[cyclopropane-1,4'-pyrido[2,3- f][1,2,5]thiadiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-Methyl-3-((5'-methyl-1',1'-dioxido-5'H-spiro[cyclopropane-1,4'-pyrido[2,3- f][1,2,5]thiadiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(t*rifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(4-Methyl-3-((5'-methyl-1',1'-dioxido-5'H-spiro[cyclopropane-1,4'-pyrido[2,3- f][1,2,5]thiadiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-Methyl-3-(((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(4-Methyl-3-(((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(3*S)-3-(3-((3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-4-Ethyl-8-methyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3- b][1,4,5]oxathiazepin-2-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8'-Chloro-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-3-Cyano-5,5-dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4- d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-3-(3-(((*S)-3-Chloro-5,5-dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4- d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-3-(trifluoromethyl)-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-3-(trifluoromethyl)-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8'-Cyano-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8'-Carbamoyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-2-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-2-Carbamoyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-2-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-2-Carbamoyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((S)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-3-(3-(((R)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-Methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5-dioxido- 7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5-dioxido- 7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5-dioxido- 7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)-yl)methyl)-4- methylphenyl)propanoic acid; (R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-benzo[f]pyrido[2,1-d][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-(((*S)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-(((*S)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-(((*S)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-(((*R)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-(((*R)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-(((*R)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-((5'- methyl-1',1'-dioxido-5'H-spiro[cyclopropane-1,4'-pyrido[2,3-f][1,2,5]thiadiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-((5'- methyl-1',1'-dioxido-5'H-spiro[cyclopropane-1,4'-pyrido[2,3-f][1,2,5]thiadiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-((5'- methyl-1',1'-dioxido-5'H-spiro[cyclopropane-1,4'-pyrido[2,3-f][1,2,5]thiadiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid; (R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((8'-fluoro-1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

(R/S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*S)- 5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*S)- 5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(R/S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)- 5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)- 5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)- 5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid; (R/S)-3-(6-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(6-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(6-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)propanoic acid;

(*S)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)propanoic acid;

(*R)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)propanoic acid;

3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid; (*S)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-4-ethyl-1,1- dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-4- ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-4- ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid;

3-(3-(((S)-5,5--Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*S)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin- 7-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin- 2-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin- 2-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(3-(((*R)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)-4-methylphenyl)-3-(3-ethyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-ethyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-ethyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-ethyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-ethyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-ethyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid; 3-(3-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)-yl)methyl)-4- methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1,1-dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9-tetrahydro-6H-azeto[2,1-d]pyrido[2,3- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9-tetrahydro-6H-azeto[2,1-d]pyrido[2,3- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9-tetrahydro-6H-azeto[2,1-d]pyrido[2,3- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9-tetrahydro-6H-azeto[2,1-d]pyrido[2,3- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(6-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid; (*S)-3-(6-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(6-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-benzo[f]pyrido[2,1- d][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-benzo[f]pyrido[2,1- d][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

3-(6-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(6-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(6-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid; (*S)-3-(4-methyl-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-methyl-3-(((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8'-Fluoro-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((3-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid; (*S)-3-(3-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid; 3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(5- methyl-6-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl- 3-(5-methyl-6-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl- 3-(5-methyl-6-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-2,2-dimethyl-3-(4-methyl-3-((8'- methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-2,2-dimethyl-3-(4-methyl-3-((8'- methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxidospiro[piperidine-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid; (*R)-3-(3-((1',1'-Dioxidospiro[piperidine-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxidospiro[azetidine-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1',1'-Dioxidospiro[azetidine-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[piperidine-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[piperidine-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((7'-(3-((2-(2-Aminoethoxy)ethyl)amino)-3-oxopropyl)-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-((7'-(3-((2-(2-aminoethoxy)ethyl)amino)-3-oxopropyl)-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid; (*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-2,2-dimethyl-3-(4-methyl-3-((8'- methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-dimethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidine-1-yl)-ethoxy)2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-dimethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(piperidine-1-yl)-ethoxy)2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-dimethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(piperidine-1-yl)-ethoxy)2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-dimethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(piperidine-1-yl)-ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-dimethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(piperidine-1-yl)-ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-dimethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin-1-yl)-ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-dimethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin-1-yl)-ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’-(3’H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(3-((7’-(2-(4,4-Difluoropiperidin-1-yl)ethoxy)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a][pyridine-7- yl)propanoic acid;

(*R)-3-(3-((7’-(((1R,3R)-3-Hydroxycyclobutyl)amino)-8’-methyl-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-7’-(((R-1-morpholinopropan-2-yl)amino)- 1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-7’-(((S-1-morpholinopropan-2-yl)amino)- 1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid; (*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-7’-(((1-morpholinopropan-2-yl)amino)- 1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-7’-((2-morpholinoethyl)amino)-1’,1’- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-7’-((2-morpholinoethyl)amino)-1’,1’- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(((S)-1-(pyrrolidine-1- yl)propan-2-yl)amino)-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(3-((1’,1’-Dioxido-7’-(2-(piperazin-1-yl)ethoxy)-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a][pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-(8’-methyl-1’,1’-dioxido-7’-(2-(piperidin-4-yl)ethoxy)- 2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a][pyridine-7- yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin-1- yl)ethoxy)-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a][pyridine-7-yl)propanoic acid;

(*S)-3-(3-1’,1’-Dioxido-7’-(2-(piperidin-1-yl)ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a][pyridine-7-yl)propanoic acid; (*S)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(piperidin-1- yl)ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin-1- yl)ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(piperidin-1-yl)ethoxy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)propanoic acid;

3-(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-((1-piperidin-1- yl)propan-2-yl)amino)-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-((7’-(2-(4-Methoxypiperidin-1-yl)ethoxy)-8’-methyl-1’,1’- dioxidospiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(piperidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(((S)-1-piperidin-1- yl)propan-2-yl)amino)spiro[cyclopropane-1,4’-pyrido [2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-1',1'-Dioxido-4,5-dihydro-2H-spiro[furan-3,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-1',1'-Dioxido-4,5-dihydro-2H-spiro[furan-3,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-(((*S)-8'-methyl-1',1'-dioxido-4,5-dihydro-2H- spiro[furan-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-(((*R)-8'-methyl-1',1'-dioxido-4,5-dihydro-2H- spiro[furan-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*S)-1',1'-Dioxido-4,5-dihydro-2H-spiro[furan-3,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-1',1'-Dioxido-4,5-dihydro-2H-spiro[furan-3,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-(((*S)-8'-methyl-1',1'-dioxido-4,5-dihydro-2H- spiro[furan-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-(((*R)-8'-methyl-1',1'-dioxido-4,5-dihydro-2H- spiro[furan-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid; 3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid

2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran- 4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-2,2-dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran- 4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(3-((1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8'-fluoro-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8-fluoro-1,1-dioxido-2',3',5',6'-tetrahydrospiro[benzo[b][1,4,5]oxathiazepine- 4,4'-pyran]-2(3H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(3S*)-3-(3-((8-fluoro-1,1-dioxido-2',3',5',6'- tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4'-pyran]-2(3H)-yl)methyl)-4-methylphenyl)-2- methyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(6-((8-fluoro-1,1-dioxido- 2',3',5',6'-tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4'-pyran]-2(3H)-yl)methyl)-5- methylpyridin-2-yl)propanoic acid;

(*S)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(6-((8-fluoro-1,1-dioxido- 2',3',5',6'-tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4'-pyran]-2(3H)-yl)methyl)-5- methylpyridin-2-yl)propanoic acid;

(*R)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(6-((8-fluoro-1,1-dioxido- 2',3',5',6'-tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4'-pyran]-2(3H)-yl)methyl)-5- methylpyridin-2-yl)propanoic acid;

(*S)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4-methyl-3- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4-methyl-3- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(S)-3-(7-(difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(R*)-3-(7-(difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(S*)-3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(R*)-3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-((4,4-dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin- 2-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((4,4-dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin- 2-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-2,2-difluoro-3-(3-((8-fluoro-1,1-dioxido-2',3',5',6'- tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4'-pyran]-2(3H)-yl)methyl)-4-methylphenyl)-3- (8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((R)-5,5-dioxido-7a,8,9,10- tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((R)-5,5-dioxido-7a,8,9,10- tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((R)-5,5-dioxido-7a,8,9,10- tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((S)-5,5-dioxido-7a,8,9,10- tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((S)-5,5-dioxido-7a,8,9,10- tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((S)-5,5-dioxido-7a,8,9,10- tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((S)-5,5-dioxido-7,7a,8,9,10,11- hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((*S)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((*S)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid; 3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((*R)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((*R)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((*R)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-((10,10-Difluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-3-(3-(((*S)-10,10-Difluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-10,10-difluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid ;

(*R)-3-(3-(((*S)-10,10-Difluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-10,10-Difluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*R)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*R)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*R)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*S)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*S)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*S)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid; 3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((R)-4-ethyl- 1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((R)-4- ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((R)-4- ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid; (*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3-(((*S)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3- (((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3- (((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid; (*R)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

3-(6-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)-yl)methyl)-5- methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-((1,1-dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)- yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin- 7-yl)propanoic acid;

(*R)-3-(6-((1,1-dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H)- yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin- 7-yl)propanoic acid;

3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(5-methyl-6-(((*S)- 3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(5-methyl-6- (((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(5-methyl-6- (((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)pyridin-2-yl)propanoic acid;

3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(5-methyl-6-(((*R)- 3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(5-methyl-6- (((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(5-methyl-6- (((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)pyridin-2-yl)propanoic acid; 3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin- 7-yl)propanoic acid;

(*S)-3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin- 7-yl)propanoic acid;

(*R)-3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin- 7-yl)propanoic acid;

3-(6-(((*S)-3-Fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-(((*S)-3-Fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*S)-3-Fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3-(((*S)- 3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3- (((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3- (((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3-(((*R)- 3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)phenyl)propanoic acid; (*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3- (((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3- (((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

3-(6-(((*S)-3-Fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-2-methyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(3*S)-3-(6-(((S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-2-methyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(3*R)-3-(6-(((*S)-3-Fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-2-methyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(6-((8'-Fluoro-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-((8'-Fluoro-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-((8'-Fluoro-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*S)-3- fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-(((*R)-3- fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid; (3*S)-3-(8-Ethyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2-methyl-3-(4- methyl-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

(3*S)-2-Methyl-3-(4-methyl-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro- 6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(3*S)-3-(8-Ethyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2-methyl-3-(4- methyl-3-(((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

(*S)-3-(8-Ethyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3- (((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

(*S)-3-(8-Ethyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3- (((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

3-(6-((3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-(((*S)-3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-(((*R)-3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*S)-3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*R)-3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; 3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((8-fluoro-1,1- dioxido-2',3',5',6'-tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4'-pyran]-2(3H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((8-fluoro- 1,1-dioxido-2',3',5',6'-tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4'-pyran]-2(3H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((8-fluoro- 1,1-dioxido-2',3',5',6'-tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4'-pyran]-2(3H)- yl)methyl)-4-methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((8'-fluoro-1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((8'-fluoro- 1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((8'-fluoro- 1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-((8'-Chloro-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8'-Chloro-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((8'-Chloro-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((8'-fluoro-1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)propanoic acid; (*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((8'-fluoro- 1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((8'-fluoro- 1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3-((8'- methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(4-methyl-3- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(4-Methyl-3-((7'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((*R)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((S)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-3-(3-(((S)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((S)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(2*S,3*R)-2-Methyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(2*R,3*R)-2-Methyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanamide;

(*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanamide;

(*R)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanamide;

3-(3-((8'-Carbamoyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8'-Carbamoyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((8'-Carbamoyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (2S,3*R)-3-(3-(Trifluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2-methylpropanoic acid;

(*S)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(5-methyl-6- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(5-methyl-6- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(R/S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3-yl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(6-methyl-5- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)pyridin-3-yl)propanoic acid; (*R)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3-yl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(6-methyl-5- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)pyridin-3-yl)propanoic acid;

(R/S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(R/S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (6-methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (6-methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (6-methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid; (R/S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3-(4- methyl-3-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

3-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((7'-methoxy- 1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((7'- methoxy-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((7'- methoxy-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

(R/S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (6-methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid; (*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (6-methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (6-methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(R/S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid; (*S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(5-methyl-4- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(5-methyl-4- ((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-((7’-(2-(3-fluoroazetidin-1-yl)ethoxy)-8’-methyl-1’,1’- dioxidospiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-2,2-dimethyl-3-(4-methyl-3-((8’-methyl-7’-(2-morpholinoethoxy)-1’,1’- dioxidospiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phenyl)-3- (8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((1’,1’-dioxido-7’-(2-(pyrrolidine-1-yl)ethoxy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((7’-(3-amino-3-oxopropyl)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S) 2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-((1-(piperidin-1- yl)propan-2-yl)oxy)-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]- 2’,(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S) 2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(((*R)-1-(piperidin-1- yl)propan-2-yl)oxy)-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]- 2’,(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S) 2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(((*S)-1-(piperidin-1- yl)propan-2-yl)oxy)-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]- 2’,(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(((*R)-1-(piperidin-1- yl)propan-2-yl)amino)-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(2-(Azetidin-1-yl)ethoxy)-8’-methyl-1’,1’-dioxidospiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((7’-(3-Cyclobutylamino-3-oxopropyl)-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(2-Hydroxyethoxy)-1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((7'-(3-(3-Hydroxypropoxy)propoxy)-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-((7'-(3-(3-Hydroxypropoxy)propoxy)-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1- yl)ethoxy)-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(6-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin- 2-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(6-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin- 2-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(5-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin- 3-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(5-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin- 3-yl)-2,2-dimethylpropanoic acid;

(*S)-2,2-dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxidospiro[oxetane-3,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((1’,1’-dioxidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-yl)-3-(3-((1’,1’- dioxidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxido-7'-(((S)-1-(piperidin-1-yl)propan-2- yl)amino)spiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid; (*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6- methyl-5-((8’-methyl-1’,1’-dioxidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]]oxathiazepin]- 2’(3’H)-yl)methyl)pyridine-3-yl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6- methyl-5-((8’-methyl-1’,1’-dioxidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]]oxathiazepin]- 2’(3’H)-yl)methyl)pyridine-3-yl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6- methyl-5-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidine-1-yl)ethoxy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]]oxathiazepin]-2’(3’H)-yl)methyl)pyridine-3-yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(6- methyl-5-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidine-1-yl)ethoxy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]]oxathiazepin]-2’(3’H)-yl)methyl)pyridine-3-yl)propanoic acid; (*R)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid; (*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid; (*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1',1'- dioxidospiro[piperidine-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1',1'- dioxidospiro[piperidine-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[piperidine-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[piperidine-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((1',1'- dioxidospiro[piperidine-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[piperidine-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(5-(((*R)-3-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-6-methylpyridin-3-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(5-(((*S)-3-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-6-methylpyridin-3-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(5-(((*R)-3-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-6-methylpyridin-3-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-3-(5-(((*S)-3-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-6-methylpyridin-3-yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-2,2-dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1- yl)ethoxy)spiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxido-7'-(((S)-1-(piperidin-1-yl)propan-2- yl)amino)spiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxido-7'-(((S)-1-(piperidin-1-yl)propan-2- yl)amino)spiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-((7’-(2-(4-fluoropiperidin-1-yl)ethoxy)-8’-methyl-1’,1’- dioxidospiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(2-(4-fluoropiperidin-1-yl)ethoxy)-8’-methyl-1’,1’- dioxidospiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid; and

(*R)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(5-methyl-4- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)pyridin-2-yl)propanoic acid.

100. A method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition associated with the KEAP1-Nrf2 interaction, comprising administering to a subject in need of such treatment an effective amount of at least one compound selected from the compounds of Formula (I) or a pharmaceutically acceptable salt thereof,

wherein

X is CH or N;

Q is CH or N;

M is CH or N;

wherein

when X is N, each of Q and M is CH;

when Q is N, each of X and M is CH; and

when M is N, each of X and Q are CH;

R15 is CH3 or Cl;

R13 is H, F or C1-C4alkyl;

R14 is H, F or C1-C4alkyl;

HetA is selected from the group consisting of

wherein

R1 is selected from the group consisting of C3-C4cycloalkyl, C1-C4alkyl and C1-C4alkyl monosubstituted with cyclopropyl or cyclobutyl;

R2 is selected from the group consisting of H, C1-C4alkyl and C1-C4perhaloalkyl;

R3 is H or C1-C4alkyl;

R4 is selected from the group consisting of C1-C4alkyl, C1-C4perhaloalkyl and

C3-C4cycloalkyl;

R7 is H or C1-C4alkyl;

R8 is C1-C4alkyl;

R9 is C1-C4alkyl;

R10 is selected from the group consisting of H, -OC3-C4cycloalkyl and

-OC1-C4perhaloalkyl;

HetB is selected from the group consisting of

wherein

Z is selected from the group consisting of O, CH2, NH and N(CH3);

T is CH or N;

Y is CH or N;

W is CH or N;

V is O or N(CH3);

R16 is H or F; R17 is H or F;

n is 0, 1 or 2;

R18 is selected from the group consisting of H, -CN, halo, C(O)NH2, C1-C4alkyl and C1- C4perhaloalkyl;

R19 is selected from the group consisting of H; CN; halo; C(O)NH2;

N(R38)C1-C6alkyl; C1-C4alkyl; C1-C4perhaloalkyl;

; OC1-C6alkyl;

OC1-C6alkyl substituted with one or two substituents selected from the group consisting of -OH, -OCH3, -O(CH2)3OH, -N(R36)R37, C1-C4alkyl,

, and

-N(R38)C1-C6alkyl substituted with one or two substituents selected from the group consisting of OH, -OCH3, -N(R36)R37, C1-C4alkyl and

and

C1-C4alkyl monosubstituted with a substituent selected from the group consisting of -C(O)NHCH2CH2OH, -C(O)NHCH2CH2OCH2CH2NH2, C(O)NH2 and OH; R20 is H or C1-C4alkyl;

R21 is selected from the group consisting of H, -CN, halo, C1-C4alkyl and C1- C4perhaloalkyl;

R22 and R23 are taken together with the carbon to which they are attached to form

(a) the moiety , wherein R is selected from the group consisting of CH2, NR38 and O, m is 0 or 1, and p is 0 or 1; or (b) the moiety ;

R22’ is selected from the group consisting of H, C1-C4alkyl and C3-C4cycloalkyl, and R23’ is selected from the group consisting of H, C1-C4alkyl and C3-C4cycloalkyl;

R24 is selected from the group consisting of H; CN; halo; C(O)NH2;

C(O)(NH)C3-C4cycloalkyl; N(R38)C1-C6alkyl; C1-C4alkyl; C1-C4perhaloalkyl;

OC1-C6alkyl;

OC1-C6alkyl substituted with one or two substituents selected from the group consisting of -OH, -OCH3, -O(CH2)3OH, -N(R36)R37, C1-C4alkyl; and

-N(R38)C1-C6alkyl substituted with one or two substituents selected from the group consisting of OH, -OCH 36

3, -N(R )R37, C1-C4alkyl,

C1-C4alkyl monosubstituted with a substituent selected from the group consisting of -C(O)NHCH2CH2OH, -C(O)NHCH2CH2OCH2CH2NH2, C(O)NH2 and OH; R25 is selected from the group consisting of H; CN; halo; C(O)NH2;

N(R38)C1-C6alkyl; C1-C4alkyl; C1-C4perhaloalkyl;

OC1-C6alkyl;

OC1-C6alkyl substituted with one or two substituents selected from the group consisting of -OH, -OCH3, -O(CH2)3OH, -N(R36)R37, C1-C4alkyl, and

-N(R38)C1-C6alkyl substituted with one or two substituents selected from the group consisting of OH, -OCH3, -N(R36)R37, C1-C4alky

C1-C4alkyl monosubstituted with a substituent selected from the group consisting of -C(O)NHCH2CH2OH, -C(O)NHCH2CH2OCH2CH2NH2, C(O)NH2 and OH; R26 is selected from the group consisting of H, -CN, halo, C1-C4alkyl and C1- C4perhaloalkyl;

R27 is H or C1-C4alkyl;

R36 and R37 are independently selected from the group consisting of H and C1-C4alkyl; R38 is H or C1-C4alkyl;

provided that when , then 101. A method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition associated with the KEAP1-Nrf2 interaction, comprising administering to a subject in need of such treatment an effective amount of at least one compound as claimed in claim 65. 102. A method as claimed in claim 100, wherein the disease, disorder or medical condition is selected from the group consisting of MS, PD, AD, ALS, CKD, pulmonary arterial hypertension, atherosclerosis, hypertension, heart failure, acute coronary syndrome, myocardial infarction, cardiac arrhythmias, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction and diabetic cardiomyopathy, COPD, asthma, pulmonary fibrosis , cigarette smoke-induced emphysema, IBD, CD , UC, psoriasis, age-related macular degeneration, Fuchs Endothelial Corneal Dystrophy, uveitis, type-1 diabetes, type-2 diabetes, insulin resistance, sepsis-induced acute kidney injury, acute kidney injury, preeclampsia, acute mountain sickness, dermatitis and topical effects of radiation, immunosuppression due to radiation exposure, non- alcoholic steatohepatitis, viral hepatitis, cirrhosis, and a toxin-induced liver disease such as acetaminophen-induced hepatic disease. 103. A method as claimed in claim 102, wherein the disease, disorder or medical condition is selected from the group consisting of IBD, CD and UC. 104. A method as claimed in claim 103, wherein the disease, disorder or medical condition is CD. 105. A method as claimed in claim 103, wherein the disease, disorder or medical condition is UC. 106. A method as claimed in claim 101, wherein the disease, disorder or medical condition is selected from the group consisting of MS, PD, AD, ALS, CKD, pulmonary arterial hypertension, atherosclerosis, hypertension, heart failure, acute coronary syndrome, myocardial infarction, cardiac arrhythmias, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction and diabetic cardiomyopathy, COPD, asthma, pulmonary fibrosis , cigarette smoke-induced emphysema, IBD, CD , UC, psoriasis, age-related macular degeneration, Fuchs Endothelial Corneal Dystrophy, uveitis, type-1 diabetes, type-2 diabetes, insulin resistance, sepsis-induced acute kidney injury, acute kidney injury, preeclampsia, acute mountain sickness, dermatitis and topical effects of radiation, immunosuppression due to radiation exposure, non- alcoholic steatohepatitis, viral hepatitis, cirrhosis, and a toxin-induced liver disease such as acetaminophen-induced hepatic disease. 107. A method as claimed in claim 101, wherein the disease, disorder or medical condition is selected from the group consisting of IBD, CD and UC.

108. A method as claimed in claim 101, wherein the disease, disorder or medical condition is CD. 109. A method as claimed in claim 101, wherein the disease, disorder or medical condition is UC.

Description:
INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION

FIELD OF THE INVENTION The present invention relates to certain sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction. BACKGROUND OF THE INVENTION KEAP1 has been shown to interact with Nrf2, a regulator of the antioxidant response, which is important for the amelioration of oxidative stress. Nrf2 activation is desirable because it leads to coordinated antioxidant and anti-inflammatory responses. However, KEAP1 represses Nrf2 activation. So, there is interest in inhibiting the interaction that KEAP1 has with Nrf2.

In more detail, nuclear factor erythroid 2-related factor 2 (Nrf2) is a basic leucine zipper transcription factor that comprises seven functional domains, Neh1 (Nrf2-ECH homology) to Neh7. Neh1 is a CNC-bZIP domain that allows Nrf2 to interact with small musculoaponeurotic fibrosarcoma (Maf) protein, other transcription partners, and DNA, while Neh3, Neh4, and Neh5 bind to other co-activators to enhance Nrf2 targeted gene expression. Neh2 contains two important motifs known as DLG and ETGE, which are essential for the interaction between Nrf2 and its negative regulator KEAP1 (Kelch-like ECH associated protein 1).

KEAP1 is a substrate adaptor for cullin-based E3 ubiquitin ligase, which binds to Nrf2 under basal conditions and inhibits the transcriptional activity of Nrf2 via ubiquitination and proteasomal degradation of Nrf2. The KELCH domains of the KEAP1 homodimer bind with the ETGE and DLG motifs of the Nrf2-Neh2 domain in the cytosol. Under oxidative stress, thiol modification of KEAP1 cysteine residues leads to conformational change in KEAP1 and dissociation of Nrf2 from KEAP1, which prevents Nrf2 ubiquitination and proteasomal degradation. Nrf2 then translocates into the nucleus and induces anti-oxidative responses by binding to ARE (antioxidant response element) in the promoter of antioxidant genes. More recently, Nrf2 has been shown to bind to promoter regions of pro-inflammatory cytokine genes (with or without ARE) and inhibit RNA Pol II recruitment, leading to inhibition of cytokine gene expression. In addition, Nrf2 negatively regulates the NF-kB signaling, a pathway that is involved in inflammation and apoptosis. Oxidative stress and inflammation are common features in many diseases. Nrf2 signaling pathway plays a critical role in antioxidant and anti- inflammatory responses by regulating >600 genes, many of which are associated with immune diseases. Preclinical and clinical data has demonstrated therapeutic potential of targeting the pathway in neuronal, kidney, cardiovascular, respiratory, eye, skin, and inflammatory bowel diseases. Nrf2 activators could also be useful for treatment of other neuronal diseases including Parkinson's disease (PD), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) (Mimoto, T. et al., Brain Research.2012, 1446, 109-118) and Friedreich's Ataxia.

In the clinic, dimethyl fumarate, a covalent small molecule that can activate Nrf2 (among other targets) via robust modification of cysteine residues on KEAP1, and is approved in the U.S. to treat multiple sclerosis (MS). Another small molecule targeting the Nrf2 pathway by covalently modifying KEAP1, bardoxolone methyl, has shown clinical efficacy in chronic kidney disease (CKD) (Aleksunes, L.M., et al., J. Pharmacol. Exp. Ther. 2010 , 335, 2-12), although the phase III trials were terminated due to adverse events. (Chin, M.P., et al., Am. J. Nephrol.2014, 39, 499-508). There is an increasing body of evidence supporting a role for the KEAP1-Nrf2 ARE pathway in the regulation of physiological processes that serve to inhibit the development and progression of multiple diseases affecting the kidney (Shelton, L. M., et al., Kidney International 2013, 84, 1090-1095).

Despite the termination of bardoxolone methyl for CKD phase III trials, this drug has ongoing clinical trials in patients with pulmonary arterial hypertension

<https://clinicaltrials.gov/ct2/show/NCT02036970>, accessed Nov.20, 2017. Nrf2 activation may be involved in myocardial repair and cardiac remodeling and useful for treatment of cardiovascular diseases including but not limited to atherosclerosis (Niture, S. K., et al., Free Radic. Biol. Med.2014, 66, 36-44), hypertension, and heart failure (Howden, R. Oxidative Medicine and Cellular Longevity 2013, 1-10), acute coronary syndrome, myocardial infarction, cardiac arrhythmias, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction and diabetic cardiomyopathy. (Jiang, S. et al., Expert Opinion on Therapeutic Targets 2016, 20, 1413-1424).

The modulation of the KEAP1-Nrf2 interaction is an attractive approach for intervention and prevention strategies in chronic obstructive pulmonary disease (COPD) (Davies, T.G. et al., J. Med. Chem.2016, 59, 3991-4006). Evidence suggests that low Nrf2 activity in the lung contributes to the pathophysiology of COPD (Yamada, K., et al., BMC Pulmonary Medicine, 2016, 16, 27), probably due to an altered equilibrium between positive and negative Nrf2 regulators. Compared to wild-type littermates, Nrf2 knockout mice show more pronounced inflammation and neutrophilic elastase activity in the bronchoalveolar lavage and exhibit a higher susceptibility to cigarette smoke - or elastase-induced pulmonary emphysema.

Conversely, KEAP1 deletion in the lungs activates Nrf2 signaling and attenuates acute cigarette smoke-induced oxidative stress and inflammation in mice (Boutten, A., et al., Trends Mol. Med. 2011, 17, 363-371). Molecules targeting the KEAP1-Nrf2 protein-protein interaction may treat COPD and other respiratory diseases such as asthma, pulmonary fibrosis (Cho, H-Y., et al., Toxicol. Appl. Pharmacol.2010, 244, 43-56, Adenuga, D. et al., Biochem. Biophys. Res. Commun.2010, 403, (3-4), 452-456), and cigarette smoke-induced emphysema (Iizuka, T. et al., Genes to Cells, 2005, 10 (12) 1113-1125.

Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is an inappropriate immune response to environmental changes and the intestinal microbiota in a genetically susceptible background. Accumulating data from both experimental models and clinical studies indicate that oxidative stress and Nrf2 signaling dysfunction contributes to the development of IBD.

Increased reactive oxygen species (ROS) and oxidative injury have been demonstrated in intestinal mucosa of patients with either UC or CD (Cracowski, J-L., et al., Am. J. Gastroenterol. 2002, 97, 99-103; Hatsugai, M., et al., J. Gastroenterol.2010, 45, 488-500). On the other hand, the levels of intestinal mucosal antioxidants are reduced in IBD patients as compared with control subjects (Rezaie, A., et al., Dig. Dis. Sci.2007, 52, 2015-2021; Kruidenier, L., et al., Aliment Pharmacol. Ther.2002, 16, 1997-2015; Catarzi, S., et al., Inflamm. Bowel Dis.2011, 17, 1674-84). The antioxidant levels and the oxidative stress biomarkers are usually correlated with the disease severity and the extent of intestinal inflammation in the IBD patients. Many of the reduced antioxidants in IBD, including glutathione, glutathione S-transferase (GST), superoxide dismutase, catalase, paraoxonase-1 and metallothionein, are regulated by Nrf2.

Genome-wide association studies have linked IBD-associated single nucleotide polymorphisms (SNPs) to the genes involved in oxidative stress response (e.g. GPX1, GPX4, PARK7, BACH2, PRDX5, ADO, SLC22A4, LRRK2, NOD2, CARD9, HSPA6, DLD, UTS2, and PEX13) (Khor, B., et al. Nature 2011, 474(7351), 307–317), many of which are Nrf2 targeted genes or regulators of Nrf2 signaling.

In line with these findings, a mutation in Nrf2 gene promoter decreases Nrf2 expression and predisposes to UC in a Japanese population (Arisawa, T. et al. Hepato-Gastroenterology 2008, 55, 394-397). In addition, one of the strongest epidemiologic observations in the IBD field is that cigarette smoking is protective against the development of UC (Cope, G. F., et al., Human Toxicol.1987, 6, 189-193) and the effect is linked to Nrf2 activation by a prominent component of cigarette smoke, carbon monoxide (CO) (Onyiah, J. C. et al., Gut Microbes 2014, 5(2), 220- 224).

Preclinical data indicates that Nrf2 plays an important role in protecting intestinal integrity and preserving tolerance to the enteric microbiota. Nrf2 knockout mice were found to be more susceptible to DSS-induced colitis, with a substantial loss of crypts compared with those of wild-type. The increased severity of colitis in Nrf2 knockout mice was found to be associated with decreased expression of antioxidant/phase II detoxifying enzymes including heme- oxygenase-1 (HO-1), NAD(P)H-quinone reductase-1 (NQO1), UDP-glucurosyltransferase 1A1 (UGT1A1), and glutathione S-transferase Mu-1 (GSTM1), and increased expression of proinflammatory genes, including IL-1b, IL-6, IL-8, iNOS, and COX-2 (Khor, T. O., et al., Cancer Res.2006, 66(24), 11580-11584). In addition, it was demonstrated that enteric microbiota activates Nrf2, leading to induction of Nrf2 targeted genes such as HO-1. Nrf2 activation/HO-1 induction prevents enteric microbiota induced colitis in IL-10 knockout mice, with augmented bacterial clearance (Onyiah, J. C., et al., Gastroenterology 2013, 144, 789-798). More recently, a non-covalent KEAP1-Nrf2 small molecule protein-protein-interaction (PPI) inhibitor was shown to protect human colonic cells against stress-induced cell damage in vitro and ameliorate DSS-induced colitis in mice (Lu, M. C., et al., Nature, Sci Rep.2016, 6, 26585). The same molecule was also shown to dampen LPS-induced serum cytokines in mice (TNFa, IFNg, IL-6, IL-12, IL-17) (Jiang, Z-Y., et al., J. Med. Chem.2015, 58(16), 6410-6421).

Oxidative stress leads to damages of the mucosal layer in the GI tract and bacterial invasion, which in turn stimulates the immune response and initiates IBD. Nrf2 can maintain mucosa homeostasis by protecting against oxidative injury and proinflammatory response in IBD. Thus, pharmacological activation of Nrf2 signaling may represent an effective strategy for the intervention of human IBD (Almenier, H. A. et al., Fronteirs in Bioscience E4, 2012, 1335- 1344).

The KEAP1-Nrf2 interaction has also been implicated in skin diseases such as psoriasis (Kadam, D. P., et al., Ind. J. Clin. Biochem.2010, 25(4), 388-392) and inflammatory eye diseases such as age-related macular degeneration (Schimel, A. M. et al., Am. J. Pathol.2011, 178, 2032-2043), Fuchs Endothelial Corneal Dystrophy (FECD) (Bitar, M. S. et al., 2012, Invest. Ophthalmol. Visual Sci, 2012, 53 (9), 5806-5813), uveitis and other inflammatory eye conditions. Nrf2 activation may have potential in treating oxidative stress-related inflammatory diseases in general. In addition, KEAP1-Nrf2 interaction inhibitors -shortly also referred to herein as“KEAP1-Nrf2 inhibitors” are envisaged as treatment candidates for other diseases (Abed, D. A. et al., Acta Pharmaceutica Sinica B, 2015, 5 (4), 285-299). They are envisaged for use in the treatment of type-1 diabetes (Aleksunes, L.M. et al., J. Pharmacol. Exp. Ther.2010, 333 (1), 140-151), type-2 diabetes (Bitar, M. S. et al., Am. J. Phsiol. Endocrinol. Metab.2011, 301 (6), E1119-1129; Rochette, L. et al., Biochimica et Biophysica Acta 2014, 1840 (9), 2709-2729, Bhakkiyalakshmi, E. et al., Pharmacol. Research 2015, 91, 104-114), and insulin resistance (Houstis, N. et al., Nature, 2006, 440 (7086) 944-948), sepsis-induced acute kidney injury and acute kidney injury (see Shelton, 2013, cited above), preeclampsia

(Kweider,N. et al., Annals of Anatomy, 2014, 196, 268-277 ), acute mountain sickness (Lisk, C. et al., Free Radical Biology and Medicine, 2013, 63, 264-273), dermatitis and topical effects of radiation (Schafer, M. et al., Genes and Development 2010, 24(10), 1045), immunosuppression due to radiation exposure (Kim, J.-H. et al., J. Clin. Investigation 2014, 124, 730-741), non- alcoholic steatohepatitis (Shimozono, R. et al., Mol. Pharmacol.2013, 84, 62-70; Chowdry, S. et al., Free Radical Biology and Medicine, 2010, 48, 357-371), viral hepatitis, cirrhosis, and toxin- induced liver disease such as acetaminophen-induced hepatic disease (see Howden, 2013, cited above).

BRIEF SUMMARY OF THE INVENTION

Embodiments of the present invention relate to compounds, pharmaceutical compositions containing them, methods of making and purifying them, methods of using them as KEAP1-Nrf2 inhibitors and methods for using them the treatment of disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction. An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition associated with the KEAP1-Nrf2 interaction using compounds of the invention or active agents of the invention.

Additional embodiments, features, and advantages of the invention will be apparent from the following detailed description and through practice of the invention.

Embodiments of this invention are compounds of Formula (I), and pharmaceutically acceptable salts thereof

,

wherein

X is CH or N;

Q is CH or N;

M is CH or N;

wherein

when X is N, each of Q and M is CH;

when Q is N, each of X and M is CH; and

when M is N, each of X and Q are CH;

R 15 is CH3 or Cl;

R 13 is H, F or C 1 -C 4 alkyl;

R 14 is H, F or C 1 -C 4 alkyl; HetA is selected from the group consisting of

wherein

R 1 is selected from the group consisting of C 3 -C 4 cycloalkyl, C 1 -C 4 alkyl and C 1 -C 4 alkyl monosubstituted with cyclopropyl or cyclobutyl;

R 2 is selected from the group consisting of H, C1-C4alkyl and C1-C4perhaloalkyl;

R 3 is H or C 1 -C 4 alkyl;

R 4 is selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 4 perhaloalkyl and

C3-C4cycloalkyl;

R 7 is H or C 1 -C 4 alkyl;

R 8 is C 1 -C 4 alkyl;

R 9 is C1-C4alkyl;

R 10 is selected from the group consisting of H, -OC3-C4cycloalkyl and

-OC 1 -C 4 perhaloalkyl;

HetB is selected from the group consisting of

,

wherein

Z is selected from the group consisting of O, CH2, NH and N(CH3);

T is CH or N;

Y is CH or N;

W is CH or N;

V is O or N(CH3); R 16 is H or F;

R 17 is H or F;

n is 0, 1 or 2;

R 18 is selected from the group consisting of H, -CN, halo, C(O)NH2, C1-C4alkyl and C1- C4perhaloalkyl;

R 19 is selected from the group consisting of H; CN; halo; C(O)NH 2 ;

N(R 38 )C1-C6alkyl; C1-C4alkyl; C1-C4perhaloalkyl; O C1-C6alkyl;

OC 1 -C 6 alkyl substituted with one or two substituents selected from the group consisting of -OH, -OCH3, -O(CH2)3OH, -N(R 36 )R 37 , C1-C4alkyl,

-N(R 38 )C 1 -C 6 alkyl substituted with one or two substituents selected from the group consisting of OH, -OCH 6

3, -N(R 3 )R 37 , C1-C4alkyl , and

and

C1-C4alkyl monosubstituted with a substituent selected from the group consisting of -C(O)NHCH2CH2OH, -C(O)NHCH2CH2OCH2CH2NH2, C(O)NH2 and OH; R 20 is H or C 1 -C 4 alkyl;

R 21 is selected from the group consisting of H, -CN, halo, C1-C4alkyl and C1- C4perhaloalkyl;

R 22 and R 23 are taken together with the carbon to which they are attached to form

(a) the moiety wherein R is selected from the group consisting of CH 2 , NR 38 and O, m is 0 or 1, and p is 0 or 1; or (b) the moiety

R 22’ is selected from the group consisting of H, C 1 -C 4 alkyl and C 3 -C 4 cycloalkyl, and R 23’ is selected from the group consisting of H, C 1 -C 4 alkyl and C 3 -C 4 cycloalkyl;

R 24 is selected from the group consisting of H; CN; halo; C(O)NH2;

C(O)(NH)C 3 -C 4 cycloalkyl N(R 38 )C 1 -C 6 alkyl; C 1 -C 4 alkyl; C 1 -C 4 perhaloalkyl;

O C1-C6alkyl;

OC1-C6alkyl substituted with one or two substituents selected from the group consisting of -OH, -OCH 6

3, -O(CH2)3OH, -N(R 3 )R 37 , C1-C4alkyl; a nd

-N(R 38 )C1-C6alkyl substituted with one or two substituents selected from the group consisting of OH, -OCH3, -N(R 36 )R 37 , C1-C4alkyl, and

and

C1-C4alkyl monosubstituted with a substituent selected from the group consisting of -C(O)NHCH2CH2OH, -C(O)NHCH2CH2OCH2CH2NH2, C(O)NH2 and OH; R 25 is selected from the group consisting of H; CN; halo; C(O)NH 2 ;

N(R 38 )C1-C6alkyl; C1-C4alkyl; C1-C4perhaloalkyl; O C1-C6alkyl;

OC1-C6alkyl substituted with one or two substituents selected from the group consisting of -OH, -OCH3, -O(CH2)3OH, -N(R 36 )R 37 , C1-C4alkyl, and

-N(R 38 )C1-C6alkyl substituted with one or two substituents selected from the group consisting of OH, -OCH3, -N(R 36 )R 37 , C1-C4alkyl, and

and

C 1 -C 4 alkyl monosubstituted with a substituent selected from the group consisting of -C(O)NHCH 2 CH 2 OH, -C(O)NHCH 2 CH 2 OCH 2 CH 2 NH 2 , C(O)NH 2 and OH; R 26 is selected from the group consisting of H, -CN, halo, C1-C4alkyl and C1- C4perhaloalkyl;

R 27 is H or C 1 -C 4 alkyl;

R 36 and R 37 are independently selected from the group consisting of H and C1-C4alkyl; R 38 is H or C1-C4alkyl;

provided that when HetA is then HetB is not

Illustrative embodiments of Formula (I) are compounds selected from the group consisting of

3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triaz ol-5-yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triaz ol-5-yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid; 3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3 -(3-(((R)-5,5-dioxido- 7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadi azepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid

(*S)-3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-((1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluorom ethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluorom ethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol- 5-yl)-3-(4-methyl-3- (((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(4-methyl-3- (((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(4-methyl-3- (((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid; 3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyri do[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-be nzo[d][1,2,3]triazol-5-yl)-2,2- dimethylpropanoic acid;

(*S)-3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(R)-3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6 -tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2, 3,5,6-tetrahydrospiro[pyran- 4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phe nyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2, 3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin] -2'(3'H)-yl)methyl)phenyl)-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-y l)propanoic acid;

3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3- (3-(((*R)-5,5-dioxido- 7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5 ]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid; (*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-(((*R)-5,5-dioxido- 7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5 ]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-(((*R)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(3-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4, 3'-oxetan]-2(3H)- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(4-Methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropa ne-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl -3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-((3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyr ido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(dif luoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(dif luoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(dif luoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid ;

(*S)-3-(3-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(dif luoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(dif luoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(6-((3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyr ido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-3-(6-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(R/S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridi n-7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid; (*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’, 1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

(*S) 2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’, 1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)- 1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tet rahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl-2,2’-dimethyl-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

(*S) 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tet rahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl-2,2’-dimethyl-3-(8- methy-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl )propanoic acid;

(*R) 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tet rahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl-2,2’-dimethyl-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

(R/S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]p yridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4 ,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4 ,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid; (*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4 ,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(R/S)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4 '-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(R/S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4 '-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3- yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3- yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3- yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(R/S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2, 2-dimethyl-3-(6-methyl-5- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2 -dimethyl-3-(6-methyl-5- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2 -dimethyl-3-(6-methyl-5- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid; (*R)-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropa ne-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl -3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-(difluoromethyl-1H-benzo[d][1,2,3 ]triazol-5-yl)-3-(3-((R- 5,5-dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][ 1,2,5]thiadiazepin-6(7H)-yl)methyl)- 4-methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl-1H-benzo[d][ 1,2,3]triazol-5-yl)-3-(3- ((R-5,5-dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1 -d][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol- 5-yl)-3-(3-((1’,1’- dioxidospiro[oxetane-3,3’-pyrido[2,3-b][1,4,5]oxathiazepin ]-2’(3’H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl-1H-benzo[d][ 1,2,3]triazol-5-yl)-3-(3- ((R-5,5-dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1 -d][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-((1’,1’- dioxidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]oxathiazepin -2’(3’H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-((1’,1’- dioxidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]oxathiazepin -2’(3’H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(4-(Difluoromethyl-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl )-3-(3-(((R-5,5-dioxido- 7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2,5]thiadi azepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(4-(Difluoromethyl-1-methyl-1H-benzo[d][1,2,3]triazol -5-yl)-3-(3-(((R-5,5- dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R) 3-(4-(Difluoromethyl-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl )-3-(3-(((R-5,5- dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid; 3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol- 5-yl)-3-(3-((1’,1’- dioxidospiro[benzo[b][1,4,5]oxathiazepin-4,3’-oxetan]-2,(3 H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol- 5-yl)-3-(4-methyl-3-((5’- methyl-1’,1’-dioxido-5’H-spiro[cyclopropane-1,4’-pyr ido[2,3-f][1,2,5]thiadiazepin]-2’(3’H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-((1’,1’- dioxidospiro[benzo[b][1,4,5]oxathiazepin-4,3’-oxetan]-2,(3 H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-((1’,1’- dioxidospiro[benzo[b][1,4,5]oxathiazepin-4,3’-oxetan]-2,(3 H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(4-methyl-3- ((5’-methyl-1’,1’-dioxido-5’H-spiro[cyclopropane-1,4 ’-pyrido[2,3-f][1,2,5]thiadiazepin]- 2’(3’H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(4-methyl-3- ((5’-methyl-1’,1’-dioxido-5’H-spiro[cyclopropane-1,4 ’-pyrido[2,3-f][1,2,5]thiadiazepin]- 2’(3’H)-yl)methyl)phenyl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol- 5-yl)-3-(4-methyl-3- (((*R)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(4-methyl-3- (((*R)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(4-methyl-3- (((*R)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

3-(4-Chloro-3-(((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H -dipyrido[2,1-d:2’,3’- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(tri fluoromethyl)-[1,2,4]triazolo[4,3- a]pyridine-7-yl)propanoic acid; (*S)-3-(4-Chloro-3-(((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-m ethyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Chloro-3-(((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-m ethyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(4-Chloro-3-((1’,1’-dioxoidospiro[oxetane-3,4’-pyrid o[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl )-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(4-Chloro-3-((1’,1’-dioxoidospiro[oxetane-3,4’- pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-me thyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-((1’,1’-dioxoidospiro[oxetane-3,4’- pyrido[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl )-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

3-(4-Chloro-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hex ahydro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-m ethyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Chloro-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)p henyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)p henyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(4-Chloro-3-(((*S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,11-hex ahydro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-m ethyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Chloro-3-(((*S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)p henyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid; (*S)-3-(4-Chloro-3-(((*S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)p henyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(4-Chloro-3-((1’,1’-dioxoidospiro[benzo[b]]oxethiazepi ne-4,3’-oxetan]-2(3H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Chloro-3-((1’,1’-dioxoidospiro[benzo[b]]oxethi azepine-4,3’-oxetan]-2(3H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-((1’,1’-dioxoidospiro[benzo[b]]oxethi azepine-4,3’-oxetan]-2(3H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((8-Fluoro-1,1-dioxidospiro[benzo[b][1,4,5]oxathia zepin]-4,1’-cyclopropan]- 2(3H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromet hyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8-Fluoro-1,1-dioxidospiro[benzo[b][1,4,5]oxathia zepine-4,3’-oxetan]-2(3H)- yl)methyl]-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-((7’-Chloro-1’,1’-dioxidospiro(cyclopropane- 1.4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl )-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((7’-((2-Hydroxyethyl)amino-1’,1’-dioxidospi ro[cyclopropane-1.4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl )-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridinn-7-yl)propanoic acid;

(*S)-3-(3-((7’-((2-Hydroxypropyl)amino-1’,1’-dioxidosp iro[cyclopropane-1.4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridinn-7-yl)propan oic acid;

(*S)-3-(3-((7’-Hydroxy-1’,1’-dioxidospiro[cyclopropane -1,4’-pyrido[2,3,- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl )-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid; 3-(4-Cyano-3-((8’-methyl-1’,1’-dioxidospiro[cyclopropa ne-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-me thyl-3-(trifluoromethyl)- [1,2,4]trizolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Cyano-3-((8’-methyl-1’,1’-dioxidospiro[cyclo propane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-me thyl-3-(trifluoromethyl)- [1,2,4]trizolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Cyano-3-((8’-methyl-1’,1’-dioxidospiro[cyclo propane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-me thyl-3-(trifluoromethyl)- [1,2,4]trizolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((7’-((3-Methoxypropyl)amino)-1’,1’-dioxidos piro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propan oic acid;

(*S)-3-(-3-((7’-((3-Hydroxypropyl)(methyl)amino)-1’,1’ -dioxidospiro[cyclopropane- 1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propan oic acid;

(*S)-3-(-3-((7’-((3-Methoxypropoxy)-1’,1’-dioxidospiro [cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl )-3-(8-methyl-3-(trifluoromethyl)- [1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(-3-((7’-((3-Hydroxyethyl)(methyl)amino)-1’,1’- dioxidospiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propan oic acid;

(*S)-3-(4-Methyl-((7’-((2-morpholinoethyl)amino)-1’,1’ -dioxidospiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propan oic acid;

(*S)-3-(3-((1’,1’-Dioxido-7’-((2-(piperidin-1-yl)ethyl )amino)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propan oic acid;

(*S)-3-(3-((7’-(Butylamino)-1’,1’-dioxidospiro[cyclopr opane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl )-3-(8-methyl-3-(trifluoromethyl)- [1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid; 3-(3-((7’-((3-Hydroxypropyl)amino)-1’,1’-dioxido-2,3,5 ,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-((3-Hydroxypropyl)amino)-1’,1’-dioxido- 2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(3-((7’-((3-Hydroxypropyl)amino)-1’,1’-dioxido- 2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

3-(3-((7’-(((R)-4-Hydroxybutan-2-yl)amino)-1’,1’-dioxi do-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

3-(3-((7’-(((S)-4-Hydroxybutan-2-yl)amino)-1’,1’-dioxi do-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(((R)-4-Hydroxybutan-2-yl)amino)-1’,1’- dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(3-((7’-(((R)-4-Hydroxybutan-2-yl)amino)-1’,1’- dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(((S)-4-Hydroxybutan-2-yl)amino)-1’,1’- dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(3-((7’-(((S)-4-Hydroxybutan-2-yl)amino)-1’,1’- dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(((S)-4-Hydroxybutan-2-yl)amino)-8’-methy l-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(((R)-3-Hydroxy-3-methylbutan-2-yl)amino)-8 ’-methyl-1’,1’-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxa thiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-((7’-(((1s,3S)-3-Hydroxycyclobutyl)amino)-8’-m ethyl-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido3- (3-((7’-(((*S)-4-hydroxybutan-2- yl)amino)-8’-methyl-1’,1’-dioxido-7’-(2-(piperidin-1 -yl)ethoxy)-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propan oic acid;

2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-3 -(3-((7’-(((*S)-4-hydroxybutan- 2-yl)amino)-8’-methyl-1’,1’-dioxido-7’-(2-(piperidin -1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(3-((7’-(3-((2-Hydroxyethyl)amino)-3-oxopropyl)-1 ,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido [2,1-d:2’,3’- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2-methyl- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid; (3*R)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-di pyrido[2,1-d:2’,3’- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2-methyl- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(3*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-di pyrido[2,1-d:2’,3’- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2-methyl- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(5,8-Dimethyl-3)-(trifluoromethyl)-[1,2,4-triazolo[4,3-a]p yridine-7-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2’,3’ -f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)-2-methylpropanoic acid;

(3*R)-3-(5,8-Dimethyl-3)-(trifluoromethyl)-[1,2,4-triazolo[4 ,3-a]pyridine-7-yl)-3-(3- (((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)-2-methylpropanoic acid;

(3*S)-3-(5,8-Dimethyl-3)-(trifluoromethyl)-[1,2,4-triazolo[4 ,3-a]pyridine-7-yl)-3-(3- (((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)-2-methylpropanoic acid;

(R/S)-3-(3-(((*S)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxa zino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxaz ino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((*S)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxaz ino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((*R)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxa zino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxaz ino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid; (*R)-3-(3-(((*R)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxaz ino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-di pyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethy l-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethy l-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethy l-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-di pyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethy l-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethy l-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethy l-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyr rolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-[3-[(5,5-Dioxo-7a,8,9,10-tetrahydro-7H-pyrrolo[2,1-d] [1,2,5]benzothiadiazepin-6- yl)methyl]-4-methyl-phenyl]-3-(1-ethyl-4-methyl-benzotriazol -5-yl)propanoic acid;

(*R)-3-[3-[(5,5-Dioxo-7a,8,9,10-tetrahydro-7H-pyrrolo[2,1-d] [1,2,5]benzothiadiazepin- 6-yl)methyl]-4-methyl-phenyl]-3-(1-ethyl-4-methyl-benzotriaz ol-5-yl)propanoic acid;

(R/S)-3-[3-[(4,4-Dimethyl-1,1-dioxo-3H-pyrido[2,3-b][1,4,5]o xathiazepin-2-yl)methyl]- 4-methyl-phenyl]-3-(1-ethyl-4-methyl-benzotriazol-5-yl)propa noic acid; (R/S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b ][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1 ,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyr rolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b] [1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1 ,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b] [1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1 ,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[ 2,3-b][1,4,5]oxathiazepin- 2-yl)methyl)-4-methylphenyl)-3-(3-methyl-[1,2,4]triazolo[4,3 -a]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b ][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(3-methyl-[1,2,4]triazolo[4,3-a ]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2 ,3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(3-methyl-[1,2,4]triazolo[4,3-a ]pyridin-7-yl)propanoic acid; (*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridi n-7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d] [1,2,3]triazol-5-yl)-3-(3- (((*R)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d] [1,2,3]triazol-5-yl)-3-(3- (((*R)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d] [1,2,3]triazol-5-yl)-3-(3- (((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid; (*R)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d] [1,2,3]triazol-5-yl)-3-(3- (((R)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d :2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(6-(((R)-4-ethyl-1,1- dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl )methyl)-5-methylpyridin-2- yl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(6-(((R)-4-ethyl-1,1- dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl )methyl)-5-methylpyridin-2- yl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(6-(((R)-4-ethyl-1,1- dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl )methyl)-5-methylpyridin-2- yl)propanoic acid;

(R/S)-3-(4-Methyl-3-(((*S)-9-methyl-5,5-dioxido-7,7a,8,9,10, 11-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl) phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(4-Methyl-3-(((S)-9-methyl-5,5-dioxido-7,7a,8,9,10,11 -hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl) phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-3-(4-Methyl-3-(((*S)-9-methyl-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl) phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(R/S)-3-(4-Methyl-3-(((*R)-9-methyl-5,5-dioxido-7,7a,8,9,10, 11-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl) phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(4-Methyl-3-(((*R)-9-methyl-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl) phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-3-(4-Methyl-3-(((*R)-9-methyl-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl) phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid; (R/S)-3-(4-Methyl-3-((5'-methyl-1',1'-dioxido-5'H-spiro[cycl opropane-1,4'-pyrido[2,3- f][1,2,5]thiadiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl -3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-Methyl-3-((5'-methyl-1',1'-dioxido-5'H-spiro[cyclo propane-1,4'-pyrido[2,3- f][1,2,5]thiadiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl -3-(t*rifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(4-Methyl-3-((5'-methyl-1',1'-dioxido-5'H-spiro[cyclo propane-1,4'-pyrido[2,3- f][1,2,5]thiadiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl -3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-Methyl-3-(((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-te trahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(4-Methyl-3-(((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-te trahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2 ,3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2, 3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2, 3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(3*S)-3-(3-((3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6 H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-3-(3-(((*R)-3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-4-Ethyl-8-methyl-1,1-dioxido-3,4-dihydro-2H -pyrido[2,3- b][1,4,5]oxathiazepin-2-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8'-Chloro-1',1'-dioxidospiro[cyclopropane-1,4'-p yrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-3-Cyano-5,5-dioxido-7a,8,10,11-tetrahydro-[ 1,4]oxazino[3,4- d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methyl phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(3-(((*S)-3-Chloro-5,5-dioxido-7a,8,10,11-tetrahydro- [1,4]oxazino[3,4- d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methyl phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-3-(trifluoromethyl)-7,7a,8,9,10 ,11-hexahydro-6H- dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-me thylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-3-(trifluoromethyl)-7,7a,8,9,10 ,11-hexahydro-6H- dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-me thylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(3-((8'-Cyano-1',1'-dioxidospiro[cyclopropane-1,4'-py rido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8'-Carbamoyl-1',1'-dioxidospiro[cyclopropane-1,4 '-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-2-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-3-(3-(((*S)-2-Carbamoyl-5,5-dioxido-7,7a,8,9,10,11-hexa hydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3 -(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-2-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-2-Carbamoyl-5,5-dioxido-7,7a,8,9,10,11-hexa hydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3 -(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((S)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyri do[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((R)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyri do[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-Methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahy drospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-(((R)-5,5-dioxido- 7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadi azepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-(((R)-5,5-dioxido- 7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadi azepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-(((R)-5,5-dioxido- 7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadi azepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-(((*R)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]th iadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid; (*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H) -yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H) -yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H) -yl)methyl)-4- methylphenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-benzo[f]pyrido[2,1-d][1, 2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(4-methyl-3-(((*S)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrro lo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(4-methyl-3-(((*S)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrro lo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(4-methyl-3-(((*S)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrro lo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(4-methyl-3-(((*R)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrro lo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(4-methyl-3-(((*R)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrro lo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid; (*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(4-methyl-3-(((*R)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrro lo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(4-methyl-3-((5'- methyl-1',1'-dioxido-5'H-spiro[cyclopropane-1,4'-pyrido[2,3- f][1,2,5]thiadiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(4-methyl-3-((5'- methyl-1',1'-dioxido-5'H-spiro[cyclopropane-1,4'-pyrido[2,3- f][1,2,5]thiadiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(4-methyl-3-((5'- methyl-1',1'-dioxido-5'H-spiro[cyclopropane-1,4'-pyrido[2,3- f][1,2,5]thiadiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[p yran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propan oic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[p yran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propan oic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[p yran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propan oic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((8'-fluoro-1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiaze pin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

(R/S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tr iazol-5-yl)-3-(3-(((*S)- 5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3' -f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid; (*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-(((*S)- 5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3' -f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(R/S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tr iazol-5-yl)-3-(3-(((*R)- 5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3' -f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-(((*R)- 5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3' -f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-(((*R)- 5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3' -f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(R/S)-3-(6-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4 ,3'-oxetan]-2(3H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benz o[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(6-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4, 3'-oxetan]-2(3H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benz o[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(6-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4, 3'-oxetan]-2(3H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benz o[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1 ,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benz o[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1, 4,5]oxathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benz o[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1, 4,5]oxathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benz o[d][1,2,3]triazol-5-yl)propanoic acid; (R/S)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3 -b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl -1H-benzo[d][1,2,3]triazol-5- yl)propanoic acid;

(*S)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl -1H-benzo[d][1,2,3]triazol-5- yl)propanoic acid; and

(*R)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl -1H-benzo[d][1,2,3]triazol-5- yl)propanoic acid;

3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triaz ol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triaz ol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-(((R)-4-ethyl-1,1- dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl )methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triaz ol-5-yl)-3-(3-(((R)-4- ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathia zepin-2-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triaz ol-5-yl)-3-(3-(((R)-4- ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathia zepin-2-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]o xathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1 ,2,3]triazol-5-yl)propanoic acid; 3-(3-(((S)-5,5--Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyr rolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- (trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- (trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- (trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][ 1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2, 3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2, 3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]o xathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1, 4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1, 4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxaz ino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(3-(((*S)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxaz ino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2 ,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromet hyl)-[1,2,4]triazolo[4,3-a]pyridin- 7-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b] [1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2 ,3-b][1,4,5]oxathiazepin- 2-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl) -[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2 ,3-b][1,4,5]oxathiazepin- 2-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl) -[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido [2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxaz ino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxaz ino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2 ,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)-4-methylphenyl)-3-(3-ethyl-8-methyl-[1,2,4] triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- ethyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- ethyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- ethyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- ethyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid; (*R)-3-(3-(((R)-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- ethyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4, 5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b] [1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b] [1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

3-(3-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-ox etan]-2(3H)-yl)methyl)-4- methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazol o[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1,1-dioxidospiro[benzo[b][1,4,5]oxathiazepine-4, 3'-oxetan]-2(3H)- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido [2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9-tetrahydro-6H-azeto[2, 1-d]pyrido[2,3- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9-tetrahydro-6H-azeto[2, 1-d]pyrido[2,3- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9-tetrahydro-6H-azeto[2, 1-d]pyrido[2,3- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9-tetrahydro-6H-azeto[2, 1-d]pyrido[2,3- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(6-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-5-methylpyridin-2-yl) -3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(6-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-5-methylpyridin-2-yl) -3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(6-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-5-methylpyridin-2-yl) -3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-ben zo[f]pyrido[2,1- d][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-ben zo[f]pyrido[2,1- d][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido [2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid; (*R)-3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

3-(6-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido [2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(6-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(6-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(4-methyl-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)pheny l)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-methyl-3-(((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)pheny l)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8'-Fluoro-1',1'-dioxidospiro[cyclopropane-1,4'-p yrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((3-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; 2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cy clopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl -3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospi ro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospi ro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1, 4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifl uoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl- 3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl- 3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyri do[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(3-(triflu oromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2, 2-dimethyl-3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2, 2-dimethyl-3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cy clopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(3-(trifl uoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid; (*S)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospi ro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospi ro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol- 5-yl)-2,2-dimethyl-3-(5- methyl-6-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6-tet rahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propan oic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-2,2-dimethyl-3- (5-methyl-6-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-2,2-dimethyl- 3-(5-methyl-6-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5, 6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-2,2-di methyl-3-(4-methyl-3-((8'- methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1, 4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-2,2-di methyl-3-(4-methyl-3-((8'- methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1, 4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid; (*R)-3-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxidospiro[piperidine-4,4'-pyrido[2,3-b] [1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifl uoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1',1'-Dioxidospiro[piperidine-4,4'-pyrido[2,3-b] [1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifl uoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxidospiro[azetidine-3,4'-pyrido[2,3-b][ 1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifl uoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1',1'-Dioxidospiro[azetidine-3,4'-pyrido[2,3-b][ 1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifl uoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospi ro[piperidine-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospi ro[piperidine-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospi ro[azetidine-3,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl -3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospi ro[azetidine-3,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((7'-(3-((2-(2-Aminoethoxy)ethyl)amino)-3-oxopropy l)-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin] -2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-((7'-(3-((2-(2-aminoethoxy)ethyl)amino)-3-oxopropy l)-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin] -2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-2,2-di methyl-3-(4-methyl-3-((8'- methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)p ropanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-d imethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidine-1-yl)-e thoxy)2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phe nyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-d imethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(piperidine-1-yl)-et hoxy)2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phe nyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-d imethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(piperidine-1-yl)-et hoxy)2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phe nyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-d imethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(piperidine-1-yl)-et hoxy)spiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phenyl)propano ic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-d imethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(piperidine-1-yl)-et hoxy)spiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phenyl)propano ic acid; (*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-d imethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin-1-yl)-et hoxy)spiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phenyl)propano ic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-d imethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin-1-yl)-et hoxy)spiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’-(3’H)-yl)methyl)phenyl)propano ic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl) ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin] -2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl) ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin] -2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl) ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*R)-3-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl) ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl )ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl )ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*R)-3-(3-((7’-(2-(4,4-Difluoropiperidin-1-yl)ethoxy)-1’ ,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a][pyridine-7- yl)propanoic acid; (*R)-3-(3-((7’-(((1R,3R)-3-Hydroxycyclobutyl)amino)-8’-m ethyl-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-7’-(((R-1-mo rpholinopropan-2-yl)amino)- 1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrid o[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-7’-(((S-1-mo rpholinopropan-2-yl)amino)- 1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrid o[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-7’-(((1-morp holinopropan-2-yl)amino)- 1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrid o[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-7’-((2-morph olinoethyl)amino)-1’,1’- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1 ,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-7’-((2-morph olinoethyl)amino)-1’,1’- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1 ,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-diox ido-7’-(((S)-1-(pyrrolidine-1- yl)propan-2-yl)amino)-2,3,5,6-tetrahydrospiro[pyran-4,4’-p yrido[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl )-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid; (*R)-3-(3-((1’,1’-Dioxido-7’-(2-(piperazin-1-yl)ethoxy )-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a][pyridine-7 -yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-(8’-methyl-1’,1’-dioxi do-7’-(2-(piperidin-4-yl)ethoxy)- 2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxa thiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a][pyridine-7- yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-diox ido-7’-(2-(pyrrolidin-1- yl)ethoxy)-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b ][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifl uoromethyl)-[1,2,4]triazolo[4,3- a][pyridine-7-yl)propanoic acid;

(*S)-3-(3-1’,1’-Dioxido-7’-(2-(piperidin-1-yl)ethoxy)s piro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl )-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a][pyridine-7-yl)propa noic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-diox ido-7’-(2-(piperidin-1- yl)ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxat hiazepin]-2’(3’H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridi ne-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-diox ido-7’-(2-(pyrrolidin-1- yl)ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxat hiazepin]-2’(3’H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridi ne-7-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridine-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(piperid in-1-yl)ethoxy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phen yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridine-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrroli din-1-yl)ethoxy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phen yl)propanoic acid;

3-(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-di oxido-7’-((1-piperidin-1- yl)propan-2-yl)amino)-2,3,5,6-tetrahydrospiro[pyran-4,4’-p yrido[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl )-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid; (*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridine-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrroli din-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-((7’-(2-(4-Methoxypiperidin-1-yl)ethoxy)-8’-me thyl-1’,1’- dioxidospiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathia zepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridine-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(piperid in-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)- yl)methyl)phenyl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-diox ido-7’-(((S)-1-piperidin-1- yl)propan-2-yl)amino)spiro[cyclopropane-1,4’-pyrido [2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-1',1'-Dioxido-4,5-dihydro-2H-spiro[furan-3, 4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2, 2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(3-(((*R)-1',1'-Dioxido-4,5-dihydro-2H-spiro[furan-3, 4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2, 2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-(((*S)-8'-methyl-1',1'-dioxi do-4,5-dihydro-2H- spiro[furan-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-y l)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-(((*R)-8'-methyl-1',1'-dioxi do-4,5-dihydro-2H- spiro[furan-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-y l)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid; (*R)-3-(3-(((*S)-1',1'-Dioxido-4,5-dihydro-2H-spiro[furan-3, 4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2, 2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-3-(3-(((*R)-1',1'-Dioxido-4,5-dihydro-2H-spiro[furan-3, 4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2, 2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-(((*S)-8'-methyl-1',1'-dioxi do-4,5-dihydro-2H- spiro[furan-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-y l)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-(((*R)-8'-methyl-1',1'-dioxi do-4,5-dihydro-2H- spiro[furan-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-y l)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridi n-7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-py rido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-py rido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-py rido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-py rido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid; (*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-py rido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-py rido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-(((*S)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]th iadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol- 5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3 -(3-(((*R)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]th iadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid; (*S)-3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6 -tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2, 3,5,6-tetrahydrospiro[pyran- 4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phe nyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-2,2-dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2, 3,5,6-tetrahydrospiro[pyran- 4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phe nyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(3-((1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2, 2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-3-(3-((1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2, 2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(3-((8'-fluoro-1',1'-dioxido-2,3,5,6-tetrahydrospiro[ pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8-fluoro-1,1-dioxido-2',3',5',6'-tetrahydrospiro [benzo[b][1,4,5]oxathiazepine- 4,4'-pyran]-2(3H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-( trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(3S*)-3-(3-((8-fluoro-1,1-dioxido-2',3',5',6'- tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4'-pyran]-2(3 H)-yl)methyl)-4-methylphenyl)-2- methyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a ]pyridin-7-yl)propanoic acid;

3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(6-((8 -fluoro-1,1-dioxido- 2',3',5',6'-tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4 '-pyran]-2(3H)-yl)methyl)-5- methylpyridin-2-yl)propanoic acid; (*S)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-( 6-((8-fluoro-1,1-dioxido- 2',3',5',6'-tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4 '-pyran]-2(3H)-yl)methyl)-5- methylpyridin-2-yl)propanoic acid;

(*R)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-( 6-((8-fluoro-1,1-dioxido- 2',3',5',6'-tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4 '-pyran]-2(3H)-yl)methyl)-5- methylpyridin-2-yl)propanoic acid;

(*S)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2 -dimethyl-3-(4-methyl-3- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2 -dimethyl-3-(4-methyl-3- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2,2-dimet hyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2,2-dimet hyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(3-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2,2-dimet hyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-3-(3-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2,2-dimet hyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(S)-3-(7-(difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazo l-5-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4 ,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(R*)-3-(7-(difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triaz ol-5-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4 ,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid; (S*)-3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4 ,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(R*)-3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4 ,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-((4,4-dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2 ,3-b][1,4,5]oxathiazepin- 2-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(tri fluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((4,4-dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2 ,3-b][1,4,5]oxathiazepin- 2-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(tri fluoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-difluoro-3-(3-((8-fluoro-1,1-dioxido-2',3',5',6'- tetrahydrospiro[benzo[b][1,4,5]oxathiazepine-4,4'-pyran]-2(3 H)-yl)methyl)-4-methylphenyl)-3- (8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin- 7-yl)propanoic acid;

3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((R)- 5,5-dioxido-7a,8,9,10- tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7 H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-( ((R)-5,5-dioxido-7a,8,9,10- tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7 H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-( ((R)-5,5-dioxido-7a,8,9,10- tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7 H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((S)- 5,5-dioxido-7a,8,9,10- tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7 H)-yl)methyl)-4- methylphenyl)propanoic acid; (*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-( ((S)-5,5-dioxido-7a,8,9,10- tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7 H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-( ((S)-5,5-dioxido-7a,8,9,10- tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7 H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((S)- 5,5-dioxido-7,7a,8,9,10,11- hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl )methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-( ((*S)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]th iadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-( ((*S)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]th iadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-(((*R) -5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]th iadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-( ((*R)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]th iadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-3-(3-( ((*R)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]th iadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid; (*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-((10,10-Difluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6 H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-10,10-Difluoro-5,5-dioxido-7,7a,8,9,10,11-h exahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3 -(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-10,10-difluoro-5,5-dioxido-7,7a,8,9,10,11-h exahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3 -(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid ;

(*R)-3-(3-(((*S)-10,10-Difluoro-5,5-dioxido-7,7a,8,9,10,11-h exahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3 -(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-10,10-Difluoro-5,5-dioxido-7,7a,8,9,10,11-h exahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3 -(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-(((*R)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid; (*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-(((*R)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-(((*R)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-(((*S)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-(((*S)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-(((*S)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-(((R)-4-ethyl- 1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin- 2-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-(((R)-4- ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathia zepin-2-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-(((R)-4- ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathia zepin-2-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H) -yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H) -yl)methyl)-4- methylphenyl)propanoic acid; (*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H) -yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiaze pin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiaze pin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiaze pin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(4-methyl-3-(((*S)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrro lo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(4-methyl-3- (((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(4-methyl-3- (((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid; 3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido [2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3 -b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trif luoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trif luoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trif luoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

3-(6-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-ox etan]-2(3H)-yl)methyl)-5- methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]t riazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-((1,1-dioxidospiro[benzo[b][1,4,5]oxathiazepine-4, 3'-oxetan]-2(3H)- yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromet hyl)-[1,2,4]triazolo[4,3-a]pyridin- 7-yl)propanoic acid;

(*R)-3-(6-((1,1-dioxidospiro[benzo[b][1,4,5]oxathiazepine-4, 3'-oxetan]-2(3H)- yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromet hyl)-[1,2,4]triazolo[4,3-a]pyridin- 7-yl)propanoic acid;

3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridi n-7-yl)-3-(5-methyl-6-(((*S)- 3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2, 1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)pyridin-2-yl)propanoic acid; (*S)-3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]p yridin-7-yl)-3-(5-methyl-6- (((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipy rido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]p yridin-7-yl)-3-(5-methyl-6- (((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipy rido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)pyridin-2-yl)propanoic acid;

3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridi n-7-yl)-3-(5-methyl-6-(((*R)- 3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2, 1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]p yridin-7-yl)-3-(5-methyl-6- (((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipy rido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]p yridin-7-yl)-3-(5-methyl-6- (((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipy rido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)pyridin-2-yl)propanoic acid;

3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]o xathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromet hyl)-[1,2,4]triazolo[4,3-a]pyridin- 7-yl)propanoic acid;

(*S)-3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1, 4,5]oxathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromet hyl)-[1,2,4]triazolo[4,3-a]pyridin- 7-yl)propanoic acid;

(*R)-3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1, 4,5]oxathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trifluoromet hyl)-[1,2,4]triazolo[4,3-a]pyridin- 7-yl)propanoic acid;

3-(6-(((*S)-3-Fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H -dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-(((*S)-3-Fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(6-(((*S)-3-Fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(4-methyl-3-(((*S)- 3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2, 1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(4-methyl-3- (((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipy rido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(4-methyl-3- (((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipy rido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(4-methyl-3-(((*R)- 3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2, 1-d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(4-methyl-3- (((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipy rido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(4-methyl-3- (((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipy rido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

3-(6-(((*S)-3-Fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H -dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-2-m ethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(3*S)-3-(6-(((S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-2-m ethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(3*R)-3-(6-(((*S)-3-Fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahy dro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2 -yl)-2-methyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid; 3-(6-((8'-Fluoro-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido [2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(8-methyl-3-(trif luoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-((8'-Fluoro-1',1'-dioxidospiro[cyclopropane-1,4'-p yrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-3-(6-((8'-Fluoro-1',1'-dioxidospiro[cyclopropane-1,4'-p yrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-(((*S)-3- fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-(((*R)-3- fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(3*S)-3-(8-Ethyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]p yridin-7-yl)-2-methyl-3-(4- methyl-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

(3*S)-2-Methyl-3-(4-methyl-3-(((*S)-3-methyl-5,5-dioxido-7,7 a,8,9,10,11-hexahydro- 6H-dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)ph enyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(3*S)-3-(8-Ethyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]p yridin-7-yl)-2-methyl-3-(4- methyl-3-(((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

(*S)-3-(8-Ethyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(4-methyl-3- (((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipy rido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid;

(*S)-3-(8-Ethyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(4-methyl-3- (((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipy rido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)propanoic acid; 3-(6-((3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipy rido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-(((*S)-3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-(((*R)-3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*S)-3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*R)-3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((8-fluoro-1,1- dioxido-2',3',5',6'-tetrahydrospiro[benzo[b][1,4,5]oxathiaze pine-4,4'-pyran]-2(3H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((8-fluoro- 1,1-dioxido-2',3',5',6'-tetrahydrospiro[benzo[b][1,4,5]oxath iazepine-4,4'-pyran]-2(3H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((8-fluoro- 1,1-dioxido-2',3',5',6'-tetrahydrospiro[benzo[b][1,4,5]oxath iazepine-4,4'-pyran]-2(3H)- yl)methyl)-4-methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((8'-fluoro-1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiaze pin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((8'-fluoro- 1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxa thiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid; (*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((8'-fluoro- 1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxa thiazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-((8'-Chloro-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido [2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(3-(difluoromethyl)-8-m ethyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8'-Chloro-1',1'-dioxidospiro[cyclopropane-1,4'-p yrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((8'-Chloro-1',1'-dioxidospiro[cyclopropane-1,4'-p yrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((8'-fluoro-1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4 ,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((8'-fluoro- 1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((8'-fluoro- 1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(4-methyl-3-((8'- methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1, 4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(4-methyl-3- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(4-methyl-3- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid; (*S)-3-(4-Methyl-3-((7'-methyl-1',1'-dioxidospiro[cyclopropa ne-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl -3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((*R)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2 ,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- (difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyr ido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- (difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyr ido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- (difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((S)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2, 3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- (difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((S)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyri do[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- (difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((S)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyri do[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- (difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(2*S,3*R)-2-Methyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidosp iro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(2*R,3*R)-2-Methyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidosp iro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido [2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanamide; (*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanamide;

(*R)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanamide;

3-(3-((8'-Carbamoyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyr ido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8'-Carbamoyl-1',1'-dioxidospiro[cyclopropane-1,4 '-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((8'-Carbamoyl-1',1'-dioxidospiro[cyclopropane-1,4 '-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(2S,3*R)-3-(3-(Trifluoromethyl)-8-methyl-[1,2,4]triazolo[4,3 -a]pyridin-7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiaze pin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2-methylpropanoic acid;

(*S)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2 -dimethyl-3-(5-methyl-6- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2 -dimethyl-3-(5-methyl-6- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid; (R/S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]p yridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3- yl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

( *S)-3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(6-methyl-5- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3- yl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-3-(8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]p yridin-7-yl)-3-(6-methyl-5- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)pyridin-3-yl)propanoic acid;

(R/S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]p yridin-7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiaze pin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiaze pin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiaze pin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid; (R/S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4 '-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(R/S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tr iazolo[4,3-a]pyridin-7-yl)-3- (6-methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)-3- (6-methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)-3- (6-methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(R/S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]p yridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospir o[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospir o[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospir o[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-2,2-dimethyl-3-(4- methyl-3-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6-tet rahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)p ropanoic acid; (*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)p ropanoic acid;

3-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((7'-methoxy- 1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((7'- methoxy-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyr ido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((7'- methoxy-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyr ido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

(R/S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tr iazolo[4,3-a]pyridin-7-yl)-3- (6-methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospir o[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propan oic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)-3- (6-methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospir o[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propan oic acid;

(*R)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)-3- (6-methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospir o[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propan oic acid;

(R/S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tr iazolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid; (*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl )ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospir o[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propan oic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl) ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl )ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin] -2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2 -dimethyl-3-(5-methyl-4- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2 -dimethyl-3-(5-methyl-4- ((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrido[2,3-b][ 1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-((7’-(2-(3-fluoroazetidin-1-yl)ethoxy)-8’-meth yl-1’,1’- dioxidospiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathia zepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-2,2-dimethyl-3-(4-methyl-3-((8’-methyl-7’-(2-morpho linoethoxy)-1’,1’- dioxidospiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathia zepin]-2’,(3’H)-yl)methyl)phenyl)-3- (8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine -7-yl)propanoic acid;

(*S)-3-(3-((1’,1’-dioxido-7’-(2-(pyrrolidine-1-yl)etho xy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid; (*S)-3-(3-((7’-(3-amino-3-oxopropyl)-1’,1’-dioxido-2,3 ,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S) 2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7 ’-((1-(piperidin-1- yl)propan-2-yl)oxy)-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyr ido[2,3-b][1,4,5]oxathiazepin]- 2’,(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethy l)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S) 2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7 ’-(((*R)-1-(piperidin-1- yl)propan-2-yl)oxy)-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyr ido[2,3-b][1,4,5]oxathiazepin]- 2’,(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethy l)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S) 2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-7 ’-(((*S)-1-(piperidin-1- yl)propan-2-yl)oxy)-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyr ido[2,3-b][1,4,5]oxathiazepin]- 2’,(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethy l)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-diox ido-7’-(((*R)-1-(piperidin-1- yl)propan-2-yl)amino)-2,3,5,6-tetrahydrospiro[pyran-4,4’-p yrido[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl )-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(2-(Azetidin-1-yl)ethoxy)-8’-methyl-1’, 1’-dioxidospiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(3-Cyclobutylamino-3-oxopropyl)-1’,1’-d ioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(2-Hydroxyethoxy)-1’,1’-dioxido-2,3,5,6 -tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid; (*S)-3-(3-((7'-(3-(3-Hydroxypropoxy)propoxy)-1',1'-dioxido-2 ,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin] -2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-((7'-(3-(3-Hydroxypropoxy)propoxy)-1',1'-dioxido-2 ,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin] -2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-7' -(2-(pyrrolidin-1- yl)ethoxy)-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][ 1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(6-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin- 2-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(6-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin- 2-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(5-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-6-methylpyridin- 3-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(5-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-6-methylpyridin- 3-yl)-2,2-dimethylpropanoic acid;

(*S)-2,2-dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-diox idospiro[oxetane-3,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-me thyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((1’,1’-dioxidospiro[oxetane-3,4’-pyrido[2,3 -b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifl uoromethyl)-[1,2,4]triazolo[4,3- a]pyridine-7-yl)propanoic acid; (*S)-3-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridine-7-yl)-3-(3-((1’,1’- dioxidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]oxathiazepin ]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxidospiro[oxetane-3,4'-pyri do[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxido-7'-(((S)-1-(piperidin-1-y l)propan-2- yl)amino)spiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathia zepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[oxetane-3,4'-pyrido[ 2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((1',1'- dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[oxetane-3,4'-pyrido[ 2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-2,2-dimethyl-3-(6- methyl-5-((8’-methyl-1’,1’-dioxidospiro[oxetane-3,4’ -pyrido[2,3-b][1,4,5]]oxathiazepin]- 2’(3’H)-yl)methyl)pyridine-3-yl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-2,2-dimethyl-3-(6- methyl-5-((8’-methyl-1’,1’-dioxidospiro[oxetane-3,4’ -pyrido[2,3-b][1,4,5]]oxathiazepin]- 2’(3’H)-yl)methyl)pyridine-3-yl)propanoic acid; (*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-2,2-dimethyl-3-(6- methyl-5-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin e-1-yl)ethoxy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]]oxathiazepin]-2’(3’H)-yl)methyl)pyr idine-3-yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[oxetane-3,4'-pyri do[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[oxetane-3,4'-pyri do[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-2,2-dimethyl-3-(6- methyl-5-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin e-1-yl)ethoxy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]]oxathiazepin]-2’(3’H)-yl)methyl)pyr idine-3-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-py rido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-py rido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-py rido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-py rido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl )ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl )ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid (*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl )ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl )ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl) ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl) ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl )ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin] -2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl )ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin] -2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl) ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin] -2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl) ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin] -2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl )ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin] -2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl )ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin] -2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrid o[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrid o[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-((1',1'- dioxidospiro[piperidine-4,4'-pyrido[2,3-b][1,4,5]oxathiazepi n]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-((1',1'- dioxidospiro[piperidine-4,4'-pyrido[2,3-b][1,4,5]oxathiazepi n]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[piperidine-4,4'-pyri do[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[piperidine-4,4'-pyri do[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[azetidine-3,4'-pyrid o[2,3-b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-((1',1'- dioxidospiro[piperidine-4,4'-pyrido[2,3-b][1,4,5]oxathiazepi n]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid; (R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[piperidine-4,4'-pyri do[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(5-(((*R)-3-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-6-methylpyridin-3-yl)-2,2 -dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-3-(5-(((*S)-3-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-6-methylpyridin-3-yl)-2,2 -dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(5-(((*R)-3-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-6-methylpyridin-3-yl)-2,2 -dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(5-(((*S)-3-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-6-methylpyridin-3-yl)-2,2 -dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-2,2-dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-7' -(2-(pyrrolidin-1- yl)ethoxy)spiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathi azepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridi n-7-yl)propanoic acid

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxido-7'-(((S)-1-(piperidin-1-y l)propan-2- yl)amino)spiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathia zepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxido-7'-(((S)-1-(piperidin-1-y l)propan-2- yl)amino)spiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathia zepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-((7’-(2-(4-fluoropiperidin-1-yl)ethoxy)-8’-met hyl-1’,1’- dioxidospiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathia zepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid; (*S)-3-(3-((7’-(2-(4-fluoropiperidin-1-yl)ethoxy)-8’-met hyl-1’,1’- dioxidospiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathia zepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)et hoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)p ropanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)et hoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)p ropanoic acid;

(*R)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2 -dimethyl-3-(5-methyl-4- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)pyridin-2-yl)propanoic acid; and

pharmaceutically acceptable salts, and combinations thereof.

DETAILED DESCRIPTION OF THE INVENTION

As used herein, the terms "including", "containing" and“comprising” are used in their open, non-limiting sense.

Unless qualified specifically in particular instances of use, the term“alkyl” refers to a straight- or branched-chain alkyl group having from 1 to 8 carbon atoms in the chain. Examples of alkyl groups include methyl (Me), ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples.“C 1 -C 4 alkyl” refers to straight- or branched-chain alkyl group having from 1 to 4 carbon atoms in the chain.

The term“cycloalkyl” refers to a saturated or partially saturated, monocyclic, fused polycyclic, or spiro polycyclic carbocycle having from 3 to 12 ring atoms per carbocycle.

Illustrative examples of cycloalkyl groups include the following entities, in the form of properly bonded moieties:

The term“halogen” or“halo” represents chlorine, fluorine, bromine, or iodine.

The term“perhaloalkyl” or“haloalkyl” refers to a straight- or branched-chain alkyl group having from 1 to 6 carbon atoms in the chain optionally substituting hydrogens with halogens. The term“C1-C4 haloalkyl” as used here refers to a straight- or branched-chain alkyl group having from 1 to 4 carbon atoms in the chain, optionally substituting hydrogens with halogens. Examples of“perhaloalkyl”,“haloalkyl” groups include trifluoromethyl (CF 3 ), difluoromethyl (CF2H), monofluoromethyl (CH2F), pentafluoroethyl (CF2CF3), tetrafluoroethyl (CHFCF3), monofluoroethyl (CH2CH2F), trifluoroethyl (CH2CF3), tetrafluorotrifluoromethylethyl

(CF(CF 3 ) 2 ), and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples.

Those of ordinary skill in the art will recognize that the species of cycloalkyl groups listed or illustrated above are not exhaustive, and that additional species within the scope of these defined terms may also be selected. The term“substituted” means that the specified group or moiety bears one or more substituents. The term "unsubstituted" means that the specified group bears no substituents. The term“optionally substituted” means that the specified group is unsubstituted or substituted by one or more substituents. Where the term“substituted” is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system.

Any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms. In particular, compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers and stereoisomers of the compounds of the general formula, and mixtures thereof, are considered within the scope of such formula. The compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof. Thus, any formula given herein is intended to represent a racemate, one or more of its enantiomeric forms, one or more of its diastereomeric forms, and mixtures thereof. Additionally, any formula given herein is intended to refer also to any one of hydrates, solvates, polymorphs and of such compounds, and mixtures thereof, even if such forms are not listed explicitly.

Reference to a compound herein stands for a reference to any one of: (a) the actually recited form of such compound, and (b) any of the forms of such compound in the medium in which the compound is being considered when named. For example, reference herein to a compound such as R-COOH, encompasses reference to any one of, for example, R-COOH(s), R- COOH(sol), and R-COO-(sol). In this example, R-COOH(s) refers to the solid compound, as it could be for example in a tablet or some other solid pharmaceutical composition or preparation; R-COOH(sol) refers to the undissociated form of the compound in a solvent; and R-COO-(sol) refers to the dissociated form of the compound in a solvent, such as the dissociated form of the compound in an aqueous environment, whether such dissociated form derives from R-COOH, from a salt thereof, or from any other entity that yields R-COO- upon dissociation in the medium being considered. In another example, an expression such as“exposing an entity to compound of formula R-COOH” refers to the exposure of such entity to the form, or forms, of the compound R-COOH that exists, or exist, in the medium in which such exposure takes place. In still another example, an expression such as“reacting an entity with a compound of formula R-COOH” refers to the reacting of (a) such entity in the chemically relevant form, or forms, of such entity that exists, or exist, in the medium in which such reacting takes place, with (b) the chemically relevant form, or forms, of the compound R-COOH that exists, or exist, in the medium in which such reacting takes place. In this regard, if such entity is for example in an aqueous environment, it is understood that the compound R-COOH is in such same medium, and therefore the entity is being exposed to species such as R-COOH(aq) and/or R-COO-(aq), where the subscript“(aq)” stands for“aqueous” according to its conventional meaning in chemistry and biochemistry. A carboxylic acid functional group has been chosen in these nomenclature examples; this choice is not intended, however, as a limitation but it is merely an illustration. It is understood that analogous examples can be provided in terms of other functional groups, including but not limited to hydroxyl, basic nitrogen members, such as those in amines, and any other group that interacts or transforms according to known manners in the medium that contains the compound. Such interactions and transformations include, but are not limited to, dissociation, association, tautomerism, solvolysis, including hydrolysis, solvation, including hydration, protonation, and deprotonation. No further examples in this regard are provided herein because these interactions and transformations in a given medium are known by any one of ordinary skill in the art.

Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number in an enriched form. Examples of isotopes that can be incorporated into compounds of the invention in a form that exceeds natural abundances include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F, 36 Cl, and 125 I, respectively. Such isotopically labelled compounds are useful in metabolic studies (preferably with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography

(SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 18 F or 11 C labeled compound may be particularly preferred for PET or SPECT studies. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. Isotopically labeled compounds of this invention can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

The term Cn-m alkyl refers to an aliphatic chain, whether straight or branched, with a total number N of carbon members in the chain that satisfies n £ N £ m, with m > n.

When the same plurality of substituents is assigned to various groups, the specific individual substituent assignment to each of such groups is meant to be independently made with respect to the specific individual substituent assignments to the remaining groups. By way of illustration, but not as a limitation, if each of groups Q and R can be H or F, the choice of H or F for Q is made independently of the choice of H or F for R, so the choice of assignment for Q does not determine or condition the choice of assignment for R, or vice-versa, unless it is expressly indicated otherwise. Illustrative claim recitation in this regard would read as“each of Q and R is independently H or F”, or“each of Q and R is independently selected from the group consisting of H and F”.

Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art.

In another example, a zwitterionic compound would be encompassed herein by referring to a compound that is known to form a zwitterion, even if it is not explicitly named in its zwitterionic form. Terms such as zwitterion, zwitterions, and their synonyms zwitterionic compound(s) are standard IUPAC-endorsed names that are well known and part of standard sets of defined scientific names. In this regard, the name zwitterion is assigned the name

identification CHEBI:27369 by the Chemical Entities of Biological Interest (ChEBI) dictionary of molecular entities. As generally well known, a zwitterion or zwitterionic compound is a neutral compound that has formal unit charges of opposite sign. Sometimes these compounds are referred to by the term“inner salts”. Other sources refer to these compounds as“dipolar ions”, although the latter term is regarded by still other sources as a misnomer. As a specific example, aminoethanoic acid (the amino acid glycine) has the formula H 2 NCH 2 COOH, and it exists in some media (in this case in neutral media) in the form of the zwitterion + H3NCH2COO-.

Zwitterions, zwitterionic compounds, inner salts and dipolar ions in the known and well- established meanings of these terms are within the scope of this invention, as would in any case be so appreciated by those of ordinary skill in the art. Because there is no need to name each and every embodiment that would be recognized by those of ordinary skill in the art, no structures of the zwitterionic compounds that are associated with the compounds of this invention are given explicitly herein. They are, however, part of the embodiments of this invention. No further examples in this regard are provided herein because the interactions and transformations in a given medium that lead to the various forms of a given compound are known by any one of ordinary skill in the art.

When referring to any formula given herein, the selection of a particular moiety from a list of possible species for a specified variable is not intended to define the same choice of the species for the variable appearing elsewhere. In other words, where a variable appears more than once, the choice of the species from a specified list is independent of the choice of the species for the same variable elsewhere in the formula, unless stated otherwise.

By way of a first example on substituent terminology, if substituent S 1

e xample is one of S 1 and S 2 , and substituent S 2

e xample is one of S 3 and S 4 , then these assignments refer to embodiments of this invention given according to the choices S 1

example is S1 and S 2

example is S3; S 1

example is S1 and S 2

e xample is S 4 ; S 1

e xample is S 2 and S 2

e xample is S 3 ; S 1

e xample is S 2 and S 2

e xample is S 4 ; and equivalents of each one of such choices. The shorter terminology“S 1

e xample is one of S 1 and S 2 , and S 2

e xample is one of S3 and S4” is accordingly used herein for the sake of brevity, but not by way of limitation. The foregoing first example on substituent terminology, which is stated in generic terms, is meant to illustrate the various substituent assignments described herein.

Furthermore, when more than one assignment is given for any member or substituent, embodiments of this invention comprise the various groupings that can be made from the listed assignments, taken independently, and equivalents thereof. By way of a second example on substituent terminology, if it is herein described that substituent Sexample is one of S1, S2, and S3, this listing refers to embodiments of this invention for which Sexample is S1; Sexample is S2; Sexample is S 3 ; S example is one of S 1 and S 2 ; S example is one of S 1 and S 3 ; S example is one of S 2 and S 3 ; S example is one of S 1 , S 2 and S 3 ; and S example is any equivalent of each one of these choices. The shorter terminology“Sexample is one of S1, S2, and S3” is accordingly used herein for the sake of brevity, but not by way of limitation. The foregoing second example on substituent terminology, which is stated in generic terms, is meant to illustrate the various substituent assignments described herein.

The nomenclature“Ci-Cj” with j > i, when applied herein to a class of substituents, is meant to refer to embodiments of this invention for which each and every one of the number of carbon members, from i to j including i and j, is independently realized. By way of example, the term C1-C3 refers independently to embodiments that have one carbon member (C1),

embodiments that have two carbon members (C 2 ), and embodiments that have three carbon members (C 3 ).

A "pharmaceutically acceptable salt” is intended to mean a salt of an acid or base of a compound represented by Formula (I) that is non-toxic, biologically tolerable, or otherwise biologically suitable for administration to the subject. See, generally, S.M. Berge, et al., “Pharmaceutical Salts”, J. Pharm. Sci., 1977, 66:1-19, and Handbook of Pharmaceutical Salts, Properties, Selection, and Use, Stahl and Wermuth, Eds., Wiley-VCH and VHCA, Zurich, 2002. Preferred pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response.

A compound of Formula (I) may possess a sufficiently acidic group, a sufficiently basic group, or both types of functional groups, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.

Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates,

metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6- dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, g-hydroxybutyrates, glycolates, tartrates, methane-sulfonates, propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, and mandelates. Compounds of Formula (I) may contain at least one nitrogen of basic character, so desired pharmaceutically acceptable salts may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such as mandelic acid, citric acid, or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid, 2-acetoxybenzoic acid, naphthoic acid, or cinnamic acid, a sulfonic acid, such as laurylsulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, any compatible mixture of acids such as those given as examples herein, and any other acid and mixture thereof that are regarded as equivalents.

Since compounds of Formula (I) contain a carboxylic acid moiety, a desired

pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases such as those given as examples herein, and any other base and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology. Illustrative examples of suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonia, carbonates, bicarbonates, primary, secondary, and tertiary amines, and cyclic amines, such as benzylamines, pyrrolidines, piperidine, morpholine, piperazine, N-methyl-glucamine and tromethamine and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.

The compounds of the invention, including their pharmaceutically acceptable salts, whether alone or in combination, (collectively,“active agent” or "active agents") of the present invention are useful as KEAP1-Nrf2 inhibitors in the methods of the invention. Such methods for modulating KEAP1-Nrf2 interaction comprise the use of an effective amount of at least one chemical compound of the invention. In some embodiments, the KEAP1-Nrf2 inhibitor is used in a subject diagnosed with or suffering from a disease, disorder, or medical condition associated with KEAP1-Nrf2 interaction, such as those described herein. Symptoms or disease states are intended to be included within the scope of "disease, disorders or medical conditions."

Accordingly, the invention relates to methods of using the active agents described herein to treat subjects diagnosed with or suffering from a disease, disorder, or medical condition associated with the KEAP1-Nrf2 interaction. The term "treat" or "treating" as used herein is intended to refer to administration of an active agent or composition of the invention to a subject for the purpose of effecting a therapeutic or prophylactic benefit through modulation of KEAP1- Nrf2 interaction. Treating includes reversing, ameliorating, alleviating, inhibiting the progress of, lessening the severity of, or preventing a disease, disorder, or condition, or one or more symptoms of such disease, disorder or condition associated with the KEAP1-Nrf2 interaction. The term "subject" refers to a mammalian patient in need of such treatment, such as a human. The term "inhibitors” or“inhibitor” refers to compounds that decrease, prevent, inactivate, desensitize or down-regulate the KEAP1-Nrf2 interaction.

In treatment methods according to the invention, an effective amount of at least one active agent according to the invention is administered to a subject suffering from or diagnosed as having such a disease, disorder, or medical condition. An "effective amount" means an amount or dose sufficient to generally bring about the desired therapeutic or prophylactic benefit in patients in need of such treatment for the designated disease, disorder, or condition. Effective amounts or doses of the active agents of the present invention may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician. For a 70-kg human, an illustrative range for a suitable dosage amount is from about 1 to 1000 mg/day in single or multiple dosage units (e.g., BID, TID, QID or as required by modality).

Once improvement of the patient's disease, disorder, or condition has occurred, the dose may be adjusted for preventive or maintenance treatment. For example, the dosage or the frequency of administration, or both, may be reduced as a function of the symptoms, to a level at which the desired therapeutic or prophylactic effect is maintained. Of course, if symptoms have been alleviated to an appropriate level, treatment may cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of symptoms.

In addition, the compounds of the invention are envisaged for use alone, in combination with one or more of other compounds of this invention, or in combination with additional active ingredients in the treatment of the conditions discussed below. The additional active ingredients may be co-administered separately with at least one compound of the invention, with active agents of the invention or included with such an agent in a pharmaceutical composition according to the invention. In an illustrative embodiment, additional active ingredients are those that are known or discovered to be effective in the treatment of conditions, disorders, or diseases associated with the KEAP1-Nrf2 interaction, such as another KEAP1-Nrf2 inhibitor or a compound active against another target associated with the particular condition, disorder, or disease. The combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of an agent according to the invention), decrease one or more side effects, or decrease the required dose of the active agent according to the invention.

When referring to inhibiting the target, an“effective amount” means an amount sufficient to affect KEAP1-Nrf2 interaction.

The active agents of the invention are envisaged for use, alone or in combination with one or more additional active ingredients, to formulate pharmaceutical compositions of the invention. A pharmaceutical composition of the invention comprises an effective amount of at least one active agent in accordance with the invention.

Pharmaceutically acceptable excipients commonly used in pharmaceutical compositions are substances that are non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith. Examples of such excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols. Delivery forms of the pharmaceutical compositions containing one or more dosage units of the active agents may be prepared using pharmaceutically acceptable excipients and compounding techniques known or that become available to those of ordinary skill in the art. The compositions may be administered in the inventive methods by a suitable route of delivery, e.g., oral, parenteral, rectal, topical, or ocular routes, or by inhalation.

The preparation may be in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, powders for reconstitution, liquid preparations, or suppositories. The compositions may be formulated for any one of a plurality of administration routes, such as intravenous infusion, topical administration, or oral administration. Preferably, the compositions may be formulated for oral administration.

For oral administration, the active agents of the invention can be provided in the form of tablets or capsules, or as a solution, emulsion, or suspension. To prepare the oral compositions, the active agents may be formulated to yield a dosage of, e.g., for a 70-kg human, an illustrative range for a suitable dosage amount is from about 1 to 1000 mg/day in single or multiple dosage units.

Oral tablets may include the active ingredient(s) mixed with compatible pharmaceutically acceptable excipients such as diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents. Suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like.

Illustrative examples of liquid oral excipients include ethanol, glycerol, water, and the like. Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are examples of disintegrating agents. Binding agents may include starch and gelatin. The lubricating agent, if present, may be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.

Capsules for oral administration include hard and soft gelatin or (hydroxypropyl)methyl cellulose capsules. To prepare hard gelatin capsules, active ingredient(s) may be mixed with a solid, semi-solid, or liquid diluent. Liquids for oral administration may be in the form of suspensions, solutions, emulsions or syrups or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose,

carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.

The active agents of this invention may also be administered by non-oral routes. For example, compositions may be formulated for rectal administration as a suppository, enema or foam. For parenteral use, including intravenous, intramuscular, intraperitoneal, or subcutaneous routes, the agents of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Such forms may be presented in unit-dose form such as ampules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation. Illustrative infusion doses range from about 1 to 1000 mg/kg/minute of agent admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.

For topical administration, the agents may be mixed with a pharmaceutical carrier at a concentration of about 0.01% to about 20% of drug to vehicle, preferably 0.1% to 10%. Another mode of administering the agents of the invention may utilize a patch formulation to affect transdermal delivery.

Active agents may alternatively be administered in methods of this invention by inhalation, via the nasal or oral routes, e.g., in a spray formulation also containing a suitable carrier.

In a further embodiment, the invention is directed to a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition associated with KEAP1-Nrf2 interaction, comprising administering to the subject in need of such treatment an effective amount of the active agent. In certain embodiments of the inventive method, the disease, disorder, or medical condition is an inflammatory bowel disease, such as Crohn’s disease and ulcerative colitis.

Other embodiments of this invention provide for a method for modulating KEAP1-Nrf2 interaction, including when KEAP1-Nrf2 interaction is in a subject, comprising exposing KEAP1-Nrf2 to an effective amount of at least one compound selected from compounds of the invention.

Embodiments of this invention are compounds of Formula (I), and pharmaceutically acceptable salts thereof

,

wherein

X is CH or N;

Q is CH or N;

M is CH or N;

wherein

when X is N, each of Q and M is CH;

when Q is N, each of X and M is CH; and

when M is N, each of X and Q are CH;

R 15 is CH 3 or Cl;

R 13 is H, F or C 1 -C 4 alkyl;

R 14 is H, F or C1-C4alkyl;

HetA is selected from the group consisting of

wherein

R 1 is selected from the group consisting of C3-C4cycloalkyl, C1-C4alkyl and C1-C4alkyl monosubstituted with cyclopropyl or cyclobutyl;

R 2 is selected from the group consisting of H, C1-C4alkyl and C1-C4perhaloalkyl;

R 3 is H or C1-C4alkyl;

R 4 is selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 4 perhaloalkyl and

C 3 -C 4 cycloalkyl;

R 7 is H or C1-C4alkyl;

R 8 is C 1 -C 4 alkyl;

R 9 is C 1 -C 4 alkyl;

R 10 is selected from the group consisting of H, -OC3-C4cycloalkyl and

-OC1-C4perhaloalkyl;

HetB is selected from the group consisting of

,

wherein

Z is selected from the group consisting of O, CH 2 , NH and N(CH 3 );

T is CH or N;

Y is CH or N;

W is CH or N;

V is O or N(CH3);

R 16 is H or F; R 17 is H or F;

n is 0, 1 or 2;

R 18 is selected from the group consisting of H, -CN, halo, C(O)NH 2 , C 1 -C 4 alkyl and C 1 - C4perhaloalkyl;

R 19 is selected from the group consisting of H; CN; halo; C(O)NH2;

N(R 38 )C 1 -C 6 alkyl; C 1 -C 4 alkyl; C 1 -C 4 perhaloalkyl;

O C1-C6alkyl;

OC 1 -C 6 alkyl substituted with one or two substituents selected from the group consisting of -OH, -OCH 3 , -O(CH 2 ) 3 OH, -N(R 36 )R 37 , C 1 -C 4 alkyl, ,

and

-N(R 38 )C 1 -C 6 alkyl substituted with one or two substituents selected from the group consisting of OH, -OCH 3 , -N(R 36 )R 37 , C 1 -C 4 alkyl , ,

C1-C4alkyl monosubstituted with a substituent selected from the group consisting of -C(O)NHCH 2 CH 2 OH, -C(O)NHCH 2 CH 2 OCH 2 CH 2 NH 2 , C(O)NH 2 and OH; R 20 is H or C1-C4alkyl;

R 21 is selected from the group consisting of H, -CN, halo, C1-C4alkyl and C1- C 4 perhaloalkyl;

R 22 and R 23 are taken together with the carbon to which they are attached to form

(a) the moiety wherein R is selected from the group consisting of CH2, NR 38 and O, m is 0 or 1, and p is 0 or 1; or (b) the moiety

R 22’ is selected from the group consisting of H, C1-C4alkyl and C3-C4cycloalkyl, and R 23’ is selected from the group consisting of H, C1-C4alkyl and C3-C4cycloalkyl;

R 24 is selected from the group consisting of H; CN; halo; C(O)NH 2 ;

C(O)(NH)C 3 -C 4 cycloalkyl; N(R 38 )C 1 -C 6 alkyl; C 1 -C 4 alkyl; C 1 -C 4 perhaloalkyl;

O C1-C6alkyl;

OC 1 -C 6 alkyl substituted with one or two substituents selected from the group consisting of -OH, -OCH 6

3, -O(CH 2 ) 3 OH, -N(R 3 )R 37 , C 1 -C 4 alkyl; and

-N(R 38 )C1-C6alkyl substituted with one or two substituents selected from the group consisting of OH, -OCH 36

3, -N(R )R 37 , C 1 -C 4 alkyl,

and and

C 1 -C 4 alkyl monosubstituted with a substituent selected from the group consisting of -C(O)NHCH 2 CH 2 OH, -C(O)NHCH 2 CH 2 OCH 2 CH 2 NH 2 , C(O)NH 2 and OH; R 25 is selected from the group consisting of H; CN; halo; C(O)NH2;

N(R 38 )C 1 -C 6 alkyl; C 1 -C 4 alkyl; C 1 -C 4 perhaloalkyl;

O C1-C6alkyl;

OC 1 -C 6 alkyl substituted with one or two substituents selected from the group consisting of -OH, -OCH 3 , -O(CH 2 ) 3 OH, -N(R 36 )R 37 , C 1 -C 4 alkyl, a nd

-N(R 38 )C 1 -C 6 alkyl substituted with one or two substituents selected from the group consisting of OH, -OCH 3 , -N(R 36 )R 37 , C 1 -C 4 alkyl,

C 1 -C 4 alkyl monosubstituted with a substituent selected from the group consisting of -C(O)NHCH 2 CH 2 OH, -C(O)NHCH 2 CH 2 OCH 2 CH 2 NH 2 , C(O)NH 2 and OH; R 26 is selected from the group consisting of H, -CN, halo, C1-C4alkyl and C1- C4perhaloalkyl;

R 27 is H or C 1 -C 4 alkyl;

R 36 and R 37 are independently selected from the group consisting of H and C1-C4alkyl; R 38 is H or C1-C4alkyl;

provided that when HetA is then HetB is not

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

R 1 is C1-C4alkyl, R 10 is H and R 2 is C1-C4alkyl.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

R 1 is C1-C4alkyl, R 10 is H and R 2 is CH3.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

1 0

, R 1 is C 1 -C 2 alkyl, R 10 is H and R 2 is CH 3 .

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

R 1 is CH2CH3, R 10 is H and R 2 is CH3.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

R 1 is CH3, R 10 is H and R 2 is CH3.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

and R 4 is C 1 -C 4 alkyl or C 1 -C 4 perhaloalkyl.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

R 7

and R 4 is C 1 -C 4 perhaloalkyl.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

a nd R 4 is C 1 -C 2 perhaloalkyl.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

R 7

and R 4 is CF 3 .

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

, R 4 is C 7

1-C 4 perhaloalkyl, R 3 is C 1 -C 4 alkyl and R is H.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

R 4 is C 1 -C 2 perhaloalkyl, R 3 is C 1 -C 4 alkyl and R 7 is H.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

R 4 is C 1 -C 2 perhaloalkyl, R 3 is C 1 -C 2 alkyl and R 7 is H.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

R 4 is C 1 -C 2 perhaloalkyl, R 3 is CH 3 and R 7 is H.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

, R 4 is CF R 3 is CH 7

3, 3 and R is H.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein X is N.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein X is CH.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein Q is N.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein Q is CH.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein M is N.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein M is CH.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein R 15 is CH3.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein R 15 is Cl.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein R 13 is CH3.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein R 13 is CH 3 and R 14 is H.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein R 13 is CH 3 and R 14 is CH 3 .

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein R 13 is H and R 14 is H.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

R 4 is CF3, R 3 is CH3, R 7 is H and X is N. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

R 4 is CF 3 , R 3 is CH 3 , R 7 is H, X is N and R 15 is CH 3 .

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

R 4 is CF 14 3, R 3 is CH 3 , R 7 is H, X is N, R 15 is CH 13

3 , R is H and R is H.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

R 4 is CF 3

3, R is CH 3 , R 7 is H, X is N, R 15 is CH 3, R 13 is CH 4

3 and R 1 is

CH3.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

R 4 is CF3, R 3 is CH 7

3, R is H and X is CH.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

R 4 is CF3, R 3 is CH3, R 7 is H, X is CH, and R 15 is Cl.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

R 1 is CH2CH3, R 10 is H, R 2 is CH3 and X is N.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

R 1 is CH2CH 10

3, R is H, R 2 is CH 15

3, X is N, R is CH3., R 13 is H and R 14 is H.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

1 0

R 1 is CH 0

2CH3, R 1 is H, R 2 is CH3, X is N and R 15 is Cl.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is

R 1 is CH2CH3, R 10 is H, R 2 is CH 15

3, X is CH, R is CH 13

3, R is H and R 14

is H.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is R 1 is CH 10

2CH 3 , R is H, R 2 is CH 3 , X is CH and R 15 is Cl.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetB is selected from the group consisting of

.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetB is selected from the group consisting of

.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetB is

.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetB is .

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetB is

.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetB is

. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetB is

R 22 and R 23 are taken together with the carbon to which they are attached to

form the moiety wherein R is CH 2 or O, m is 0 or 1, and p is 0 or 1.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetB is , R 22 and R 23 are taken together with the carbon to which they are attached to

form the moiety wherein R is O, m is 0 or 1, and p is 0 or 1.

An additional illustrative embodiment of the invention is a compound of Formula (I), HetB is

R 22 and R 23 are taken together with the carbon to which they are attached to

form the moiety wherein R is O, m is 1, and p is 1.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetB is

, R 22 and R 23 are taken together with the carbon to which they are attached to

form the moiety wherein R is O, m is 1, p is 1, R 13 is C 4

1-C4alkyl, and R 1 is C1-

C4alkyl.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetB is R 22 and R 23 are taken together with the carbon to which they are attached to

form the moiety wherein R is O, m is 1, p is 1, R 13 is CH 3 , and R 14 is CH 3 .

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein

HetA i , HetB is ,R 4 is CF3, R 3 is CH3, R 7 is H, X is CH, R 15 is CH 3 , R 22 and R 23 are taken together with the carbon to which they are attached to form the

moiety wherein R is O, m is 1, p is 1, R 13 is CH3, and R 14 is CH3

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein

HetA is HetB is ,R 4 is CHF2, R 3 is CH3, R 7 is H, X is CH, Q is CH, M is CH, W is N, R 24 is H, R 21 is H, R 15 is CH3, R 22 and R 23 are taken together with the

carbon to which they are attached to form the moiety wherein R is O, m is 1, p is 1,

R 13 is CH 3 , and R 14 is CH 3.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein HetA is HetB is R 4 is CF3, R 3 is CH3, R 7 is H, X is CH,

R 15 is CH 3 , R 22 and R 23 are taken together with the carbon to which they are attached to form the

moiety wherein R is O, m is 1, p is 1, R 13 is CH 3 , R 14 is CH 3 and R 24 is OC 2 -C 4 alkyl or OC 2 -C 4 alkyl is substituted with

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein

HetA is HetB is R 4 is cyclopropyl, R 3 is CH 7

3, R is H, X is CH, Q is CH, M is CH, R 15 is CH3, R 22 and R 23 are taken together with the carbon to which they

are attached to form the moiety wherein R is O, m is 1, p is 1, R 13 is CH 3 , and R 14 is

CH 3.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein

HetA is HetB is R 1 is CH2CH3, R 2 is CH3, R 10 is H, X is CH, Q is CH, M is N, R 15 is CH 3 , R 22 and R 23 are taken together with the carbon to which they are

attached to form the moiety wherein R is O, m is 1, p is 1, R 13 is CH 3 , and R 14 is CH 3.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein

HetA is HetB is , R 1 is cyclopropyl, R 2 is CH 3 , R 10 is H, X is CH, Q is CH, M is N, R 15 is CH3, R 22 and R 23 are taken together with the carbon to which they

are attached to form the moiety wherein R is O, m is 1, p is 1, R 13 is CH 14

3, and R is

CH 3.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein R 1 is C1-C4alkyl that is substituted with one of cyclopropyl and cyclobutyl. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein R 18 is OC1-C4alkyl substituted with one of -OH, -N(R 36 )R 37 and

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein R 18 is NHC 1 -C 4 alkyl substituted with one of OH and CH 3 .

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein R 18 is C1-C4alkyl is substituted with one of C(O)NHCH2CH2OH and OH. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein R 24 is OC1-C4alkyl substituted with one of -OH, -N(R 36 )R 37 and .

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein R 24 is NHC 1 -C 4 alkyl substituted with one of OH and CH 3 .

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein R 24 is C1-C4alkyl is substituted with one of C(O)NHCH2CH2OH and OH.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein R 25 is OC 1 -C 4 alkyl substituted with one of -OH, -N(R 36 )R 37 and .

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein R 25 is NHC 1 -C 4 alkyl substituted with one of OH and CH 3 .

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein R 25 is C1-C4alkyl is substituted with one of C(O)NHCH2CH2OH and OH. Additional illustrative embodiments of the invention are compounds of Formula (I) selected from the group consisting of

3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triaz ol-5-yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triaz ol-5-yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3 -(3-(((R)-5,5-dioxido- 7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadi azepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid (*S)-3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-((1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluorom ethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluorom ethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol- 5-yl)-3-(4-methyl-3- (((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(4-methyl-3- (((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(4-methyl-3- (((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyri do[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-be nzo[d][1,2,3]triazol-5-yl)-2,2- dimethylpropanoic acid; (*S)-3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(R)-3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'- pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6 -tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2, 3,5,6-tetrahydrospiro[pyran- 4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phe nyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6 -tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3- (3-(((*R)-5,5-dioxido- 7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5 ]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-(((*R)-5,5-dioxido- 7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1,2,5 ]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid; (*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-(((*R)-5,5- dioxido-7a,8,10,11-tetrahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(3-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4, 3'-oxetan]-2(3H)- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(4-Methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropa ne-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl -3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-((3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyr ido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(dif luoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(dif luoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(dif luoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid ;

(*S)-3-(3-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(dif luoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(dif luoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(6-((3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyr ido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-3-(6-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(6-(((*S)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(R/S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridi n-7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid; (*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’, 1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

(*S) 2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’, 1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)- 1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tet rahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl-2,2’-dimethyl-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

(*S) 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tet rahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl-2,2’-dimethyl-3-(8- methy-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl )propanoic acid;

(*R) 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tet rahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl-2,2’-dimethyl-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

(R/S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]p yridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4 ,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4 ,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4 ,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid; (R/S)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4 '-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(R/S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4 '-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3- yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3- yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3- yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(R/S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2, 2-dimethyl-3-(6-methyl-5- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2 -dimethyl-3-(6-methyl-5- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2 -dimethyl-3-(6-methyl-5- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropa ne-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl -3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; 3-(1-(Cyclopropylmethyl)-4-(difluoromethyl-1H-benzo[d][1,2,3 ]triazol-5-yl)-3-(3-((R- 5,5-dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][ 1,2,5]thiadiazepin-6(7H)-yl)methyl)- 4-methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl-1H-benzo[d][ 1,2,3]triazol-5-yl)-3-(3- ((R-5,5-dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1 -d][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol- 5-yl)-3-(3-((1’,1’- dioxidospiro[oxetane-3,3’-pyrido[2,3-b][1,4,5]oxathiazepin ]-2’(3’H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl-1H-benzo[d][ 1,2,3]triazol-5-yl)-3-(3- ((R-5,5-dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1 -d][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-((1’,1’- dioxidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]oxathiazepin -2’(3’H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-((1’,1’- dioxidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]oxathiazepin -2’(3’H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(4-(Difluoromethyl-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl )-3-(3-(((R-5,5-dioxido- 7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2,5]thiadi azepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(4-(Difluoromethyl-1-methyl-1H-benzo[d][1,2,3]triazol -5-yl)-3-(3-(((R-5,5- dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R) 3-(4-(Difluoromethyl-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl )-3-(3-(((R-5,5- dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol- 5-yl)-3-(3-((1’,1’- dioxidospiro[benzo[b][1,4,5]oxathiazepin-4,3’-oxetan]-2,(3 H)-yl)methyl)-4- methylphenyl)propanoic acid; 3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol- 5-yl)-3-(4-methyl-3-((5’- methyl-1’,1’-dioxido-5’H-spiro[cyclopropane-1,4’-pyr ido[2,3-f][1,2,5]thiadiazepin]-2’(3’H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-((1’,1’- dioxidospiro[benzo[b][1,4,5]oxathiazepin-4,3’-oxetan]-2,(3 H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-((1’,1’- dioxidospiro[benzo[b][1,4,5]oxathiazepin-4,3’-oxetan]-2,(3 H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(4-methyl-3- ((5’-methyl-1’,1’-dioxido-5’H-spiro[cyclopropane-1,4 ’-pyrido[2,3-f][1,2,5]thiadiazepin]- 2’(3’H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(4-methyl-3- ((5’-methyl-1’,1’-dioxido-5’H-spiro[cyclopropane-1,4 ’-pyrido[2,3-f][1,2,5]thiadiazepin]- 2’(3’H)-yl)methyl)phenyl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol- 5-yl)-3-(4-methyl-3- (((*R)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(4-methyl-3- (((*R)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(4-methyl-3- (((*R)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

3-(4-Chloro-3-(((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H -dipyrido[2,1-d:2’,3’- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(tri fluoromethyl)-[1,2,4]triazolo[4,3- a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-(((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-m ethyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid; (*R)-3-(4-Chloro-3-(((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-m ethyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(4-Chloro-3-((1’,1’-dioxoidospiro[oxetane-3,4’-pyrid o[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl )-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(4-Chloro-3-((1’,1’-dioxoidospiro[oxetane-3,4’- pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-me thyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-((1’,1’-dioxoidospiro[oxetane-3,4’- pyrido[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl )-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

3-(4-Chloro-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hex ahydro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-m ethyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Chloro-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)p henyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)p henyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(4-Chloro-3-(((*S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,11-hex ahydro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-m ethyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Chloro-3-(((*S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)p henyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-(((*S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)p henyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid; 3-(4-Chloro-3-((1’,1’-dioxoidospiro[benzo[b]]oxethiazepi ne-4,3’-oxetan]-2(3H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Chloro-3-((1’,1’-dioxoidospiro[benzo[b]]oxethi azepine-4,3’-oxetan]-2(3H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-((1’,1’-dioxoidospiro[benzo[b]]oxethi azepine-4,3’-oxetan]-2(3H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((8-Fluoro-1,1-dioxidospiro[benzo[b][1,4,5]oxathia zepin]-4,1’-cyclopropan]- 2(3H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromet hyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8-Fluoro-1,1-dioxidospiro[benzo[b][1,4,5]oxathia zepine-4,3’-oxetan]-2(3H)- yl)methyl]-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-((7’-Chloro-1’,1’-dioxidospiro(cyclopropane- 1.4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl )-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((7’-((2-Hydroxyethyl)amino-1’,1’-dioxidospi ro[cyclopropane-1.4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl )-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridinn-7-yl)propanoic acid;

(*S)-3-(3-((7’-((2-Hydroxypropyl)amino-1’,1’-dioxidosp iro[cyclopropane-1.4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridinn-7-yl)propan oic acid;

(*S)-3-(3-((7’-Hydroxy-1’,1’-dioxidospiro[cyclopropane -1,4’-pyrido[2,3,- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl )-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(4-Cyano-3-((8’-methyl-1’,1’-dioxidospiro[cyclopropa ne-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-me thyl-3-(trifluoromethyl)- [1,2,4]trizolo[4,3-a]pyridine-7-yl)propanoic acid; (*S)-3-(4-Cyano-3-((8’-methyl-1’,1’-dioxidospiro[cyclo propane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-me thyl-3-(trifluoromethyl)- [1,2,4]trizolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Cyano-3-((8’-methyl-1’,1’-dioxidospiro[cyclo propane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-me thyl-3-(trifluoromethyl)- [1,2,4]trizolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((7’-((3-Methoxypropyl)amino)-1’,1’-dioxidos piro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propan oic acid;

(*S)-3-(-3-((7’-((3-Hydroxypropyl)(methyl)amino)-1’,1’ -dioxidospiro[cyclopropane- 1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propan oic acid;

(*S)-3-(-3-((7’-((3-Methoxypropoxy)-1’,1’-dioxidospiro [cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl )-3-(8-methyl-3-(trifluoromethyl)- [1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(-3-((7’-((3-Hydroxyethyl)(methyl)amino)-1’,1’- dioxidospiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propan oic acid;

(*S)-3-(4-Methyl-((7’-((2-morpholinoethyl)amino)-1’,1’ -dioxidospiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propan oic acid;

(*S)-3-(3-((1’,1’-Dioxido-7’-((2-(piperidin-1-yl)ethyl )amino)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propan oic acid;

(*S)-3-(3-((7’-(Butylamino)-1’,1’-dioxidospiro[cyclopr opane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl )-3-(8-methyl-3-(trifluoromethyl)- [1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(3-((7’-((3-Hydroxypropyl)amino)-1’,1’-dioxido-2,3,5 ,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid; (*S)-3-(3-((7’-((3-Hydroxypropyl)amino)-1’,1’-dioxido- 2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(3-((7’-((3-Hydroxypropyl)amino)-1’,1’-dioxido- 2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

3-(3-((7’-(((R)-4-Hydroxybutan-2-yl)amino)-1’,1’-dioxi do-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

3-(3-((7’-(((S)-4-Hydroxybutan-2-yl)amino)-1’,1’-dioxi do-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(((R)-4-Hydroxybutan-2-yl)amino)-1’,1’- dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(3-((7’-(((R)-4-Hydroxybutan-2-yl)amino)-1’,1’- dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(((S)-4-Hydroxybutan-2-yl)amino)-1’,1’- dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(3-((7’-(((S)-4-Hydroxybutan-2-yl)amino)-1’,1’- dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(((S)-4-Hydroxybutan-2-yl)amino)-8’-methy l-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(((R)-3-Hydroxy-3-methylbutan-2-yl)amino)-8 ’-methyl-1’,1’-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxa thiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-((7’-(((1s,3S)-3-Hydroxycyclobutyl)amino)-8’-m ethyl-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido3- (3-((7’-(((*S)-4-hydroxybutan-2- yl)amino)-8’-methyl-1’,1’-dioxido-7’-(2-(piperidin-1 -yl)ethoxy)-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propan oic acid;

2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-3 -(3-((7’-(((*S)-4-hydroxybutan- 2-yl)amino)-8’-methyl-1’,1’-dioxido-7’-(2-(piperidin -1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(3-((7’-(3-((2-Hydroxyethyl)amino)-3-oxopropyl)-1 ,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido [2,1-d:2’,3’- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2-methyl- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(3*R)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-di pyrido[2,1-d:2’,3’- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2-methyl- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid; (3*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-di pyrido[2,1-d:2’,3’- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2-methyl- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(5,8-Dimethyl-3)-(trifluoromethyl)-[1,2,4-triazolo[4,3-a]p yridine-7-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2’,3’ -f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)-2-methylpropanoic acid;

(3*R)-3-(5,8-Dimethyl-3)-(trifluoromethyl)-[1,2,4-triazolo[4 ,3-a]pyridine-7-yl)-3-(3- (((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)-2-methylpropanoic acid; and

(3*S)-3-(5,8-Dimethyl-3)-(trifluoromethyl)-[1,2,4-triazolo[4 ,3-a]pyridine-7-yl)-3-(3- (((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)-2-methylpropanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. Additional illustrative embodiments of the invention are compounds of Formula (I) selected from the group consisting of

(*S)-3-(3-((1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluorom ethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(4-Methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropa ne-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl -3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(6-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is selected from the group consisting of

(*S)-3-(3-((1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluorom ethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2, 3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin] -2'(3'H)-yl)methyl)phenyl)-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-y l)propanoic acid;

(*S)-3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(4-Methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropa ne-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl -3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(dif luoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is selected from the group consisting of

(*S)-3-(3-((1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluorom ethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid; (*S)-3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(4-Methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropa ne-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl -3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is selected from the group consisting of

(*S)-3-(3-((1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluorom ethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid

(*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(dif luoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is

(*S)-3-(3-((1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluorom ethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is (*S)-3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid; and

pharmaceutically acceptable salts thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is selected from the group consisting of

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxido-2, 3,5,6-tetrahydrospiro[pyran- 4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phe nyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid; and

pharmaceutically acceptable salts thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is

(*S)-3-(4-Methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropa ne-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl -3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is

(*S)-3-(3-(((*R)-3-cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(3-(dif luoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is selected from the group consisting of (*S)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(R/S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridi n-7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’, 1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

(*S) 2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’, 1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid; (*R)-2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)- 1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tet rahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl-2,2’-dimethyl-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

(*S) 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tet rahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl-2,2’-dimethyl-3-(8- methy-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl )propanoic acid;

(*R) 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’dioxido-2,3,5,6-tetr ahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl-2,2’-dimethyl-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

(R/S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]p yridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4 ,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4 ,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4 ,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(R/S)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4 '-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid; (R/S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4 '-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3- yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3- yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3- yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(R/S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2, 2-dimethyl-3-(6-methyl-5- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2 -dimethyl-3-(6-methyl-5- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2 -dimethyl-3-(6-methyl-5- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropa ne-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl -3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is selected from the group consisting of

(*S)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid; (*R)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(R/S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridi n-7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’, 1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

(*S) 2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’, 1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)- 1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid; 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tet rahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl-2,2’-dimethyl-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

(*S) 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tet rahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl-2,2’-dimethyl-3-(8- methy-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl )propanoic acid;

(*R) 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’dioxido-2,3,5,6-tetr ahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl-2,2’-dimethyl-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is selected from the group consisting of

2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’, 1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

(*S) 2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’, 1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)- 1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tet rahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl-2,2’-dimethyl-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

(*S) 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’-dioxido-2,3,5,6-tet rahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl-2,2’-dimethyl-3-(8- methy-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl )propanoic acid; (*R) 3-(3-((7’-(3-Hydroxypropoxy)-1’,1’dioxido-2,3,5,6-tetr ahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl-2,2’-dimethyl-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is selected from the group consisting of

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid;

(*S) 2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’, 1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4 ,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid;

(*S)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3- yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is (*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethylpropanoic acid; and

pharmaceutically acceptable salts thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(5-((1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-6- methylpyridin-3-yl)-2,2-dimethylpropanoic acid; and

pharmaceutically acceptable salts thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is

(*S) 2,2-Dimethyl-3-(4-methyl-3-((7’-(2-morpholinoethoxy)-1’, 1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-y l)propanoic acid; and

pharmaceutically acceptable salts thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-3-(3-((1',1'- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4 ,5]oxathiazepin]-2'(3'H)-yl)methyl)- 4-methylphenyl)-2,2-dimethylpropanoic acid; and

pharmaceutically acceptable salts thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is (*S)-3-(4-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid; and

pharmaceutically acceptable salts, thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is

(*S)-3-(5-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-6-methylpyridin-3- yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid; and

pharmaceutically acceptable salts thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is selected from the group consisting of

3-(1-(Cyclopropylmethyl)-4-(difluoromethyl-1H-benzo[d][1,2,3 ]triazol-5-yl)-3-(3-((R- 5,5-dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][ 1,2,5]thiadiazepin-6(7H)-yl)methyl)- 4-methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl-1H-benzo[d][ 1,2,3]triazol-5-yl)-3-(3- ((R-5,5-dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1 -d][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol- 5-yl)-3-(3-((1’,1’- dioxidospiro[oxetane-3,3’-pyrido[2,3-b][1,4,5]oxathiazepin ]-2’(3’H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl-1H-benzo[d][ 1,2,3]triazol-5-yl)-3-(3- ((R-5,5-dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1 -d][1,2,5]thiadiazepin-6(7H)- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-((1’,1’- dioxidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]oxathiazepin -2’(3’H)-yl)methyl)-4- methylphenyl)propanoic acid; (*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-((1’,1’- dioxidospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]oxathiazepin -2’(3’H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(4-(Difluoromethyl-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl )-3-(3-(((R-5,5-dioxido- 7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2,5]thiadi azepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(4-(Difluoromethyl-1-methyl-1H-benzo[d][1,2,3]triazol -5-yl)-3-(3-(((R-5,5- dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R) 3-(4-(Difluoromethyl-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl )-3-(3-(((R-5,5- dioxido-7a,8,9,10-tetrahydropyridi[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol- 5-yl)-3-(3-((1’,1’- dioxidospiro[benzo[b][1,4,5]oxathiazepin-4,3’-oxetan]-2,(3 H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol- 5-yl)-3-(4-methyl-3-((5’- methyl-1’,1’-dioxido-5’H-spiro[cyclopropane-1,4’-pyr ido[2,3-f][1,2,5]thiadiazepin]-2’(3’H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-((1’,1’- dioxidospiro[benzo[b][1,4,5]oxathiazepin-4,3’-oxetan]-2,(3 H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-((1’,1’- dioxidospiro[benzo[b][1,4,5]oxathiazepin-4,3’-oxetan]-2,(3 H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(4-methyl-3- ((5’-methyl-1’,1’-dioxido-5’H-spiro[cyclopropane-1,4 ’-pyrido[2,3-f][1,2,5]thiadiazepin]- 2’(3’H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(4-methyl-3- ((5’-methyl-1’,1’-dioxido-5’H-spiro[cyclopropane-1,4 ’-pyrido[2,3-f][1,2,5]thiadiazepin]- 2’(3’H)-yl)methyl)phenyl)propanoic acid; 3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol- 5-yl)-3-(4-methyl-3- (((*R)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(4-methyl-3- (((*R)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(4-methyl-3- (((*R)-7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)phenyl)propanoic acid;

3-(4-Chloro-3-(((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H -dipyrido[2,1-d:2’,3’- f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-methyl-3-(tri fluoromethyl)-[1,2,4]triazolo[4,3- a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-(((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-m ethyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Chloro-3-(((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-m ethyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(4-Chloro-3-((1’,1’-dioxoidospiro[oxetane-3,4’-pyrid o[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl )-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(4-Chloro-3-((1’,1’-dioxoidospiro[oxetane-3,4’- pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-me thyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-((1’,1’-dioxoidospiro[oxetane-3,4’- pyrido[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl )-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

3-(4-Chloro-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,11-hex ahydro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-m ethyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid; (*R)-3-(4-Chloro-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)p henyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)p henyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(4-Chloro-3-(((*S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,11-hex ahydro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)phenyl)-3-(8-m ethyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Chloro-3-(((*S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)p henyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-(((*S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- dipyrido[2,1-d:2’,3’-f][1,2,5]thiadiazepin-6-yl)methyl)p henyl)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(4-Chloro-3-((1’,1’-dioxoidospiro[benzo[b]]oxethiazepi ne-4,3’-oxetan]-2(3H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Chloro-3-((1’,1’-dioxoidospiro[benzo[b]]oxethi azepine-4,3’-oxetan]-2(3H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Chloro-3-((1’,1’-dioxoidospiro[benzo[b]]oxethi azepine-4,3’-oxetan]-2(3H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((8-Fluoro-1,1-dioxidospiro[benzo[b][1,4,5]oxathia zepin]-4,1’-cyclopropan]- 2(3H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromet hyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8-Fluoro-1,1-dioxidospiro[benzo[b][1,4,5]oxathia zepine-4,3’-oxetan]-2(3H)- yl)methyl]-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid; (*S)-3-(3-((7’-Chloro-1’,1’-dioxidospiro(cyclopropane- 1.4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl )-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((7’-((2-Hydroxyethyl)amino-1’,1’-dioxidospi ro[cyclopropane-1.4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl )-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridinn-7-yl)propanoic acid;

(*S)-3-(3-((7’-((2-Hydroxypropyl)amino-1’,1’-dioxidosp iro[cyclopropane-1.4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridinn-7-yl)propan oic acid;

(*S)-3-(3-((7’-Hydroxy-1’,1’-dioxidospiro[cyclopropane -1,4’-pyrido[2,3,- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl )-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(4-Cyano-3-((8’-methyl-1’,1’-dioxidospiro[cyclopropa ne-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-me thyl-3-(trifluoromethyl)- [1,2,4]trizolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(4-Cyano-3-((8’-methyl-1’,1’-dioxidospiro[cyclo propane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-me thyl-3-(trifluoromethyl)- [1,2,4]trizolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-3-(4-Cyano-3-((8’-methyl-1’,1’-dioxidospiro[cyclo propane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phenyl)-3-(8-me thyl-3-(trifluoromethyl)- [1,2,4]trizolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-((7’-((3-Methoxypropyl)amino)-1’,1’-dioxidos piro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propan oic acid;

(*S)-3-(-3-((7’-((3-Hydroxypropyl)(methyl)amino)-1’,1’ -dioxidospiro[cyclopropane- 1,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propan oic acid;

(*S)-3-(-3-((7’-((3-Methoxypropoxy)-1’,1’-dioxidospiro [cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl )-3-(8-methyl-3-(trifluoromethyl)- [1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid; (*S)-3-(-3-((7’-((3-Hydroxyethyl)(methyl)amino)-1’,1’- dioxidospiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propan oic acid;

(*S)-3-(4-Methyl-((7’-((2-morpholinoethyl)amino)-1’,1’ -dioxidospiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propan oic acid;

(*S)-3-(3-((1’,1’-Dioxido-7’-((2-(piperidin-1-yl)ethyl )amino)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7-yl)propan oic acid;

(*S)-3-(3-((7’-(Butylamino)-1’,1’-dioxidospiro[cyclopr opane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl )-3-(8-methyl-3-(trifluoromethyl)- [1,2,4[triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(3-((7’-((3-Hydroxypropyl)amino)-1’,1’-dioxido-2,3,5 ,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-m ethylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-((3-Hydroxypropyl)amino)-1’,1’-dioxido- 2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(3-((7’-((3-Hydroxypropyl)amino)-1’,1’-dioxido- 2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

3-(3-((7’-(((R)-4-Hydroxybutan-2-yl)amino)-1’,1’-dioxi do-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

3-(3-((7’-(((S)-4-Hydroxybutan-2-yl)amino)-1’,1’-dioxi do-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(((R)-4-Hydroxybutan-2-yl)amino)-1’,1’- dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(3-((7’-(((R)-4-Hydroxybutan-2-yl)amino)-1’,1’- dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(((S)-4-Hydroxybutan-2-yl)amino)-1’,1’- dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(3-((7’-(((S)-4-Hydroxybutan-2-yl)amino)-1’,1’- dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(((S)-4-Hydroxybutan-2-yl)amino)-8’-methy l-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4[triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-((7’-(((R)-3-Hydroxy-3-methylbutan-2-yl)amino)-8 ’-methyl-1’,1’-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxa thiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-((7’-(((1s,3S)-3-Hydroxycyclobutyl)amino)-8’-m ethyl-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido3- (3-((7’-(((*S)-4-hydroxybutan-2- yl)amino)-8’-methyl-1’,1’-dioxido-7’-(2-(piperidin-1 -yl)ethoxy)-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propan oic acid; 2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-dioxido-3 -(3-((7’-(((*S)-4-hydroxybutan- 2-yl)amino)-8’-methyl-1’,1’-dioxido-7’-(2-(piperidin -1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)phenyl)-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(3-((7’-(3-((2-Hydroxyethyl)amino)-3-oxopropyl)-1 ,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido [2,1-d:2’,3’- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2-methyl- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(3*R)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-di pyrido[2,1-d:2’,3’- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2-methyl- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

(3*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-di pyrido[2,1-d:2’,3’- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-2-methyl- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid;

3-(5,8-Dimethyl-3)-(trifluoromethyl)-[1,2,4-triazolo[4,3-a]p yridine-7-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2’,3’ -f][1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)-2-methylpropanoic acid;

(3*R)-3-(5,8-Dimethyl-3)-(trifluoromethyl)-[1,2,4-triazolo[4 ,3-a]pyridine-7-yl)-3-(3- (((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)-2-methylpropanoic acid; and

(3*S)-3-(5,8-Dimethyl-3)-(trifluoromethyl)-[1,2,4-triazolo[4 ,3-a]pyridine-7-yl)-3-(3- (((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2’,3’-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)-2-methylpropanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is selected from the group consisting of

(R/S)-3-(3-(((*S)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxa zino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxaz ino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((*S)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxaz ino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((*R)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxa zino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxaz ino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((*R)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxaz ino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-di pyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethy l-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethy l-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethy l-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid; (R/S)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-di pyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethy l-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethy l-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(1-ethy l-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyr rolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-[3-[(5,5-Dioxo-7a,8,9,10-tetrahydro-7H-pyrrolo[2,1-d] [1,2,5]benzothiadiazepin-6- yl)methyl]-4-methyl-phenyl]-3-(1-ethyl-4-methyl-benzotriazol -5-yl)propanoic acid;

(*R)-3-[3-[(5,5-Dioxo-7a,8,9,10-tetrahydro-7H-pyrrolo[2,1-d] [1,2,5]benzothiadiazepin- 6-yl)methyl]-4-methyl-phenyl]-3-(1-ethyl-4-methyl-benzotriaz ol-5-yl)propanoic acid;

(R/S)-3-[3-[(4,4-Dimethyl-1,1-dioxo-3H-pyrido[2,3-b][1,4,5]o xathiazepin-2-yl)methyl]- 4-methyl-phenyl]-3-(1-ethyl-4-methyl-benzotriazol-5-yl)propa noic acid;

(R/S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b ][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1 ,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyr rolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid; (R/S)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3- f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(1- ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b] [1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1 ,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b] [1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1 ,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[ 2,3-b][1,4,5]oxathiazepin- 2-yl)methyl)-4-methylphenyl)-3-(3-methyl-[1,2,4]triazolo[4,3 -a]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b ][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(3-methyl-[1,2,4]triazolo[4,3-a ]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2 ,3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(3-methyl-[1,2,4]triazolo[4,3-a ]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid; (*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridi n-7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d] [1,2,3]triazol-5-yl)-3-(3- (((*R)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d] [1,2,3]triazol-5-yl)-3-(3- (((*R)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d] [1,2,3]triazol-5-yl)-3-(3- (((*S)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d] [1,2,3]triazol-5-yl)-3-(3- (((R)-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d :2',3'-f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(6-(((R)-4-ethyl-1,1- dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl )methyl)-5-methylpyridin-2- yl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(6-(((R)-4-ethyl-1,1- dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl )methyl)-5-methylpyridin-2- yl)propanoic acid; (*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(6-(((R)-4-ethyl-1,1- dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl )methyl)-5-methylpyridin-2- yl)propanoic acid;

(R/S)-3-(4-Methyl-3-(((*S)-9-methyl-5,5-dioxido-7,7a,8,9,10, 11-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl) phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(4-Methyl-3-(((S)-9-methyl-5,5-dioxido-7,7a,8,9,10,11 -hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl) phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-3-(4-Methyl-3-(((*S)-9-methyl-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl) phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(R/S)-3-(4-Methyl-3-(((*R)-9-methyl-5,5-dioxido-7,7a,8,9,10, 11-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl) phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(4-Methyl-3-(((*R)-9-methyl-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl) phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-3-(4-Methyl-3-(((*R)-9-methyl-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- pyrazino[2,1-d]pyrido[2,3-f][1,2,5]thiadiazepin-6-yl)methyl) phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(R/S)-3-(4-Methyl-3-((5'-methyl-1',1'-dioxido-5'H-spiro[cycl opropane-1,4'-pyrido[2,3- f][1,2,5]thiadiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl -3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-Methyl-3-((5'-methyl-1',1'-dioxido-5'H-spiro[cyclo propane-1,4'-pyrido[2,3- f][1,2,5]thiadiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl -3-(t*rifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(4-Methyl-3-((5'-methyl-1',1'-dioxido-5'H-spiro[cyclo propane-1,4'-pyrido[2,3- f][1,2,5]thiadiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl -3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-3-(4-Methyl-3-(((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-te trahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(4-Methyl-3-(((*S)-7a-methyl-5,5-dioxido-7a,8,9,10-te trahydropyrido[2,3- f]pyrrolo[2,1-d][1,2,5]thiadiazepin-6(7H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2 ,3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2, 3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2, 3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(3*S)-3-(3-((3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6 H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-Chloro-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-4-Ethyl-8-methyl-1,1-dioxido-3,4-dihydro-2H -pyrido[2,3- b][1,4,5]oxathiazepin-2-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8'-Chloro-1',1'-dioxidospiro[cyclopropane-1,4'-p yrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-3-(3-(((*S)-3-Cyano-5,5-dioxido-7a,8,10,11-tetrahydro-[ 1,4]oxazino[3,4- d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methyl phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(3-(((*S)-3-Chloro-5,5-dioxido-7a,8,10,11-tetrahydro- [1,4]oxazino[3,4- d]pyrido[2,3-f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methyl phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-3-(trifluoromethyl)-7,7a,8,9,10 ,11-hexahydro-6H- dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-me thylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-3-(trifluoromethyl)-7,7a,8,9,10 ,11-hexahydro-6H- dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-me thylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(3-((8'-Cyano-1',1'-dioxidospiro[cyclopropane-1,4'-py rido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8'-Carbamoyl-1',1'-dioxidospiro[cyclopropane-1,4 '-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-2-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-2-Carbamoyl-5,5-dioxido-7,7a,8,9,10,11-hexa hydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3 -(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-2-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydr o-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-2-Carbamoyl-5,5-dioxido-7,7a,8,9,10,11-hexa hydro-6H-dipyrido[2,1- d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3 -(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-3-(3-(((S)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyri do[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((R)-3-Cyano-5,5-dioxido-7a,8,9,10-tetrahydropyri do[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-Methyl-3-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahy drospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-(((R)-5,5-dioxido- 7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadi azepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-(((R)-5,5-dioxido- 7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadi azepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-(((R)-5,5-dioxido- 7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thiadi azepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-(((*R)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]th iadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H) -yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H) -yl)methyl)-4- methylphenyl)propanoic acid; (*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-((1,1- dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetan]-2(3H) -yl)methyl)-4- methylphenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-benzo[f]pyrido[2,1-d][1, 2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(4-methyl-3-(((*S)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrro lo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(4-methyl-3-(((*S)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrro lo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(4-methyl-3-(((*S)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrro lo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(4-methyl-3-(((*R)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrro lo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(4-methyl-3-(((*R)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrro lo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(4-methyl-3-(((*R)- 7a-methyl-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrro lo[2,1-d][1,2,5]thiadiazepin-6(7H)- yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(4-methyl-3-((5'- methyl-1',1'-dioxido-5'H-spiro[cyclopropane-1,4'-pyrido[2,3- f][1,2,5]thiadiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(4-methyl-3-((5'- methyl-1',1'-dioxido-5'H-spiro[cyclopropane-1,4'-pyrido[2,3- f][1,2,5]thiadiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid; (*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(4-methyl-3-((5'- methyl-1',1'-dioxido-5'H-spiro[cyclopropane-1,4'-pyrido[2,3- f][1,2,5]thiadiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[p yran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propan oic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[p yran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propan oic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[p yran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-3-yl)propan oic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3-((8'-fluoro-1',1'- dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxathiaze pin]-2'(3'H)-yl)methyl)-4- methylphenyl)propanoic acid;

(R/S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tr iazol-5-yl)-3-(3-(((*S)- 5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3' -f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-(((*S)- 5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3' -f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(R/S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tr iazol-5-yl)-3-(3-(((*R)- 5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3' -f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-(((*R)- 5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3' -f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid; (*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-(((*R)- 5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3' -f][1,2,5]thiadiazepin-6- yl)methyl)-4-methylphenyl)propanoic acid;

(R/S)-3-(6-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4 ,3'-oxetan]-2(3H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benz o[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(6-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4, 3'-oxetan]-2(3H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benz o[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(6-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4, 3'-oxetan]-2(3H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benz o[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1 ,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benz o[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1, 4,5]oxathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benz o[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(6-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1, 4,5]oxathiazepin]-2'(3'H)- yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl-1H-benz o[d][1,2,3]triazol-5-yl)propanoic acid;

(R/S)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3 -b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl -1H-benzo[d][1,2,3]triazol-5- yl)propanoic acid;

(*S)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl -1H-benzo[d][1,2,3]triazol-5- yl)propanoic acid; and

(*R)-3-(6-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-5-methylpyridin-2-yl)-3-(1-ethyl-4-methyl -1H-benzo[d][1,2,3]triazol-5- yl)propanoic acid; and pharmaceutically acceptable salts, and combinations thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is selected from the group consisting of

3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triaz ol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triaz ol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-(((R)-4-ethyl-1,1- dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl )methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triaz ol-5-yl)-3-(3-(((R)-4- ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathia zepin-2-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(7-(Difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triaz ol-5-yl)-3-(3-(((R)-4- ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathia zepin-2-yl)methyl)-4- methylphenyl)propanoic acid;

3-(3-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]o xathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1 ,2,3]triazol-5-yl)propanoic acid;

3-(3-(((S)-5,5--Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyr rolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- (trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- (trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- (trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][ 1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2, 3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-4-Ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2, 3-b][1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]o xathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1, 4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-((1',1'-Dioxidospiro[oxetane-3,4'-pyrido[2,3-b][1, 4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxaz ino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*S)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxaz ino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; 3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2 ,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromet hyl)-[1,2,4]triazolo[4,3-a]pyridin- 7-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b] [1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2 ,3-b][1,4,5]oxathiazepin- 2-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl) -[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2 ,3-b][1,4,5]oxathiazepin- 2-yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl) -[1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido [2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(3-(((S)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxaz ino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*R)-5,5-Dioxido-7a,8,10,11-tetrahydro-[1,4]oxaz ino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrrolo[2 ,1-d][1,2,5]thiadiazepin- 6(7H)-yl)methyl)-4-methylphenyl)-3-(3-ethyl-8-methyl-[1,2,4] triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- ethyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydrobenzo[f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- ethyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- ethyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((R)-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- ethyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(3- ethyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4, 5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid; (*S)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b] [1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*R)-3-(3-((4,4-Dimethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b] [1,4,5]oxathiazepin-2- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

3-(3-((1,1-Dioxidospiro[benzo[b][1,4,5]oxathiazepine-4,3'-ox etan]-2(3H)-yl)methyl)-4- methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazol o[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1,1-dioxidospiro[benzo[b][1,4,5]oxathiazepine-4, 3'-oxetan]-2(3H)- yl)methyl)-4-methylphenyl)-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido [2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9-tetrahydro-6H-azeto[2, 1-d]pyrido[2,3- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9-tetrahydro-6H-azeto[2, 1-d]pyrido[2,3- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9-tetrahydro-6H-azeto[2, 1-d]pyrido[2,3- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9-tetrahydro-6H-azeto[2, 1-d]pyrido[2,3- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(6-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrr olo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-5-methylpyridin-2-yl) -3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(6-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-5-methylpyridin-2-yl) -3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(6-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-5-methylpyridin-2-yl) -3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(3-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-ben zo[f]pyrido[2,1- d][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-ben zo[f]pyrido[2,1- d][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido [2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(6-(((*S)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

3-(6-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido [2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid; (*S)-3-(6-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*R)-3-(6-(((*R)-5,5-Dioxido-7,7a,8,9,10,11-hexahydro-6H-dip yrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-5-methylpyridin-2-yl)-3-( 1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoic acid;

(*S)-3-(4-methyl-3-(((*S)-3-methyl-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)pheny l)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(4-methyl-3-(((*R)-3-methyl-5,5-dioxido-7,7a,8,9,10,1 1-hexahydro-6H- dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepin-6-yl)methyl)pheny l)-3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-3-fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-(((*R)-3-fluoro-5,5-dioxido-7,7a,8,9,10,11-hexahyd ro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((8'-Fluoro-1',1'-dioxidospiro[cyclopropane-1,4'-p yrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-3- (8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((3-Cyano-5,5-dioxido-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepin-6-yl)methyl)-4-methylphenyl)-3-(8-meth yl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cy clopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl -3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospi ro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*R)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospi ro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1, 4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifl uoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl- 3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1',1'-Dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl- 3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4'-pyri do[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(3-(triflu oromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2, 2-dimethyl-3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2, 2-dimethyl-3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cy clopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(3-(trifl uoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospi ro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospi ro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid; (*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol- 5-yl)-2,2-dimethyl-3-(5- methyl-6-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6-tet rahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin-2-yl)propan oic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-2,2-dimethyl-3- (5-methyl-6-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-2,2-dimethyl- 3-(5-methyl-6-((7'-(2-morpholinoethoxy)-1',1'-dioxido-2,3,5, 6-tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-2,2-di methyl-3-(4-methyl-3-((8'- methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1, 4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-2,2-di methyl-3-(4-methyl-3-((8'- methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3-b][1, 4,5]oxathiazepin]-2'(3'H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*R)-3-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-4-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid; (*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxidospiro[piperidine-4,4'-pyrido[2,3-b] [1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifl uoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1',1'-Dioxidospiro[piperidine-4,4'-pyrido[2,3-b] [1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifl uoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-3-(3-((1',1'-Dioxidospiro[azetidine-3,4'-pyrido[2,3-b][ 1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifl uoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((1',1'-Dioxidospiro[azetidine-3,4'-pyrido[2,3-b][ 1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifl uoromethyl)-[1,2,4]triazolo[4,3- a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospi ro[piperidine-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospi ro[piperidine-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospi ro[azetidine-3,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)-3-(8-methyl -3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8'-methyl-1',1'-dioxidospi ro[azetidine-3,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-((7'-(3-((2-(2-Aminoethoxy)ethyl)amino)-3-oxopropy l)-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin] -2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3-((7'-(3-((2-(2-aminoethoxy)ethyl)amino)-3-oxopropy l)-1',1'-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin] -2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazin-6-yl)-2,2-di methyl-3-(4-methyl-3-((8'- methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)phenyl)p ropanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-d imethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidine-1-yl)-e thoxy)2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phe nyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-d imethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(piperidine-1-yl)-et hoxy)2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phe nyl)propanoic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-d imethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(piperidine-1-yl)-et hoxy)2,3,5,6-tetrahydrospiro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phe nyl)propanoic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-d imethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(piperidine-1-yl)-et hoxy)spiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phenyl)propano ic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-d imethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(piperidine-1-yl)-et hoxy)spiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phenyl)propano ic acid;

(*S)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-d imethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin-1-yl)-et hoxy)spiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’,(3’H)-yl)methyl)phenyl)propano ic acid;

(*R)-3-(3,7-Dimethyl-7H-pyrrolo[2,3-c]pyridazine-6-yl)-2,2-d imethyl-3-(4-methyl-3- ((8’-methyl-1’,1’-dioxido-7’-(2-(pyrrolidin-1-yl)-et hoxy)spiro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’-(3’H)-yl)methyl)phenyl)propano ic acid; (*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl) ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin] -2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl) ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin] -2'(3'H)-yl)methyl)pyridin-2- yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl) ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*R)-3-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(piperidin-1-yl) ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl )ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*R)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl )ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

(*R)-3-(3-((7’-(2-(4,4-Difluoropiperidin-1-yl)ethoxy)-1’ ,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a][pyridine-7- yl)propanoic acid;

(*R)-3-(3-((7’-(((1R,3R)-3-Hydroxycyclobutyl)amino)-8’-m ethyl-1’,1’-dioxido-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-7’-(((R-1-mo rpholinopropan-2-yl)amino)- 1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrid o[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-7’-(((S-1-mo rpholinopropan-2-yl)amino)- 1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrid o[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-7’-(((1-morp holinopropan-2-yl)amino)- 1’,1’-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrid o[2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-7’-((2-morph olinoethyl)amino)-1’,1’- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1 ,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-7’-((2-morph olinoethyl)amino)-1’,1’- dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1 ,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-diox ido-7’-(((S)-1-(pyrrolidine-1- yl)propan-2-yl)amino)-2,3,5,6-tetrahydrospiro[pyran-4,4’-p yrido[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl )-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*R)-3-(3-((1’,1’-Dioxido-7’-(2-(piperazin-1-yl)ethoxy )-2,3,5,6-tetrahydrospiro[pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a][pyridine-7 -yl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-(8’-methyl-1’,1’-dioxi do-7’-(2-(piperidin-4-yl)ethoxy)- 2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxa thiazepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a][pyridine-7- yl)propanoic acid; (*S)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-diox ido-7’-(2-(pyrrolidin-1- yl)ethoxy)-2,3,5,6-tetrahydrospiro[pyran-4,4’-pyrido[2,3-b ][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifl uoromethyl)-[1,2,4]triazolo[4,3- a][pyridine-7-yl)propanoic acid;

(*S)-3-(3-1’,1’-Dioxido-7’-(2-(piperidin-1-yl)ethoxy)s piro[cyclopropane-1,4’-pyrido[2,3- b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)-4-methylphenyl )-2,2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a][pyridine-7-yl)propa noic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-diox ido-7’-(2-(piperidin-1- yl)ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxat hiazepin]-2’(3’H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridi ne-7-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-diox ido-7’-(2-(pyrrolidin-1- yl)ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxat hiazepin]-2’(3’H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridi ne-7-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridine-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(piperid in-1-yl)ethoxy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phen yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridine-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrroli din-1-yl)ethoxy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phen yl)propanoic acid;

3-(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-di oxido-7’-((1-piperidin-1- yl)propan-2-yl)amino)-2,3,5,6-tetrahydrospiro[pyran-4,4’-p yrido[2,3-b][1,4,5]oxathiazepin]- 2’(3’H)-yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl )-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridine-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrroli din-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)- yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-((7’-(2-(4-Methoxypiperidin-1-yl)ethoxy)-8’-me thyl-1’,1’- dioxidospiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxathia zepin]-2’(3’H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridine-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(piperid in-1-yl)ethoxy)-2,3,5,6- tetrahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepi n]-2’(3’H)- yl)methyl)phenyl)propanoic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-diox ido-7’-(((S)-1-piperidin-1- yl)propan-2-yl)amino)spiro[cyclopropane-1,4’-pyrido [2,3-b][1,4,5]oxathiazepin]-2’(3’H)- yl)methyl)phenyl)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridine-7-yl)propanoic acid;

(*S)-3-(3-(((*S)-1',1'-Dioxido-4,5-dihydro-2H-spiro[furan-3, 4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2, 2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(3-(((*R)-1',1'-Dioxido-4,5-dihydro-2H-spiro[furan-3, 4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2, 2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-(((*S)-8'-methyl-1',1'-dioxi do-4,5-dihydro-2H- spiro[furan-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-y l)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-(((*R)-8'-methyl-1',1'-dioxi do-4,5-dihydro-2H- spiro[furan-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-y l)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-3-(3-(((*S)-1',1'-Dioxido-4,5-dihydro-2H-spiro[furan-3, 4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2, 2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-3-(3-(((*R)-1',1'-Dioxido-4,5-dihydro-2H-spiro[furan-3, 4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2, 2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid; (*R)-2,2-Dimethyl-3-(4-methyl-3-(((*S)-8'-methyl-1',1'-dioxi do-4,5-dihydro-2H- spiro[furan-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-y l)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*R)-2,2-Dimethyl-3-(4-methyl-3-(((*R)-8'-methyl-1',1'-dioxi do-4,5-dihydro-2H- spiro[furan-3,4'-pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-y l)methyl)phenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(*R)-3-(3-(((R)-5,5-Dioxido-7a,8,9,10-tetrahydropyrido[2,3-f ]pyrrolo[2,1- d][1,2,5]thiadiazepin-6(7H)-yl)methyl)-4-methylphenyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoic acid;

(R/S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridi n-7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-py rido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-py rido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-py rido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-py rido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-py rido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-2,2-dimethyl-3-(6- methyl-5-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-py rido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)pyridin-3-yl)propanoic acid; (R/S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-(((*S)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]th iadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3-(((*S)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol- 5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(1-(Cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azol-5-yl)-3-(3-(((R)-5,5- dioxido-7a,8,9,10-tetrahydropyrido[2,3-f]pyrrolo[2,1-d][1,2, 5]thiadiazepin-6(7H)-yl)methyl)-4- methylphenyl)propanoic acid;

3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3 -(3-(((*R)-5,5-dioxido- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]th iadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*R)-3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid;

(*S)-3-(7-Cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5- yl)-3-(3-(((*R)-5,5- dioxido-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][ 1,2,5]thiadiazepin-6-yl)methyl)-4- methylphenyl)propanoic acid; and

pharmaceutically acceptable salts, and combinations thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is selected from the group consisting of

(*R)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2 -dimethyl-3-(4-methyl-3- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*R)-3-(3-(((*S)-1',1'-Dioxido-4,5-dihydro-2H-spiro[furan-3, 4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2, 2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid;

(*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-py rido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid;

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-diox ido-7’-(2-(pyrrolidin-1- yl)ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxat hiazepin]-2’(3’H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridi ne-7-yl)propanoic acid;

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridine-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrroli din-1-yl)ethoxy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phen yl)propanoic acid;

(*S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2 -dimethyl-3-(5-methyl-4- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)pyridin-2-yl)propanoic acid;

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl )ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid;

and pharmaceutically acceptable salts thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is

(*R)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2 -dimethyl-3-(4-methyl-3- ((8'-methyl-1',1'-dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid; and

pharmaceutically acceptable salts thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is

(*S)-3-(6-((1',1'-Dioxido-2,3,5,6-tetrahydrospiro[pyran-4,4' -pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-5-methylpyridin-2- yl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid; and

pharmaceutically acceptable salts thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridin-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4' -pyrido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid; and

pharmaceutically acceptable salts thereof.

An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is

(*R)-3-(3-(((*S)-1',1'-Dioxido-4,5-dihydro-2H-spiro[furan-3, 4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)-4-methylphenyl)-2, 2-dimethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ic acid; and

pharmaceutically acceptable salts thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is

: (*S)-3-(3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-2,2-dimethyl-3-(4- methyl-3-((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-py rido[2,3-b][1,4,5]oxathiazepin]- 2'(3'H)-yl)methyl)phenyl)propanoic acid; and

pharmaceutically acceptable salts thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is

(*S)-2,2-Dimethyl-3-(4-methyl-3-((8’-methyl-1’,1’-diox ido-7’-(2-(pyrrolidin-1- yl)ethoxy)spiro[cyclopropane-1,4’-pyrido[2,3-b][1,4,5]oxat hiazepin]-2’(3’H)-yl)methyl)phenyl)- 3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridi ne-7-yl)propanoic acid; and

pharmaceutically acceptable salts thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is

(*S)-3-(3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridine-7-yl)-2,2-dimethyl-3- (4-methyl-3-((8’-methyl-1’,1’-dioxido-7’-(2-(pyrroli din-1-yl)ethoxy)spiro[cyclopropane-1,4’- pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)methyl)phen yl)propanoic acid; and

pharmaceutically acceptable salts thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is

(*S)-3-(1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2 -dimethyl-3-(5-methyl-4- ((8'-methyl-1',1'-dioxidospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepin]-2'(3'H)- yl)methyl)pyridin-2-yl)propanoic acid; and

pharmaceutically acceptable salts thereof. An additional illustrative embodiment of the invention is a compound of Formula (I), wherein the compound is

(*S)-2,2-Dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]tri azolo[4,3-a]pyridin-7-yl)-3- (5-methyl-6-((8'-methyl-1',1'-dioxido-7'-(2-(pyrrolidin-1-yl )ethoxy)spiro[cyclopropane-1,4'- pyrido[2,3-b][1,4,5]oxathiazepin]-2'(3'H)-yl)methyl)pyridin- 2-yl)propanoic acid; and

pharmaceutically acceptable salts thereof. Abbreviations and acronyms used herein include those listed in Table 1.

Table 1: Table of Abbreviations

Illustrative compounds useful in methods of this invention are described below by reference to the illustrative synthetic schemes (“Schemes”) and specific examples for their preparation. Compounds of Formula (I)

are synthesized in accordance with the Schemes. By way of illustration, but not as a limitation, compounds according to this invention are prepared according to the following general preparation procedures given by Schemes 1-12. One of ordinary skill in the art will recognize that, to obtain the various compounds herein, starting materials may be suitably selected so that the ultimately desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product. Alternatively, it may be necessary or desirable to employ, in the place of the ultimately desired substituent, a suitable group that may be carried through the reaction scheme and replaced as appropriate with the desired substituent.

Unless otherwise specified, the variables in Schemes 1-12 are as defined above in reference to Formula (I). The following general features concerning reaction temperatures, protecting groups PG, leaving groups LG, and substituent R 35 refer, as applicable, to all the Schemes 1-12.

If no temperature or temperature range is stated, it is to be understood that the reaction is to be run at room temperature.

The term PG in the following schemes represents a protecting group such as an acetyl (Ac), or a t-butyldimethylsilyl (TBS).

The conditions to protect an alcohol as an acetyl include treatment of the alcohol with (i) acetyl chloride in the presence of a base such as triethylamine, DIPEA or pyridine in a reaction medium provided by solvents such as dichloromethane, DMF or THF at a temperature ranging from about 0 °C to about room temperature wherein DMAP may optionally be added, or (ii) acetic anhydride in the presence of a base such as triethylamine, DIPEA or pyridine in a reaction medium provided by solvents such as dichloromethane, DMF or THF at a temperature ranging from about 0 °C to about room temperature, wherein DMAP may optionally be added. These conditions are referred to as“acetyl protection conditions”. The conditions to remove an acetyl group include using a base such as potassium carbonate in a reaction medium provided by solvents such as THF, methanol, ethanol, water, or mixtures thereof. These deprotection conditions are referred to as“acetyl group deprotection conditions”.

Other conditions to protect an alcohol rely on its protection as a TBS ether by coupling the alcohol with TBS-Cl or TBS-OTf in the presence of a base such as imidazole, 2,6-lutidine, triethylamine, DIPEA or pyridine in a reaction medium provided by solvents such as

dichloromethane, DMF or THF at a temperature ranging from about 0 °C to about room temperature, wherein DMAP may optionally be added. These conditions are referred to as“TBS protecting group conditions”. The TBS group is removed by (i) TBAF in a solvent such as THF or DMF at a temperature ranging from about 0 °C to about 70 °C, or (ii) HCl or CSA in a reaction medium provided by solvents such as THF, ethanol, methanol, water or mixtures thereof at a temperature ranging from about 0 °C to about room temperature. These deprotection conditions are referred to as“TBS group deprotection conditions”.

R 35 is defined as C1-C4alkyl.

The term LG refers to a leaving group. Examples of leaving groups include I, Cl, Br, OMs and OTs.

When isomerically pure samples are desired, isomeric mixtures of compounds synthesized according to Scheme 1 can be separated by chiral SFC or HPLC. Scheme 1

and HetBH is

As shown in Scheme 1, compound II is converted to compound IV by coupling it with one of compounds IIIa’-d’ (HetBH) under Mitsunobu reaction conditions. This Mitsunobu reaction is performed by using diisopropyl azodicarboxylate or di-tert-butyl azodicarboxylate in the presence of triphenylphosphine or solid-supported triphenylphosphine in a reaction medium provided by solvents such as THF, DMF, dichloromethane, or mixtures thereof, at a temperature range from about room temperature to about the reflux temperature of the solvent. These conditions are referred to as“Mitsunobu reaction conditions”. Compound IIIa’ is made as shown in Schemes 10a and 12a, compound IIIb’ is made as shown in Schemes 10b and 12b, compound IIIc’ is made as shown in Scheme 10c and compound IIId’ is made as shown in Scheme 10d. Compound V is converted to compound IV by coupling it with one of compounds IIIa’-d’ (HetBH) in an alkylation reaction. This alkylation reaction is performed by using a base such as sodium hydride or potassium tert-butoxide, in a reaction medium provided by solvents such as THF or DMF. Alternatively, compound IV is made as shown in Scheme 3b. Compound IV is converted to compound (I) under hydrolysis reaction conditions, employing an aqueous solution of NaOH or LiOH, in a reaction medium provided by solvents such as water, THF, 1,4- dioxane, methanol, ethanol, or mixtures thereof, at a temperature range from about room temperature to about the reflux temperature of the solvent. These conditions are referred to as “basic hydrolysis reaction conditions” Compound VI (PG is Ac) is converted to compound II under acetyl group deprotection conditions. Alternatively, compound II is made as shown in Scheme 3b. Compound VI (PG is TBS) is converted to compound V by treatment with a chlorinating agent such as thionyl chloride with or without DMF as an additive in a reaction medium provided by solvents such as dichloromethane or dichloroethane, to yield compound V. Compound VI is made as shown in Schemes 2, 3b and 4. Scheme 2

As shown in Scheme 2, compound VIIa is converted to compound VIIb by a two-step process. The first step in this two-step process is reduction of benzoate VIIa to a benzyl alcohol (structure not shown) with a reducing agent such as LiAlH 4 in a reaction medium provided by a solvent such as THF at a temperature ranging from about 0 °C to about 15 °C. The second step in this two-step protocol is the protection of the benzyl alcohol as a TBS ether under TBS protection conditions. Compound VIIb is converted to compound IX by initially treating compound VIIB with a reagent such as n-butyllithium at a low temperature such as about‒78 °C in a reaction medium provided by a solvent such as THF, forming an organolithium intermediate (structure not shown), this organolithium intermediate is then treated with compound VIIIa (made as shown in Schemes 4 and 9) or VIIIb (made as shown in Scheme 5) to form compound IX. Compound IX is converted to compound VI by coupling with a silylketene acetal X, using trichloroacetonitrile in the presence of the additives DBU and trifluoromethanesulfonamide in a reaction medium provided by a solvent such as acetonitrile, at a temperature ranging from about room temperature to about the reflux temperature of the reaction solvent. Alternatively, this coupling can also be accomplished by using a compound X and a reagent such as BF3-Et2O or TiCl 4 in a reaction medium provided by a solvent such as dichloromethane. Compound XIV is also made with a different HetA group as shown in Scheme 8. Scheme 3a

As shown in Scheme 3a, HetA-Br (XIa or XIb) is converted to compound XIV by a palladium catalyzed coupling with compound XII with a palladium catalyst such as Pd(dppf)Cl2 or Pd(dppf)Cl 2 ^CH 2 Cl 2 in the presence of a base additive such as potassium carbonate or sodium carbonate in a reaction medium provided by a solvent such as mixture of 1,4-dioxane and water at a temperature ranging from about room temperature to about the reflux temperature of the solvent. When compound XIII is used, compounds XIa (made as shown in Schemes 6 and 7) or XIb (as made as shown in Scheme 5) are treated with a palladium catalyst such as Herrmann’s palladacycle, Pd(dppf)Cl 2 , Pd(dtbpf)Cl 2 , Pd(PPh 3 ) 4 or Pd(OAc) 2 in the presence of additives such as tetrabutylammonium chloride hydrate or P(o-tol) 3 and bases such as sodium acetate, triethylamine, diisopropylethyl amine or N,N-dicyclohexylmethyl amine in a reaction medium provided by a solvent such as DMF or DMA, at a temperature ranging from about room temperature to about the reflux temperature of the solvent. Scheme 3b

As shown in Scheme 3b, Compound XIV (made as shown in Scheme 3a) is converted into compound II, by coupling it to compound XV, using a rhodium-catalyzed conjugate addition reaction. This conjugate addition reaction is accomplished with a rhodium catalyst such as

[Rh(COD)Cl]2 in the presence of a base such as triethylamine, sodium carbonate, or KOH; in a reaction medium provided by a solvent such as 1,4-dioxane, water, THF, isopropanol, or mixtures thereof; at a temperature ranging from about room temperature to about the reflux temperature of the solvent. These reaction condition are herein referred to as "rhodium- catalyzed conjugate addition reaction conditions”. Compound XIV is converted to compound VI by treating it with compound XVI under rhodium-catalyzed conjugate addition reaction conditions. Compound VIIb is converted to compound XVI by treating it with

bis(pinacolato)diboron, a catalyst such as Pd(dppf)Cl2, an additive such as KOAc in a reaction medium provided by a solvent such as DMF, DMSO, toluene, or 1,4-dioxane at a temperature ranging from about room temperature to about the reflux temperature of the solvent.

As illustrated in Scheme 4, compound XVII is converted to compound XVIII by a three- step process. In the first step, compound XVII is converted into an ester (structure not shown) using a reagent such as thionyl chloride in a reaction medium provided by a solvent such as methanol or ethanol at a temperature ranging from about 0 °C to about 50 °C. In the second step, the ester group formed in step one is converted to the corresponding alcohol by reduction (structure not shown) with a reagent such as sodium borohydride in a reaction medium provided by a solvent such as THF at a temperature ranging from about 0 °C to about 30 °C. In the third step, the alcohol formed in step two is converted into compound XVIII using acetyl protection conditions. Compound XVIII is converted into compound XIX under Heck reaction conditions using compound XIII, a catalyst such as Pd(OAc)2, additives such as triethylamine and TBAB, in a reaction medium provided by a solvent such as DMF at a temperature of about 120 °C.

Compound XIX is converted to compound VI by coupling it with compound XX using rhodium- catalyzed conjugate addition reaction conditions. Scheme 5

As shown in Scheme 5, compound XXI is converted to compound XXII by treatment with aqueous hydrazine at a temperature from about room temperature to about 65 °C.

Compound XXII is converted to compound XIb by a cyclization reaction with an acid anhydride such as LXXVII. Alternatively, compound XXII is treated with R 4 CO 2 H (LXXVIII) in a reaction medium provided by a solvent such as propionic acid at a temperature from about room temperature to about 140 °C to provide XIb. Compound XIb is converted to compound XX by treating with bis(pinacolato)diboron, Pd(dppf)Cl 2 , and KOAc in a reaction medium provided by a solvent such as DMF, DMSO, toluene, or 1,4-dioxane, at a temperature of about 70 °C‒100 °C. Compound XIb is converted to compound XXIII by treatment with potassium

vinyltrifluoroborate, a palladium catalyst such as (Ph 3 P) 4 Pd, Pd(OAc) 2 , Pd(dppf)Cl 2 or

Pd(dppf)Cl2 ^CH2Cl2, a base such as K3PO4, TEA, K2CO3 or NaOAc in a reaction medium provided by a solvent such as a mixture of 1,4-dioxane and water, at a temperature of about 100 °C‒110 °C. Compound XXIII is converted to compound VIIIb by (i) treatment with ozone in a reaction medium provided by a solvent such as dichloromethane, MeOH, or mixtures thereof, at a temperature of about -78 °C followed by the addition of triphenylphosphine or dimethylsulfide, or (ii) treatment with OsO 4 in a reaction medium provided by a solvent such as mixture of 1,4- dioxane and water, followed by sodium periodate or (iii) treatment with K2OsO4 ^2H2O in the presence of sodium periodate in a reaction medium provided by a solvent such as mixture of 1,4- dioxane and water. Scheme 6

As depicted in Scheme 6, compound XXIV is converted to compound XXV by treatment with R 36 -LG (LXXVI), wherein R 36 is -C3-C4cycloalkyl or -C1-C4perhaloalkyl and LG is defined above, in the presence of a base such as cesium hydroxide hydrate or potassium carbonate in a reaction medium provided by a solvent such as DMSO, DMF and water or mixtures thereof at a temperature of about 150 °C. Compound XXV is converted to compound XXVI by (i) a halogenation reaction with bromine in the presence of sodium acetate in a reaction medium provided by a solvent such as acetic acid or (ii) with NBS in a reaction medium provided by a solvent such as acetic acid. Compound XXVI is converted to compound XXVII by alkylation of the aniline with R 1 -LG (LXXIX), wherein LG is a leaving group as defined above, in the presence of a base such as sodium hydride in a reaction medium provided by a solvent such as DMF. Compound XXVII is converted to compound XXVIII by a reduction of the nitro group with iron or zinc in a reaction medium provided by a solvent such as acetone, ethanol, water, acetic acid, aqueous ammonium chloride solution, or mixtures thereof, at a temperature of about 0 °C to a temperature of about room temperature. Alternatively, this reduction is accomplished by hydrogenation using a catalyst which is a finely grained solid composed mostly of nickel derived from a nickel-aluminum alloy, such as Raney nickel, in a reaction medium provided by a solvent such as ethanol under an atmosphere of hydrogen gas. Compound XXVIII is converted to compound XIa by cyclization with sodium nitrate in the presence of an acid such as aqueous sulfuric acid or aqueous HCl in a reaction medium provided by a solvent such as water, acetic acid, or methanol, or mixture thereof.

As illustrated in Scheme 7, compound XXIX is converted to compound XXV by displacement of the fluorine atom with R 1 -NH2 (LXXX); with or without a base such as triethylamine; with or without a reaction medium provided by a solvent such as ethanol or acetonitrile at a temperature ranging between about 50 °C to about 150 °C for an amount of time ranging between 4‒48 hours. Compound XXV is converted to compound XIa by a three-step process which includes a bromination reaction, a nitro group reduction reaction, and a cyclization reaction. The conditions for these reactions are as described in Scheme 6 as follows: the bromination reaction conditions are as described in the conversion of XXV to XXVI, the nitro group conditions are as described in the conversion of XXVII to XXVIII and the cyclization reaction conditions are as described in the conversion of XXVIII to XIa.

Alternatively, compound XXV is converted to compound XIa using a similar three-step process wherein the order of the reaction steps is a nitro group reduction reaction then a cyclization reaction, followed by a bromination reaction.

As described in Scheme 8, compound L is converted to compound LI by a two-step process. In the first step, the chlorine atom is displaced by R 9 -NH2 (LXXXI) in a reaction medium provided by a solvent such as methanol at temperature of about 110 °C. In the second step, the aniline produced in the first step (structure not shown) is treated with bromine in a reaction medium provided by a solvent such as acetic acid to provide compound LI. Compound LI is converted to compound LII by coupling to 3,3-diethoxyprop-1-yne (structure not shown) using a palladium catalyst such as Pd(PPh 3 ) 2 Cl 2 in the presence of an additives such as CuI and triethylamine at a temperature of about 65 °C for about 1.5 hours. Compound LII is converted to compound LIII by treatment with a reagent such as TBAF in a reaction medium provided by a solvent such as THF at a temperature of about 65 °C. Compound LIII is converted to compound LIV using an acid such as HCl in a reaction medium provided by a solvent such as 1,4-dioxane. Compound LIV is converted to compound XIV with a reagent such as ethyl 2- (diethoxyphosphoryl)acetate (structure not shown) using a base such as sodium hydride in a reaction medium provided by a solvent such as THF. Scheme 9 w herein in this scheme HetA is

As shown in Scheme 9, compound XIV is converted to compound VIIIa by treatment with ozone in a reaction medium provided by a solvent such as dichloromethane, MeOH, or mixtures thereof, at a temperature of about -78 °C to about 15 °C followed by the addition of triphenylphosphine or dimethylsulfide. Scheme 10a

As depicted in Scheme 10a, compound LVa is converted to compound LVIIa by coupling to an amine reagent LVIa using a base such as potassium carbonate in a reaction medium provided by mixture of solvents such as THF and water. These conditions are referred to as “sulfonamide forming reaction conditions”. Compound LVIIa is converted to compounds IIIa’ via a two-step process. The first step of this two-step process is removal of the tert-butyl carboxy protecting group to produce the free amine (free amine structure not shown). In this first step compound LVIIa is treated with TFA in a reaction medium provided by a solvent such as dichloromethane. These conditions are referred to as“tert-butyl carboxy protecting group removal conditions”. In the second step of this two-step process, the free amine produced in step one is cyclized to IIIa’ by treating with a base such as triethylamine or DIPEA at a temperature ranging from about reflux temperature of THF or toluene to about 160 °C in a reaction medium provided by a solvent such as toluene, DMSO, or THF. These conditions are referred to as“base cyclization conditions”. When this reaction is conducted with compound LVIa wherein Z is N- Cbz, then the Cbz group of compound IIIa’ can be removed using hydrogenolysis conditions such as Pd(OH)2/C under H2 in a solvent such as MeOH from a temperature ranging from about room temperature to about 50 °C. These conditions are referred to as“Cbz protecting group removal conditions”. The free amine that is produced from this Cbz removal can then be methylated by treatment with 37% aqueous HCHO and NaBH3CN in a solvent mixture such as MeOH:DCM (2:1) at a temperature range of about room temperature to about 50 °C to provide compound IIIa’ wherein Z is NMe. Scheme 10b

As depicted in Scheme 10b, compound LVb is converted to compound LVIIb by coupling to an amine reagent LVIb (made as shown in Scheme 11) using sulfonamide forming reaction conditions. Compound LVIIb is converted to compound IIIb via a two-step process. In this first step, compound LVIIb is subjected to tert-butyl carboxy protecting group removal conditions. In the second step of this two-step process, the free amine produced in step one is cyclized to IIIb’ using base cyclization conditions. Scheme 10c

As depicted in Scheme 10c, compound LVc is converted to compound LVIIc by coupling to an amine reagent LVIc using sulfonamide forming reaction conditions. Compound LVIIc is converted to compound IIIc’ by treating with a base such as potassium carbonate or potassium tert-butoxide in a reaction medium provided by a solvent such as DMSO or water, or mixtures thereof, at a temperature range of about 80 °C to about 110 °C for a time range between 2‒40 hours. These conditions are referred to as“alternative base cyclization conditions”. In amine reagent, LVIc, when R 22 and R 23 are taken together with the carbon to which they are attached to form an azetidine, pyrrolidine or piperidine, the nitrogen atom of the azetidine, pyrrolidine or piperidine is protected with a protecting group such as tert-butyl carboxy group. This protecting group could then be removed after compound IIIc’ has been formed using“tert-butyl carboxy protecting group removal conditions”.

As depicted in Scheme 10d, compound LVd is converted to compound LVIId by coupling to an amine reagent LVId using sulfonamide forming reaction conditions. Compound LVII is converted to compound III’ using alternative base cyclization conditions.

As depicted in Scheme 10e, compound LVd is converted to compound CXX by coupling to an amine reagent XXXe using sulfonamide forming reaction conditions. Compound CXX is converted to compound CXXI by removal of the protecting group (PG) using Cbz protecting group removal conditions when PG is Cbz. Compound CXXI is converted to compound III’d using alternative base cyclization conditions. Scheme 11

As described in Scheme 11, compound LX is converted to compound LXI by treating compound LX with a base such as LDA in a reaction medium provided by a solvent such as THF, ether, hexanes, toluene, and mixtures thereof and then adding an alkyl halide reagent R 20 -LG (LXXXII). Compound LXI is converted to compound LVIb using a catalyst which is a finely grained solid composed mostly of nickel derived from a nickel-aluminum alloy, such as Raney nickel, in a reaction medium provided by a solvent mixture such as methanol and aqueous ammonia, under a hydrogen atmosphere.

As shown in Scheme 12a, compound LXX is converted to compound LXXI by treating with HBF4 and tert-butyl nitrite in a reaction medium provided by a solvent such as acetonitrile at a temperature of about 0 °C. Compound LXXI, shown in brackets above, is not isolated, and is converted to compound LXXII by adding the reaction solution containing LXXI to a separate solution of CuCl in a reaction medium provided by a solvent such as acetic acid which is saturated by bubbling with SO2 gas. Compound LXXII is converted to compound LXXXIV using a two-step process wherein compound LXXII is coupled with compound LVIa using sulfonamide forming reaction conditions. This product is then subjected to tert-butyl carboxy protecting group removal conditions to provide compound LXXXIV. Compound LXXXIV is converted to compound LXXIII using base catalyzed cyclization condition or alternative base catalyzed cyclization condition. Compound LXXIII is converted to compounds IIIa’, wherein R 26 is -CN, by a palladium-catalyzed cyanation reaction. This cyanation reaction is achieved by using a palladium catalyst such as Pd(dppf)Cl2 or Pd2(dba)3, using zinc cyanide, zinc as an additive, and with or without X-Phos added, in a reaction medium provided by a solvent such as DMF or DMA, at a temperature of about 110 °C to about 140 °C for a time range of 3‒16 hours. These conditions are referred to as“palladium-catalyzed cyanation reaction conditions”. Scheme 12b

As shown in Scheme 12b, compound LXXIV is converted to compound LXXXIII using a two-step process wherein compound LXXIV is coupled with compound LVIb (made as shown in Scheme 11) using sulfonamide forming reaction conditions. This product is then subjected to tert-butyl carboxy protecting group removal conditions to provide compound LXXXIII.

Compound LXXXIII is converted to compound LXXV using base catalyzed cyclization condition or alternative base catalyzed cyclization condition. Compound LXXV is converted to compound IIIb’, wherein R 18 is -CN, using palladium-catalyzed cyanation reaction conditions.

As shown in Scheme 13, compound XC is converted to compound XCI by subjecting it to acidic hydrolysis conditions such as aqueous HCl in a reaction medium provided by solvents such as water, dioxane, THF or mixtures thereof at a temperature range from about room temperature to about reflux temperature of the solvent. Compound XCI is converted to compound XCII under carbonylation conditions, employing a catalyst such as Pd(OAc)2, an additive such as dccp•2HBF 4 in the presence of a base such as K 2 CO 3 in a reaction medium provided by a solvent such as MeOH at a temperature range from about room temperature to about reflux temperature of the solvent under an atmosphere of CO at a pressure range of about 15 psi to about 50 psi. Compound XCII is converted to XCIII by treating it with POBr3 in a reaction medium provided by a solvent such as toluene at a temperature range from about room temperature to about reflux temperature of the solvent. Compound XCIII is converted to compound XCIV by reduction with a reagent such as sodium borohydride in a reaction medium provided by a solvent such as THF at a temperature ranging from about 0 °C to about 30 °C. Compound XCIV is converted to compound XCV by subjecting it to TBS protecting group conditions.

As shown in Scheme 14, compound XCVI is converted to compound XCVII by reduction with a reagent such as sodium borohydride in a reaction medium provided by a solvent such as THF at a temperature ranging from about 0 °C to about 30 °C. Compound XCVII is converted to compound XCVIII subjecting XCVII to TBS protecting group conditions. Scheme 15

As shown in Scheme 15, compound XVII is converted to compound XCIX using thionyl chloride in a reaction medium provided by a solvent such as methanol at a temperature ranging from about 0 °C to about 50 °C. XCIX is converted to compound C by reduction with a reagent such as sodium borohydride in a reaction medium provided by a solvent such as THF at a temperature ranging from about 0 °C to about 30 °C. Compound C is converted to compound CI by subjecting C to TBS protecting group conditions. Compound CI is converted to compound CII under carbonylation conditions, employing a catalyst such as Pd(dppf) 2 Cl 2 in the presence of a base such as TEA in a reaction medium provided by solvents such as MeOH, DMF or mixtures thereof at a temperature range from about room temperature to about 100 °C under an atmosphere of CO at a pressure range of about 15 psi to about 50 psi. Compound CII is converted to CIII by treating with DIBAL-H in a reaction medium provided by a solvent such as dichloromethane at a temperature ranging from about -78 °C to about -50 °C.

As shown in Scheme 16, compound CVIII is prepared from compound CIV through several different pathways depending on the conditions used and on the choice of the R 24 substituent. For example, compound CIV is converted to compound CV through a two-step reaction. In the first step, compound XXXa or XXXb is treated with tBuOK or NaH in a reaction medium provided by a solvent such as t-butanol when using tBuOK or THF when using NaH. The product from this first step is then added to a solution of compound CIV in a in a reaction medium provided by solvent such as DMSO at a temperature ranging from about room temperature to about 100 °C. Alternatively, compound CIV is converted to compound CV through a different two-step process. In the first step, compound XXXa or XXXb is treated with tBuOK or NaH in a reaction medium provided by a solvent such as t-butanol when using tBuOK or THF when using NaH. The product from this first step is then added to a solution of compound CIV in a solvent medium such as toluene under palladium catalysis conditions using reagents such as NaH, Pd 2 dba 3 , racemic 2-(di-t-butylphosphino)-1,1'-binaphthyl, at a temperature ranging from about room temperature to about reflux temperature of solvent. Alternatively, compound CIV is converted to compound CV by treating compound CIV with compound XXXc or XXXd in a reaction medium provided by a solvent such as DMSO at a temperature ranging from about room temperature to about 100 °C. Compound CV is converted to compound CVII by coupling it with compound II under Mitsunobu reaction conditions. Alternatively, compound CV is converted to compound CVII by coupling with compound V in an alkylation reaction. This alkylation reaction is performed by treating compound CV with a base such as sodium hydride, potassium tert-butoxide or K2CO3, in a reaction medium provided by solvents such as THF, DMF, CH 3 CN or mixtures thereof. Compound V is then added to this mixture to provide compound CVII. These conditions are referred to as“alkylation reaction conditions”.

Compound CIV is converted to compound CVI by coupling it with II under Mitsunobu reaction conditions. Alternatively, compound CIV is converted to compound CVI by coupling with compound V under alkylation reaction conditions. Compound CVI is converted to CVII using conditions described above for conversion of compound CIV to compound CV. Compound CVII is converted to compound CVIII under basic hydrolysis reaction conditions. Alternatively, the hydrolysis is also performed under acidic conditions using TFA in a reaction medium provided by solvent such as DCM at a temperature range from about room temperature to about the reflux temperature of the solvent. These conditions are referred to as“acidic hydrolysis conditions”. In instances where the R 35 is Bn, hydrogenation conditions are employed for removal of the benzyl group such as transfer hydrogenation conditions using Pd/C as the catalyst and cyclohexadiene in a reaction medium provided by a solvent such as ethanol at a temperature range of about room temperature to about reflux temperature of the solvent. Alternatively, the benzyl group is removed using 10% Pd(OH) 2 /C or 10%Pd/C in a reaction medium such as methanol as the solvent at a temperature range of about room temperature to about 50 °C under an atmosphere of H 2 gas wherein the reaction may be conducted in a conventional reaction flask or using a continuous flow hydrogenation reactor. The above conditions to remove a benzyl group are referred to as“benzyl deprotection conditions”. When compounds XXXb and XXXc are used, the protecting group, PG, is removed using TBS deprotection conditions when PG is TBS or benzyl protecting group conditions when PG is benzyl.

Scheme 17

wherein in the scheme R 29 = halo, R 35 is CH 3 or Bn and

R 24 is:

As shown in Scheme 19, compound CVIII is prepared from compound CIV by a pathway that proceeds through key intermediates CXX and CXXI. Compound CIV is transformed into compound CXX by a two-step sequence. In the first step, using Heck reaction conditions, compound CIV where R 29 is halo is converted to compound CIV where R 29 is

(CH 3 ) 3 (C)C(O)CH=CH (structure not shown), using tert-butyl acrylate, a catalyst such as palladium acetate, additives such as triethylamine and 2-(di-tert-butylphosphino)biphenyl, in a reaction medium provided by a solvent such as DMF at a temperature of about 120 °C. In the second step, compound CIV where R 29 is (CH3)3(C)C(O)CH=CH- is reduced to compound CIV where R 29 is (CH 3 ) 3 (C)C(O)CH 2 CH 2 ( Compound CXX) under an atmosphere of hydrogen gas, at a pressure of about 50 psi, using a catalyst such as palladium on carbon, in a reaction medium provided by a solvent such as methanol at a temperature of about room temperature. Compound CXX is transformed into compound CXXI by a two-step sequence. In the first step, compound CXX and compound II (shown in Scheme 1) are coupled under Mitsunobu reaction conditions as described above in Scheme 1. In the second step, the tert-butyl carboxy protecting group is removed under reaction conditions described above in Scheme 10a. Compound CXXI is transformed into compound CVIII by either a two-step reaction sequence or a three-step reaction sequence depending on the R 24 substituent. If the R 24 substituent contains a primary amide (substituent AA), a secondary cyclobutyl-substituted amide (substituent BB), or an ethanolamine amide group (substituent CC), then the two-step reaction sequence is used. In the first step of the two-step reaction sequence, an amide bond is formed with the appropriate amine in the presence of additives such as HATU and DIPEA in a reaction medium provided by a solvent such as DMF at a temperature of about room temperature. In the second step of the two-step reaction sequence, the R 35 acid protective group is removed under basic hydrolysis conditions (R 35 = methyl) or under hydrogenation conditions (R 35 = Bn) as described in Scheme 16. In the instance where the R 24 substituent is the N-(2-(2-aminoethoxy)ethyl)propionamide group (substituent DD), the three-step reaction sequence is followed. This three-step reaction sequence consists of the above two-step reaction sequence followed by the addition of a third step wherein the terminal NH2 of substituent DD is deprotected. The deprotection of the Boc group under the tert-butyl carboxy protecting group removal conditions described in Scheme 10a. The following examples are provided to further illustrate aspects of the invention and various preferred embodiments.

In obtaining the compounds described in the examples below and the corresponding analytical data, the following experimental and analytical protocols were followed unless otherwise indicated.

Reaction mixtures were magnetically stirred at room temperature. Where solutions are characterized as“dried,” they were generally dried over a drying agent such as Na 2 SO 4 or MgSO4. Where mixtures, solutions, and extracts were“concentrated”, they were typically concentrated on a rotary evaporator under reduced pressure.

Thin-layer chromatography was performed using Merck silica gel 60 F2542.5 cm x 7.5 cm, 250 mm or 5.0 cm x 10.0 cm, 250 mm pre-coated silica gel plates. Normal-phase flash column chromatography was performed on silica gel (SiO2) eluting with 2 M NH3 in MeOH/ CH2Cl2, unless otherwise noted.

Mass spectra (MS) were obtained on an Agilent series 1100 MSD using electrospray ionization (ESI) in positive mode unless otherwise indicated. Calculated (calcd.) mass corresponds to the exact mass.

High Performance Liquid Chromatography was performed as described for the individual compounds. Compound purification was made in some cases by acidic HPLC that entailed purification on a reverse phase HPLC system using different mobile phases that started initially with a mobile phase of 5% ACN in H 2 O (both with 0.05% TFA) that was held for 1 min, then changed to a gradient of 5-99% ACN over 6 min, which was held at 99% ACN for 3 min, with a flow rate of 80 mL/min. The following endcapped columns were used: Waters Xbridge Prep OBD C18 (pore size 130 Å, surface area 185 m 2 /g, carbon load of 18 %), Phenomenex Luna C18, (pore size 100 Å, surface area 440 m 2 /g, carbon load of 19 %), Phenomenex Synergi-Max C 18 (pore size 100 Å, surface area 475 m 2 /g, carbon load of 11-19 %), SunFire Prep C18 OBD (pore size 100 Å, surface area 340 m 2 /g, carbon load of 16 %), and Phenomenex Gemini (pore size 110 Å, surface area 375 m 2 /g, carbon load of 14%).

SFC was performed as described for individual compounds using the following stationary phase columns Chiralpak AD-H, Chiralpak IG, Chiralpak IC, Chiralpak AS-H, Chiralcel OJ-H, Chiralcel OZ-H, Phenomenex cellulose-2, Whelk O1 (S,S). The mobile phases used are described in the individual experimental write ups and usually consisted of varying amounts of CO2 and alcoholic solvents such as methanol, ethanol, isopropanol, EtOH/H2O containing 0.1% NH 3 .

Nuclear magnetic resonance (NMR) spectra were obtained on Bruker model DRX spectrometers. The format of the 1 H NMR data below is: chemical shift in ppm downfield of the tetramethylsilane reference or to residual protium in the solvent (multiplicity, coupling constant J in Hz, integration).

Chemical names were generated by either using ChemDraw (CambridgeSoft, Cambridge, MA) or ACD/Name Version 9 (Advanced Chemistry Development, Toronto, Ontario, Canada).

To provide a more concise description, some of the quantitative expressions given herein are not qualified with the term“about”. It is understood that, whether the term“about” is used explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including equivalents and approximations due to the experimental and/or measurement conditions for such given value.

Whenever a yield is given as a percentage, such yield refers to a mass of the entity for which the yield is given with respect to the maximum amount of the same entity that could be obtained under the particular stoichiometric conditions. Reagent concentrations that are given as percentages refer to mass ratios, unless indicated differently. Intermediate 1: 7,7a,8,9,10,11-Hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]th iadiazepine 5,5-dioxide.

Step A: tert-Butyl 2-((2-chloropyridine-3-sulfonamido)methyl)piperidine-1-carbo xylate. K2CO3 (22.6 g, 163 mmol) was added to a mixture of tert-butyl 2-(aminomethyl)piperidine-1- carboxylate (50.08 g, 233.7 mmol), in THF (525 mL) and H2O (105 mL). 2-Chloropyridine-3- sulfonyl chloride (33.0 g, 156 mmol) was then added and the mixture was stirred at room temperature for 6.5 hours. The mixture was concentrated to dryness under reduced pressure and partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate. These extractions resulted in several organic solvent fractions which were combined, dried over anhydrous MgSO 4 , filtered and concentrated to dryness under reduced pressure and purified by flash column chromatography (eluent: hexanes/ethyl acetate, 1:0 to 1:1, gradient elution) to afford the title compound (60 g, 99%) as a white solid. MS (ESI): mass calcd. for

C16H24ClN3O4S, 389.1; m/z found, 290.1 [M– BOC + H] + . 1 H NMR (400 MHz, CDCl3) ^ 8.57 (dd, J = 4.8, 1.9 Hz, 1H), 8.40 (dd, J = 7.8, 1.9 Hz, 1H), 7.44 (dd, J = 7.8, 4.8 Hz, 1H), 5.73 (s, 1H), 4.38 (dt, J = 10.2, 5.5 Hz, 1H), 3.93 (d, J = 14.2 Hz, 1H), 3.34 (s, 1H), 2.93 (dt, J = 12.3, 5.1 Hz, 1H), 2.74– 2.69 (m, 1H), 2.05 (s, 1H), 1.62– 1.52 (m, 3H), 1.48 (s, 9H), 1.39 (tdd, J = 10.1, 4.8, 2.5 Hz, 2H). Step B: 7,7a,8,9,10,11-Hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]th iadiazepine 5,5- dioxide. A solution of 20% TFA in DCM (165 mL, 2.15 mol) was added to tert-butyl 2-((2- chloropyridine-3-sulfonamido)methyl)piperidine-1-carboxylate (55.0 g, 141 mmol). The resulting mixture was stirred for 2.5 hours at room temperature, concentrated to dryness under reduced pressure and re-dissolved in toluene (645 mL). TEA (119.1 mL, 857.2 mmol) was added and the resulting mixture was heated to reflux for 15 hours, cooled to room temperature, and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: hexanes/ethyl acetate, 1:0 to 0:1, gradient elution) to afford the title compound (31 g, 82% (95% purity)). MS (ESI): mass calcd. for C 11 H 15 N 3 O 2 S, 253.1; m/z found, 254.2 [M+H] + . 1 H NMR (500 MHz, CDCl 3 ) d 8.24 (dd, J = 4.7, 1.9 Hz, 1H), 7.92 (dd, J = 7.8, 1.8 Hz, 1H), 6.77 (dd, J = 7.8, 4.6 Hz, 1H), 5.30 (s, 1H), 4.36– 4.20 (m, 2H), 3.49 (t, J = 12.7 Hz, 1H), 3.44– 3.31 (m, 2H), 1.84– 1.74 (m, 3H), 1.71– 1.55 (m, 3H). Intermediate 2: (*S)-7,7a,8,9,10,11-Hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepine 5,5-dioxide.

The racemic mixture of 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepine 5,5-dioxide enantiomers (Intermediate 1, 31g) was separated by chiral SFC (stationary phase: Chiralpak AD-H 5 µm 250 x 30 mm, Mobile phase: 70% CO 2 , 30% MeOH) to afford two enantiomers. The first eluting isomer (14.6 g) was designated (*S). MS (ESI): mass calcd. for C11H15N3O2S, 253.1; m/z found, 254.2 [M+H] + . 1 H NMR (500 MHz, CDCl3) d 8.25 (dd, J = 4.6, 1.8 Hz, 1H), 7.93 (dd, J = 7.8, 1.8 Hz, 1H), 6.77 (dd, J = 7.8, 4.6 Hz, 1H), 5.24 (t, J = 6.0 Hz, 1H), 4.37– 4.28 (m, 1H), 4.24 (dt, J = 13.3, 4.9 Hz, 1H), 3.50 (ddd, J = 13.4, 11.9, 6.4 Hz, 1H), 3.47– 3.32 (m, 2H), 1.87– 1.75 (m, 3H), 1.72– 1.56 (m, 3H). Intermediate 3: (*R)-7,7a,8,9,10,11-Hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepine 5,5-dioxide.

The second eluting isomer from the separation of isomers by chiral SFC described in Intermediate 2 (15.2 g) was designated (*R). MS (ESI): mass calcd. for C 11 H 15 N 3 O 2 S, 253.1; m/z found, 254.0 [M+H] + . 1 H NMR (500 MHz, CDCl3) d 8.23 (dd, J = 4.7, 1.9 Hz, 1H), 7.90 (dd, J = 7.8, 1.8 Hz, 1H), 6.75 (dd, J = 7.8, 4.6 Hz, 1H), 5.42 (t, J = 5.9 Hz, 1H), 4.31 (dq, J = 12.0, 4.7 Hz, 1H), 4.23 (dt, J = 13.3, 4.8 Hz, 1H), 3.50 (ddd, J = 13.5, 12.0, 6.4 Hz, 1H), 3.47– 3.31 (m, 2H), 1.85– 1.73 (m, 3H), 1.69– 1.55 (m, 3H). Intermediate 4: (R)-6,7,7a,8,9,10-Hexahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepine 5,5-dioxide.

Step A: tert-Butyl (R)-2-(((2-chloropyridine)-3-sulfonamido)methyl)pyrrolidine- 1- carboxylate. Water (17 mL) was added to a solution of tert-butyl (R)-2- (aminomethyl)pyrrolidine-1-carboxylate (7.50 g, 37.4 mmol) in THF. K2CO3 (3.67 g, 26.6 mmol) and 2-chloropyridine-3-sulfonyl chloride (5.25 g, 24.8 mmol) were sequentially added and the resulting mixture was stirred at room temperature for 2 hours. THF was removed under reduced pressure and the mixture was partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate. These extractions resulted in several organic solvent fractions which were combined, washed with brine, dried over anhydrous MgSO 4 , filtered and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: 0 to 20% EtOAc/DCM, gradient elution) to afford the title compound (8.9 g, 95%). 1 H NMR (500 MHz, DMSO-d 6 ) d 8.64 (dd, J = 4.8, 1.8 Hz, 1H), 8.39– 8.26 (m, 2H), 7.66 (dd, J = 7.8, 4.8 Hz, 1H), 3.74– 3.51 (m, 1H), 3.12 (t, J = 14.1 Hz, 3H), 2.93– 2.78 (m, 1H), 1.94– 1.63 (m, 4H), 1.36 (s, 9H). Step B: (R)-6,7,7a,8,9,10-Hexahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5 ]thiadiazepine 5,5- dioxide. TFA in DCM (1:4 v/v, 80 mL) was added to tert-butyl (R)-2-(((2-chloropyridine)-3- sulfonamido)methyl)pyrrolidine-1-carboxylate (8.50g, 22.6 mmol) at room temperature. The resulting mixture was stirred for 1 hour and the solvents were removed under reduced pressure. THF (80 mL) and TEA (20 mL, 143.8 mmol) were added and the resulting mixture was heated to reflux for 18 hours. The reaction mixture was cooled to room temperature and the solvents were removed under reduced pressure. Ethyl acetate was added to the residue. The resulting solution was washed with brine, dried over anhydrous MgSO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: 0 to 30% EtOAc/DCM, gradient elution) to afford the title compound (4.7 g, 86%). MS (ESI): mass calcd. for C10H13N3O2S, 239.1; m/z found, 240.1 [M+H] + . 1 H NMR (600 MHz, DMSO-d6) d 8.27 (dd, J = 4.7, 1.8 Hz, 1H), 8.06 (s, 1H), 7.94 (dd, J = 7.7, 1.8 Hz, 1H), 6.85 (dd, J = 7.7, 4.7 Hz, 1H), 4.25– 4.15 (m, 1H), 3.66– 3.56 (m, 1H), 3.56– 3.48 (m, 1H), 3.29 (dd, J = 13.2, 3.4 Hz, 1H), 3.03 (dd, J = 13.2, 11.9 Hz, 1H), 2.15– 2.02 (m, 1H), 1.94– 1.84 (m, 2H), 1.74– 1.65 (m, 1H). Intermediate 5: 2',3'-Dihydrospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxa thiazepine] 1',1'-dioxide.

Step A: 2-Chloro-N-((1-hydroxycyclopropyl)methyl)pyridine-3-sulfonam ide. A solution of 2-chloropyridine-3-sulfonyl chloride (13.0 g, 61.3 mmol) in THF (30 mL) was added dropwise to a mixture of 1-(aminomethyl)cyclopropanol (5.0 g, 57 mmol), K2CO3 (15.0 g, 109 mmol), THF (20 mL), and H2O (10 mL) at 0 °C. The resulting mixture was stirred for 12 hours with gradual warming to room temperature before concentrating to dryness under reduced pressure. The residue was diluted with water (150 mL) and the aqueous layer was extracted with ethyl acetate (100 mL x 3). These extractions resulted in several organic solvent fractions which were combined, dried over anhydrous Na 2 SO 4 , filtered and concentrated to dryness under reduced pressure to afford the title compound (10 g) as a yellow oil, which was used in the next step without further purification. MS (ESI): mass calcd. for C9H11ClN2O3S, 262.0; m/z found, 262.8 [M+H] + .

Step B: 2',3'-Dihydrospiro[cyclopropane-1,4'-pyrido[2,3-b][1,4,5]oxa thiazepine] 1',1'- dioxide. t-BuOK (10 g, 89 mmol) was added in portions to a solution of 2-chloro-N-((1- hydroxycyclopropyl)methyl)pyridine-3-sulfonamide (10 g) in DMSO (50 mL) at 0 °C. The resulting mixture was heated to 80 °C for 4 hours before concentrating to dryness under reduced pressure. The residue was diluted with H 2 O (100 mL), and the pH adjusted to pH ~6 with 1 N aqueous HCl. The aqueous layer was extracted with ethyl acetate (100 mL x 3). These extractions resulted in several organic solvent fractions which were combined, dried over anhydrous Na 2 SO 4 , filtered and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 1:0 to 1:4, gradient elution) to afford the title compound (4.3 g, 47%) as a yellow solid. MS (ESI): mass calcd. for C 9 H 10 N 2 O 3 S, 226.0; m/z found, 227.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 ) d 8.44 - 8.35 (m, 1H), 8.24 - 8.13 (m, 2H), 7.42 - 7.37 (m, 1H), 3.54 - 3.43 (m, 2H), 0.91 - 0.84 (m, 2H), 0.77 - 0.70 (m, 2H). Intermediate 6: 8'-Methyl-2',3'-dihydrospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepine] 1',1'-dioxide.

Step A: 2-Chloro-N-((1-hydroxycyclopropyl)methyl)-5-methylpyridine-3 -sulfonamide. 2-Chloro-5-methylpyridine-3-sulfonyl chloride (89.0 g, 394 mmol) in THF (300 mL) was added dropwise to a mixture of 1-(aminomethyl)cyclopropanol (68.5 g, 413 mmol) and K2CO3 (136 g, 984 mmol) in THF (1.3 L) and H2O (400 mL) while keeping the inner temperature around 0 ~ 5 °C. The reaction mixture was allowed to warm to room temperature and stirred at 25 °C for 16 hours. The reaction mixture was diluted with water (500 mL) and the aqueous layer was extracted with ethyl acetate (500 mL x 1, 300 mL x 2). These extractions resulted in several organic solvent fractions which were combined, washed with brine (800 mL), dried over

Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by column chromatography (eluent: petroleum ether/ethyl acetate/ethanol, 9:3:1 to 3:1:0, gradient elution), followed by trituration in MTBE (120 mL) to afford the title compound (42 g, 39%). MS (ESI) : mass calcd. for C 10 H 13 ClN 2 O 3 S, 276.1; m/z found, 276.8 [M+H] + .

Step B: 8'-Methyl-2',3'-dihydrospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepine] 1',1'-dioxide. An aqueous solution of K2CO3 (3 M, 152 mL) was added to a mixture of 2-chloro-N-((1-hydroxycyclopropyl)methyl)-5-methylpyridine-3 -sulfonamide (42.0 g, 152 mmol) in DMSO (800 mL) and the solution was stirred at 95 °C for 40 hours under N2. A black brown suspension was obtained. The mixture was diluted with H2O (1.5 L) and 4 N HCl in MeOH was added to the solution until the pH was ~ 7. The aqueous layer was extracted with EtOAc (1 L and then 500 mL x 6). These extractions resulted in several organic solvent fractions which were combined, washed with brine (1 L), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 1:1 to 1:4, gradient elution) and triturated in MTBE (100 mL) for 0.5 hours to afford the title compound (21.5 g, 59%). MS (ESI): mass calcd. for C10H12N2O3S, 240.1; m/z found, 241.3. [M+H] + . 1 H NMR (400 MHz, DMSO-d6) d 8.24 (d, J = 1.8 Hz, 1H) 8.13 (br s, 1H) 8.05 (d, J = 2.0 Hz, 1H) 3.49 (s, 2H) 2.34 (s, 3H) 0.86 - 0.93 (m, 2H) 0.69 - 0.79 (m, 2H). Intermediate 7: 2,3-Dihydrospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetane] 1,1-dioxide.

Step A: 2-Fluoro-N-((3-hydroxyoxetan-3-yl)methyl)benzenesulfonamide. A mixture of 3-(aminomethyl)oxetan-3-ol (30.0 g, 291 mmol), 2-fluorobenzene-1-sulfonyl chloride (38.0 g, 195 mmol), K 2 CO 3 (23.0 g, 217 mmol), THF (240 mL) and H 2 O (60 mL) were stirred at room- temperature for 2.5 hours. The reaction mixture was poured into H2O (50 mL) and extracted with ethyl acetate (50 mL x 3). These extractions resulted in several organic solvent fractions which were combined, washed with brine (20 mL), dried over anhydrous MgSO 4 , filtered and concentrated to dryness under reduced pressure to afford the title compound (40 g) which was used in the next step without further purification. MS (ESI): mass calcd. for C10H12FNO4S, 261.1; m/z found, 262.2 [M+H] + .

Step B: 2,3-Dihydrospiro[benzo[b][1,4,5]oxathiazepine-4,3'-oxetane]1 ,1-dioxide. A mixture of 2-fluoro-N-((3-hydroxyoxetan-3-yl)methyl)benzenesulfonamide (40 g), t-BuOK (47.0 g, 419 mmol), and DMSO (150 mL) was sparged with N2 for 5 minutes and was stirred at 95 °C for 4 hours. The reaction mixture was cooled to room temperature, acidified to pH ~2 with 5 N aqueous HCl, and poured into H 2 O (50 mL). The resulting suspension was filtered and washed with H2O (30 mL) and petroleum ether (20 mL). The solid was triturated with petroleum ether/ethyl acetate (4:1, 50 mL) and filtered, dried under reduced pressure to afford the title compound (23.6 g, 62%) as a yellow solid. To obtain a second portion of the title compound, the filtrate was extracted with ethyl acetate (50 mL x 3). The combined organic extracts were washed with brine (30 mL), dried over anhydrous MgSO4, filtered and concentrated to dryness under reduced pressure to give a second portion of the title compound, which was purified by preparative HPLC using a Phenomenex Synergi Max-RP, 250 x 50 mm x 10 mm column (eluent: 10% to 40% (v/v) CH3CN and H2O with 0.225% HCOOH) to afford pure product. The product was suspended in water (20 mL), the mixture frozen using dry ice/acetone, and then lyophilized to dryness to afford the title compound (6.35 g,) as a yellow solid. Total compound obtained from this experiment was 30.0 g. LC-MS (ESI): RT = 3.27 min, mass calcd. for C10H11NO4S 241.0, m/z found 242.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 ) d 8.13 (t, J = 6.7 Hz, 1H), 7.71 (dd, J = 7.8, 1.7 Hz, 1H), 7.61 (dt, J = 7.8, 1.7 Hz, 1H), 7.44 - 7.40 (m, 1H), 7.35 - 7.30 (m, 1H), 4.43 (d, J = 7.3 Hz, 2H), 4.33 (d, J = 7.5 Hz, 2H), 3.74 (d, J = 6.6 Hz, 2H). Intermediate 8: 7a-Methyl-6,7,7a,8,9,10-hexahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepine 5,5-dioxide.

Step A: tert-Butyl 2-cyano-2-methylpyrrolidine-1-carboxylate. n-BuLi (20 mL, 2.5 M in n-hexane, 50 mmol) was added dropwise to a solution of diisopropylamine (8.6 mL, 61 mmol) and THF (120 mL) at -78 °C. The resulting mixture was stirred at -78 °C for 30 minutes and was added dropwise to a solution of tert-butyl 2-cyanopyrrolidine-1-carboxylate (8.0 g, 41 mmol) in THF (150 mL) at -78 °C. The resulting mixture was stirred at -78 °C for 2 hours and then it was treated with MeI (5.0 mL, 80 mmol). This mixture was stirred at 0 °C for 2 hours before it was quenched with water (100 mL). The aqueous layer was extracted with ethyl acetate (100 mL x 3). These extractions resulted in several organic solvent fractions which were combined, dried over anhydrous Na 2 SO 4 , filtered and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 50:1 to 5:1, gradient elution) to afford the title compound (5 g, 58%) as a yellow oil. 1 H NMR (400 MHz, CDCl 3 ) d 3.59 (br s, 1H), 3.48 - 3.36 (m, 1H), 2.58 - 2.45 (m, 1H), 2.04 - 1.85 (m, 3H), 1.70 (br s, 3H), 1.52 (br s, 9H).

Step B: tert-Butyl 2-(aminomethyl)-2-methylpyrrolidine-1-carboxylate. Raney Ni (1 g) was added to a mixture of tert-butyl 2-cyano-2-methylpyrrolidine-1-carboxylate (1.0 g, 4.8 mmol), methanol (20 mL), and 25% aqueous NH 3 (5 mL) under Ar. The resulting mixture was stirred under H2 (15 psi) at room temperature for 2 hours. The suspension was filtered through diatomaceous earth such as Celite ® and the filtrate was concentrated to dryness under reduced pressure to afford the title compound (750 mg, 74%) as a yellow oil. 1 H NMR (400 MHz, CDCl 3 ) d 3.61 (d, J = 5.1 Hz, 1H), 3.41 - 3.28 (m, 1H), 3.23 (d, J = 13.0 Hz, 1H), 3.08 (d, J = 13.0 Hz, 1H), 2.72 - 2.59 (m, 1H), 2.12 - 1.96 (m, 1H), 1.69 - 1.54 (m, 2H), 1.47 (d, J = 13.9 Hz, 12H).

Step C: tert-Butyl 2-((2-chloropyridine-3-sulfonamido)methyl)-2-methylpyrrolidi ne-1- carboxylate. 2-Chloropyridine-3-sulfonyl chloride (3.5 g, 16 mmol) was added in portions to a mixture of tert-butyl 2-(aminomethyl)-2-methylpyrrolidine-1-carboxylate (3.6 g, 17 mmol), K 2 CO 3 (2.74 g, 20.0 mmol) in THF (60 mL) and H 2 O (15 mL). The resulting mixture was stirred at room temperature for 16 hours before diluting with H2O (25 mL) and extracting the aqueous layer with ethyl acetate (50 mL x 2). These extractions resulted in several organic solvent fractions which were combined, dried over anhydrous Na 2 SO 4 , filtered and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 10:1 to 5:1, gradient elution) to afford the title compound (5.5 g, 85%). MS (ESI): mass calcd. for C 16 H 24 ClN 3 O 4 S, 389.1; m/z found, 412.0 [M+Na] + . Step D: 2-Chloro-N-((2-methylpyrrolidin-2-yl)methyl)pyridine-3-sulfo namide. TFA (6.5 mL, 85 mmol) was added to a solution of tert-butyl 2-((2-chloropyridine-3- sulfonamido)methyl)-2-methylpyrrolidine-1-carboxylate (5.5 g, 14 mmol) in dichloromethane (20 mL). The resulting mixture was stirred at room temperature for 5 hours and concentrated to dryness under reduced pressure to afford the title compound (4 g) as a yellow oil, which was used in the next step without further purification. MS (ESI): mass calcd. for C 11 H 16 ClN 3 O 2 S, 289.1; m/z found, 289.9 [M+H] + .

Step E: 7a-Methyl-6,7,7a,8,9,10-hexahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepine 5,5-dioxide. DIPEA (9.1 mL,55 mmol) was added to a solution of 2- chloro-N-((2-methylpyrrolidin-2-yl)methyl)pyridine-3-sulfona mide (4.0 g, 14 mmol) and DMSO (30 mL). The resulting mixture was stirred at 160 °C for 6 hours before cooling to room temperature and concentrating to dryness under reduced pressure. The residue was dissolved in ethyl acetate (200 mL) and the resulting mixture was washed with H 2 O (100 mL x 3). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative HPLC using a Phenomenex Gemini column, 150 x 25 mm x 5 mm (eluent: 15% to 35% (v/v) CH 3 CN and H 2 O with 0.05% NH 3 ) to afford the title compound. The product was suspended in water (50 mL), the mixture frozen using dry ice/acetone, and then lyophilized to dryness to afford the title compound (2.9 g, 82%). MS (ESI): mass calcd. for C 11 H 15 N 3 O 2 S, 253.1; m/z found, 254.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 ) d 8.39 - 8.32 (m, 1H), 8.04 - 7.99 (m, 1H), 7.98 - 7.92 (m, 1H), 7.02 - 6.96 (m, 1H), 3.92 - 3.82 (m, 1H), 3.31 - 3.20 (m, 2H), 3.17 - 3.08 (m, 1H), 2.01 - 1.68 (m, 4H), 0.78 (s, 3H). Intermediate 9: 7,7a,8,9,10,11-Hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]th iadiazepine- 3-carbonitrile 5,5-dioxide.

Step A: 5-Bromo-2-chloropyridine-3-sulfonyl chloride. HBF 4 (29.0 mL, 189 mmol) was added dropwise to a solution of 5-bromo-2-chloropyridin-3-amine (25.0 g, 121 mmol) in acetonitrile (200 mL) and the temperature of the solution was kept between 0 °C to 5 °C. The resulting mixture was stirred at 0 °C for 10 minutes before adding tert-butyl nitrite (22.0 mL, 185 mmol) dropwise under an atmosphere of N 2 . The resulting mixture was stirred at 0 °C for another 2 hours to afford solution one. While solution one was stirring, a separate second solution was prepared wherein a mixture of copper (I) chloride (18.0 g, 182 mmol) and acetic acid (200 mL) was cooled to 0 °C, and SO 2 gas was bubbled through the solution (> 1.3 M) for 1 hour. Solution one was then added dropwise to solution two at 0 °C under N 2 atmosphere. The resulting mixture was stirred for 16 hours with gradual warming to room temperature. The suspension was filtered and washed with ethyl acetate (30 mL x 2). The filtrate was

concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: petroleum ether) to afford the title compound (24.5 g, 71%) as a brown liquid. 1 H NMR (400 MHz, DMSO-d6) d 8.50 (d, J = 2.6 Hz, 1H), 8.27 (d, J = 2.4 Hz, 1H).

Step B: tert-Butyl 2-(((5-bromo-2-chloropyridine)-3-sulfonamido)methyl)piperidi ne-1- carboxylate. tert-Butyl 2-(aminomethyl)piperidine-1-carboxylate (18.1 g, 84.5 mmol) was added to a suspension of K2CO3 (34.9 g, 253 mmol) in THF (150 mL) and H2O (30 mL) at 0 °C. The reaction mixture was stirred for 10 minutes at 0 °C and then treated with 5-bromo-2- chloropyridine-3-sulfonyl chloride (24.5 g, 84.2 mmol). The resulting mixture was stirred at 0 °C for 2.5 hours and concentrated to dryness under reduced pressure. The residue was dissolved in water (50 mL) and the aqueous layer was extracted with ethyl acetate (50 mL x 3). These extractions resulted in several organic solvent fractions which were combined, washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 1:0 to 7:3, gradient elution) to afford the title compound (31 g, 74%) as a yellow solid. MS (ESI): mass calcd. for C16H23BrClN3O4S, 467.0; m/z found, 490.1 [M+Na] + .

Step C: 5-Bromo-2-chloro-N-(piperidin-2-ylmethyl)pyridine-3-sulfonam ide. TFA (69.0 mL, 995 mmol) was added dropwise to a solution of tert-butyl 2-((5-bromo-2-chloropyridine-3- sulfonamido)methyl)piperidine-1-carboxylate (31 g, 66 mmol) in dichloromethane (120 mL) at 0 °C. The resulting mixture was stirred for 16 hours with gradual warming to room temperature. It was then concentrated to dryness under reduced pressure to afford the title compound (35 g), which was used in the next step without further purification. MS (ESI): mass calcd. for

C11H15BrClN3O2S, 367.0; m/z found, 367.8 [M+H] + .

Step D: 3-Bromo-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepine 5,5-dioxide. DIPEA (120 mL, 881 mol) was added to a mixture of 5- bromo-2-chloro-N-(piperidin-2-ylmethyl)pyridine-3-sulfonamid e (35 g) in toluene (120 mL). The resulting solution was stirred at 130 °C for 2 hours before cooling to room temperature and concentrating to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 1:0 to 3:1, gradient elution) to afford the title compound (19 g, 96%) as a yellow solid. MS (ESI): mass calcd. for C 11 H 14 BrN 3 O 2 S, 331.0; m/z found, 331.7 [M+H] + .

Step E: 7,7a,8,9,10,11-Hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]th iadiazepine-3- carbonitrile 5,5-dioxide. Zn(CN)2 (16.7 g, 142 mmol) was added to a mixture of 3-bromo- 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]th iadiazepine 5,5-dioxide (23.0 g, 69.2 mmol), Zn (906 mg, 13.9 mmol), and DMF (100 mL). The mixture was sparged with Ar for 5 minutes and then treated with Pd(dppf)Cl2 (5.07 g, 6.93 mmol). The resultant mixture was sparged with Ar for another 5 minutes and then stirred at 140 °C for 3 hours before cooling to room temperatrue. The reaction mixture was filtered and the solid was rinsed with ethyl acetate (10 mL x 2). The filtrate was concentrated to dryness under reduced pressure and purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 1:0 to 1:1) to afford the title compound as a brown solid. MS (ESI): mass calcd. for C 12 H 14 N 4 O 2 S, 278.1; m/z found, 278.9 [M+H] + . Intermediate 10: (*R)-7,7a,8,9,10,11-Hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepine-3-carbonitrile 5,5-dioxide.

The mixture of 7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f][1,2,5]th iadiazepine- 3-carbonitrile 5,5-dioxide enantiomers (Intermdiate 9, 30.0 g) was separated by chiral SFC (stationary phase: Phenomenex cellulose-2, 10 µm 250 x 50 mm, Mobile phase: 60% CO2, 40% EtOH/H2O with 0.1% NH3) to provide 2 enantiomers. The first eluting enantiomer (12.9 g) was designated (*R). MS (ESI): mass calcd. for C 12 H 14 N 4 O 2 S, 278.1; m/z found, 279.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) d 8.62 (d, J = 2.0 Hz, 1H), 8.32 (d, J = 2.0 Hz, 1H), 8.48 - 8.00 (m, 1H), 4.45 - 4.33 (m, 2H), 3.54 (t, J = 13.0 Hz, 1H), 3.42 - 3.35 (m, 1H), 3.26 (dd, J = 13.6, Hz, 1H), 1.79 - 1.49 (m, 6H). Intermediate 11: (*S)-7,7a,8,9,10,11-Hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepine-3-carbonitrile 5,5-dioxide.

The second eluting enantiomer from the separation of isomers by chiral SFC described in Intermediate 10 was designated (*S) (13.1 g, 43%). MS (ESI): mass calcd. for C12H14N4O2S, 278.08; m/z found, 279.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 ) d 8.62 (d, J = 2.0 Hz, 1H), 8.33 - 8.30 (m, 1H), 8.32 (d, J = 2.0 Hz, 1H), 4.44 - 4.34 (m, 2H), 3.54 (t, J = 13.2 Hz, 1H), 3.42 - 3.35 (m, 1H), 3.26 (dd, J = 13.2, 3.6 Hz, 1H), 1.79 - 1.49 (m, 6H). Intermediate 12: 6,7,7a,8,10,11-Hexahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepine 5,5-dioxide.

Step A: tert-Butyl 4-(((2-chloropyridine)-3-sulfonamido)methyl)-1,3-oxazinane-3 - carboxylate. 2-Chloropyridine-3-sulfonyl chloride (8.9 g, 42 mmol) was added to a mixture of tert-butyl 4-(aminomethyl)-1,3-oxazinane-3-carboxylate (10 g, 46 mmol) and potassium carbonate (6.8 g, 49 mmol) in THF (150 mL) at room temperature. After 5 hours, the mixture was concentrated under reduced pressure and the residue was partitioned between water and ethyl acetate. The layers were separated and the aqueous layer was extracted with ethyl acetate. These extractions resulted in several organic solvent fractions which were combined, dried over Na 2 SO 4 , and filtered. Upon standing a solid crashed out of the filtrate. Ethyl ether was added and the slurry was stirred at room temperature, the solids were filtered off to provide the title compound (16.5 g, 100%) as a solid. MS (ESI): mass calcd. for C15H22ClN3O5S, 391.1; m/z found, 292.0 [M‒CO t

2Bu] + . 1 H NMR (500 MHz, CDCl 3 ) d 8.61– 8.55 (m, 1H), 8.45– 8.39 (m, 1H), 7.44 (dd, J = 7.8, 4.8 Hz, 1H), 5.85– 5.32 (m, 1H), 4.28– 4.04 (m, 1H), 3.92– 3.67 (m, 3H), 3.60– 3.55 (m, 1H), 3.48– 3.40 (m, 1H), 3.23– 2.97 (m, 2H), 1.50 (s, 9H).

Step B: 6,7,7a,8,10,11-Hexahydro-[1,4]oxazino[3,4-d]pyrido[2,3-f][1, 2,5]thiadiazepine 5,5-dioxide. Trifluoroacetic acid in DCM (165 mL) was added to tert-butyl 4-(((2- chloropyridine)-3-sulfonamido)methyl)-1,3-oxazinane-3-carbox ylate (23 g, 58.7 mmol) at room temperature. After 2.5 hours, the mixture was concentrated under reduced pressure and the residue was dissolved in toluene (270 mL). TEA (50.0 mL, 357 mmol) was added and the reaction mixture was stirred at 130 °C for 15 hours. The reaction was allowed to cool to room temperature and concentrated under reduced pressure. The residue was purified by flash column chromatography (0 to 100% ethyl acetate/hexanes, gradient elution) to provide the title compound (18.0 g) as a white solid. MS (ESI): mass calcd. for C 10 H 13 N 3 O 3 S, 255.3; m/z found, 256.1 [M+H] + . 1 H NMR (400 MHz, CDCl3) d 8.25 (dd, J = 4.6, 1.8 Hz, 1H), 7.94 (dd, J = 7.8, 1.8 Hz, 1H), 6.82 (dd, J = 7.9, 4.6 Hz, 1H), 5.46 (t, J = 5.7 Hz, 1H), 4.38 (ddt, J = 12.0, 4.7, 2.7 Hz, 2H), 4.20 - 3.98 (m, 1H), 3.89 - 3.65 (m, 4H), 3.58 - 3.38 (m, 2H). Intermediate 13: (*S)-6,7,7a,8,10,11-Hexahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepine 5,5-dioxide.

The mixture of 6,7,7a,8,10,11-hexahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepine 5,5-dioxide enantiomers (Intermediate 12, 18 g) was separated by chiral SFC (stationary phase: Chiralpak AS-H 5 µm 250 x 20 mm, Mobile phase: 60% CO 2 , 40% MeOH) to afford two enantiomers. The first eluting isomer (8.25 g) was designated (*S). MS (ESI): mass calcd. for C10H13N3O3S, 255.3; m/z found, 256.1 [M+H] + . 1 H NMR (500 MHz, CDCl 3 ) d 8.28 (dd, J = 4.6, 1.8 Hz, 1H), 7.96 (dd, J = 7.8, 1.8 Hz, 1H), 6.84 (dd, J = 7.9, 4.6 Hz, 1H), 5.29 (t, J = 5.6 Hz, 1H), 4.46– 4.37 (m, 2H), 4.05 (dt, J = 11.2, 3.7 Hz, 1H), 3.91– 3.82 (m, 1H), 3.85– 3.76 (m, 2H), 3.74 (dd, J = 12.2, 2.0 Hz, 1H), 3.60– 3.45 (m, 2H). Intermediate 14: (*R)-6,7,7a,8,10,11-Hexahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepine 5,5-dioxide.

The second eluting isomer (8.25 g) from the separation of isomers by chiral SFC described in Intermediate 13 was designated (*R). MS (ESI): mass calcd. for C10H13N3O3S, 255.3; m/z found, 256.1 [M+H] + . 1 H NMR (500 MHz, CDCl 3 ) d 8.28 (dd, J = 4.6, 1.8 Hz, 1H), 7.97 (dd, J = 7.8, 1.8 Hz, 1H), 6.85 (dd, J = 7.8, 4.6 Hz, 1H), 5.23 (t, J = 5.6 Hz, 1H), 4.46– 4.38 (m, 2H), 4.05 (dt, J = 11.3, 3.7 Hz, 1H), 3.92– 3.83 (m, 1H), 3.86– 3.77 (m, 2H), 3.74 (dd, J = 12.2, 2.0 Hz, 1H), 3.60– 3.46 (m, 2H). Intermediate 15: Ethyl (E)-3-(6-(acetoxymethyl)-5-methylpyridin-2-yl)acrylate.

Step A: Methyl 6-chloro-3-methylpicolinate. SOCl 2 (90.1 g, 757.6 mmol) was added to a solution of 6-chloro-3-methylpicolinic acid (65.0 g, 379 mmol) in MeOH (300 mL) at 0 °C. The resulting solution was stirred for 15 minutes at 0 °C, 0.5 hours at 20-30 °C, and 6 hours at 50 °C. The reaction mixture was concentrated under reduced pressure and diluted with EtOAc (300 mL). The organic fraction was washed with saturated aqueous Na 2 CO 3 solution (100 mL x 3), brine (300 mL), dried over Na2SO4, filtered and concentrated to afford the title compound (133.0 g, 94 %) as a yellow oil. 1 H NMR (400 MHz CDCl3) d 7.53 (d, J = 8.0 Hz, 1H), 7.31 (d, J = 12 Hz, 1H), 3.89 (s, 3H), 2.49 (s, 3H).

Step B: 6-Chloro-3-methylpyridin-2-yl)methanol. To a suspension of methyl 6-chloro-3- methylpicolinate (65.0 g, 350 mmol) in THF (300 mL) at 0 °C under N2, was added NaBH4 (79.5 g, 2.1 mol) in portions. The resulting mixture was heated to 70 °C and stirred for 20 minutes. The reaction was then cooled to 20-30 °C and MeOH (60.0 mL) was added dropwise over 15 minutes and effervescence was observed. This mixture was stirred at 60 °C for 3 hours. The reaction was then cooled to room temperature, quenched with saturated aqueous NH 4 Cl solution (500mL) and stirred for 1.5 hours. The organic layer was separated and the aqueous layer was extracted with EtOAc (250 mL x 3). These extractions resulted in several organic solvent fractions which were combined, washed with brine (100 mL), dried over Na2SO4, filtered and concentrated to afford the title compound (104.0 g, 94 %) as a yellow oil. 1 H NMR (400 MHz CDCl3) d 7.34 (d, J = 8.0 Hz, 1H), 7.06 (d, J = 8 Hz, 1H), 4.57 (s, 2H), 2.12 (s, 3H).

Step C: 6-Chloro-3-methylpyridin-2-yl)methyl acetate. Acetyl chloride (213.8 g, 2.09 mol) was added to a solution of 6-chloro-3-methylpyridin-2-yl)methanol (110.0 g, 697.9 mmol) and TEA (353 g, 3.49 mol) in THF (1.0 L) at 0 °C. The reaction mixture was stirred for 16 hours and gradually warmed to 40 °C over a period of 24 hours. The mixture was concentrated under reduced pressure and diluted with EtOAc (350 mL). The organic portion was washed with saturated aqueous NaHCO 3 solution (250 mL x 3), brine (300 mL x3), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to afford the title compound. The residue was purified by flash column chromatography (petroleum ether/ethyl acetate, 100:1 to 50:1, gradient elution) to afford the title compound (95.0 g, 68 %) as a yellow solid. 1 H NMR (400 MHz, CDCl3) d 7.42 (d, J = 8.0 Hz, 1H), 7.16 (d, J = 8 Hz, 1H), 5.10 (s, 2H), 2.28 (s, 3H), 2.07 (s, 3H).

Step D: Ethyl (E)-3-(6-(acetoxymethyl)-5-methylpyridin-2-yl)acrylate. DMF (500 mL) was added to a suspension of 6-chloro-3-methylpyridin-2-yl)methyl acetate (56.0 g, 280 mmol), ethyl acrylate (112 g, 1.12 mol), TEA (56.77 g, 561.0 mmol), TBAB (78.40 g, 243.2 mmol), DPPF (22.40 g, 40.41 mmol) and Pd(OAc)2 (9.07 g, 40.4 mmol). The mixture was sparged with N 2 for 10 minutes, heated to 120 °C and stirred at this temperature under N 2 atmosphere for 24 hours. The reaction mixture was cooled to room temperature, diluted with EtOAc (100 mL) and the organic portion was washed sequentially with 10 % aqueous NaHCO3 solution (500 mL) and brine (500 mL). The resulting organic portion was dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (petroleum ether/ethyl acetate, 60:1 to 15:1, gradient elution) to afford the title compound (47 g, 63%) as a green oil. MS (ESI): mass calcd. for C14H17NO4, 263.1; m/z found, 263.9 [M+H] + . 1 H NMR: (400 MHz CDCl 3 ) d 7.65 (d, J = 15.6 Hz, 1 H), 7.50 (d, J = 8.0 Hz, 1 H), 7.30 (d, J = 8 Hz, 1 H), 6.87 (d, J = 16 Hz, 1 H), 5.24 (s, 2 H), 4.29– 4.24 (m, 2 H), 2.36 (s, 3 H), 2.16 (s, 3 H), 1.33 (t, J = 8 Hz, 3 H). Intermediate 16: 5-Bromo-1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazole.

Step A: N-Ethyl-3-methyl-2-nitroaniline. Ethylamine (210 mL, 3.22 mol) was added to a solution of 1-fluoro-3-methyl-2-nitrobenzene (50.0 g, 322 mmol) in ethanol (500 mL). The mixture was stirred at 50 °C for 48 hours. The reaction mixture was concentrated under reduced pressure and the red oil residue (57.0 g, 98%) was used in the next step without purification. 1 H NMR: (400 MHz, CDCl 3 ) ^ 7.22 (t, J = 8.0 Hz, 1H), 6.66 (d, J = 8.6 Hz, 1H), 6.52 (d, J = 7.4 Hz, 1H), 6.46 (br s, 1H), 3.21 - 3.30 (m, 2H), 2.48 (s, 3H), 1.28 - 1.36 (m, 3H).

Step B: 4-Bromo-N-ethyl-3-methyl-2-nitroaniline. Two batches of this reaction sequence were carried out in parallel. NBS (23.4 g, 131 mmol) was added in one portion to a mixture of N-ethyl-3-methyl-2-nitroaniline (25.0 g, 138 mmol) in AcOH (125 mL) at 15 °C. The mixture was stirred for 12 hours. The reaction mixtures from the two parallel batches were combined. The resulting mixture was concentrated under reduced pressure. DCM (500 mL) was added. The organic phase was washed with H2O (300 mL x 2), aqueous saturated NaHCO3 solution (300 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure to afford the title compound (70.0 g, 97%) as a red solid which was used in the next step without further purification.

Step C: 4-Bromo-N 1 -ethyl-3-methylbenzene-1,2-diamine. In one portion, Fe (32.3 g, 578 mmol) was added to a mixture of 4-bromo-N-ethyl-3-methyl-2-nitroaniline (50.0 g, 192 mmol) and NH4Cl (62.1 g, 1.16 mol) in a mixture of ethanol (400 mL) and H2O (100 mL) at 50 °C. The resulting mixture was stirred for 12 hours. The reaction mixture was filtered and concentrated under reduced pressure. The residue was then treated with H 2 O (200 mL) and the aqueous layer was extracted with DCM (200 mL x 3). These extractions resulted in several organic solvent fractions which were combined and washed with brine (100 mL x 2), dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure to afford the title compound (42.0 g, 94 %) as a red solid which was used in the next step without further purification. 1 H NMR: (400 MHz, CDCl3) d 7.02 (d, J = 8.4 Hz, 1H), 6.46 (d, J = 8.4 Hz, 1H), 3.45 (br s, 2H), 3.12 (d, J = 6.6 Hz, 2H), 2.32 (br s, 3H), 1.31 (t, J = 6.4 Hz, 3H).

Step D: 5-Bromo-1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazole. To a mixture of 4- bromo-N 1 -ethyl-3-methylbenzene-1,2-diamine (42.0 g, 183 mmol) in AcOH (200 mL) at 10 °C was added in one portion a solution of NaNO2 (13.9 g, 201 mmol) in water (10.9 mL). The mixture was stirred at 15 °C for 12 hours. The reaction mixture was concentrated under reduced pressure and added to H2O (200 mL). This mixture was extracted with DCM (200 mL x 3). These extractions resulted in several organic solvent fractions which were combined, washed with brine (100 mL x 2), dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 10:1 to 5:1, gradient elution) to afford the title compound (25.0 g, 40%) as a brown solid. MS (ESI): mass calcd. for C 9 H 10 BrN 3 , 239.0; m/z found, 240.0 [M+H] + . 1 H NMR: (400 MHz, CDCl 3 ) d 7.60 (d, J = 8.8 Hz, 1H), 7.24 (d, J = 8.8 Hz, 1H), 4.66 (q, J = 7.6 Hz, 2H), 2.84 (s, 3H), 1.55 - 1.67 (m, 3H). Intermediate 17: Ethyl (E)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)acryl ate.

A mixture of 5-bromo-1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazole (Intermediate 16, 13.0 g, 54.1 mmol), ethyl prop-2-enoate (6.51 g, 64.9 mmol, 7.08 mL), Pd(PPh3)4 (5.0 g, 4.33 mmol), TEA (10.9 g, 108 mmol, 15.0 mL) in DMF (65 mL) was sparged with N 2 and then heated to 130 °C for 12 hours under N2. The residue was poured into water (200 mL) and stirred for 10 minutes. The aqueous layer was extracted with ethyl acetate (200 mL x 3). These extractions resulted in several organic solvent fractions which were combined, washed with brine (100 mL x 2), dried with anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 10:1 to 3:1, gradient elution) to afford the title compound (13.0 g, 92%) as a yellow solid. MS (ESI): mass calcd. for C 14 H 17 N 3 O 2 , 259.1; m/z found, 260.1 [M+H] + . 1 H NMR: (400 MHz, CDCl 3 ) d 8.15 (d, J = 15.4 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.36 (d, J = 8.4 Hz, 1H), 6.42 (d, J = 15.8 Hz, 1H), 4.63 - 4.74 (m, 2H), 4.31 (d, J = 6.6 Hz, 2H), 2.93 (br s, 3H), 1.64 (t, J = 6.6 Hz, 3H), 1.37 (t, J = 6.2 Hz, 3H). Intermediate 18: (5-Bromo-2-methylphenyl)methanol.

Two batches of the reaction were carried out in parallel. LiAlH 4 (4.74 g, 124 mmol) was added to a solution of methyl 5-bromo-2-methylbenzoate (26.0 g, 113 mmol) in THF (260 mL) at 0 °C over a period of 10 minutes under N2. The reaction mixture was warmed to 15 °C and stirred for 12 hours. The reaction mixture was quenched by sequential addition of the following: water (4.75 mL), 15% aqueous NaOH (4.75 mL), and water (14.2 mL). The aqueous phase was extracted with DCM (300 mL), and this organic solvent fraction was dried over anhydrous Na 2 SO 4 and filtered. The filtrate from the two batches were combined and concentrated under reduced pressure to afford the title compound (42.0 g, 92%) as a white solid which was used in the next step without purification. 1 H NMR: (400 MHz, CDCl3) ^ 7.54 (s, 1H), 7.33 (dd, J = 7.8, 1.6 Hz, 1H), 7.00 - 7.09 (m, 1H), 4.67 (s, 2H), 2.28 (s, 3H). Intermediate 19: ((5-Bromo-2-methylbenzyl)oxy)(tert-butyl)dimethylsilane.

TBSCl (89.96 g, 596.8 mmol) was added to a solution of 5-bromo-2- methylphenyl)methanol (80.0 g, 398 mmol) and imidazole (54.2 g, 796 mmol) in DMF (1.5 L) and the reaction mixture was stirred at 25 °C for 16 hour under N 2 . The reaction mixture was poured into H2O (2 L) and extracted with EtOAc (1 L x 3). These extractions resulted in several organic solvent fractions which were combined, washed with brine (2 L), dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate) to afford the title compound (106 g, 83%) as a colorless liquid. 1 H NMR (500 MHz, CDCl3) d 7.44 (d, J = 2.1 Hz, 1H), 7.16 (dd, J = 8.0, 2.3 Hz, 1H), 6.87 (dd, J = 8.1, 0.8 Hz, 1H), 4.53 (s, 2H), 2.08 (s, 3H), 0.84 (s, 9H). Intermediate 20: 2-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benz yl acetate.

Step A: 5-Bromo-2-methylbenzyl acetate. A solution of acetyl chloride (10.6 mL, 149 mmol) in DCM (30 mL) was added dropwise at 0 °C over a period of 30 minutes to a mixture of (5-bromo-2-methylphenyl)methanol (25.0 g, 124 mmol) and Et 3 N (25.1 g, 248 mmol) in DCM (200 mL). After the addition, the reaction mixture was stirred at 15 °C for 3 hours. Water (200 mL) was added to the reaction mixture and the aqueous layer was extracted with DCM (200 mL x 2). These extractions resulted in several organic solvent fractions which were combined, dried over Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (petroleum ether/ethyl acetate, 1:0 to 15:1, gradient elution) to afford the title compound (26.0 g, 86%) as a light yellow oil. 1 H NMR: (400 MHz, CDCl 3 ) ^ 7.48 (d, J = 0.8 Hz, 1H), 7.36 (dd, J = 8.2, 1.6 Hz, 1H), 7.07 (d, J = 8.2 Hz, 1H), 5.08 (s, 2H), 2.29 (s, 3H), 2.13 (s, 3H).

Step B: 2-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benz yl acetate. B 2 Pin 2 (32.6 g, 128 mmol), AcOK (15.7 g, 160 mmol) and Pd(dppf)Cl2 (7.83 g, 10.7 mmol) were sequentially added to a solution of 5-bromo-2-methylbenzyl acetate (26.0 g, 106 mmol) in 1,4- dioxane (150 mL). The mixture was stirred at 90 °C for 12 hours. The reaction mixture was concentrated under reduced pressure and purified by flash column chromatography (eluent:

petroleum ether/ethyl acetate, 1:0 to 15:1, gradient elution) to afford the title compound (5.0 g, 16%) as a white solid. 1 H NMR: (400 MHz, CDCl 3 ) ^ ^7.76 (s, 1H), 7.70 (d, J = 7.4 Hz, 1H), 7.22 (d, J = 7.4 Hz, 1H), 5.14 (s, 2H), 2.38 (s, 3H), 2.10 (s, 3H), 1.35 (s, 12H). Intermediate 21: Ethyl 3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3- (hydroxymethyl)-4-methylphenyl)propanoate.

Step A: Ethyl 3-(3-(acetoxymethyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoate. Five batches of this reaction sequence were carried out in parallel. [Rh(COD)Cl]2 (1.33 g, 2.7 mmol) was added to a mixture of ethyl (E)-3-(1-ethyl-4- methyl-1H-benzo[d][1,2,3]triazol-5-yl)acrylate (Intermediate 17, 7.0 g, 27 mmol), 2-methyl-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl acetate (Intermediate 20, 15.6 g, 54.0 mmol) and KOH (1.51 g, 27 mmol) in 1,4-dioxane (80 mL) and H2O (8 mL). The mixture was stirred at 110 °C for 12 hours under N 2 . The five batches of reaction mixtures were combined, filtered and concentrated under reduced pressure and purified by flash column chromatography (eluent:

petroleum ether/ethyl acetate, 2:1) to afford the title compound (30.0 g, 52%) as a yellow oil. 1 H NMR: (400 MHz, CDCl 3 ) d 7.26 - 7.37 (m, 2H), 7.04 - 7.16 (m, 3H), 5.02 (s, 2H), 4.96 (t, J = 7.5 Hz, 1H), 4.62 (q, J = 7.6 Hz, 2H), 3.95 - 4.07 (m, 2H), 2.94 - 3.15 (m, 2H), 2.83 (br s, 3H), 2.22 - 2.31 (m, 3H), 2.03 - 2.09 (m, 3H), 1.58 (t, J = 7.2 Hz, 3H), 1.08 (t, J = 7.0 Hz, 3H). Step B: Ethyl 3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3- (hydroxymethyl)-4-methylphenyl)propanoate. A mixture of ethyl 3-(3-(acetoxymethyl)-4- methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol- 5-yl)propanoate (1.39 g, 3.00 mmol) and potassium carbonate (870.4 mg, 6.298 mmol) in ethanol (15 mL) was stirred at room temperature overnight. The reaction mixture was concentrated to dryness under reduced pressure, then dissolved in water and DCM. The resulting biphasic mixture was separated and the aqueous layer was extracted with DCM. These extractions resulted in several organic solvent fractions which were combined, dried over MgSO4, filtered and concentrated to dryness under reduced pressure to provide the title compound (1.14 g, 96 %) as a foam that was used without further purification. MS (ESI): mass calcd. for C 22 H 27 N 3 O 3 , 381.2; m/z found, 382.1 [M+H] + . Intermediate 22: 1-Ethyl-4-methyl-1H-benzo[d][1,2,3]triazole-5-carbaldehyde.

Ozone was bubbled into a solution of ethyl (E)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)acrylate (Intermediate 17, 13.0 g, 50.1 mmol) in DCM (130 mL) at -78 °C for 45 minutes. The reaction mixture was warmed to 15°C and the ozone was purged from the reaction mixture by bubbling oxygen through the solution. Me2S (30 mL) was added and the mixture was stirred at 15 °C for 12 hours. The reaction mixture was concentrated and purified by flash column chromatography (petroleum ether/ethyl acetate, 10:1 to 1:1, gradient elution) to afford the title compound (5.6 g, 58%) as a yellow solid. MS (ESI): mass calcd. for C10H11N3O, 189.1; m/z found, 190.1 [M+H] + . 1 H NMR: (400 MHz, CDCl3) d 10.53 (s, 1H), 8.01 (d, J = 8.4 Hz, 1H), 7.44 (d, J = 8.4 Hz, 1H), 4.63 - 4.77 (m, 2H), 3.18 (s, 3H), 1.66 (t, J = 6.6 Hz, 3H). Intermediate 23: 4-Bromo-2-hydrazinyl-3-methylpyridine.

A mixture of hydrazine hydrate (87.4 g, 1.75 mol) and 4-bromo-2-fluoro-3- methylpyridine (32.50 g, 171.0 mmol) was stirred at 25 °C for 6 days. Then aqueous NaOH solution (70 mL, 3 M) and water (70 mL) were added to the mixture and the suspension was stirred at 25 °C for 1 hour. The solid was filtered, washed with water (100 mL), and the solid was dried under reduced pressure to afford the title compound (28.9 g, 84%) as a white solid, which was used in the next step without further purification. 1 H NMR: (400 MHz, CD 3 OD) d 7.78 (d, J = 5.6 Hz, 1 H), 6.88 (d, J = 5.6 Hz, 1 H), 2.20 (s, 3 H). Intermediate 24: 7-Bromo-8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]p yridine.

TFAA (151.5 mL, 1.1 mol) was slowly added to 4-bromo-2-hydrazinyl-3-methylpyridine (Intermediate 23, 10.0 g, 49.5 mmol) and the mixture was heated to reflux for 24 hours under an atmosphere of N 2 . The residue was dissolved in EtOAc (100 mL). The resulting solution washed with aqueous saturated NaHCO3 solution (50 mL x 2), brine (80 mL), dried over Na2SO4, and concentrated under reduced pressure to afford the title compound (13.0 g, 93.8%) as a yellow solid, which was used in the next step without further purification. 1 H NMR: (400 MHz, CDCl 3 ) d 7.95 (d, J = 7.2 Hz, 1 H), 7.19 (d, J = 7.2 Hz, 1 H), 2.79 (s, 3 H). Intermediate 25: Ethyl 3-(3-(hydroxymethyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ate.

Step A: Ethyl (E)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]py ridin-7- yl)acrylate. A suspension of 7-bromo-8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]p yridine (Intermediate 24, 10.0 g, 35.7 mmol), ethyl acrylate (10.7 g, 107.1 mmol), Pd(PPh3)4 (3.3 g, 2.9 mmol) and TEA (10.8 g, 107.1 mmol) in DMF (100 mL) was sparged with N2 for 10 minutes and then the mixture was heated to 110 °C and stirred under an atmosphere of N 2 for 58 hours. Water (100 mL) was added and the mixture was stirred at 25 °C for 10 minutes. The aqueous layer was extracted with CH2Cl2 (80 mL x 2). These extractions resulted in several organic solvent fractions which were combined, washed with water (50 mL x 4), brine (50 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 6:1) to afford the title compound (10.7 g, 84 %) as a white solid. 1 H NMR: (400 MHz, CDCl 3 ) d 8.07 (d, J = 7.2 Hz, 1 H), 7.98 (d, J = 16.0 Hz, 1 H), 7.21 (d, J = 7.2 Hz, 1 H), 6.50 (d, J = 16.0 Hz, 2 H), 4.31 (q, J = 7.2 Hz, 2 H), 2.86 (s, 3H) , 1.36 (t, J = 7.2 Hz, 3 H).

Step B: Ethyl 3-(3-(acetoxymethyl)-4-methylphenyl)-3-(8-methyl-3-(trifluor omethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoate. Eight batches of the reaction were carried out in parallel. A mixture of ethyl (E)-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]py ridin-7- yl)acrylate (2.0 g, 6.7 mmol), 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benz yl acetate (Intermediate 20, 2.91 g, 10.0 mmol), [Rh(COD)Cl] 2 (329.5 mg, 0.668 mmol) and Na 2 CO 3 (708.4 mg, 6.7 mmol) in 1,4-dioxane (18 mL) and water (3 mL), was sparged with N 2 for 10 minutes and stirred at 80 °C under an atmosphere of N2 for 25 hours. The eight batches of the reaction were combined. The resulting mixture was filtered to remove solids and the filtrate was collected. The filtrate was concentrated under reduced pressure and the residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 15:1 to 8:1, gradient elution) to afford the title compound (18.0 g, 75%) as a yellow gum. 1 H NMR: (400 MHz, CDCl 3 ) ^ 8.01 (d, J = 7.2 Hz, 1 H), 7.18 - 7.07 (m, 3 H), 6.95 (d, J = 7.2 Hz, 1 H), 5.07 (s, 2 H), 4.97 (t, J = 8.0 Hz, 1 H), 4.08 (q, J = 7.2 Hz, 2 H), 3.14 (dd, J = 15.6, 6.8 Hz, 1 H), 3.01 (dd, J = 15.6, 6.8 Hz, 1 H), 2.86 (s, 3 H), 2.31 (s, 3 H), 2.09 (s, 3 H), 1.17 (t, J = 7.2 Hz, 3 H).

Step C: Ethyl 3-(3-(hydroxymethyl)-4-methylphenyl)-3-(8-methyl-3-(trifluor omethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoate. Two batches of the reaction were carried out in parallel. Ethyl 3-(3-(acetoxymethyl)-4-methylphenyl)-3-(8-methyl-3-(trifluor omethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoate (8.5 g, 18.3 mmol) was dissolved in ethanol (200 mL) and stirred at 25 °C. 2 M Aqueous HCl (90 mL) was added to the above solution and the mixture was stirred at 25 °C for 24 hours. The two batches of the reaction were combined and the resulting reaction mixture was slowly quenched with aqueous saturated NaHCO3 solution. Ethanol was removed under reduced pressure and the aqueous layer was extracted with CH 2 Cl 2 (200 mL x 3). These extractions resulted in several organic solvent fractions which were combined, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate, 8:1 to 4:1, gradient elution) to afford the title compound (10.0 g, 65%) as a yellow gum. MS (ESI): mass calcd. for C21H22F3N3O3, 421.2; m/z found, 422.2 [M+H] + . 1 H NMR: (400 MHz, CDCl3) d 7.99 (d, J = 7.2 Hz, 1 H), 7.25 (s, 1 H), 7.13 (d, J = 7.6 Hz, 1 H), 7.06 (d, J = 8.0 Hz, 1 H), 6.92 (d, J = 7.2 Hz, 1 H), 4.96 (t, J = 8.0 Hz, 1 H), 4.67 (s, 2 H), 4.06 (q, J = 7.2 Hz, 2 H), 3.15 (dd, J = 15.6, 6.8 Hz, 1 H), 3.01 (dd, J = 15.6, 6.8 Hz, 1 H), 2.85 (s, 3 H), 2.29 (s, 3 H), 1.16 (t, J = 7.2 Hz, 3 H). Intermediate 26: Ethyl (*S)-3-(3-(hydroxymethyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ate.

The mixture of ethyl 3-(3-(hydroxymethyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ate enantiomers (Intermediate 25, 16 g) was separated by chiral SFC (stationary phase: Chiralpak AD-H 5 µm 250 x 30 mm, Mobile phase: 65% CO2, 35% MeOH) to afford two enantiomers. The first eluting isomer (8.04 g) was designated (*S). MS (ESI): mass calcd. for C21H22F3N3O3, 421.2; m/z found, 422.2 [M+H] + . 1 H NMR (500 MHz, CDCl 3 ) d 7.99 (d, J = 7.2 Hz, 1H), 7.27– 7.26 (m, 1H), 7.14– 7.10 (m, 1H), 7.07– 7.03 (m, 1H), 6.93 (d, J = 7.3 Hz, 1H), 5.01– 4.91 (m, 1H), 4.67 (d, J = 3.2 Hz, 2H), 4.11 – 4.02 (m, 2H), 3.20– 3.11 (m, 1H), 3.08– 2.98 (m, 1H), 2.84 (s, 3H), 2.28 (s, 3H), 2.15– 2.06 (m, 1H), 1.20– 1.13 (m, 3H). Intermediate 27: Ethyl (*R)-3-(3-(hydroxymethyl)-4-methylphenyl)-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ate.

The second eluting isomer (7.94 g) from the separation of isomers by chiral SFC described in Intermediate 26 was designated (*R). MS (ESI): mass calcd. for C 21 H 22 F 3 N 3 O 3 , 421.2; m/z found, 422.2 [M+H] + . 1 H NMR (500 MHz, CDCl 3 ) d 7.99 (d, J = 7.2 Hz, 1H), 7.29– 7.24 (m, 1H), 7.14– 7.10 (m, 1H), 7.08– 7.03 (m, 1H), 6.93 (d, J = 7.3 Hz, 1H), 4.99– 4.94 (m, 1H), 4.67 (d, J = 5.0 Hz, 2H), 4.12– 4.01 (m, 2H), 3.20– 3.11 (m, 1H), 3.08– 2.97 (m, 1H), 2.84 (s, 3H), 2.28 (s, 3H), 2.15– 2.09 (m, 1H), 1.16 (t, J = 7.1 Hz, 3H). Intermediate 28: 8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine- 7- carbaldehyde.

Step A: 8-Methyl-3-(trifluoromethyl)-7-vinyl-[1,2,4]triazolo[4,3-a]p yridine. A mixture of 7-bromo-8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]p yridine (Intermediate 24, 38.0 g, 136 mmol), potassium trifluoro(vinyl)borate (36.3 g, 271 mmol), K3PO4 (86.0 g, 405 mmol), 1,4-dioxane (400 mL), and H2O (80 mL) was sparged with Ar for 5 minutes and then treated with Pd(dppf)Cl 2 (5.0 g, 6.8 mmol). The resulting mixture was sparged with Ar for another 5 minutes and then stirred at 110 °C for 16 hours. After cooling to room temperature, the resulting suspension was filtered. The filtrate was poured into H2O (100 mL) and the aqueous layer was extracted with ethyl acetate (200 mL x 3). These extractions resulted in several organic solvent fractions which were combined, dried over anhydrous Na 2 SO 4 , filtered and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 10:1 to 1:1, gradient elution) to afford the title compound (33 g, 99%) as a brown solid. MS (ESI): mass calcd. for C10H8F3N3227.1 m/z, found 227.9 [M+H] + .

Step B: 8-Methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine- 7-carbaldehyde. K2OsO4•2H2O (1.6 g, 4.3 mmol) was added to a solution of 8-methyl-3-(trifluoromethyl)-7- vinyl-[1,2,4]triazolo[4,3-a]pyridine (25.0 g, 110 mmol) and 1,4-dioxane (600 mL) in distilled H 2 O (600 mL). The resulting mixture was treated with NaIO 4 (75.0 g, 351 mmol), stirred at room temperature for 2 hours and then concentrated to dryness under reduced pressure. The residue was diluted with H 2 O (100 mL) and the aqueous layer was extracted with ethyl acetate (150 mL x 3). These extractions resulted in several organic solvent fractions which were combined, dried over anhydrous Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 10 : 1 to 1 :1, gradient elution) to afford the title compound (22 g, 87%) as a gray solid. MS (ESI): mass calcd. for C9H6F3N3O, 229.1 m/z; found 230.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) d 10.44 (s, 1H), 8.52 (d, J = 6.4 Hz, 1H), 7.42 (d, J = 7.2 Hz, 1H), 2.98 (s, 3H). Intermediate 29: 5-Bromo-1-cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazole.

Step A: N-Cyclopropyl-3-methyl-2-nitroaniline. Three batches of the reaction were carried out in parallel. A mixture of 1-fluoro-3-methyl-2-nitrobenzene (10 g, 64.46 mmol), cyclopropanamine (18.40 g, 322.3 mmol, 22.33 mL) and TEA (13.05 g, 128.9 mmol) in MeCN (30 mL) was stirred at 112 °C for 16 hours. After cooling to room temperature, the reaction mixtures from the three batches were combined, diluted with EtOAc (200 mL) and sequentially washed with 10 % aqueous NaHCO3 solution (100 mL) and brine (100 mL). The organic layer was concentrated under reduced pressure to afford the title compound (35 g, 94%) as a yellow solid, which was used without further purification. Step B: 4-Bromo-N-cyclopropyl-3-methyl-2-nitroaniline. NBS (30.79 g, 172.9 mmol) was added to a mixture of N-cyclopropyl-3-methyl-2-nitroaniline (35.0 g, 182 mmol) in AcOH (300 mL) at 20 °C, and the reaction was stirred at 20 °C for 6 hours. The reaction was poured into water (1000 mL) and the aqueous layer was extracted with EtOAc (500 mL x 2). These extractions resulted in several organic solvent fractions which were combined, washed with aqueous saturated NaHCO 3 (500 mL x 3) solution, dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to afford the title compound (46 g, 93%) as a red solid. MS (ESI): mass calcd. for C10H11BrN2O2, 270.0; m/z found, 270.9 [M+H] + .

Step C: 4-Bromo-N 1 -cyclopropyl-3-methylbenzene-1,2-diamine. A mixture of Raney Ni (8.60 g, 100 mmol) and 4-bromo-N-cyclopropyl-3-methyl-2-nitroaniline (30.0 g, 110 mmol) in ethanol (300 mL) was stirred at room temperature under H2 (50 psi) for 6 hours. The reaction mixture was filtered, washed with ethanol (50 mL x 2) and the solvents were removed under reduced pressure to afford the title compound (21 g, 61%) as a red solid. MS (ESI): mass calcd. for C10H13BrN2, 240.0; m/z found, 240.7 [M+H] + .

Step D: 5-Bromo-1-cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazole. A solution of NaNO 2 (7.76 g, 112 mmol) in H 2 O (30 mL) was added to a solution of 4-bromo-N 1 -cyclopropyl- 3-methylbenzene-1,2-diamine (26.0 g, 107 mmol) in 2 M HCl (250 mL, 500 mmol) at 0 °C and the reaction was stirred at 0-10 °C for 1 hour. CH2Cl2 (300 mL) was added to the reaction mixture, and the aqueous phase was extracted with CH 2 Cl 2 (200 mL x 2). These extractions resulted in several organic solvent fractions which were combined, washed with brine (200 mL), dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (eluent: petroleum ether/CH 2 Cl 2 , 10:1 to 3:1, gradient elution) to afford the title compound (8.4 g, 27%) as an off white solid. MS (ESI): mass calcd. for C10H10BrN3, 251.0; m/z found, 251.8 [M+H] + . 1 H NMR (500 MHz, CDCl3) d 7.61 (d, J = 8.7 Hz, 1H), 7.38– 7.35 (m, 1H), 3.80– 3.69 (m, 1H), 2.82 (s, 3H), 1.38– 1.27 (m, 4H). Intermediate 30: 8-Methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine.

A mixture of 7-bromo-8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]p yridine (Intermediate 24, 1.2 g, 4.3 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (5.4 g, 21 mmol), KOAc (1.26 g, 12.8 mmol) and toluene (15 mL) was sparged with N 2 for 5 minutes and then treated with Pd(dppf)Cl2 (314 mg, 0.429 mmol). The mixture was sparged with N2 for another 5 minutes and then stirred at 80 °C for 36 hours. After cooling to room temperature, the suspension was filtered through diatamaceous earth such as Celite ® and washed with ethyl acetate (30 mL). The filtrate was concentrated to dryness under reduced pressure and the residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 50:1 to 5:1, gradient elution) to afford the title compound (1.1 g, 63%) as a white solid. 1 H NMR (400 MHz, CDCl3) ^ ^ 7.98 (d, J = 6.8 Hz, 1H), 7.30 (d, J = 7.1 Hz, 1H), 2.95 (s, 3H), 1.36 (s, 12H). Intermediate 31: Ethyl 3-(3-(chloromethyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)propanoate.

Thionyl chloride (0.85 mL, 12 mmol) was added to a solution of ethyl 3-(1-ethyl-4- methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(hydroxymethyl)- 4-methylphenyl)propanoate (Intermediate 21, 2.94 g, 7.71 mmol) in DCM (38 mL). Five drops of DMF were added to the solution, and the reaction was stirred at room temperature for 4 hours. The reaction was quenched with saturated aqueous NaHCO3, then extracted with DCM. These extractions resulted in several organic solvent fractions which were combined, dried over MgSO 4 , filtered, and concentrated to dryness under reduced pressure to provide the title compound (3.05 g, 99%) as an oil which was used without further purification. MS (ESI): mass calcd. for C22H26ClN3O2, 399.2; m/z found, 400.0 [M+H] + . Intermediate 32: Ethyl 3-(3-(chloromethyl)-4-methylphenyl)-3-(1-cyclopropyl-4-methy l- 1H-benzo[d][1,2,3]triazol-5-yl)propanoate.

Step A: Ethyl (E)-3-(1-cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl )acrylate. 1,4-Dioxane (17 mL) and water (5 mL) were added to a mixture of 5-bromo-1-cyclopropyl-4- methyl-1H-benzo[d][1,2,3]triazole (Intermediate 29, 1.25 g, 4.96 mmol), potassium carbonate (1.38 g, 9.99 mmol), Pd(dppf)Cl 2 (364 mg, 0.497 mmol), and ethyl (E)-3-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)acrylate (1.37 g, 6.05 mmol). The mixture was heated to 90 °C and stirred for 4.5 hours. After this time, the reaction was cooled to room temperature, then filtered through a pad of diatomaceous earth such as Celite ® . The pad was rinsed with ethyl acetate. The filtrate was collected, washed with brine, then dried over MgSO 4 , filtered and concentrated to dryness under reduced pressure. The product was purified by flash column chromatography (0 to 20% ethyl acetate/DCM, gradient elution) to afford the title compound (980 mg, 73 %). MS (ESI): mass calcd. for C 15 H 17 N 3 O 2 , 271.1; m/z found, 272.2 [M+H] + .

Step B: Ethyl 3-(1-cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3- (3- (hydroxymethyl)-4-methylphenyl)propanoate. (3-(Hydroxymethyl)-4-methylphenyl)boronic acid (907 mg, 5.46 mmol), triethylamine (0.76 mL, 5.5 mmol), and [Rh(COD)Cl] 2 (92 mg, 0.19 mmol) were added to a solution of ethyl (E)-3-(1-cyclopropyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)acrylate (980 mg, 3.6 mmol) in 1,4-dioxane (25 mL) and water (12 mL). The mixture was stirred at 95 °C for 2 hours. Additional (3-(hydroxymethyl)-4- methylphenyl)boronic acid (905 mg, 5.45 mmol) and [Rh(COD)Cl] 2 (92 mg, 0.19 mmol) were then added and the reaction was stirred at 95 °C for 1 hour. After this time, the reaction was cooled to room temperature, then diluted with water and ethyl acetate. The resulting biphasic mixture was separated and the aqueous layer was extracted with ethyl acetate. These extractions resulted in several organic solvent fractions which were combined, dried over MgSO 4 , filtered and concentrated to dryness under reduced pressure. The product was purified by flash column chromatography (0 to 50% ethyl acetate/hexanes, gradient elution) to afford the title compound (1.2 g, 84%). MS (ESI): mass calcd. for C 23 H 27 N 3 O 3 , 393.2; m/z found, 394.1 [M+H] + .

Step C: Ethyl 3-(3-(chloromethyl)-4-methylphenyl)-3-(1-cyclopropyl-4-methy l-1H- benzo[d][1,2,3]triazol-5-yl)propanoate. The title compound (1.2 g, 97%) was prepared using analogous conditions as described in Intermediate 31 where ethyl 3-(1-cyclopropyl-4-methyl- 1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(hydroxymethyl)-4-methy lphenyl)propanoate was used instead of ethyl 3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(hy droxymethyl)-4- methylphenyl)propanoate. MS (ESI): mass calcd. for C23H26ClN3O2, 411.2; m/z found, 412.1 [M+H] + . Intermediate 33: 5-Bromo-7-(difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triaz ole.

Step A: 2-(Difluoromethoxy)-6-nitroaniline. To a solution of 2-amino-3-nitrophenol (20.2 g, 131 mmol) in DMF (130 mL) and water (13 mL) was added sodium

chlorodifluoroacetate (49.8 g, 327 mmol) and K 2 CO 3 (27.1 g, 196 mmol). The reaction mixture was heated under Ar to 100 ^C under a reflux condenser for 2.5 hours. The reaction mixture was diluted with water (300 mL) and extracted with EtOAc (300 mL). The organic phase was washed with 1 N aqueous NaOH (200 mL). The basic aqueous phase was extracted with EtOAc (200 mL). These extractions resulted in several organic solvent fractions which were combined, dried over Na 2 SO 4 , filtered, and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: 40% DCM/heptane), to afford the title compound (14.6 g, 55%) as a yellow oil. 1 H NMR (400 MHz, CDCl3) d 8.02 (dd, J = 8.8, 1.3 Hz, 1H), 7.30 - 7.25 (m, 1H), 6.67 (dd, J = 8.8, 7.8 Hz, 1H), 6.54 (t, J = 72.8 Hz, 1H), 6.47 - 6.25 (m, 2H).

Step B: 4-Bromo-2-(difluoromethoxy)-6-nitroaniline. To a solution of 2- (difluoromethoxy)-6-nitroaniline (14.6 g, 71.3 mmol) in AcOH (182 mL) was added sodium acetate (9.36 g, 114 mmol) followed by bromine (4.05 mL, 78.5 mmol). The reaction mixture was stirred at room temperature under air for 20 minutes. Water (180 mL) was added and the precipitate was collected by vacuum filtration and air-dried. This yellow solid was further dried under vacuum, to afford the title compound (15.3 g, 76%). MS (ESI): mass calcd. for

C 7 H 5 BrF 2 N 2 O 3 , 284.0; m/z found, 284.9 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) d 8.19 (d, J = 2.0 Hz, 1H), 7.39 (d, J = 2.5 Hz, 1H), 6.56 (t, J = 72.0 Hz, 1H), 6.49 - 6.26 (m, 2H).

Step C: 4-Bromo-2-(difluoromethoxy)-N-methyl-6-nitroaniline. To a solution of 4- bromo-2-(difluoromethoxy)-6-nitroaniline (15.3 g, 54.2 mmol) in DMF (100 mL) at 0 ^C was added NaH (60% dispersion in mineral oil, 2.60 g, 65.0 mmol) and the reaction mixture was stirred at 0 ^C under Ar for 45 minutes. Iodomethane (3.71 mL, 59.6 mmol) was then added and the reaction mixture was stirred for 30 minutes at 0 ^C. The reaction mixture was poured into water (250 mL). The mixture was filtered and the precipitate was washed with water, air-dried, and dried under vacuum to yield the title compound (15.7 g) which was used without further purification in the next reaction. MS (ESI): mass calcd. for C8H7BrF2N2O3, 298.0; m/z found, 299.0 [M+H] + .

Step D: 4-Bromo-6-(difluoromethoxy)-N 1 -methylbenzene-1,2-diamine. To a solution of 4-bromo-2-(difluoromethoxy)-N-methyl-6-nitroaniline (15.7 g, 52.9 mmol) in AcOH (160 mL) was added zinc (10.4 g, 159 mmol). The reaction mixture was stirred for 16 hours under Ar at room temperature. The reaction mixture was filtered through a bed of diatomaceous earth such as Celite ® , washing thoroughly with EtOAc. The filtrate was concentrated to provide a residue. The residue was concentrated twice from toluene under reduced pressure to remove residual AcOH. The residue was purified by flash column chromatography (eluent: 0 to 40%

EtOAc/heptanes, gradient elution), to afford the title compound (6.34 g, 45%) as a red oil. MS (ESI): mass calcd. for C8H9BrF2N2O, 268.0; m/z found, 269.0 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) d 6.72 (d, J = 2.0 Hz, 1H), 6.65 - 6.63 (m, 1H), 6.47 (t, J = 73.8 Hz, 1H), 3.88 - 4.16 (m, 2H), 2.66 (s, 3H). Step E: 5-Bromo-7-(difluoromethoxy)-1-methyl-1H-benzo[d][1,2,3]triaz ole. To 4- bromo-6-(difluoromethoxy)-N 1 -methylbenzene-1,2-diamine (6.34 g, 23.7 mmol) was added H 2 SO 4 (10% aqueous solution, 24 mL, 450 mmol). The resulting suspension was cooled to 0 ^C. Sodium nitrite (2.29 g, 33.2 mmol) was added slowly over 6 minutes, and the reaction mixture was stirred at 0 ^C for 30 minutes. Water (50 mL) was added and the mixture was filtered. The collected tan solid was washed with water (twice) and air-dried. It was subsequently dried further under vacuum to provide the title compound (6.71 g) which was used without further purification in the next step. MS (ESI): mass calcd. for C 8 H 6 BrF 2 N 3 O, 279.0; m/z found, 280.0 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) d 8.05 (d, J = 1.0 Hz, 1H), 7.28– 7.27 (m, 1H), 6.72 (t, J = 72.0 Hz, 1H), 4.45 (s, 3H). Intermediate 34: 5-Bromo-7-cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazole.

Step A: 2-Cyclopropoxy-6-nitroaniline. A mixture of cesium hydroxide monohydrate (16.08 g, 95.76 mmol), DMSO (50 mL), 2-amino-3-nitrophenol (14.71 g, 95.44 mmol), and cyclopropyl bromide (21.1 g, 174 mmol) was placed in a 500 mL high pressure flask with a screw cap, flushed with argon for 1 minute, then sealed and stirred at 150 °C. After 16 hours, the reaction was cooled to room temperature, treated with additional cyclopropyl bromide (24.44 g, 202.0 mmol), argon was bubbled through the solution for 30 seconds, then the reaction vessel was re-sealed and stirred at 150 °C. After 24 hours, the reaction was cooled to room temperature and the reaction mixture was allowed to sit for 9 weeks. The reaction mixture was then poured into water (400 mL) and 5:1 diethyl ether : DCM (600 mL) was added. A dark emulsion formed and it was filtered through diatomaceous earth such as Celite ® to allow the organic and aqueous layers to separate. The aqueous layer of the filtrate was separated and was extracted with DCM (1 x 600 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated to dryness under reduced pressure. The residue was initially purified by flash column

chromatography (eluent: heptanes/ethyl acetate, 95:5 to 70:30, gradient elution). Since impurities were still present, the residue was subsequently purified again by flash column chromatography (eluent: heptanes/ethyl acetate, 95:5 to 80:20, gradient elution) to provide the title compound (2.22 g, 12%). MS (ESI): mass calcd. for C 9 H 10 N 2 O 3 , 194.1; m/z found, 195.0 [M+H] + . 1 H NMR (400 MHz, CDCl3) d 7.75 (dd, J=1.3, 8.8 Hz, 1H), 7.28 - 7.24 (m, 1H), 6.62 (t, J=8.2 Hz, 1H), 6.33 (br s, 2H), 3.83 - 3.78 (m, 1H), 0.90 - 0.80 (m, 4H).

Step B: 4-Bromo-2-cyclopropoxy-6-nitroaniline. A mixture of 4-bromo-2- cyclopropoxy-6-nitroaniline (2.10 g, 10.8 mmol), HOAc (23 mL), and sodium acetate (1.405 g, 17.13 mmol) was stirred at 10-15 °C while a solution of bromine (1.92 g, 12.0 mmol) in HOAc (5 mL) was added dropwise over 6 minutes. The cooling bath was immediately removed and the reaction stirred at room temperature. After 2.5 hours, the reaction was treated with water (90 mL) over 3-4 minutes, filtered, and the filter cake washed with water (2 x 25 mL) and dried under reduced pressure to provide the title compound (2.92 g, 99%). MS (ESI): mass calcd. for C 9 H 9 BrN 2 O 3 , 272.0; m/z found, 273.0, 275.0 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) d 7.92 (d, J = 2.0 Hz, 1H), 7.32 (d, J = 2.0 Hz, 1H), 6.36 (br s, 2H), 3.80 (tt, J = 5.8, 3.0 Hz, 1H), 0.95 - 0.82 (m, 5H).

Step C: 4-Bromo-2-cyclopropoxy-N-methyl-6-nitroaniline. A solution of 4-bromo-2- cyclopropoxy-6-nitroaniline (2.79 g, 10.2 mmol) and DMF (41 mL) was stirred at 0 ^C under argon while NaH (60.8% dispersion in mineral oil, 0.451 g, 11.4 mmol) was added in one portion. The reaction was stirred for 30 minutes. While keeping the reaction mixture at 0 °C, a solution of MeI (1.605 g, 11.31 mmol) in DMF (8.5 mL, 10.2 mmol) was added dropwise over 10 minutes. The reaction was stirred at 0 °C for an additional 40 minutes, and was then treated with water (60 mL) dropwise over 6 minutes. Stirring was stopped while still at 0 ^C for ~30 minutes and the reaction mixture was then filtered. The filter cake was washed with water (2 x 25 mL), dried under reduced pressure, and purified by flash column chromatography (eluent: heptanes/ethyl acetate, 100:0 to 80:20, gradient elution) to provide the title compound (1.54 g, 53%). MS (ESI): mass calcd. for C10H11BrN2O3, 286.0; m/z found, 287.1, 289.1 [M+H] + . 1 H NMR (400 MHz, CDCl3) d 7.87 (d, J = 2.0 Hz, 1H), 7.65 (br s, 1H), 7.32 (d, J = 2.5 Hz, 1H), 3.72 (tt, J = 5.9, 3.0 Hz, 1H), 3.13 (d, J = 5.1 Hz, 3H), 0.90 - 0.80 (m, 4H).

Step D: 4-Bromo-6-cyclopropoxy-N 1 -methylbenzene-1,2-diamine. A solution of 4- bromo-2-cyclopropoxy-N-methyl-6-nitroaniline (1.51 g, 5.26 mmol) and HOAc (26 mL) was stirred at room temperature while iron powder (1.47 g, 26.3 mmol) was added in one portion. The reaction was stirred for 2 hours and then diluted with EtOAc (30 mL) and filtered through diatomaceous earth such as Celite ® . The filter cake was washed with EtOAc (4 x 30 mL), the combined filtrates were concentrated to dryness under reduced pressure, and the residue was partitioned between EtOAc (100 mL) and 10 M NaOH (20 mL). The resulting emulsion was filtered through diatomaceous earth such as Celite ® and the filter cake washed with EtOAc (2 x 50 mL). The aqueous layer was extracted with EtOAc (1 x 100 mL) and the organic solvent fractions were combined, dried over Na2SO4, filtered and concentrated to dryness under reduced pressure to provide the title compound. MS (ESI): mass calcd. for C 10 H 13 BrN 2 O, 256.0; m/z found, 257.0, 259.0 [M+H] + . 1 H NMR (400MHz, CDCl 3 ) d 6.78 (d, J = 2.0 Hz, 1H), 6.53 (d, J = 2.0 Hz, 1H), 3.94 - 3.82 (m, 2H), 3.82 - 3.58 (m, 1H), 2.65 - 2.57 (m, 3H), 0.84 - 0.70 (m, 4H).

Step E: 5-Bromo-7-cyclopropoxy-1-methyl-1H-benzo[d][1,2,3]triazole. A thick slurry of 4-bromo-6-cyclopropoxy-N 1 -methylbenzene-1,2-diamine (1.39 g, 5.41 mmol) in water (4.9 mL) and H2SO4 (1.2 mL, 23 mmol) at 0 °C was treated with a solution of sodium nitrite (0.536 g, 7.77 mmol) in water (4.9 mL) as an intermittent thin stream by syringe over 4 minutes with periodic spatula stirring of the thick mixture. The mixture was intermittently stirred with a spatula and shaken at 0 ^C for an additional 10 minutes, at which point the reaction thinned to an easily stirring mixture. After 35 minutes at 0 °C, the reaction was quenched with water (10 mL), allowed to chill in the ice bath, and filtered. The filter cake was washed with water (4 x 10 mL) and the filter cake was dried under reduced pressure to provide the title compound (1.31 g, 90%) which was used without further purification. MS (ESI): mass calcd. for C 10 H 10 BrN 3 O, 267.0; m/z found, 268.0, 270.0 [M+H] + . 1 H NMR (400 MHz, CDCl3) d 7.77 (d, J = 1.5 Hz, 1H), 7.21 (d, J = 1.0 Hz, 1H), 4.39 (s, 3H), 3.94 - 3.88 (m, 1H), 0.98 - 0.85 (m, 4H). Intermediate 35: Ethyl (E)-3-(1-(cyclopropylmethyl)-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)acrylate.

Step A: N-(Cyclopropylmethyl)-3-methyl-2-nitroaniline. A solution of 3-fluoro-2- nitrotoluene (6.92 g, 44.6 mmol), cyclopropylmethylamine (4.45 g, 62.6 mmol) and TEA (6.2 mL, 45 mmol) was heated in a sealed tube to 150 °C under argon. After 4 hours, the reaction was cooled to room temperature, combined, and partitioned between EtOAc (80 mL) and 1 M NaH2PO4 (80 mL). The organic solvent fraction was dried over Na2SO4, filtered, and concentrated to dryness under reduced pressure to provide the title compound contaminated with 7 mol% EtOAc (9.36 g, 102%). MS (ESI): mass calcd. for C 11 H 14 N 2 O 2 , 206.2; m/z found, 207.1 [M+H] + . 1 H NMR (400 MHz, CDCl3) d 7.21 (t, J = 7.8 Hz, 1H), 6.62 (d, J = 8.6 Hz, 2H), 6.51 (d, J = 7.6 Hz, 1H), 3.04 (dd, J = 7.1, 5.1 Hz, 2H), 2.47 (s, 3H), 1.18 - 1.08 (m, 1H), 0.66 - 0.55 (m, 2H), 0.33 - 0.24 (m, 2H).

Step B: 4-Bromo-N-(cyclopropylmethyl)-3-methyl-2-nitroaniline. A mixture of N- (cyclopropylmethyl)-3-methyl-2-nitroaniline (9.2 g, 44.6 mmol), HOAc (90 mL), and N- bromosuccinimide (7.93 g, 44.6 mmol) was stirred at 0 °C for 4 minutes and then was warmed to room temperature. After 3 hours, the reaction was concentrated under reduced pressure to give 35 g of a clear orange-red oil. 10 M NaOH (40 mL) was added in portions to the clear orange- red oil, and then the reaction mixture was partitioned between water (60 mL) and EtOAc (100 mL). The aqueous layer (pH ~14) was extracted with EtOAc (1 x 50 mL), and the organic solvent fractions were combined, dried over Na2SO4, filtered, and concentrated to dryness under reduced pressure to provide the title compound (12.1 g, 95%). MS (ESI): mass calcd. for C 11 H 13 BrN 2 O 2 , 284.0; m/z found, 285.0, 287.0 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) d 7.46 (d, J = 9.1 Hz, 1H), 6.52 (d, J = 9.1 Hz, 1H), 5.78 (br s, 1H), 2.99 (dd, J = 7.1, 5.1 Hz, 2H), 2.44 (s, 3H), 1.14 - 1.04 (m, 1H), 0.63 - 0.54 (m, 2H), 0.29 - 0.22 (m, 2H).

Step C: 4-Bromo-N 1 -(cyclopropylmethyl)-3-methylbenzene-1,2-diamine. A mixture of 4-bromo-N-(cyclopropylmethyl)-3-methyl-2-nitroaniline (11.71 g, 41.07 mmol), HOAc (123 mL), and iron powder (11.48 g, 205.6 mmol) was stirred at room temperature for 2.5 hours. The reaction was then filtered through diatomaceous earth such as Celite ® , and the filter cake was washed with EtOAc (2 x 50 mL). The filtrate was concentrated under reduced pressure to provide 33.7 g of a dark oil. Then, 3 M NaOH (133 mL) and EtOAc (1 x 100 mL) was added to the residue, the resulting emulsion was filtered through diatomaceous earth such as Celite ® and the filter cake washed with EtOAc (2 x 50 mL). This resulted in several organic solvent fractions which were combined, dried over Na2SO4, filtered and concentrated to dryness under reduced pressure to provide the title compound (9.6 g, 91%). MS (ESI): mass calcd. for

C 11 H 15 BrN 2 , 255.2; m/z found, 255.1, 257.1 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) d 6.99 (d, J = 8.6 Hz, 1H), 6.41 (d, J = 8.6 Hz, 1H), 3.51 (br s, 3H), 2.90 (d, J = 6.6 Hz, 2H), 2.31 (s, 3H), 1.21 - 1.07 (m, 1H), 0.63 - 0.50 (m, 2H), 0.29 - 0.14 (m, 2H).

Step D: 5-Bromo-1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azole. A solution containing 4-bromo-N 1 -(cyclopropylmethyl)-3-methylbenzene-1,2-diamine (9.34 g, 36.6 mmol), HOAc (110 mL), and MeOH (110 mL) was stirred at 0 °C while a solution of sodium nitrite (3.55 g, 51.4 mmol) in water (50 mL) was added dropwise over 5 minutes via pressure- equalizing addition funnel. The reaction was stirred at room temperature for 2 hours, and then partially concentrated under reduced pressure to remove the volatile organic solvents. The remaining solution was poured onto ice (300 mL), neutralized with solid K2CO3 to pH ~7, and extracted with EtOAc (2 x 100 mL). These extractions resulted in multiple organic solvent fractions which were combined, dried over Na2SO4, filtered, and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography using two different sets of conditions. The first column used heptanes/ethyl acetate, 80:20 to 60:40, gradient elution as the eluent and the second column used heptanes/ethyl acetate 90:10 to 75:25, gradient elution as the eluent to provide the title compound (3.9 g, 40%). MS (ESI): mass calcd. for C11H12BrN3, 265.0; m/z found, 266.0, 268.0 [M+H] + . 1 H NMR (400MHz, CDCl 3 ) d 7.60 (d, J = 8.6 Hz, 1H), 7.28 (d, J = 9.6 Hz, 1H), 4.49 (d, J = 7.1 Hz, 2H), 2.84 (s, 3H), 1.43 - 1.33 (m, 1H), 0.70 - 0.59 (m, 2H), 0.54 - 0.46 (m, 2H).

Step E: Ethyl (E)-3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tria zol-5- yl)acrylate. A mixture of 5-bromo-1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]tri azole (3.9 g, 14.7 mmol), DMF (7.3 mL), DIPEA (7.6 mL, 44 mmol), tri-o-tolylphosphine (0.894 g, 2.94 mmol), ethyl acrylate (3.2 mL, 29 mmol), and Pd(OAc)2 (0.331 g, 1.47 mmol) was stirred under argon at 80 °C . After 60 hours, the reaction was cooled to room temperature, partitioned between 0.5 M NaH2PO4 (100 mL) and 1:1 EtOAc : diethyl ether (100 mL). The organic solvent fraction was separated and washed with 0.5 M NaH2PO4 (1 x 100 mL), dried over Na2SO4, filtered, and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: heptanes/ethyl acetate, 60:40 to 80:20, gradient elution) to provide 2.9 g of the title compound which still contained some impurities. To further purify the title compound it was heated to reflux in 200 mL diethyl ether for ~10 minutes, cooled to room temperature, and filtered. The filtrate was concentrated to dryness under reduced pressure to provide the title compound (2.49 g, 60%). MS (ESI): mass calcd. for C16H19N3O2, 285.2; m/z found, 286.2 [M+H] + . 1 H NMR (400 MHz, CDCl3) d 8.15 (d, J = 15.7 Hz, 1H), 7.71 (d, J = 9.1 Hz, 1H), 7.39 (d, J = 9.1 Hz, 1H), 6.42 (d, J = 15.7 Hz, 1H), 4.50 (d, J = 7.1 Hz, 2H), 4.30 (q, J = 7.1 Hz, 2H), 2.93 (s, 3H), 1.44 - 1.34 (m, 4H), 0.69 - 0.62 (m, 2H), 0.52 - 0.47 (m, 2H). Intermediate 36: 2,2',3,3',5,6-Hexahydrospiro[pyran-4,4'-pyrido[2,3- b][1,4,5]oxathiazepine] 1',1'-dioxide.

Step A: 2-Chloropyridine-3-sulfonyl chloride (4.24 g, 20.0 mmol) was added to a mixture of 4-(aminomethyl)tetrahydro-2H-pyran-4-ol (2.62g, 20.0 mmol) and K2CO3 (4.14 g, 30.0 mmol) in THF (70 mL) and water (15 mL) at room temperature. After 2 hours, H 2 O (30 mL) was added and the aqueous layer was extracted with EtOAc (60 mL x 2). These extractions resulted in several organic solvent fractions which were combined and concentrated under reduced pressure to provide 2-chloro-N-((1-hydroxycyclohexyl)methyl)pyridine-3-sulfonami de. MS (ESI): mass calcd. for C 21 H 17 ClN 2 O 3 S, 304.1; m/z found, 307.1 [M+H] + .

Step B: 2-Chloro-N-((1-hydroxycyclohexyl)methyl)pyridine-3-sulfonami de was re- dissolved in DMF (20 mL), and K t OBu (5.60 g, 50 mmol) was added and the mixture was heated at 110 °C for 2 hours. The mixture was cooled to room temperature and pH was adjusted to ~3-4 by adding 1 M aqueous HCl solution. The precipitated solid was filtered and dried under reduced pressure to afford the tile compound (3.20 g, 59%). MS (ESI): mass calcd. for

C 11 H 14 N 2 O 4 S, 270.1; m/z found, 271.0 [M+H] + . 1 H NMR (500 MHz, CD 3 OD) ^ 8.56– 8.37 (m, 1H), 8.25 (dd, J = 7.7, 1.9 Hz, 1H), 7.49– 7.29 (m, 1H), 4.01 (s, 2H), 3.75– 3.52 (m, 4H), 1.84 – 1.57 (m, 4H). Intermediate 37: 8'-Methyl-2,2',3,3',5,6-Hexahydrospiro[pyran-4,4'-pyrido[2,3 - b][1,4,5]oxathiazepine] 1',1'-dioxide.

Step A: 2-Chloro-N-((4-hydroxytetrahydro-2H-pyran-4-yl)methyl)-5-met hylpyridine-3- sulfonamide. 2-Chloro-5-methylpyridine-3-sulfonyl chloride (2.60 g, 20 mmol) was added to a mixture of 4-(aminomethyl)tetrahydro-2H-pyran-4-ol (2.62 g, 20.0 mmol) and K2CO3 (4.14 g, 30.0 mmol) in THF (70 mL) and water (15 mL) at room temperature. After 2 hours, H 2 O (30 mL) and ethyl acetate were added. The layers were separated and the aqueous layer was further extracted with ethyl acetate (60 mL x 2). These extractions resulted in several organic solvent fractions which were combined and concentrated to provide the title compound (4.30 g, 68%). MS (ESI): mass calcd. for C 12 H 17 ClN 2 O 4 S, 320.1; m/z found, 321.1 [M+H] + . 1 H NMR (500 MHz, CD3OD) ^ 8.51– 8.36 (m, 1H), 8.34– 8.24 (m, 1H), 3.81– 3.57 (m, 4H), 2.99 (s, 2H), 2.45 (s, 3H), 1.76– 1.60 (m, 2H), 1.54– 1.37 (m, 2H).

Step B: 8'-Methyl-2,2',3,3',5,6-hexahydrospiro[pyran-4,4'-pyrido[2,3 - b][1,4,5]oxathiazepine] 1',1'-dioxide. 2-Chloro-N-((4-hydroxytetrahydro-2H-pyran-4- yl)methyl)-5-methylpyridine-3-sulfonamide (4.20 g, 13.2 mmol) was dissolved into DMSO (12 mL), and K t OBu (3.68 g, 32.8 mmol) was added. The mixture was heated to 95 °C for 2 hours. The mixture was then cooled, the pH of the mixture was adjusted to 5 by adding 5 M aqueous HCl solution. Ethyl acetate was added to the solution. The aqueous layer was separated and extracted with ethyl acetate (50 mL x 3). These extractions resulted in several organic solvent fractions which were combined and concentrated. The residue was purified by flash column chromatography (10% EtOAc/hexanes) to provide the title compound (1.70 g, 45%). MS (ESI): mass calcd. for C12H16N2O4S, 284.1; m/z found, 285.1 [M+H] + . 1 H NMR (500 MHz, CD3OD) ^ 8.29 (d, J = 2.2 Hz, 1H), 8.07 (d, J = 2.2 Hz, 1H), 4.14– 3.90 (m, 2H), 3.79– 3.63 (m, 2H), 3.54 (s, 2H), 2.41 (s, 3H), 1.67 (d, J = 6.0 Hz, 4H). Intermediate 38: 7-Bromo-3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]py ridine.

2,2-Difluoroacetic anhydride (34.50 g, 197.9 mmol) was added slowly to 4-bromo-2- hydrazinyl-3-methylpyridine (Intermediate 23, 2.00 g, 9.99 mmol). The reaction initially started to reflux and the solids turned yellow, but within 5 minutes the reaction was homogeneous. The reaction mixture was warmed to 50 °C. After 18 hours, the reaction mixture was concentrated under reduced pressure. Ethyl acetate (100 mL) was added, followed by saturated aqueous NaHCO3 until the pH of the solution was 7-8 and the layers were separated. The aqueous layer was extracted with ethyl acetate. These extractions resulted in several organic solvent fractions which were combined and washed sequentially with water and brine solution. The organics were dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (0 to 100% EtOAc/hexanes, gradient elution) to afford the title compound (2.50 g, 96%) as a white solid. MS (ESI): mass calcd. for C 8 H 6 BrF 2 N 3 , 262.1; m/z found, 262.0 [M+H] + . 1 H NMR (400 MHz, CDCl3) d 8.11 (d, J = 7.2 Hz, 1H), 7.18 - 7.09 (m, 2H), 2.76 (d, J = 0.8 Hz, 3H). Intermediate 39: (*S)-7a-Methyl-6,7,7a,8,9,10-hexahydropyrido[2,3-f]pyrrolo[2 ,1- d][1,2,5]thiadiazepine 5,5-dioxide.

The mixture of 7a-methyl-6,7,7a,8,9,10-hexahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepine 5,5-dioxide enantiomers (Intermediate 8, 2.9 g) was separated by chiral SFC (stationary phase: Whelk O1 (S,S) 5 µm 250 x 21.1 mm, Mobile phase: 65% CO 2 , 35% isopropanol) to afford two enantiomers. The first eluting isomer (1.3 g) was designated (*S). MS (ESI): mass calcd. for C11H15N3O2S, 253.1; m/z found, 254.1 [M+H] + . 1 H NMR (500 MHz, CDCl 3 ) d 8.40– 8.36 (m, 1H), 8.13– 8.10 (m, 1H), 6.93– 6.88 (m, 1H), 4.85– 4.72 (m, 1H), 4.06– 3.97 (m, 1H), 3.67– 3.56 (m, 2H), 3.18– 3.11 (m, 1H), 2.07– 1.88 (m, 4H), 0.94 (s, 3H). Intermediate 40: (*R)-7a-Methyl-6,7,7a,8,9,10-hexahydropyrido[2,3-f]pyrrolo[2 ,1- d][1,2,5]thiadiazepine 5,5-dioxide.

The second eluting isomer (1.25 g) from the separation of isomers by chiral SFC described in Intermediate 39 was designated (*R). MS (ESI): mass calcd. for C11H15N3O2S, 253.1; m/z found, 254.1 [M+H] + . 1 H NMR (500 MHz, CDCl 3 ) d 8.41– 8.36 (m, 1H), 8.14– 8.09 (m, 1H), 6.92– 6.89 (m, 1H), 4.90– 4.74 (m, 1H), 4.07– 3.94 (m, 1H), 3.69– 3.56 (m, 2H), 3.19– 3.09 (m, 1H), 2.07– 1.88 (m, 4H), 0.94 (s, 3H). Intermediate 41: 5-bromo-2-methylbenzyl pivalate.

Pivaloyl chloride (119 mL, 966 mmol) was added dropwise to a solution of (5-bromo-2- methylphenyl)methanol (87.8 g, 437 mmol), triethylamine (243 mL, 1.75 mol), and

dichloromethane (800 mL) that had been cooled to 0 °C. The resulting mixture was allowed to slowly warm to room temperature and stirred for 4 hours before pouring it into water (600 mL). The aqueous layer was extracted with dichloromethane (300 mL x 2). These extractions resulted in several organic solvent fractions which were combined, washed with brine (300 mL), dried over anhydrous Na 2 SO 4 , filtered, and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: petroleum ether) to afford the title compound (160 g, 96%) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) d 7.44 (d, J = 2.2 Hz, 1H), 7.39 (dd, J = 8.1, 2.2 Hz, 1H), 7.15 (d, J = 8.1 Hz, 1H), 5.03 (s, 2H), 2.21 (s, 3H), 1.13 (s, 9H).

Intermediate 42: 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benz yl pivalate.

A mixture of 5-bromo-2-methylbenzyl pivalate (Intermediate 41, 40.0 g, 140 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (53.5 g, 211 mmol), KOAc (55.1 g, 561 mmol), and 1,4-dioxane (600 mL) was sparged with N2 for 5 minutes and then treated with Pd(dppf)Cl2 (8.2 g, 11 mmol). The mixture was sparged with N2 for another 5 minutes and then heated to 90 °C for 4 hours before cooling to room-temperature. This mixture was then poured into H2O (200 mL), and extracted with ethyl acetate (200 mL x 3). These extractions resulted in several organic solvent fractions which were combined, washed with brine (50 mL), dried over anhydrous Na 2 SO 4 , filtered, and concentrated to dryness under reduced pressure. This residue was initially purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 10:1) and further purified by preparative HPLC using a SANPONT C18, 250 mm x 50 mm x 5 mm column (eluent: 50% to 95% (v/v) CH 3 CN and H 2 O with 0.1% TFA) to afford the titile compound as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) d 7.60 (s, 1H), 7.54 (d, J = 7.5 Hz, 1H), 7.24 (d, J = 7.5 Hz, 1H), 5.09 (s, 2H), 2.31 (s, 3H), 1.28 (s, 12H), 1.14 (s, 9H). Intermediate 43: Tert-butyldimethyl((2-methyl-5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzyl)oxy)silane.

1,1’-Bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (655 mg, 0.79 mmol) was added to a mixture of ((5-bromo-2-methylbenzyl)oxy)(tert- butyl)dimethylsilane (Intermediate 19, 5.00 g, 15.9 mmol), bis(pinacolato)diboron (8.19 g, 32.3 mmol), potassium acetate (4.64 g, 47.3 mmol) and 1,4-dioxane (45.0 mL). The reaction mixture was stirred at 90 ^C under nitrogen for 4 hours. After filtration of the mixture through a pad of diatomaceous earth, the filtrate was concentrated under reduced pressure. The resulting residue was partitioned between ethyl acetate and water and the aqueous layer was further extracted with ethyl acetate. These extractions resulted in several organic solvent fractions which were combined and dried over Na 2 SO 4 , filtered, and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: 0 to 50% ethyl

acetate/hexanes, gradient elution) to afford the title compound (4.00 g, 70%). 1 H NMR (400 MHz, CDCl 3 ) ^ 7.67 (d, J = 1.3 Hz, 1H), 7.55-7.51 (m, 1H), 7.06 (d, J = 7.4 Hz, 1H), 4.61 (s, 2H), 2.25 (s, 3H), 1.24 (s, 12H), 0.84 (s, 9H), 0.10 (s, 6H). Intermediate 45 : 3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridine-7 - carbaldehyde.

Step A: 3-(Difluoromethyl)-8-methyl-7-vinyl-[1,2,4]triazolo[4,3-a]py ridine. Pd(dppf)Cl 2 (11.1 g, 15.2 mmol) was added to a mixture of 7-bromo-3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridine (Intermediate 38, 40.0 g, 152 mmol,), potassium vinyl

trifluoroborate (40.9 g, 305 mmol) and K 3 PO 4 (97.2 g, 457 mmol) in H 2 O (100 mL) and 1,4- dioxane (400 mL) at 25 °C. The mixture was heated to 80 °C and stirred for 1 hour under N2. The brownish suspension was filtered, the filtrate was poured into H2O (200 mL) and this aqueous suspension was extracted with DCM (300 mL x 3). These extractions resulted in several organic solvent fractions which were combined and washed with brine (300 mL x 3), dried with anhydrous Na2SO4, filtered and concentrated to dryness under reduced pressure. The product was triturated with petroleum ether (300 mL) and filtered, dried under vacuum to afford the title compound (30 g, 89%) as an off white solid. Step B: 3-(Difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridine-7 -carbaldehyde. K2OsO4.2H2O (2.11 g, 5.74 mmol) was added to a solution consisting of 3-(difluoromethyl)-8- methyl-7-vinyl-[1,2,4]triazolo[4,3-a]pyridine (30.0 g, 143 mmol) in 1,4-dioxane (450 mL) and H2O (450 mL) at 25°C, and then NaIO4 (92.0 g, 430 mmol) was added. The resulting suspension was stirred at 25 °C for 2 hours then filtered and the filtrate was concentrated to dryness under reduced pressure. The resulting residue was diluted with water and the aqueous phase was extracted with CH 2 Cl 2 (500 mL x 3). These extractions resulted in several organic solvent fractions which were combined, washed with brine (500 mL x 2), dried with anhydrous Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was triturated with petroleum ether (500 mL), then the solvent was filtered off and the solid was dried in a vacuum oven to afford the title compound (20.6 g, 67%) as an off white solid. MS (ESI): mass calcd. for C9H7F2N3O, 211.1; m/z found, 211.9 [M+H] + . 1 H NMR (400 MHz, CDCl3) d 10.55 (s, 1H), 8.28 (d, J = 7.2 Hz, 1H), 7.47 (d, J = 7.2 Hz, 1H), 7.40 - 7.17 (m, 1H), 3.12 (s, 3H). Intermediate 46: 5-Bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-2-methylpyr idine.

Step A: (5-Bromo-2-methylpyridin-3-yl)methanol. NaBH 4 (9.40 g, 248 mmol) was added in portions to a solution of ethyl 5-bromo-2-methylnicotinate (20.2 g, 82.8 mmol) and MeOH (100 mL) at 0 °C. The resulting mixture was stirred for 4 hours with gradual warming to room temperature. The mixture was quenched with H 2 O (80 mL) and extracted with dichloromethane (120 mL x 3). These extractions resulted in several organic solvent fractions which were combined, and dried over anhydrous Na2SO4, filtered, and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 100: 0 to 4: 1, gradient elution) to afford the title compound (14.2 g) as an oil. 1 H NMR (400 MHz, DMSO-d6) d 8.39 (d, J = 2.0 Hz, 1H), 7.86 (d, J = 1.3 Hz, 1H), 5.47 (t, J = 5.5 Hz, 1H), 4.50 (d, J = 5.5 Hz, 2H), 2.34 (s, 3H). Step B: 5-Bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-2-methylpyr idine. TBSCl (14.5 g, 96.2 mmol) was added to a solution of (5-bromo-2-methylpyridin-3-yl)methanol (13 g, 64 mmol), 1H-imidazole (13.1 g, 192 mmol), and dichloromethane (120 mL). The mixture was stirred at room temperature for 20 minutes. The reaction mixture was filtered through a pad of diatomaceous earth and the pad was washed with ethyl acetate (60 mL). The combined organic extracts were concentrated to dryness under reduced pressure and purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 100:0 to 10:1, gradient elution) to afford the title compound (16.8 g, ). The still impure product (16.8 g) was combined with another batch prepared from (5-bromo-2-methylpyridin-3-yl)methanol (14.2 g, 70.3 mmol) to give a total of 35.4 g which was dissolved in ethyl acetate and washed with saturated aqueous NaHCO 3 (200 mL x 2), dried over anhydrous Na2SO4, filtered, and concentrated to dryness under reduced pressure. The residue was further purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 100:0 to 10:1, gradient elution) and further purified by preparative HPLC using a Phenomenex Synergi Max-RP, 250 mm x 50 mm x 10 mm column (eluent: 50% to 99% (v/v) CH3CN and H2O with 10 mM NH4HCO3) to afford the title compound. The product was suspended in water (50 mL), the mixture frozen using dry ice/acetone, and then lyophilized to dryness to afford the title compound (26 g, 58%). MS (ESI): mass calcd. for C 13 H 22 BrNOSi, 315.1; m/z found, 316 [M+H] + ; 1 H NMR (400 MHz, DMSO-d6) d 8.41 (d, J = 2.2 Hz, 1H), 7.83 (d, J = 2.2 Hz, 1H), 4.67 (s, 2H), 2.35 (s, 3H), 0.89 (s, 9H), 0.08 (s, 6H). Intermediate 47: 2-Bromo-4-(((tert-butyldimethylsilyl)oxy)methyl)-5-methylpyr idine.

Step A: 4-Iodo-5-methylpyridin-2(1H)-one. Concentrated HCl (200 mL) was added to 2- fluoro-4-iodo-5-methylpyridine (100 g, 422 mmol) in 1,4-dioxane: water (1:1, 400 mL). The resulting mixture was heated to 100 °C for 2 hours and then cooled to room-temperature. The reaction was then quenched with water (400 mL) and stirred at room-temperature for 1 hour. The mixture was then cooled to 0 °C, and the solids were isolated via filtration. The filter cake was washed with diethyl ether (100 mL) before drying under reduced pressure to afford the title compound (79 g, 80%). MS (ESI): mass calcd. for C6H6INO, 234.9; m/z found, 235.8 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 ) d 7.47 (s, 1H), 7.23 (s, 1H), 2.10 (s, 3H).

Step B: Methyl 5-methyl-2-oxo-1,2-dihydropyridine-4-carboxylate.4-Iodo-5- methylpyridin-2(1H)-one (59.5 g, 253 mmol), MeOH (1 L), and K2CO3 (35.0 g, 253 mmol) were added to a 2 L hydrogenation bottle. The resultant mixture was purged with N 2 for 5 minutes and then treated with Pd(OAc) 2 (11.4 g, 50.8 mmol) and dcpp•2HBF 4 (31.0 g, 50.6 mmol). The resultant mixture was stirred under CO (50 psi) at 80 °C for 36 hours. The suspension was filtered through a pad of diatomaceous earth and the filtrate concentrated to dryness under reduced pressure. The residue was triturated with ethyl acetate (500 mL) and the solids isolated by filtration. The filter cake was washed with ethyl acetate (50 mL) before drying under reduced pressure to afford the title compound (58 g), which was used in the next step without further purification.

Step C: Methyl 2-bromo-5-methylisonicotinate. POBr3 (222.3 g, 775.4 mmol) was added to a solution of 5-methyl-2-oxo-1,2-dihydropyridine-4-carboxylate (45.0 g) in toluene (500 mL). The resulting mixture was heated to 120 °C for 15 hours before cooling to room-temperature. The mixture was combined with another batch prepared from methyl-2-oxo-1,2-dihydropyridine- 4-carboxylate (13.0 g) and the resulting mixture was poured into ice/water (500 mL). The pH of resultant solution was adjusted to pH = 8 with aqueous NaOH (5 N). and then the solution was extracted with ethyl acetate (500 mL x 2). These extractions resulted in several organic solvent fractions which were combined, washed with brine (400 mL x 2), dried over anhydrous Na2SO4, filtered, and concentrated to dryness under reduced pressure. The product was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 100:1 to 20:1, gradient elution) to afford the title compound (18 g) as a light yellow solid. 1 H NMR (400 MHz, CDCl3) d 8.32 (s, 1H), 8.39 - 8.23 (m, 1H), 7.89 (s, 1H), 3.94 (s, 3H), 2.51 (s, 3H).

Step D: (2-Bromo-5-methylpyridin-4-yl)methanol. NaBH 4 (5.92 g, 157 mmol) was added to a solution of methyl 2-bromo-5-methylisonicotinate (18 g, 78 mmol) in MeOH (400 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 1 hour before quenching with H2O (50 mL). The solvent was removed under reduced pressure and the resulting mixture was extracted with ethyl acetate (150 mL x 3). These extractions resulted in several organic solvent fractions which were combined, dried over anhydrous Na2SO4, filtered, and concentrated to dryness under reduced pressure to afford the title compound (17 g) as a white solid. MS (ESI): mass calcd. for C 7 H 8 BrNO, 200.9; m/z found, 201.8 [M+H] + ; 1 H NMR (400 MHz, DMSO-d 6 ) d 8.10 (s, 1H), 7.54 (s, 1H), 5.55 (br s, 1H), 4.51 (s, 2H), 2.18 - 2.09 (m, 3H).

Step E: 2-Bromo-4-(((tert-butyldimethylsilyl)oxy)methyl)-5-methylpyr idine. TBSCl (7.76 g, 51.5 mmol) was added to a solution of (2-bromo-5-methylpyridin-4-yl)methanol (8.00 g, 39.6 mmol), 1H-imidazole (8.08 g, 119 mmol), and dichloromethane (100 mL). The resulting mixture was stirred at room-temperature for 1 hour. The mixture was combined with another batch prepared from (2-bromo-5-methylpyridin-4-yl)methanol (1.6 g, 7.9 mmol). The combined mixture was concentrated to dryness under reduced pressure to give a residue that was purified by preparative HPLC using a SANPONT C18, 250 mm x 80 mm x 10 mm column (eluent: 70% to100% (v/v) CH3CN and H2O with 10 mM NH4HCO3). The fractions that contained the desired product were collected, suspended in water (25 mL), the mixture frozen using dry ice/acetone, and then lyophilized to dryness to afford the title compound (10 g, 67%) as a white solid. MS (ESI): mass calcd. for C13H22BrNOSi 315.1 m/z found 316.0 [M+H] + ; 1 H NMR (400 MHz, CDCl 3 ) d 8.07 (s, 1H), 7.59 (s, 1H), 4.64 (s, 2H), 2.15 (s, 3H), 0.97 (s, 9H), 0.14 (s, 6H). Intermediate 48: Methyl 3-(3-(hydroxymethyl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-y l)propanoate.

Step A: 5-(Hydroxy(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin e-7-yl)methyl)-2- methylbenzyl pivalate. To a mixture of 3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- carbaldehyde (Intermediate 28, 2.00 g, 8.73 mmol), 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzyl pivalate (Intermediate 42, 3.80 g, 11.4 mmol), and K 2 CO 3 (3.74 g, 27.1 mmol) in THF was added tri(1-naphthyl)phosphine (106 mg, 0.60 mmol) and palladium II chloride (285 mg, 0.67 mmol). After heating at 60 ^C for 24 hours, the reaction mixture was cooled, poured into water and extracted with ethyl acetate. These extractions resulted in several organic solvent fractions which were combined, washed with brine, dried over Na2SO4, filtered, and concentrated to dryness under reduced pressure. The residue was purified by flash silica gel chromatography (eluent: 0-60% ethyl acetate/hexanes) to afford the title compound (1.90 g, 50.0%). MS (ESI): mass calcd. for C22H24F3N3O3, 435.2; m/z found, 436.1 [M+H] + .

Step B: 5-(Chloro-(3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin e-7-yl)methyl)-2- methylbenzyl pivalate. To a solution of 5-(hydroxy(3-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridine-7-yl)methyl)-2-methylbenzyl pivalate (1.80 g, 4.13 mmol) in DCM (50 mL) was added dropwise thionyl chloride (3.50 mL, 47.8 mmol). After 24 hours the reaction mixture was slowly added to saturated aqueous bicarbonate and extracted with diethyl ether. These extractions resulted in several organic solvent fractions which were combined, washed with brine, dried over Na2SO4, filtered, and concentrated to dryness under reduced pressure. The residue was purified by flash silica gel chromatography (eluent: 0-50% ethyl acetate/hexanes) to afford the title compound (1.40 g, 75%). MS (ESI): mass calcd. for C22H23ClF3N3O2, 453.1; m/z found, 454.1 [M+H] + .

Step C: Methyl 2,2-dimethyl-3-(4-methyl-3-((pivaloyloxy)methyl)phenyl)-3-(8 -methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propan oate. To a mixture of 5-(chloro-(3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)methyl )-2-methylbenzyl pivalate (1.10 g, 2.42 mmol), dimethylketene methyl trimethylsilyl acetal (1.61 mL, 7.93 mmol) in DCM (32 mL) was added indium III bromide (200 mg, 0.56 mmol). After 18 hours the reaction was poured into saturated aqueous sodium bicarbonate and extracted with DCM. These extractions resulted in several organic solvent fractions which were combined, washed with brine, dried over MgSO 4 , filtered, and concentrated to dryness under reduced pressure. The residue was purified by flash silica gel chromatography (eluent: 0-50% ethyl acetate/hexanes) to afford the title compound (760 mg, 60%). MS (ESI): mass calcd. for C27H32F3N3O4, 519.2; m/z found, 520.2 [M+H] + .

Step D: 3-(3-(Hydroxymethyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methy l-3- (trifluomethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoa te. A solution of sodium methoxide in methanol (1.0 mL, 4.37 mmol, 25% w/w) was added to a solution of methyl 2,2-dimethyl-3- (4-methyl-3-((pivaloyloxy)methyl)phenyl)-3-(8-methyl-3-(trif luoromethyl)-[1,2,4]triazolo[4,3- a]pyridine-7-yl)propanoate (760 mg, 1.46 mmol) in methanol and stirred for 2 hours. The reaction was poured into saturated aqueous ammonium chloride and extracted three times with DCM. These extractions resulted in several organic solvent fractions which were combined, washed with brine, dried over Na 2 SO 4 , filtered, and concentrated to dryness under reduced pressure. The residue was purified by flash silica gel chromatography (eluent: 0-80% ethyl acetate/hexanes) to afford the title compound (630 mg, 99%). An alternative preparation of this compound is described in the preparation of Intermediate 48, steps A-I. MS (ESI): mass calcd. for C 27 H 32 F 3 N 3 O 4 , 435.2; m/z found, 436.2 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 ) d 8.41 (d, J = 7.3 Hz, 1H), 7.27 (d, J = 7.4 Hz, 2H), 7.12 (dd, J = 7.8, 2.1 Hz, 1H), 7.06 (d, J = 7.9 Hz, 1H), 5.03 (t, J = 5.4 Hz, 1H), 4.76 (s, 1H), 4.43 (d, J = 5.4 Hz, 2H), 3.52 (s, 3H), 2.68 (s, 3H), 2.18 (s, 3H), 1.33 (s, 3H), 1.28 (s, 3H). Intermediate 49: Methyl 3-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7- yl)-3-(3-(hydroxymethyl)-4-methylphenyl)-2,2-dimethylpropano ate.

Step A: (3-(((Tert-butyldimethylsilyl)oxy)methyl)-4-methylphenyl)(3- (difluoromethyl)- 8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)methanol. A mixture of 3-(difluoromethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridine-7-carbaldehyde (Intermediate 19 , 0.5 g, 2.4 mmol), tert- butyldimethyl((2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxabo rolan-2-yl)benzyl)oxy)silane (Intermediate 45, 1.3 g, 3.5 mmol), palladium (II) chloride (22 mg, 0.1 mmol), potassium carbonate (1.0 g, 7.3 mmol), and tri-1-naphthylphosphine (57 mg, 0.1 mmol) were charged to a reaction vessel, followed by addition of THF (15 mL). The vial was caped and degassed by bubbling argon through the reaction for 5 minutes, then the reaction was stirred overnight in a pre-heated block at 75°C. The reaction was cooled to room temperature, then filtered through diatomaceous earth and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (0-100% ethyl acetate/hexanes, gradient elution) to afford the title compound (0.9 g, 85%). MS (ESI): mass calcd. for C23H31F2N3O2Si, 447.2; m/z found, 448.3 [M+H] + . 1 H NMR (500 MHz, CDCl3) d 8.15 (d, J = 7.2 Hz, 1H), 7.38 (d, J = 7.2 Hz, 1H), 7.29 (d, J = 2.0 Hz, 1H), 7.20 (dd, J = 7.7, 2.0 Hz, 1H), 7.15 (s, 1H), 7.09 - 7.02 (m, 1H), 6.08 (s, 1H), 4.61 (s, 2H), 3.26 (s, 1H), 2.57 (s, 3H), 2.17 (s, 3H), 0.80 (s, 9H), 0.00 (d, J = 4.7 Hz, 6H).

Step B: 7-((3-(((Tert-butyldimethylsilyl)oxy)methyl)-4-methylphenyl) chloromethyl)-3- (difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridine. Thionyl chloride (1.6 mL, 23 mmol) was added to a solution of (3-(((tert-butyldimethylsilyl)oxy)methyl)-4-methylphenyl)(3- (difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl )methanol (7.8 g, 17 mmol) and 2,6- di-tert-butylpyridine (7.8 ml, 35 mmol) in DCM (86 mL). The reaction was stirred at room temperature for 1 hour. The reaction was quenched with saturated aqueous NaHCO3, then extracted twice with DCM. These extractions resulted in several organic solvent fractions which were combined, dried over MgSO 4 , filtered, and concentrated to dryness under reduced pressure. The product was purified by flash column chromatography (0-100% ethyl acetate/hexanes, gradient elution) to provide the title compound (7.5 g, 92%). MS (ESI): mass calcd. for

C 23 H 30 ClF 2 N 3 OSi, 465.2; m/z found, 466.2 [M+H] + . 1 H NMR (500 MHz, CDCl 3 ) d 8.15 (d, J = 7.3 Hz, 1H), 7.42– 7.36 (m, 1H), 7.31 (s, 1H), 7.26– 7.03 (m, 4H), 6.42 (s, 1H), 4.62 (s, 2H), 4.08 (q, J = 7.1 Hz, 1H), 2.74 (d, J = 0.7 Hz, 3H), 2.19 (s, 3H), 0.79 (s, 9H), 0.29– -0.22 (m, 6H).

Step C: Methyl 3-(3-(((tert-butyldimethylsilyl)oxy)methyl)-4-methylphenyl)- 3-(3- (difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl )-2,2-dimethylpropanoate. ((1- Methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane (16 ml, 79 mmol) was added to a solution of 7-((3-(((tert-butyldimethylsilyl)oxy)methyl)-4-methylphenyl) chloromethyl)-3- (difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridine (7.5 g, 16 mmol) in DCM (80 ml). Indium(III) bromide (1.7 g, 4.9 mmol) was added and the reaction was stirred at room

temperature for 3 hours. The reaction was filtered, concentrated and purified by flash column chromatography (0-100% ethyl acetate/hexanes, gradient elution) to afford the title compound (6.0 g, 70 % ). MS (ESI): mass calcd. for C28H39F2N3O3Si, 531.3; m/z found, 532.3 [M+H] + . 1 H NMR (500 MHz, CDCl 3 ) d 8.09 (d, J = 7.3 Hz, 1H), 7.23 (d, J = 1.7 Hz, 1H), 7.18 (s, 1H), 7.14 - 7.06 (m, 1H), 7.06 - 6.96 (m, 2H), 4.79 (s, 1H), 4.60 (s, 2H), 3.54 (s, 3H), 2.73 - 2.67 (m, 3H), 2.16 (s, 3H), 1.39 (s, 3H), 1.32 (s, 3H), 1.23 (t, J = 7.1 Hz, 0H), 0.83 (s, 9H), 0.00 (dd, J = 16.9, 5.9 Hz, 6H).

Step D: Methyl 3-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin -7-yl)-3-(3- (hydroxymethyl)-4-methylphenyl)-2,2-dimethylpropanoate. Tetrabutylammonium fluoride (1 M in THF, 23 ml, 23 mmol) was added to a solution of methyl 3-(3-(((tert- butyldimethylsilyl)oxy)methyl)-4-methylphenyl)-3-(3-(difluor omethyl)-8-methyl- [1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethylpropanoate (6.0 g, 11 mmol) in THF (62 ml). The reaction was stirred at room temperature for 1 hour. The reaction was quenched with saturated aqueous NH 4 Cl, then extracted twice with ethyl acetate. These extractions resulted in several organic solvent fractions which were combined, dried over MgSO 4 , filtered, concentrated to and purified by flash column chromatography (0-100% ethyl acetate/hexanes, gradient elution) to afford the title compound (4.6, 98% ). MS (ESI): mass calcd. for C22H25F2N3O3, 417.2; m/z found, 418.2 [M+H] + . 1 H NMR (500 MHz, CDCl 3 ) d 8.14 (d, J = 7.3 Hz, 1H), 7.29 (d, J = 4.7 Hz, 1H), 7.18 (d, J = 7.7 Hz, 2H), 7.09 (d, J = 1.3 Hz, 2H), 4.81 (s, 1H), 4.68 (d, J = 3.8 Hz, 2H), 4.13 (q, J = 7.1 Hz, 1H), 3.58 (s, 3H), 2.73 (s, 3H), 2.28 (s, 3H), 1.35 (s, 6H). Intermediate 50: Methyl 3-(4-(hydroxymethyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8 - methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-y l)propanoate.

Step A: (4-(((Tert-butyldimethylsilyl)oxy)methyl)-5-methylpyridin-2- yl)(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)methano l. n-Butyllithium (2.0 M, 3.1 ml, 6.2 mmol) was added dropwise to a stirring solution of 2-bromo-4-(((tert- butyldimethylsilyl)oxy)methyl)-5-methylpyridine (Intermediate 47, 2.0 g, 6.3 mmol) in THF (14 ml) at -78 °C under nitrogen. This reaction was stirred at -78 °C for 2 minutes to prepare the lithiate reaction mixture. A solution 3-(trifluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridine- 7-carbaldehyde (Intermediate 28, 1.2 g, 5.1 mmol) in THF (10 ml) was added to the lithiate reaction mixture dropwise. The resulting reaction mixture was stirred at -78 °C for 5 minutes. The reaction was then quenched with saturated aqueous NaHCO3, and then extracted twice with EtOAc. These extractions resulted in several organic solvent fractions which were combined, dried over MgSO4, filtered, and concentrated to dryness under reduced pressure. The product was purified by flash column chromatography (0-100% ethyl acetate/hexanes, gradient elution) to provide the title compound (1.0 g, 42%). MS (ESI): mass calcd. for C 22 H 29 F 3 N 4 O 2 Si, 466.2; m/z found, 467.3 [M+H] + . 1 H NMR (500 MHz, CDCl 3 ) d 8.30 (t, J = 0.8 Hz, 1H), 8.05 - 7.99 (m, 1H), 7.25 (s, 1H), 7.16 (d, J = 7.2 Hz, 1H), 6.19 (s, 1H), 5.94 (s, 1H), 4.65 (dd, J = 15.6, 1.1 Hz, 1H), 4.60 (dd, J = 15.6, 1.0 Hz, 1H), 2.86 (s, 3H), 2.20 (s, 3H), 2.06 (s, 1H), 1.27 (t, J = 7.1 Hz, 1H), 0.78 (s, 9H), 0.84 - 0.72 (m, 1H), 0.05 (s, 3H).

Step B: 7-((4-(((Tert-butyldimethylsilyl)oxy)methyl)-5-methylpyridin -2- yl)chloromethyl)-8-methyl-3-(trifluoromethyl)-[1,2,4]triazol o[4,3-a]pyridine. Thionyl chloride (0.3 mL, 4.2 mmol) was added to a solution of (4-(((tert-butyldimethylsilyl)oxy)methyl)-5- methylpyridin-2-yl)(8-methyl-3-(trifluoromethyl)-[1,2,4]tria zolo[4,3-a]pyridin-7-yl)methanol (1.5 g, 3.2 mmol) and 2,6-di-tert-butylpyridine (1.4 ml, 6.4 mmol) in DCM (16 mL). The reaction was stirred at room temperature for 1 hour. The reaction was quenched with saturated aqueous NaHCO 3 , then extracted twice with DCM. These extractions resulted in several organic solvent fractions which were combined, dried over MgSO4, filtered, and concentrated to dryness under reduced pressure. The product was purified by flash column chromatography (0-100% ethyl acetate/hexanes, gradient elution) to provide the title compound (1.0 g, 64% yield). MS (ESI): mass calcd. for C22H28ClF3N4OSi, 484.2; m/z found, 485.2 [M+H] + . 1 H NMR (500 MHz, CDCl 3 ) d 8.15 (t, J = 0.8 Hz, 1H), 7.96 (d, J = 7.2 Hz, 1H), 7.62 (s, 1H), 7.25 (d, J = 7.3 Hz, 1H), 6.35 (s, 1H), 4.58 (d, J = 1.0 Hz, 2H), 3.98 (q, J = 7.1 Hz, 1H), 2.71 (d, J = 0.7 Hz, 3H), 2.08 (s, 3H), 1.12 (t, J = 7.1 Hz, 1H), 0.80 (s, 9H), 0.86 - 0.74 (m, 1H), 0.05 (s, 3H).

Step C: Methyl 3-(4-(((tert-butyldimethylsilyl)oxy)methyl)-5-methylpyridin- 2-yl)-2,2- dimethyl-3-(8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3 -a]pyridin-7-yl)propanoate. ((1- Methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane (6.1 ml, 30 mmol) was added to a solution of 7-((4-(((tert-butyldimethylsilyl)oxy)methyl)-5-methylpyridin -2-yl)chloromethyl)-8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine (3.0 g, 6.2 mmol) in DCM (31 ml). Indium(III) bromide (0.67 g, 1.9 mmol) was added and the reaction was stirred at room temperature for 3 hours. The reaction was filtered, concentrated and purified by flash column chromatography (0- 100% ethyl acetate/hexanes, gradient elution) to afford the title compound (0.5 g, 15% yield). MS (ESI): mass calcd. for C 27 H 37 F 3 N 4 O 3 Si, 550.2; m/z found, 551.2 [M+H] + . 1 H NMR (500 MHz, CDCl3) d 8.22 (d, J = 0.8 Hz, 1H), 7.91 (d, J = 7.4 Hz, 1H), 7.28 (d, J = 7.3 Hz, 1H), 7.06 (s, 1H), 5.04 (s, 1H), 4.60 - 4.49 (m, 2H), 3.59 (s, 3H), 2.86 (s, 3H), 2.11 (s, 3H), 2.01 (s, 1H), 1.28 (s, 3H), 1.22 (t, J = 7.1 Hz, 1H), 0.74 (s, 9H), 0.76 - 0.70 (m, 1H), 0.14 - 0.07 (m, 6H).

Step D: Methyl 3-(4-(hydroxymethyl)-5-methylpyridin-2-yl)-2,2-dimethyl-3-(8 -methyl- 3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propa noate. Tetrabutylammonium fluoride (1 M in THF, 1.4 ml, 1.4 mmol) was added to a solution of methyl 3-(4-(((tert- butyldimethylsilyl)oxy)methyl)-5-methylpyridin-2-yl)-2,2-dim ethyl-3-(8-methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)propano ate (0.5 g, 0.9 mmol) in THF (5 ml). The reaction was stirred at room temperature for 1 hour. The reaction was quenched with saturated aqueous NH 4 Cl, then extracted twice with ethyl acetate. These extractions resulted in several organic solvent fractions which were combined, dried over MgSO4, filtered, concentrated and purified by flash column chromatography (0-100% ethyl acetate/hexanes, gradient elution) to afford the title compound (280 mg, 71% yield). MS (ESI): mass calcd. for C 21 H 23 F 3 N 4 O 3 , 436.2; m/z found, 437.2 [M+H] + . 1 H NMR (500 MHz, CDCl 3 ) d 8.28 (d, J = 0.8 Hz, 1H), 7.92 (d, J = 7.3 Hz, 1H), 7.47 (d, J = 7.4 Hz, 1H), 7.23 (s, 1H), 5.00 (s, 1H), 4.71 - 4.66 (m, 2H), 3.60 (s, 4H), 2.86 - 2.82 (m, 3H), 2.19 (s, 3H), 1.40 (s, 3H), 1.32 (s, 3H). Intermediate 51: Methyl 3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(5- (hydroxymethyl)-6-methylpyridin-3-yl)-2,2-dimethylpropanoate .

Step A: (5-(((Tert-butyldimethylsilyl)oxy)methyl)-6-methylpyridin-3- yl)(1-ethyl-4- methyl-1H-benzo[d][1,2,3]triazol-5-yl)methanol. n-Butyllithium (2.5 M, 9.2 ml, 23 mmol) was added dropwise to a stirring solution of 5-bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-2- methylpyridine (Intermediate 46, 4.8 g, 15 mmol) in THF (20 ml) at -78 °C under nitrogen. The reaction mixture was stirred at -78 °C for 2 minutes to prepare the lithiate reaction mixture. A solution 1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazole-5-carbaldehyde (Intermediate 22, 2.9 g, 15 mmol) in THF (10 ml) was added to the lithiate reaction mixture dropwise. The reaction was stirred at -78 °C for 5 minutes. The reaction was quenched with saturated aqueous NaHCO3, and then extracted twice with EtOAc. These extractions resulted in several organic solvent fractions which were combined, dried over MgSO 4 , filtered, and concentrated to dryness under reduced pressure. The product was purified by flash column chromatography (0-100% ethyl

acetate/hexanes, gradient elution) to provide the title compound (4.0 g, 61%). MS (ESI): mass calcd. for C 23 H 34 N 4 O 2 Si, 426.2; m/z found, 427.2 [M+H] + . 1 H NMR (600 MHz, CDCl 3 ) d 7.25 (dd, J = 8.3, 1.7 Hz, 2H), 7.16 (d, J = 8.7 Hz, 1H), 6.66 (d, J = 7.8 Hz, 1H), 6.04 (s, 1H), 5.64 (s, 1H), 4.79 (d, J = 0.9 Hz, 2H), 4.53 (q, J = 7.3 Hz, 2H), 2.80 (s, 3H), 2.28 (s, 3H), 1.47 (t, J = 7.3 Hz, 3H), 0.81 (s, 9H), 0.00 (d, J = 1.1 Hz, 6H).

Step B: Methyl 3-(5-(((tert-butyldimethylsilyl)oxy)methyl)-6-methylpyridin- 3-yl)-3-(1- ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylp ropanoate. Trichloroacetonitrile (1.4 g, 9.4 mmol) and DBU (0.1 g, 0.7 mmol) were added to a solution of (5-(((tert- butyldimethylsilyl)oxy)methyl)-6-methylpyridin-3-yl)(1-ethyl -4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)methanol (2.0 g, 4.7 mmol) in ACN (25 ml). The reaction was stirred at room temperature under nitrogen for 1 hour. ((1-Methoxy-2-methylprop-1-en-1- yl)oxy)trimethylsilane (1.6 g, 9.4 mmol) was then added to the reaction, followed by

trifluoromethanesulfonamide (0.7 g, 2.3 mmol), and the reaction was stirred at room temperature under nitrogen for 3 hours. The reaction was quenched with saturated aqueous NaHCO 3 , then extracted twice with EtOAc. These extractions resulted in several organic solvent fractions which were combined, dried over MgSO4, filtered, and concentrated to dryness under reduced pressure. The product was purified by flash column chromatography (0-50% EtOAc/hexanes, gradient elution) to provide the title compound that was carried forward without further purification (1.5 g, 63% yield). MS (ESI): mass calcd. for C28H42N4O3Si, 510.3; m/z found, 511.3 [M+H] + .

Step C: Methyl 3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(5- (hydroxymethyl)-6-methylpyridin-3-yl)-2,2-dimethylpropanoate . Tetrabutylammonium fluoride (1 M in THF, 11.7 ml, 11.7 mmol) was added to a solution of methyl 3-(5-(((tert- butyldimethylsilyl)oxy)methyl)-6-methylpyridin-3-yl)-3-(1-et hyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoate (3.0 g, 5.8 mmol) and 3 drops of DMF in THF (60 ml). The reaction was stirred at room temperature for 1.5 hours. The reaction was quenched with saturated aqueous NaHCO3, then extracted twice with EtOAc. These extractions resulted in several organic solvent fractions which were combined, dried over MgSO 4 , filtered, and concentrated to an oil under reduced pressure. The product was purified by flash column chromatography (0-100% ethyl acetate/hexanes, gradient elution) to provide the title compound (1.8 g, 77 % yield). MS (ESI): mass calcd. for C 22 H 28 N 4 O 3 , 396.2; m/z found, 397.2 [M+H] + . 1 H NMR (500 MHz, CDCl 3 ) d 8.28 (d, J = 2.3 Hz, 1H), 7.67 (d, J = 2.4 Hz, 1H), 7.58 (d, J = 8.8 Hz, 1H), 7.29 (d, J = 8.7 Hz, 1H), 4.83 (s, 1H), 4.69 - 4.56 (m, 4H), 4.35 (s, 1H), 3.50 (s, 3H), 2.74 (s, 3H), 2.37 (s, 3H), 1.57 (t, J = 7.3 Hz, 3H), 1.36 (s, 3H), 1.29 (s, 3H). Intermediate 52: 2-hydrazinyl-4-iodo-3-methylpyridine.

A mixture of hydrazine hydrate (47.0 mL, 630 mmol) and 2-fluoro-4-iodo-3- methylpyridine (23.39 g, 98.69 mmol) was stirred at 60 °C for 24 hours. The mixture was cooled to room temperature and then aqueous NaOH solution (60 mL, 3M) and water (60 mL) were added to the mixture and the suspension was stirred at 25 °C for 45 minutes. The solid was filtered, washed with water, and the solid was dried under reduced pressure to afford the title compound as a white solid (20.4 g, 83%), which was used in the next step without further purification. MS (ESI): mass calcd. for C6H8IN3, 249.05; m/z found, 250 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 ) d 7.57 (d, J = 5.3 Hz, 1H), 7.44 (s, 1H), 7.03 (d, J = 5.3 Hz, 1H), 4.17 (s, 2H), 2.19– 2.11 (m, 3H). Intermediate 53: 7-iodo-8-methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]py ridine

TFAA (53.0 mL, 375 mmol) was slowly added to a mixture of 2-hydrazinyl-4-iodo-3- methylpyridine (Intermediate 52, 20.4 g, 81.9 mmol) in toluene (40 mL). The mixture was heated to 60 °C for 22 hours under an atmosphere of nitrogen. The solvents were removed under reduced pressure, and the residue was dissolved in ethyl acetate. The resulting solution was washed with saturated aqueous NaHCO3 solution, brine, dried and concentrated under reduced pressure. The residue was triturated with DCM/hexanes to afford the title compound as a white solid. MS (ESI): mass calcd. for C 8 H 5 F 3 IN 3 , 327.0; m/z found, 328.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) d 8.24 (d, J = 7.2 Hz, 1H), 7.52 (d, J = 7.2 Hz, 1H), 2.68 (d, J = 0.8 Hz, 3H). Intermediate 54: 7-Bromo-3-cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin e.

Step A: 4-Bromo-2-hydrazinyl-3-methylpyridine. Hydrazine hydrate (391 mL, 8.04 mol) was added to 4-bromo-2-fluoro-3-methylpyridine (240 g, 1.3 mol) and the white suspension was heated to 60 °C for 7 hours. The white suspension was concentrated under reduced pressure and the resulting white precipitate was collected by filtration. The solid was triturated with methyl tert-butyl ether (200 mL) to provide the title compound (255 g, 99.7% yield) as a white solid, which was used in the next step without further purification, MS (ESI): mass calcd. for

C 6 H 8 BrN 3 , 203.0; m/z found, 203.8 [M+H]+.

Step B: 7-Bromo-3-cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin e.

Cyclopropanecarbaldehyde (28.5 mL, 381 mmol) was added to a solution of 4-bromo-2- hydrazinyl-3-methylpyridine (70.0 g, 346 mmol) in EtOH (700 mL), and the light yellow mixture was stirred at 30 °C for 3 hours. H2O (175 mL), CuBr2 (1.62 mL, 34.6 mmol), and oxone (255.5 g, 415.7 mmol) were then added portion-wise and the resulting yellow solution was stirred for an additional 3 hours at 30 °C. The mixture was filtered and the filtrate was concentrated under reduced pressure. Water (200 mL) was added to the reaction mixture, the pH was adjusted to 8 with saturated aqueous NaHCO 3 , and the aqueous layer was extracted with dichloromethane (200 mL x 3). These extractions resulted in several organic solvent fractions which were combined and washed with brine (500 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was triturated with EtOAc (200 mL) and filtered. The resulting solid cake was dried under reduced pressure to afford the title compound (48 g, 52 % yield) as a solid, which was used without further purification, MS (ESI): mass calcd. for C 10 H 10 BrN 3 , 253.0; m/z found, 253.8 [M+H]+. . Intermediate 55: Methyl 3-(3-cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl )- 3-(3-(hydroxymethyl)-4-methylphenyl)-2,2-dimethylpropanoate.

Step A: 3-Cyclopropyl-8-methyl-7-vinyl-[1,2,4]triazolo[4,3-a]pyridin e. A mixture of 7- bromo-3-cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridine (Intermediate 54, 48.0 g, 190 mmol), potassium trifluoro(vinyl)borate (25.5 g, 190 mmol), potassium phosphate (121.6 g, 573.1 mmol), and Pd(dppf)Cl2 (16.1 g, 19.8 mmol) in EtOH (720 mL) was degassed and purged with nitrogen 3 times and then the suspension was stirred at 85 °C for 12 hours under nitrogen. The mixture was concentrated under reduced pressure and the resulting residue was filtered through diatomaceous earth, and rinsed with DCM (200 mL).  The filtrate was concentrated, and purified by FCC (5% MeOH/DCM) to afford the title compound (38.0 g, 80%, 80% purity). MS (ESI): mass calcd. for C 12 H 13 N 3 , 199.1; m/z found, 200.2 [M+H] + .

Step B: 3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridine-7-carb aldehyde.

Potassium osmate (2.44 g, 6.62 mmol) was added to a solution of 3-cyclopropyl-8-methyl-7- vinyl-[1,2,4]triazolo[4,3-a]pyridine (33.0 g, 166 mmol), dioxane (825 mL) and H 2 O (825 mL). Then sodium periodate (113.3 g, 530 mmol) was added and the suspension was stirred at 30 °C for 2 hours. The reaction mixture was filtered through a plug of diatomaceous earth and the filtrate was concentrated under reduced pressure. The resulting residue was then diluted by addition of H2O (200 mL) and the aqueous layer was extracted with DCM (200 mL x 3). These extractions resulted in several organic solvent fractions which were combined, washed with brine, dried over sodium sulfate, filtered, and concentrated to dryness under reduced pressure. The product was triturated with DCM/hexanes (50 ml/250ml) and further purified by flash column chromatography (5% EtOAc/DCM) to afford the title compound (20.9 g, 62%). MS (ESI): mass calcd. for C 11 H 11 N 3 O, 201.1; m/z found, 202.0 [M+H] + .

Step C: (3-(((Tert-butyldimethylsilyl)oxy)methyl)-4-methylphenyl)(3- cyclopropyl-8- methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)methanol. 3-Cyclopropyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridine-7-carbaldehyde (3.0 g, 15 mmol), tert-butyldimethyl((2-methyl-5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)silane (Intermediate 43, 6.9 g, 18 mmol), palladium (II) chloride (0.26 g, 1.5 mmol), potassium carbonate (6.2 g, 45 mmol), and tri-1- naphthylphosphine (0.93 g, 2.2 mmol) were charged to a flask. The flask was evacuated and back-filled with nitrogen. THF (75ml) was degassed with argon, then added via syringe. Argon was bubbled through the reaction mixture for 1 minute, then the reaction was stirred overnight in a pre-heated block at 75 °C under a reflux condenser and nitrogen. The reaction was cooled to room temperature, then filtered through diatomaceous earth and concentrated to dryness under reduced pressure. The product was purified by flash column chromatography (dry loaded with silica gel, 0-5% MeOH/DCM, gradient elution) to afford the title compound that was carried forward without further purification (0.66 g, 10 % ). MS (ESI): mass calcd. for C 25 H 35 N 3 O 2 Si, 437.2; m/z found, 438.3 [M+H] + . An alternative method that was used to prepare (3-(((tert- butyldimethylsilyl)oxy)methyl)-4-methylphenyl)(3-cyclopropyl -8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)methanol is shown below: 3-Cyclopropyl-7-iodo-8-methyl-[1,2,4]triazolo[4,3- a]pyridine (Intermediate 162, 5.05 g, 16.9 mmol) in 2-methyltetrahydrofuran (60 mL) was cooled in an ice bath under nitrogen, resulting in a suspension. Isopropylmagnesium chloride lithium chloride complex solution (1.3 M, 17 mL, 22 mmol) was added dropwise to the suspension and the reaction was removed from the ice bath and allowed to warm to room temperature for 30 minutes.3-(((Tert-butyldimethylsilyl)oxy)methyl)-4-methylben zaldehyde (Intermediate 163, 5.34 g, 20.2 mmol) was then added to the reaction via syringe using 2- methyltetrahydrofuran (4 mL). The suspension was stirred for 2 hours and became an orange solution, then was diluted with water and ethyl acetate. The resulting biphasic mixture was separated and the aqueous layer was extracted with ethyl acetate. These extractions resulted in several organic solvent fractions which were combined, dried over MgSO4, filtered, and concentrated to dryness under reduced pressure. The material was purified by flash column chromatography (0-10% MeOH/DCM) to afford the title compound (5.99 g, 81% yield). MS (ESI): mass calcd. for C25H35N3O2Si, 437.2; m/z found, 438.3 [M+H] + .

Step D: 7-((3-(((Tert-butyldimethylsilyl)oxy)methyl)-4-methylphenyl) chloromethyl)-3- cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridine. Thionyl chloride (0.2 mL, 3 mmol) was added to a solution of (3-(((tert-butyldimethylsilyl)oxy)methyl)-4-methylphenyl)(3- cyclopropyl- 8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)methanol (0.59 g, 1.3 mmol) and 2,6-di-tert- butylpyridine (0.7 ml, 3.1 mmol) in DCM (7 mL). The reaction was stirred at room temperature for 1 hour. The reaction was quenched with saturated aqueous NaHCO3, then extracted twice with DCM. These extractions resulted in several organic solvent fractions which were combined, dried over MgSO 4 , filtered, and concentrated to dryness under reduced pressure. The product was purified by flash column chromatography (dry loaded with silica gel, 0-50% ethyl acetate/hexanes, gradient elution) to provide the title compound (200 mg, 32 %). MS (ESI): mass calcd. for C 25 H 34 ClN 3 OSi, 455.2; m/z found, 456.2 [M+H] + .

Step E: Methyl 3-(3-(((tert-butyldimethylsilyl)oxy)methyl)-4-methylphenyl)- 3-(3- cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2 -dimethylpropanoate. ((1-Methoxy- 2-methylprop-1-en-1-yl)oxy)trimethylsilane (0.6 ml, 3.0 mmol) was added to a solution of 7-((3- (((tert-butyldimethylsilyl)oxy)methyl)-4-methylphenyl)chloro methyl)-3-cyclopropyl-8-methyl- [1,2,4]triazolo[4,3-a]pyridine (267 mg, 0.585 mmol) in DCM (3 mL). Indium(III) bromide (114 mg, 0.322 mmol) was added and the reaction was stirred at room temperature for 3 hours. The reaction mixture was filtered, concentrated under a stream of nitrogen, and purified by flash column chromatography (0-10% MeOH/EtOAc, gradient elution) to afford the title compound (197 mg, 64 %). MS (ESI): mass calcd. for C30H43N3O3Si, 521.3; m/z found, 522.3 [M+H] + .

Step F: Methyl 3-(3-cyclopropyl-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl )-3-(3- (hydroxymethyl)-4-methylphenyl)-2,2-dimethylpropanoate. Tetrabutylammonium fluoride (1 M in THF, 0.5 ml, 0.5 mmol) was added to a solution of methyl 3-(3-(((tert- butyldimethylsilyl)oxy)methyl)-4-methylphenyl)-3-(3-cyclopro pyl-8-methyl-[1,2,4]triazolo[4,3- a]pyridin-7-yl)-2,2-dimethylpropanoate (197 mg, 0.38 mmol) in THF (2 ml). The reaction was stirred at room temperature for 1 hour. Additional tetrabutylammonium fluoride (1 M in THF, 0.1 ml, 0.1 mmol) was added and the reaction was stirred at room temperature for an additional 3.5 hours. The reaction was quenched with saturated aqueous NH 4 Cl, then extracted twice with ethyl acetate. These extractions resulted in several organic solvent fractions which were combined, dried over MgSO4, filtered, and concentrated to dryness under reduced pressure to provide the title compound (145 mg, 94 %) which was used without further purification. MS (ESI): mass calcd. for C 24 H 29 N 3 O 3 , 407.2; m/z found, 408.2 [M+H] + . Intermediate 56: Methyl 3-(1-cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3- (5-(hydroxymethyl)-6-methylpyridin-3-yl)-2,2-dimethylpropano ate.

Step A: 1-Cyclopropyl-4-methyl-5-vinyl-1H-benzo[d][1,2,3]triazole. A mixture of 5- bromo-1-cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazole (Intermediate 29, 17 g, 67.4 mmol), potassium trifluoro(vinyl)borate (18.1 g, 135 mmol), potassium phosphate (42.9 g, 202 mmol) , and Pd(dppf)Cl2 (2.75 g, 3.37 mmol) were added to a flask, which was then evacuated and back- filled with nitrogen.1,4-Dioxane (170 ml) and water (30 ml) were bubbled with nitrogen for 10 minutes, then added to the solid reagents. The reaction mixture was heated to 100 °C under a reflux condenser and nitrogen for 4 hours. The reaction was then cooled to room temperature and filtered through diatomaceous earth, rinsing with EtOAc. The filtrate was washed with brine, then dried over MgSO 4 , filtered, and concentrated to dryness under reduced pressure. The product was purified by FCC (0-20% EtOAc/hexanes) to afford the title compound that was carried forward without further purification (2.1g, 52%). MS (ESI): mass calcd. for C12H13N3, 199.1; m/z found, 200.2 [M+H] + . Step B: 1-Cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazole-5-carbalde hyde. Potassium osmate (2.22 g, 6.0 mmol) was added to a solution of 1-cyclopropyl-4-methyl-5-vinyl-1H- benzo[d][1,2,3]triazole (30 g, 150 mmol), 1,4-dioxane (750 ml) and H 2 O (750 ml). Then sodium periodate (103 g, 482 mmol) was added. The suspension was stirred at 25 °C for 2 hours. The reaction mixture was filtered through a plug of diatomaceous earth, rinsing with EtOAc. The filtrate was extracted twice with EtOAc. These extractions resulted in several organic solvent fractions which were washed with brine, combined, dried over sodium sulfate, filtered, and concentrated to dryness under reduced pressure. The residue was purified by FCC (10-30% EtOAc/hexanes) to provide a residue. This residue was then stirred with hexanes (100 ml) for 2 hours, filtered, and the filter cake was dried under reduced pressure to afford the title compound (21.2 g, 70%). MS (ESI): mass calcd. for C11H11N3O, 201.1; m/z found, 201.9 [M+H] + .

Step C: (5-(((Tert-butyldimethylsilyl)oxy)methyl)-6-methylpyridin-3- yl)(1-cyclopropyl- 4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)methanol. n-Butyllithium (1.6 M, 9 ml, 14 mmol) was added dropwise to a solution of 5-bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)-2- methylpyridine (Intermediate 46, 4.05 g, 12.8 mmol) in THF under nitrogen (95 ml) which was cooled to -78 °C to prepare the lithiate reaction mixture. In a separate flask, 1-cyclopropyl-4- methyl-1H-benzo[d][1,2,3]triazole-5-carbaldehyde (2.81 g, 14 mmol) was mixed with THF (70 ml) and the resulting suspension was stirred and heated to form a solution. After all the solids had dissolved, this 1-cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazole-5-carbalde hyde solution was cooled to room temperature, then added to the lithiate reaction mixture as a stream. The resulting reaction mixture was then removed from the -78 °C bath and allowed to warm to room temperature for 30 minutes. The reaction was quenched with saturated aqueous NaHCO 3 , and then extracted twice with EtOAc. These extractions resulted in several organic solvent fractions which were combined, dried over MgSO4, filtered, and concentrated to dryness under reduced pressure. The product was purified by flash column chromatography (dry loaded with silica gel, 0-5% MeOH/DCM, gradient elution) to provide the title compound (1.96 g, 35 %). MS (ESI): mass calcd. for C24H34N4O2Si, 438.2; m/z found, 439.3 [M+H] + .

Step D: Methyl 3-(5-(((tert-butyldimethylsilyl)oxy)methyl)-6-methylpyridin- 3-yl)-3-(1- cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dim ethylpropanoate.

Trichloroacetonitrile (0.9 ml, 9 mmol) and DBU (0.15 ml, 1 mmol) were added to a solution of (5-(((tert-butyldimethylsilyl)oxy)methyl)-6-methylpyridin-3- yl)(1-cyclopropyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)methanol (1.91 g, 4.4 mmol) in ACN (22 ml). The reaction was stirred at room temperature under nitrogen for 1 hour. ((1-Methoxy-2-methylprop-1-en-1- yl)oxy)trimethylsilane (4.4 ml, 22 mmol) was then added to the reaction, followed by

trifluoromethanesulfonamide (1.28 g, 4.6 mmol), and the reaction was stirred at room

temperature under nitrogen for 3 hours. The reaction was quenched with saturated aqueous NaHCO 3 , then extracted twice with EtOAc. These extractions resulted in several organic solvent fractions which were combined, dried over MgSO4, filtered, and concentrated to dryness under reduced pressure. The product was purified by flash column chromatography (0-50%

EtOAc/hexanes, gradient elution) to provide the title compound that was carried forward without further purification (1.5 g, 66 %). MS (ESI): mass calcd. for C29H42N4O3Si, 522.3; m/z found, 523.4 [M+H] + .

Step E: Methyl 3-(1-cyclopropyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3- (5- (hydroxymethyl)-6-methylpyridin-3-yl)-2,2-dimethylpropanoate . Tetrabutylammonium fluoride (1 M in THF, 5.7 ml, 5.7 mmol) was added to a solution of methyl 3-(5-(((tert- butyldimethylsilyl)oxy)methyl)-6-methylpyridin-3-yl)-3-(1-cy clopropyl-4-methyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoate (1.5 g, 2.9 mmol) and 3 drops of DMF in THF (29 ml). The reaction was stirred at room temperature for 1.5 hours. The reaction was quenched with saturated aqueous NaHCO 3 , then extracted twice with EtOAc. These extractions resulted in several organic solvent fractions which were combined, dried over MgSO 4 , filtered, and concentrated to an oil under reduced pressure. The product was purified by flash column chromatography (0-100% EtOAc/hexanes, gradient elution) to provide the title compound (0.77 g, 66 %). MS (ESI): mass calcd. for C 23 H 28 N 4 O 3 , 408.2; m/z found, 409.2 [M+H] + , 1 H NMR (400 MHz, CDCl3) d 8.33– 8.28 (m, 1H), 7.63– 7.56 (m, 2H), 7.42 (d, J = 8.7 Hz, 1H), 4.82 (s, 1H), 4.68– 4.57 (m, 2H), 3.77– 3.66 (m, 1H), 3.51 (s, 3H), 3.26 (s, 1H), 2.74 (s, 3H), 2.40 (s, 3H), 1.39– 1.23 (m, 10H). Intermediate 57: 6-(((tert-Butyldimethylsilyl)oxy)methyl)-5- methylpicolinaldehyde.

Step A: Methyl 6-chloro-3-methylpicolinate. Thionyl chloride (208 g, 1.75 mol) was added to a solution of 6-chloro-3-methylpicolinic acid (200 g, 1.17 mol) in methanol (300 mL) and the reaction mixture was warmed to 65 °C. After 3 hours, the reaction mixture was concentrated under reduced pressure, and saturated aqueous NaHCO 3 solution (1 L) was added. The aqueous layer was extracted twice with ethyl acetate which resulted in several organic solvent fractions which were combined, dried over Na2SO4, filtered, and concentrated to dryness under reduced pressure to provide the title compound as a dark-brown solid (210 g, 97%). 1 H NMR (400 MHz, CDCl 3 ) 7.57 (d, J = 8.0 Hz, 1 H) 7.36 (d, J = 8.0 Hz, 1 H) 3.95 (s, 3 H) 2.53 (s, 3 H).

Step B: (6-Chloro-3-methylpyridin-2-yl)methanol. Sodium borohydride (257 g, 6.79 mol) was added to a stirring solution of methyl 6-chloro-3-methylpicolinate (210 g, 1.13 mol) in THF (200 mL) and the mixture was warmed to 66 °C. After 30 minutes, the mixture was cooled to room temperature and methanol (50 mL) was added dropwise. The resulting solution was warmed to 66 °C. After 2 hours, the reaction mixture was cooled to room temperature, saturated aqueous NH 4 Cl solution was added and the biphasic mixture was stirred for 1.5 hours. The mixture was filtered and the aqueous layer was extracted twice with ethyl acetate. This resulted in several organic solvent fractions which were combined, washed with saturated aqueous NaCl solution, dried over Na 2 SO 4 , filtered, and concentrated to dryness under reduced pressure to provide the title compound as a light yellow oil (140 g, 78%). 1 H NMR (400 MHz, CDCl3) d 7.35– 7.33(d, J = 8.0 Hz, 1 H), 7.07– 7.05(d, J = 8 Hz, 1 H), 4.57 (s, 2 H), 2.12 (s, 3 H).

Step C: 2-(((tert-Butyldimethylsilyl)oxy)methyl)-6-chloro-3-methylpy ridine. TBSCl (36.8 g, 244 mmol) was added to a stirring solution of (6-chloro-3-methylpyridin-2-yl)methanol (35 g, 222 mmol) and imidazole (30.2 g, 444 mmol) in dichloromethane (450 mL). After 16 hours, dichloromethane (400 mL) was added and the mixture was washed sequentially with water and saturated aqueous NaCl solution. The organic layer was dried over Na 2 SO 4 , filtered, and concentrated to dryness under reduced pressure to provide a residue. The residue was purified by flash column chromatography (petroleum ether (containing 1% triethylamine)/ethyl acetate (50:1 to 5:1) gradient elution) to afford the title compound as a colorless liquid (58 g, 94%). MS (ESI): mass calcd. for C 13 H 22 ClNOSi, 271.1; m/z found, 271.9 [M+H] + . 1 H NMR (400 MHz, CDCl3) 7.39 (d, J = 7.6 Hz, 1 H) 7.12 (d, J = 7.6 Hz, 1 H) 4.75 (s, 2 H) 2.36 (s, 3 H) 0.87 (s, 9 H) 0.07 (s, 6 H).

Step D: Methyl 6-(((tert-butyldimethylsilyl)oxy)methyl)-5-methylpicolinate. A mixture containing 2-(((tert-butyldimethylsilyl)oxy)methyl)-6-chloro-3-methylpy ridine (65 g, 239 mmol), triethylamine (66.6 mL), and Pd(dppf)2Cl2 (17.5 g, 23.9 mmol) in DMF (350 mL) and methanol (350 mL) was stirred at 80 °C under a 50 psi atmosphere of carbon monoxide. After 16 hours, the reaction mixture was filtered, concentrated under reduced pressure, and the residue was dissolved in ethyl acetate. This mixture was washed with water and the aqueous layers were extracted with ethyl acetate. This resulted in several organic fractions which were combined, dried over Na 2 SO 4 , filtered, and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (petroleum ether-ethyl acetate containing 1% triethylamine) to afford the title compound as a light yellow solid (60 g, 84%). 1 H NMR (400 MHz, CDCl 3 ) 7.95 (d, J = 7.6 Hz, 1 H) 7.58 (d, J = 7.8 Hz, 1 H) 4.88 (s, 2 H) 3.97 (s, 3 H) 2.47 (s, 3 H) 0.88 (s, 9 H) 0.07 (s, 6 H).

Step E. 6-(((tert-Butyldimethylsilyl)oxy)methyl)-5-methylpicolinalde hyde. A 1 M solution of DIBAL-H in dichloromethane (264 mL, 264 mmol) was added dropwise to a stirring mixture of methyl 6-(((tert-butyldimethylsilyl)oxy)methyl)-5-methylpicolinate (68 g, 219 mmol) in dichloromethane (1.5 L) at a rate that maintained an internal temperature of less than‒60 °C. After 2 hours, methanol (20 mL) was added and the reaction allowed to warm to room

temperature. Saturated aqueous potassium sodium tartrate solution (1 L) was added and the resulting biphasic mixture was stirred for 1 hour. The mixture was extracted twice with dichloromethane which resulted in several organic solvent fractions which were combined, washed with saturated aqueous NaCl solution, dried over Na 2 SO 4 , filtered, and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (petroleum ether-ethyl acetate) to afford the title compound as a light yellow solid (33.1 g, 53%). MS (ESI): mass calcd. for C 14 H 23 NO 2 Si, 265.2; m/z found, 266.1[M+H] + . 1 H NMR (400 MHz, CDCl3) 10.03 (s, 1 H) 7.81 (d, J = 7.8 Hz, 1 H) 7.62 (d, J = 7.8 Hz, 1 H) 4.91 (s, 2 H) 2.50 (s, 3 H) 0.90 (s, 9 H) 0.09 (s, 6 H). Intermediate 58: ethyl 3-(1-(cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d][1,2, 3]triazol-5- yl)-3-(3-(hydroxymethyl)-4-methylphenyl)propanoate.

Step A: 1-chloro-3-(difluoromethyl)-2-nitrobenzene. Diethylamino sulfurtrifluoride (32.6 g, 202 mmol) was added to a 0 °C (ice/water) solution consisting of 3-chloro-2- nitrobenzaldehyde (15 g, 81 mmol) and dichloromethane (200 mL). The resultant mixture was stirred for 3 hours with gradual warming to room-temperature before quenching with H2O (200 mL) and extracting with dichloromethane (3X). These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 1:0 to 20:1, gradient elution) to give the title compound (12 g, 64%). 1 H NMR (400 MHz, DMSO-d 6 ) d 8.06 - 7.95 (m, 1H), 7.86 - 7.77 (m, 2H), 7.42 - 7.11 (m, 1H).

Step B: N-(Cyclopropylmethyl)-3-(difluoromethyl)-2-nitroaniline.1-Ch loro-3- (difluoromethyl)-2-nitrobenzene (2.0 g, 9.6 mmol) and cyclopropylmethanamine (10 mL) were added to a 20 mL sealed tube. The resultant mixture was stirred at 80 °C for 16 hours before cooling to room-temperature, quenching with water (60 mL), and extracting with ethyl acetate (3X). These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 1:0 to 5:1, gradient elution) to give the title compound (2.1 g, 90%). MS (ESI): mass calcd. for C 11 H 12 F 2 N 2 O 2 242.1, m/z found 242.7 [M+H] + . Step C: 4-Bromo-N-(cyclopropylmethyl)-3-(difluoromethyl)-2-nitroanil ine. N- (Cyclopropylmethyl)-3-(difluoromethyl)-2-nitroaniline (2.1 g, 8.7 mmol), NBS (1.54 g, 8.65 mmol), and DMF (10 mL) were added to a 50 mL round-bottomed flask. The resultant mixture was stirred at room-temperature for 4 hours before quenching with water (50 mL) and extracting with ethyl acetate (3X). These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure. The resulting residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 1:0 to 5:1, gradient elution) to give the title compound (2.1 g, 68%). 1 H NMR (400 MHz, DMSO-d6) d 7.47 (d, J = 9.0 Hz, 1H), 7.09 - 6.79 (m, 2H), 6.22 (t, J = 5.6 Hz, 1H), 2.86 (t, J = 6.2 Hz, 2H), 0.91 - 0.79 (m, 1H), 0.28 - 0.18 (m, 2H), 0.05 - 0.04 (m, 2H).

Step D: 4-Bromo-N 1 -(cyclopropylmethyl)-3-(difluoromethyl)benzene-1,2-dia mine. Zn (3.4 g, 52 mmol) was added to a solution of 4-bromo-N-(cyclopropylmethyl)-3-(difluoromethyl)- 2-nitroaniline (2.1 g, 6.5 mmol), NH 4 Cl (5.6 g, 105 mmol), and THF (20 mL). The resultant mixture was stirred at room-temperature for 16 hours. The suspension was filtered through a pad of diatomaceous earth and the pad was washed with ethyl acetate (1X). The filtrate was concentrated to dryness under reduced pressure to afford the title product (1.8 g, 95%). MS (ESI): mass calcd. for C 11 H 13 BrF 2 N 2 290.0, m/z found 292.8 [M+H] + .

Step E: 5-Bromo-1-(cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d] [1,2,3]triazole. A solution of NaNO 2 (5.7 g, 83 mmol) and H 2 O (10 mL) were added to a 0 °C (ice/water) mixture of 4-bromo-N 1 -(cyclopropylmethyl)-3-(difluoromethyl)benzene-1,2-dia mine (8.0 g, 27 mmol), 4-methylbenzenesulfonic acid hydrate (18.3 g, 96.2 mmol), and CH3CN (100 mL). The resultant mixture was stirred at 0 °C for 3 hours before quenching with aq. NaHCO 3 (300 mL) and extracting with ethyl acetate (3X). These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 1:0 to 5:1) to give the title compound (6.2 g, 75%). MS (ESI): mass calcd. for C 11 H 10 BrF 2 N 3 301.0, m/z found 303.7 [M+H] + .

Step F: (E)-Ethyl 3-(1-(cyclopropylmethyl)-4-(difluoromethyl)-1H- benzo[d][1,2,3]triazol-5-yl)acrylate.5-Bromo-1-(cyclopropylm ethyl)-4-(difluoromethyl)-1H- benzo[d][1,2,3]triazole (2.0 g, 6.6 mmol), (E)-ethyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)acrylate (3.0 g, 13 mmol), and Na2CO3 (1.4 g, 13 mmol) were added to a 100 mL three- necked round-bottomed flask and the resulting mixture dissolved in 1,4-dioxane (30 mL) and H 2 O (6 mL). The mixture was sparged with N 2 for 5 minutes and then treated with Pd(dppf)Cl 2 (484 mg, 0.661 mmol). The mixture was sparged with N2 for another 5 minutes and then stirred and heated at 100 °C for 16 hours before cooling to room-temperature, quenching with water (60 mL) and extracting with ethyl acetate (3X). These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure. The resulting residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 20:1 to 5:1, gradient elution) to give the title compound (2.0 g, 80%) as a black solid. MS (ESI): mass calcd. for C 16 H 17 F 2 N 3 O 2 321.1, m/z found 321.9 [M+H] + .

Step G: Ethyl 3-(1-(cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d][1,2, 3]triazol-5- yl)-3-(3-(hydroxymethyl)-4-methylphenyl)propanoate. (E)-Ethyl 3-(1-(cyclopropylmethyl)-4- (difluoromethyl)-1H-benzo[d][1,2,3]triazol-5-yl)acrylate (1.5 g, 4.7 mmol), (3-(hydroxymethyl)- 4-methylphenyl)boronic acid (2.3 g, 14 mmol), aqueous KOH (5.6 mL, 1.0 M, 5.6 mmol), and 1,4-dioxane (20 mL) were added to a 100 mL round-bottomed flask. The mixture was sparged with N 2 for 5 minutes and then treated with chloro(1,5-cyclooctadiene)rhodium(I) dimer (230 mg, 0.47 mmol). The reaction mixture was stirred at room-temperature for 16 hours before quenching with H2O (60 mL) and extracting with ethyl acetate (3X). These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure. The resulting residue was purified by reverse phase preparative HPLC (eluent: MeCN/water with 0.05% NH3, 3:7 to 7:3, gradient elution). The product was suspended in water (10 mL), the mixture frozen using dry ice/acetone, and then lyophilized to dryness to afford the title compound (510 mg, 24%). MS (ESI): mass calcd. for C 24 H 27 F 2 N 3 O 3 443.20, m/z found 444.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) d 8.07 - 7.75 (m, 2H), 7.57 (d, J = 8.8 Hz, 1H), 7.31 (s, 1H), 7.18 - 7.12 (m, 1H), 7.07 - 7.01 (m, 1H), 5.17 - 5.07 (m, 1H), 5.01 (t, J = 5.3 Hz, 1H), 4.58 (d, J = 7.3 Hz, 2H), 4.43 - 4.35 (m, 2H), 3.97 - 3.88 (m, 2H), 3.28 - 3.19 (m, 1H), 3.14 - 3.05 (m, 1H), 2.14 (s, 3H), 1.38 - 1.26 (m, 1H), 1.01 (t, J = 7.2 Hz, 3H), 0.55 - 0.39 (m, 4H). Intermediate 59: 2 ,3 -dihydrospiro[oxetane-3,4’-pyrido[2,3-b][1,4,5]oxath iazepine] 1’,1’- dioxide.

Step A: 3-(Nitromethyl)oxetan-3-ol. Et3N (0.5 mL) was added drop-wise to a solution consisting of oxetan-3-one (10.0 g, 139 mmol) and MeNO 2 (25 mL). The resultant mixture was stirred at room-temperature for 16 hours before concentrating to dryness to give the product, which was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 10:1 to 1:1 gradient elution) to afford the title compound (15 g, 81%). 1 H NMR (400 MHz, CDCl 3 ) d 4.76 (s, 2H), 4.68 - 4.59 (m, 4H), 4.26 (s, 1H).

Step B: 3-(Aminomethyl)oxetan-3-ol. Dry Pd/C (1.0 g, 10 wt.%, 0.95 mmol) was added to a solution of 3-(nitromethyl)oxetan-3-ol (10 g, 75 mmol) and ethanol (50 mL) under N 2 . The resultant mixture was stirred under H 2 (1 atm) at room-temperature for 16 hours. The suspension was filtered through a pad of diatomaceous earth and the pad washed with ethanol (50 mL). The filtrate was concentrated to dryness under reduced pressure to afford the product (8 g), which was used in the next step without further purification. 1 H NMR (400 MHz, DMSO-d 6 ) d 5.52 (br s, 2H), 4.45 (d, J = 6.6 Hz, 2H), 4.37 - 4.32 (m, 2H), 2.97 (s, 2H), 2.69 (s, 1H).

Step C: 2-Chloro-N-((3-hydroxyoxetan-3-yl)methyl)pyridine-3-sulfonam ide.2- Chloropyridine-3-sulfonyl chloride (10 g, 47 mmol) was added to a solution of 3- (aminomethyl)oxetan-3-ol (7.3 g), K 2 CO 3 (7.8 g, 56 mmol), THF (90 mL), and H 2 O (20 mL). The resultant mixture was stirred at room-temperature for 16 hours before concentrating to dryness under reduced pressure. The residue was dissolved water (30 mL) and extracted with ethyl acetate (3X). These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure to afford the title compound (7 g), which was used in the next step without further purification. MS (ESI): mass calcd. for C 9 H 11 ClN 2 O 4 S 278.01, m/z found 279.1[M+H] + .

Step D: 2',3'-dihydrospiro[oxetane-3,4'-pyrido[2,3-b][1,4,5]oxathiaz epine] 1',1'-dioxide. t-BuOK (7.1 g, 63 mmol) was added to a solution consisting of 2-chloro-N-((3-hydroxyoxetan-3- yl)methyl)pyridine-3-sulfonamide (6.5 g) and DMSO (24 mL). The resultant mixture was stirred while heating at 95 °C for 2 hours before cooling to room-temperature, diluting with water (20 mL), acidifying pH to 4 with 1 N HCl, and extracting with ethyl acetate (50 mL x 4). These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure, which was purified by preparative HPLC using a preparative HPLC (eluent: CH3CN/H2O with 0.225% HCOOH, 1:99 to 1:4 gradient elution) to afford pure product. The product was suspended in water (20 mL), the mixture was frozen using dry ice/acetone, and then lyophilized to dryness to afford the title compound (2.1 g). MS (ESI): mass calcd. for C9H10N2O4S 242.0, m/z found 243.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) d 8.52 (dd, J = 2.0, 4.9 Hz, 1H), 8.36 (br s, 1H), 8.16 (dd, J = 2.0, 7.7 Hz, 1H), 7.50 - 7.35 (m, 1H), 4.40 (s, 4H), 3.90 - 3.77 (m, 2H). Intermediate 60: ethyl 3-(4-difluoromethyl)-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl )-3-(3- hydroxymethyl)-4-methylphenyl)propanoate.

Step A: 3-(Difluoromethyl)-N-methyl-2-nitroaniline.1-Chloro-3-(diflu oromethyl)-2- nitrobenzene (9.0 g, 43 mmol) and methanamine (30 mL, 33% purity in ethanol) were added to a 100 mL sealed tube. The resultant mixture was stirred at 70 °C for 16 hours before cooling to room-temperature and concentrating to dryness under reduced pressure to afford the title compound (10 g), which was used in the next step without further purification. 1 H NMR (400 MHz, CDCl 3 ) d 7.51 - 7.45 (m, 1H), 7.43 - 7.13 (m, 1H), 7.07 (d, J = 7.3 Hz, 1H), 6.98 (d, J = 8.6 Hz, 1H), 3.01 (d, J = 5.1 Hz, 3H).

Step B: 4-Bromo-3-(difluoromethyl)-N-methyl-2-nitroaniline. NBS (8.8 g, 49 mmol) was added to a solution of 3-(difluoromethyl)-N-methyl-2-nitroaniline (10.0 g, 49.5 mmol) and DMF (100 mL). The resultant mixture was stirred at room-temperature for 16 hours before pouring it into water (300 mL) and extracting with ethyl acetate (3X). These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure. The residue was purified by flash chromatography (eluent: petroleum ether/ethyl acetate 1:0 to 5:1, gradient elution) to afford the title compound (13 g, 93%). 1 H NMR (400 MHz, CDCl 3 ) d 8.00 (br s, 2H), 7.56 (d, J = 9.0 Hz, 1H), 7.06 - 6.80 (m, 1H), 6.78 (d, J = 2.6 Hz, 1H), 5.63 (br s, 1H), 2.91 (d, J = 5.1 Hz, 3H).

Step C: 4-Bromo-3-(difluoromethyl)-N 1 -methylbenzene-1,2-diamine. Zn (22.3 g, 341 mmol) was added to a mixture of 4-bromo-3-(difluoromethyl)-N-methyl-2-nitroaniline (12.0 g, 42.7 mmol), NH 4 Cl (36.5 g, 682 mmol), and THF (300 mL). The resultant mixture was stirred at room-temperature for 16 hours. The suspension was filtered through a pad of diatomaceous earth and the pad washed with ethyl acetate (200 mL). The filtrate was concentrated to dryness under reduced pressure to give the product, which was purified by flash chromatography (eluent:

petroleum ether/ethyl acetate, 50:1 to 10:1, gradient elution) to afford the title compound (9.5 g, 89%). 1 H NMR (400 MHz, DMSO-d6) d 7.40 - 7.06 (m, 1H), 7.03 - 6.95 (m, 1H), 6.58 (d, J = 8.6 Hz, 1H), 2.91 - 2.82 (m, 3H).

Step D: 5-Bromo-4-(difluoromethyl)-1-methyl-1H-benzo[d][1,2,3]triazo le. A solution consisting of NaNO2 (7.4 g, 0.11 mol) and H2O (20 mL) was added to a 0 °C (ice/water) mixture consisting of 4-bromo-3-(difluoromethyl)-N 1 -methylbenzene-1,2-diamine (9.0 g, 36 mmol), p- toluenesulfonic acid monohydrate (23.9 g, 126 mmol), and CH 3 CN (300 mL). The resultant mixture was stirred at 0 °C for 3 hours before quenching with sat. NaHCO3 (500 mL) and extracting with ethyl acetate (3X). These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure. The residue was purified by flash chromatography (eluent: petroleum ether/ethyl acetate, 1:0 to 5:1, gradient elution) to afford the title compound (5.0 g, 47%). 1 H NMR (400 MHz, DMSO-d 6 ) d (d, J = 8.8 Hz, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.55 (t, J = 52.4 Hz, 1H), 4.40 - 4.26 (m, 3H).

Step E: (E)-Ethyl 3-(4-(difluoromethyl)-1-methyl-1H-benzo[d][1,2,3]triazol-5- yl)acrylate.5-Bromo-4-(difluoromethyl)-1-methyl-1H-benzo[d][ 1,2,3]triazole (3.2 g, 12 mmol), (E)-ethyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)acrylate (5.5 g, 24 mmol), and Na 2 CO 3 (3.9 g, 37 mmol) were dissolved in 1,4-dioxane (100 mL) and H2O (20 mL). The mixture was sparged with nitrogen for 5 minutes and then treated with Pd(dppf)Cl2 (0.89 g, 1.2 mmol). The mixture was sparged with nitrogen for another 5 minutes and then stirred at 100 °C for 16 hours under nitrogen before cooling to room-temperature and diluting with ethyl acetate (100 mL). The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated to dryness under reduced pressure to give the product, which was purified by flash chromatography (eluent:

petroleum ether/ethyl acetate, 1:0 to 1:2, gradient elution) to afford the title compound (2.3 g, 93%). MS (ESI): mass calcd. for C13H13F2N3O2281.1 m/z 281.9.

Step F: Ethyl 3-(4-(difluoromethyl)-1-methyl-1H-benzo[d][1,2,3]triazol-5-y l)-3-(3- (hydroxymethyl)-4-methylphenyl)propanoate. (E)-Ethyl 3-(4-(difluoromethyl)-1-methyl-1H- benzo[d][1,2,3]triazol-5-yl)acrylate (500 mg, 1.78 mmol), (3-(hydroxymethyl)-4- methylphenyl)boronic acid (885 mg, 5.33 mmol), and aq. KOH (1.8 mL, 1 M, 1.8 mmol) were added to a sealed tube and the resulting mixture dissolved in 1,4-dioxane (15 mL). The mixture was sparged with Ar for 20 minutes and then treated with [Rh(cod)Cl] 2 (88 mg, 0.18 mmol). The mixture was sparged with Ar for another 20 minutes. The resultant mixture was stirred at room- temperature for 16 hours under Ar. The suspension was filtered and the filtrate concentrated to dryness under reduced pressure to give the product, which was purified by flash chromatography (eluent: petroleum ether/ethyl acetate, 10:1 to 0:1, dichloromethane/methanol, 20:1, isocratic) to afford the title compound (378.7 mg, 52%). MS (ESI): mass calcd. for C21H23F2N3O3403.17 m/z, found 404.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 ) d 8.07 - 7.75 (m, 2H), 7.60 (d, J = 8.8 Hz, 1H), 7.33 - 7.30 (m, 1H), 7.19 - 7.12 (m, 1H), 7.06 (d, J = 8.0 Hz, 1H), 5.14 (t, J = 7.8 Hz, 1H), 5.01 (t, J = 5.3 Hz, 1H), 4.46 - 4.36 (m, 2H), 4.30 (s, 3H), 3.99 - 3.90 (m, 2H), 3.30 - 3.21 (m, 1H), 3.15 - 3.06 (m, 1H), 2.16 (s, 3H), 1.04 (t, J = 7.2 Hz, 3H). Intermediate 61: 5‘-methyl-2‘,3‘-dihydro-5’H-spiro[cyclopropane-1,4 -pyrido[2,3- f][1,2,5]thiadiazepine] 1‘,1‘-dioxide.

Step A: tert-Butyl (1-carbamoylcyclopropyl)carbamate. Pyridine (11.8 g,149 mmol) was added drop-wise to a mixture of 1- ((tertbutoxycarbonyl)amino)cyclopropanecarboxylic acid (50.0 g, 248 mmol), Boc2O (70.5 g, 323 mmol), NH4HCO3 (24.6 g, 311 mmol), and MeCN (500 mL)

over a period of 10 minutes. The mixture was stirred at room temperature for 16 hours before concertrating to dryness under reduced pressure. The residue wa s diluted with H2O(100 mL), pHadjusted to 7 with 1 N HCl, and then the resultant mixture extrac ted with ethyl acetate(3X). The combined organic extracts were dried over anhydrous Na 2 SO 4, fil tered, and concentrated to dryness under reduced pressure to afford the title compound

(40.1 g, 80 %), which was used in the next step without further purification. 1 H NMR (400 MHz, DMSO-d 6 ) d 6.42 (br s, 1H), 5.71 (br s, 1H), 5.18 (br s, 1H), 1.61 - 1.56 (m, 2H), 1.46 - 1.45 (m, 9H), 1.09 - 0.98 (m, 2H).

Step B: tert-Butyl (1-cyanocyclopropyl)carbamate. TFAA (47.3 g, 225 mmol) was added drop-wise to solution of tert-butyl (1-carbamoylcyclopropyl)carbamate (30.0 g, 150 mmol), triethylamine (62.7 g, 450 mmol), and dichloromethane (180 mL) over a period of 1 hour. The resultant mixture was stirred at room-temperature for 4 hours before concentrating to dryness under reduced pressure to give the product, which was purified by FCC (eluent: petroleum ether/ethyl acetate, 1:0 to 5:1, gradient elution) to afford the title compound (22.5 g, 82.3%). 1 H NMR (400 MHz, CDCl3) d 6.60 (br s, 1H), 2.63 (s, 9H), 1.28 (s, 2H), 1.24 - 1.20 (m, 1H), 1.07 - 1.01 (m, 1H).

Step C: tert-Butyl (1-cyanocyclopropyl)(methyl)carbamate. Sodium hydride in mineral oil (15.0 g, 60% purity, 375 mmol) was added in portions to a 0 °C (ice/water) solution of tert- butyl (1-cyanocyclopropyl)carbamate (22.5 g, 123 mmol) and THF (150 mL). The resultant mixture was treated with iodomethane (34.7 g, 244 mmol) by drop-wise addition at 0 °C and then stirred for 12 hours with gradual warming to room-temperature before quenching with sat. NH4Cl (100 mL) and extracting with ethyl acetate (3X). These extractions resulted in several fractions which were combined, washed with brine, dried over sodium sulfate and concentrated to dryness under reduced pressure to afford the title compound (23.0 g), which was used in the next step without further purification. 1 H NMR (400 MHz, CDCl3) d 2.90 (s, 3H), 1.48 (s, 9H), 1.27 - 1.26 (m, 2H), 0.86 - 0.82 (m, 2H).

Step D: tert-Butyl (1-(aminomethyl)cyclopropyl)(methyl)carbamate. Raney Ni (2 g) was added to a 1 L round-bottomed flask containing a mixture of tert-butyl (1- cyanocyclopropyl)(methyl)carbamate (23 g), methanol (200 mL), and 25% aqueous

NH 3 (aq) (5 mL) under Ar. The resultant mixture was stirred under H 2 (15 psi) at room- temperature for 15 hours. The suspension was filtered through a pad of diatomaceous earth and the pad was washed with ethyl acetate. The filtrate was concentrated to dryness under reduced pressure to afford the title product (25 g), which was used in the next step without further purification. 1 H NMR (400 MHz, CDCl 3 ) d 2.86 (br s, 3H), 1.84 - 1.80 (m, 2H), 1.44 (br s, 9H), 1.23 - 1.22 (m, 2H), 0.85 - 0.81 (m, 2H).

Step E: tert-Butyl (1-((2-chloropyridine-3- sulfonamido)methyl)cyclopropyl)(methyl)carbamate. A solution of 2-chloropyridine-3-sulfonyl chloride (20 g, 94 mmol) and THF (50 mL) was added drop-wise to a 0 °C mixture of tert-butyl (1-(aminomethyl)cyclopropyl)(methyl)carbamate (20 g), K2CO3 (20.0 g, 145 mmol), THF (150 mL), and H 2 O (40 mL). The mixture was stirred for 12 hours with gradual warming to room- temperature before concentrating to dryness under reduced pressure. The residue

was diluted with water (100 mL) and extracted with ethyl acetate (2X). These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure to afford the title compound (30 g), which was used in the next step without purification. MS (ESI): mass calcd. for

C15H22ClN3O4S 375.1 m/z, found 398.0 [M+Na] + . 1 H NMR (400 MHz, CDCl3) d 8.58 - 8.54 (m, 1H), 8.40 - 8.35 (m, 1H), 7.45 - 7.36 (m, 1H), 6.83 (br s, 1H), 3.07 - 2.98 (m, 2H), 2.82 (s, 3H), 1.47 (s, 9H), 0.97 - 0.93 (m, 2H), 0.85 - 0.78 (m, 2H).

Step F: 2-Chloro-N-((1-(methylamino)cyclopropyl)methyl)pyridine-3-su lfonamide. TFA (30.0 mL, 433 mmol) was added to a 0 °C solution of tert-butyl (1-((2-chloropyridine-3- sulfonamido)methyl)cyclopropyl)(methyl)carbamate (35 g) and dichloromethane (100 mL). The mixture was stirred for 2 hours with gradual warming to room-temperature before concentrating to dryness under reduced pressure to afford the title compound (30 g), which was used in the next step without further purification. MS (ESI): calcd. for C 10 H 14 ClN 3 O 2 S 275.1 , m/z found 275.9 [M+H] + .

Step G: 5'-Methyl-3',5'-dihydro-2'H-spiro[cyclopropane-1,4'-pyrido[2 ,3- f][1,2,5]thiadiazepine] 1',1'-dioxide. DIPEA (30.0 mL, 172 mmol) was added drop-wise to a solution of 2-chloro-N-((1-(methylamino)cyclopropyl)methyl)pyridine-3-su lfonamide (10 g) and DMSO (60 mL). The resultant mixture was stirred while heating at 160 °C for 2 hours before cooling to room-temperature and concentrating to dryness under reduced pressure. The residue was diluted with H 2 O (200 mL) and extracted with ethyl acetate (3X). These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure. The resulting residue was triturated with ethyl acetate: petroleum ether (1:10, 80 mL). The suspension was isolated via filtration and the filter cake washed with ethyl acetate: petroleum ether (1: 30, 30 mL) before drying under reduced pressure to afford the title compound (3.58 g, 41%). MS (ESI): mass calcd. For C10H13N3O2S 239.1 m/z, found 240.0

[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 ) d 8.30 - 8.19 (m, 1H), 8.15 - 7.79 (m, 2H), 6.98 - 6.89 (m, 1H), 3.32 - 3.06 (m, 2H), 3.02 (s, 3H), 0.99 - 0.57 (m, 4H). Intermediate 62: (2-Chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phe nyl)methanol.

(5-Bromo-2-chlorophenyl)methanol (15.0 g, 67.7 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'- bi(1,3,2-dioxaborolane) (27.5 g, 108 mmol), KOAc (19.9 g, 203 mmol), and 1,4-dioxane (100 mL) were added to a 250 mL round-bottomed flask under N 2 . The mixture was sparged with N 2 for 5 minutes and then treated with Pd(dppf)Cl 2 •CH 2 Cl 2 (4.96 g, 6.07 mmol). The mixture was sparged with N2 for another 5 minutes and then stirred at 100 °C for 16 hours before cooling to room-temperature. The resultant mixture was filtered, and the filtrate was concentrated to dryness under reduced pressure to afford the product, which was purified by preparative HPLC (eluent: CH3CN/H2O and H2O with 0.04% NH3, 1:5 to 1:1, gradient elution) to afford pure product. The product was suspended in water (10 mL), the mixture frozen using dry

ice/acetone, and then lyophilized to dryness to afford the title product (6.8 g) as a white solid. The white solid (6.8 g) was further purified by FCC (eluent: petroleum ether/ethyl acetate, 20:1 to 0:1) to afford the title compound (4.0 g, 22%). MS (ESI): mass calcd. for

C 13 H 18 BClO 3 268.1 m/z, found 251.0 [M-H 2 O+H] + . 1 H NMR (400 MHz, CDCl 3 ) d 7.88 (s, 1H), 7.68 - 7.63 (m, 1H), 7.35 (d, J = 7.9 Hz, 1H), 4.77 (d, J = 6.4 Hz, 2H), 1.90 (t, J = 6.6 Hz, 1H), 1.33 (s, 12H). Intermediate 63: (S*)-3-Methyl-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2', 3'- f][1,2,5]thiadiazepine 5,5-dioxide.

Step A: 2-Chloro-5-methylpyridine-3-sulfonyl chloride. HBF4 (7.6 mL, 48 mmol) was added drop-wise to a 100 mL three-necked round-bottomed flask containing a 0 °C solution of 2- chloro-5-methylpyridin-3-amine (5.0 g, 35 mmol) and acetonitrile (30 mL). The resultant mixture was stirred at 0 °C for 10 minutes before adding tert-Butyl nitrite (6.3 mL, 53 mmol) drop-wise at 0 °C. The resultant mixture was stirred at 0 °C for another 1 hour. Copper(I) chloride (5.5 g, 56 mmol) and acetic acid (50 mL) were added to a 250 mL three-necked round- bottomed flask. The resultant mixture was cooled to 0 °C, bubbled with SO2 gas (> 1.3 M) at 0 °C for 1 hour, and then treated with the above 2-chloro-5-methylpyridine-3-diazonium tetrafluoroborate solution by drop-wise addition at 0 °C. The resultant mixture was stirred for 4 hours with gradual warming to room-temperature before quenching with sat. NaHCO3 (100 mL). The resultant mixture was stirred for 20 minutes and then extracted with ethyl acetate (3X). These extractions resulted in several fractions which were combined, washed with water (2X), dried over sodium sulfate and concentrated to dryness under reduced pressure to give the product, which was purified by FCC (eluent: petroleum ether/ethyl acetate, 1:0 to 10:1, gradient elution) to afford the title compound (3 g, 38%). 1 H NMR (400 MHz, CDCl 3 ) d 8.51 (s, 1H), 8.27 - 8.19 (m, 1H), 2.46 (s, 3H).

Step B: tert-Butyl 2-((2-chloro-5-methylpyridine-3-sulfonamido)methyl)piperidin e-1- carboxylate. A solution consisting of 2-chloro-5-methylpyridine-3-sulfonyl chloride (2.5 g, 11 mmol) and THF (10 mL) was added drop-wise to a 0 °C mixture of tert-butyl 2- (aminomethyl)piperidine-1-carboxylate (2.5 g, 12 mmol), K2CO3 (2.5 g, 18 mmol), THF (10 mL), and H2O (5 mL). The resultant mixture was stirred for 2 hours with gradual warming to room-temperature before concentrated to dryness under reduced pressure. The residue was diluted with water (100 mL) and the resultant mixture extracted with ethyl acetate (2X). These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure to afford the title compound (3.5 g, 77%). MS (ESI): mass calcd. for C17H26ClN3O4S 403.1, found 426.0 [M+Na] + .

Step C: 2-Chloro-5-methyl-N-(piperidin-2-ylmethyl)pyridine-3-sulfona mide. TFA (5.0 mL, 72 mmol) was added to a 0 °C solution consisting of tert-butyl 2-((2-chloro-5- methylpyridine-3-sulfonamido)methyl)piperidine-1-carboxylate (3.5 g, 8.7 mmol) and dichloromethane (20 mL). The resultant mixture was stirred for 12 hours with gradual warming to room-temperature before concentrated to dryness under reduced pressure to afford the title compound (3.1 g), which was used in the next step without further purification. MS

(ESI): mass calcd. for C 12 H 18 ClN 3 O 2 S 303.1, found 303.9 [M+H] + .

Step D: 3-Methyl-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepine 5,5-dioxide. DIPEA (8.0 mL, 46 mmol) was added drop-wise to a solution of 2-chloro-5-methyl-N-(piperidin-2-ylmethyl)pyridine-3-sulfona mide (3.0 g) and DMSO (20 mL). The resultant mixture was stirred and heated at 160 °C for 2 hours before concentrating to dryness under reduced pressure. The residue was diluted with H2O (200 mL), and the resultant mixture extracted with ethyl acetate (3X). These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure to give the product, which was purified by FCC (eluent: petroleum ether/ethyl acetate, 1:0 to 3:1, gradient elution) to afford the title compound (1.6 g). MS (ESI): mass calcd. for C12H17N3O2S 267.1 , m/z found 267.9 [M+H] + .

Step E: (S*)-3-Methyl-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2', 3'- f][1,2,5]thiadiazepine 5,5-dioxide. The mixture of 3-Methyl-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepine 5,5-dioxide (1.6 g, 6.0 mmol) isomers were separated by purified by chiral SFC (stationary phase: AD 250 mm x 50 mm, mobile phase: 40% CO 2 , 40% EtOH and H2O with 0.1% NH3) to afford two diastereomers. The first eluting isomer (370 mg) was designated *S: 1 H NMR (400 MHz, DMSO-d6) d 8.11 - 8.07 (m, 1H), 8.05 - 7.99 (m, 1H), 7.72 - 7.66 (m, 1H), 4.19 - 4.06 (m, 2H), 3.47 - 3.38 (m, 1H), 3.32 - 3.24 (m, 1H), 3.19 - 3.10 (m, 1H), 2.18 (s, 3H), 1.72 - 1.49 (m, 6H). Intermediate 64: (S*)-3-fluoro-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2', 3'- f][1,2,5]thiadiazepine 5,5-dioxide.

Step A: 2-Chloro-5-fluoropyridin-3-amine. Fe (15.2 g, 272 mmol) was added in portions to a solution of 2-chloro-5-fluoro-3-nitropyridine (12 g, 68 mmol) and HOAc (200 mL). The reaction mixture was stirred at 80°C for 0.5 hours before cooling to room-temperature and concentrating to dryness under reduced pressure. The residue was suspended in ethyl acetate (100 mL), the resultant suspension filtered through a pad of Celite ® , and the pad washed with ethyl acetate (20 mL). The filtrate was neutralized with sat. NaHCO3 (200 mL) and the resultant mixture extracted with ethyl acetate (3X). These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure to give the product (11 g), which was used in the next step without further purification. MS (ESI): mass calcd. for C 5 H 4 ClFN 2 146.0, found 146.8 [M+H] + .

Step B: 2-Chloro-5-fluoropyridine-3-sulfonyl chloride. HBF 4 (59.2 mL, 380 mmol) was added drop-wise to a 1 L three-necked round-bottomed flask containing a 0 °C mixture of 2- chloro-5-fluoropyridin-3-amine (40.0 g, 273 mmol) and acetonitrile (300 mL). The resultant mixture was stirred at 0 °C for 10 minutes before drop-wise addition of tert-butyl nitrite (48.8 mL, 410 mmol) at 0 °C. The resultant mixture was stirred at 0 °C for another 1 hour. Copper(I) chloride (30.3 g, 303 mmol) and acetic acid (100 mL) were added to a 1 L three-necked round- bottomed flask. The resultant mixture was cooled to 0 °C, bubbled with SO 2 gas (> 1.3 M) at 0 °C for 1 hour followed by drop-wise addition of the 2-chloro-5-fluoropyridine-3-diazonium tetrafluoroborate solution at 0 °C. The resultant mixture was stirred for 4 hours with gradual warming to room-temperature before quenching with sat. NaHCO 3 (100 mL). The resultant mixture was stirred for 20 minutes and then extracted with ethyl acetate (3X). These extractions resulted in several fractions which were combined, washed with water (2X), brine (1X), dried over sodium sulfate and concentrated to dryness under reduced pressure to afford the product which was purified by FCC (eluent: petroleum ether/ethyl acetate, 1:0 to 9:1, gradient) to afford the title compound (30 g).

Step C: tert-Butyl 2-((2-chloro-5-fluoropyridine-3-sulfonamido)methyl)piperidin e-1- carboxylate. A solution consisting of tert-butyl 2-(aminomethyl)piperidine-1-carboxylate (30.7 g, 143 mmol) and THF (100 mL) was added drop-wise to a 0 °C mixture consisting of 2-chloro- 5-fluoropyridine-3-sulfonyl chloride (30 g), K2CO3 (28.8 g, 208 mmol), THF (100 mL), and H2O (40 mL). The resultant mixture was stirred for 2 hours with gradual warming to room- temperature before concentrating to dryness under reduced pressure. The residue was diluted with water (80 mL) and extracted with ethyl acetate (3X). These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure to afford the product, which was purified by FCC (eluent: petroleum ether/ethyl acetate, 1:0 to 5:1, gradient) to afford the title compound (35 g, 64%). MS (ESI): mass calcd. for C 16 H 23 ClFN 3 O 4 S 407.1, found 308.1 [M+H-Boc] + .

Step D: 2-Chloro-5-fluoro-N-(piperidin-2-ylmethyl)pyridine-3-sulfona mide. TFA (40 mL) was added to a solution of tert-butyl 2-((2-chloro-5-fluoropyridine-3- sulfonamido)methyl)piperidine-1-carboxylate (23.0 g, 56.4 mmol) and dichloromethane (80 mL). The resultant mixture was stirred at room temperature for 3 hours before concentrating to dryness under reduced pressure to afford the title product (17 g), which was used in the next step without purification. MS (ESI): mass calcd. for C11H15ClFN3O2S 307.1, found 308.0 [M+H] + .

Step E: 3-Fluoro-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'-f] [1,2,5]thiadiazepine 5,5-dioxide. DIPEA (50.0 mL, 287 mmol) was added drop-wise to a solution of 2-chloro-5- fluoro-N-(piperidin-2-ylmethyl)pyridine-3-sulfonamide (17 g) and DMSO (150 mL) at room temperature. The resultant mixture was stirred at 160 °C for 2 hours before concentrating to dryness under reduced pressure. The residue was diluted with H 2 O (200 mL), and the resultant mixture extracted with ethyl acetate (3X). These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure to give the product, which was purified by FCC (eluent: petroleum ether/ethyl acetate, 1:0 to 3:1, gradient) to afford the title compound (11 g). MS (ESI): mass calcd. for C11H14FN3O2S 271.1, m/z found 271.9 [M+H] + .

Step F: (*S)-3-Fluoro-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2', 3'- f][1,2,5]thiadiazepine 5,5-dioxide. The mixture of 3-Fluoro-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepine 5,5-dioxide (11 g , 40 mmol) isomers were separated by purified by chiral SFC (AS 250 mm x 50 mm, mobile phase: 30% CO 2 , 30% EtOH and H 2 O with 0.1% NH 3 ) to afford two diastereomers. The first eluting isomer (5.2 g) was designated *S. MS (ESI): mass calcd. for C11H14FN3O2S 271.1, m/z found 272.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) d 8.29 (d, J = 3.2 Hz, 1H), 8.22 (br s, 1H), 7.86 - 7.74 (m, 1H), 4.20 - 4.08 (m, 2H), 3.47 (t, J = 12.8 Hz, 1H), 3.30 - 3.22 (m, 1H), 3.21 - 3.11 (m, 1H), 1.71 - 1.48 (m, 6H). Intermediate 65: 8-fluoro-2,3-dihydrospiro[benzo][b][1,4,5]oxathiazepine-4,1 -cyclopropane] 1’,1’-dioxide.

Step A: 2,5-difluoro-N-((1-hydroxycyclopropyl)methyl)benzenesulfonam ide. In a 250 mL round bottom flask was added 1-(aminomethyl))cyclopropanol (3.1 g, 35 mmol), THF (90 mL) and water (21 mL). To this mixture was added potassium carbonate (3.9 g, 28 mmol) and 2,5-difluorobenzenesulfonyl chloride (5.0 g, 23 mmol). After stirring at r.t. for 18 h. the mixture was partitioned between ethyl acetate/water and the aqueous layer extracted once more with ethyl acetate. These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: ethyl acetate/hexanes, 0:1 to 1:0, gradient elution) providing the title product. MS (ESI): mass calcd. for C 10 H 11 F 2 NO 3 S 263.0, m/z found 264.0 [M+H] + .

Step B: 8-fluoro-2,3-dihydrospiro[benzo][b][1,4,5]oxathiazepine-4,1 -cyclopropane] 1’,1’-dioxide. To a 100mL round bottom flask was added 2,5-difluoro-N-((1- hydroxycyclopropyl)methyl)benzenesulfonamide (938 mg, 3.6 mmol), potassium carbonate (3.5 mL, 10.5 mmol, 3M solution in water), and DMSO (15 mL). The reaction was heated to 90 ^C and allowed to stir for 20 h. The reaction was cooled, volume reduced to about half, poured into water and extracted with ethyl acetate (5X). These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: ethyl acetate/hexanes, 0:1 to 1:0, gradient elution) to afford the title compound (365 mg, 42%). MS (ESI): mass calcd. for C 10 H 10 FNO 3 S 243.0, m/z found 243.9 [M+H] + . Intermediate 66: 8-fluoro-2,3-dihydrospiro[benzo][b][1,4,5]oxathiazepine-4,3 -oxetane] 1’,1’- dioxide.

The title compound (820 mg, 34%) was prepared using analogous conditions as described in Intermediate 65 where 3-(aminomethyl)oxetan-3-ol was used instead of 1- (aminomethyl))cyclopropanol in step A. MS (ESI): mass calcd. for C 10 H 10 FNO 4 S 259.0, m/z found 260.0 [M+H] + . 1 H NMR (400 MHz, CDCl3) d 7.47 (dd, J = 7.4, 3.0 Hz, 1H), 7.34 (dd, J = 8.8, 4.3 Hz, 1H), 7.25 - 7.20 (m, 1H), 5.08 (s, 1H), 4.67 (d, J = 7.5 Hz, 2H), 4.38 - 4.27 (m, 2H), 3.95 (d, J = 5.7 Hz, 2H). Intermediate 67: 7’-chloro-2’,3’-dihydrospiro[cyclopropane-1,4’-pyrid o[2,3- b][1,4,5]oxathiazepine] 1’,1’-dioxide.

Step A: 2,6-dichloropyridine-3-sulfonyl chloride. SOCl 2 (365 g, 3.07 mol) was added dropwise to H2O (1.6 L) chilled to 0-5 °C and allowed to stir at 0-15 °C for 16 h. To a second flask was added 2,6-dichloropyridin-3-amine (100 g, 613 mmol) and HCl (745 g, 7.36 mol, 36% purity). To this mixture was added a solution of NaNO 2 (50.8 g, 736 mmol) in H 2 O (160 mL) at 0°C. After addition, the orange suspension was stirred at 0 °C for 0.5 h. CuCl (6.07 g, 61.3 mmol) was added to the first flask followed by immediate drop-wise addition of the suspension from the second flask at 0-5 °C. The suspension was stirred at 0-5 °C for 1 h. The suspension was extracted with EtOAc (3X). These extractions resulted in several fractions which were washed with brine (2X), combined, dried over sodium sulfate and concentrated to dryness under reduced pressure. The residue was stirred in petroleum ether (300 mL) for 1 hr. The mixture was filtered, and the cake was washed with petroleum ether (50 mL). The cake was dried in vacuum to give the desired product (94.1 g, 48% yield). MS (ESI): mass calcd. for C5H2Cl3NO2S 244.9, m/z found 297.1. 1 H NMR (400 MHz, CDCl3) d 8.39 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H).

Step B: 2,6-dichloro-N-((1-hydroxycyclopropyl)methyl)pyridine-3-sulf onamide. To a mixture of 1-(aminomethyl)cyclopropane-1-ol (18.5 g, 212 mmol) and K2CO3 (42.0 g, 304.2 mmol) in THF (500 mL) and H 2 O (150 mL) was added 2,6-dichloropyridine-3-sulfonyl chloride (50.0 g, 202 mmol) in THF (150 mL) drop-wise while keeping the reaction temperature between 0-5°C. The reaction mixture was stirred at 20 °C for 16 hrs. followed by extraction of the suspension with EtOAc (3X). These extractions resulted in several fractions which were combined, washed with water (1X), brine (1X), dried over sodium sulfate and concentrated to dryness under reduced pressure. The residue was purified by flash silica gel chromatography (eluent: ethyl acetate/petroleum ether, 0:1 to 1:3, gradient elution) to afford the title compound (63.1 g, 86.9%). MS (ESI): mass calcd. for C 9 H 10 Cl 2 N 2 O 3 S 296.0, m/z found 296.9 [M+H] + .

Step C: 7’-chloro-2’,3’-dihydrospiro[cyclopropane-1,4’-pyrid o[2,3- b][1,4,5]oxathiazepine] 1’,1’-dioxide. To a solution of 2,6-dichloro-N-((1- hydroxycyclopropyl)methyl)pyridine-3-sulfonamide (61.3 g, 173 mmol) in DMSO (1.2 L) was added K 2 CO 3 (71.8 g, 519 mmol). The yellow suspension was stirred at 60°C for 4 hrs. The suspension was poured into water (3 L), and extracted with EtOAc (3X). These extractions resulted in several fractions which were combined, washed with water (2X) and brine (1X), dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC (eluent: MeCN/water (0.1%TFA), 1:9 to 2:3, gradient elution) to afford the title compound (18.5 g, 40.0%). MS (ESI): mass calcd. for C 9 H 19 ClN 2 O 3 S 260.0, m/z found 261.0 [M+H] + . Intermediate 68: 7’-chloro-2,2’,3,3’,5,6-hexahydrospiro[pyran-4,4’-py rido[2,3- b][1,4,5]oxathiazepine] 1’,1’-dioxide.

Step A: 4-hydroxytetrahydro-2H-4-carbonitrile. To a solution of tetrahydro-4H-4-one (50.0 g, 499 mmol) in THF (1.5 L) was added TMSCN (49.5 g, 499 mmol) followed by

BF 3 .Et 2 O (74.4 g, 524 mmol). The internal temperature of the reaction was maintained below 10 °C during the addition of the BF3.Et2O. The reaction mixture was stirred at 20 °C for 3 hrs. The reaction mixture was diluted with sat. aq. NaHCO3 (1.5 L) and extracted with EtOAc (3X). These extractions resulted in several fractions which were combined, washed with brine (1X), dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (eluent: ethyl acetate/petroleum ether, 0:1 to 3:7, gradient elution) to afford the title compound (56.4 g, 88.8%).

Step B: 4-(aminomethyl)tetrahydro-2H-pyran-4-ol. To a solution of LAH (19.0 g, 487 mmol) in THF (500 mL) at 0 °C under N2was added dropwise 4-hydroxytetrahydropyran-4- carbonitrile (56.4 g, 443 mmol) in THF (100 mL). The reaction was allowed to warm to 20 °C followed by addition of H 2 O (19 mL), 15% NaOH (19 mL) and H 2 O (19 mL). The reaction was filtered and concentrated under reduced pressure to give the title compound (43.6 g, 74.9%), which was used directly in the next step without purification.

Step C.2,6-dichloro-N-((4-hydroxytetrahydro-2H-pyran-4-yl)methyl) pyridine-3- sulfonamide. To a mixture of 4-(aminomethyl)tetrahydro-2H-pyran-4-ol (30.0 g, 229 mmol) and K2CO3 (45.2 g, 327 mmol) in THF (300 mL) and H2O (90 mL) was added drop-wise 2,6- dichloropyridine-3-sulfonyl chloride (63.1 g, 217 mmol) in THF (90 mL) keeping the inner temperature between 0 °C and 5 °C. The reaction mixture was then stirred at 15 °C for 13 hrs. The suspension was poured into water (200 mL) and extracted with EtOAc (3X). These extractions resulted in several fractions which were combined, washed with brine (1X), dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (eluent: ethyl acetate/petroleum ether, 0:1 to 3:7, gradient elution) to afford the title compound (45.4 g, 58.0%). MS (ESI): mass calcd. for C 11 H 14 Cl 2 N 2 O 4 S 340.0, m/z found 341.1 [M+H] + .

Step D: 7’-chloro-2,2’,3,3’,5,6-hexahydrospiro[pyran-4,4’-py rido[2,3- b][1,4,5]oxathiazepine] 1’,1’-dioxide. To a solution of 2,6-dichloro-N-((4-hydroxytetrahydro- 2H-pyran-4-yl)methyl)pyridine-3-sulfonamide (14.6 g, 42.8 mmol) in THF (300 mL) was added t-BuOK (4.80 g, 42.8 mmol). The mixture was stirred at 10 °C for 1.5 hrs. The suspension was poured into water (50 mL), extracted with EtOAc (5X). These extractions resulted in several fractions which were combined, washed with brine (1X), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure washed. The residue was stirred in 30 mL mixture of petroleum ether:ethyl acetate (3:1, 50 mL) for 30 min. The mixture was filtered off and the cake was washed with petroleum ether and ethyl acetate (5:1, 20 mL) and dried under vacuum to give the title compound (10.7 g, 48.4%). MS (ESI): mass calcd. for C 11 H 13 ClN 2 O 4 S 304.0, m/z found 304.8 [M+H] + . 1 H NMR (400 MHz, DMSO) d 8.55 (s, 1H) 8.17 (d, J = 8.0, 1H) 7.5 (d, J = 8.0 Hz, 1H) 3.75 (m, 2H) 3.62 (d, J = 11.3 Hz, 2H) 3.53 (s, 2H) 1.64 (m, 4H) Intermediate 69: Methyl 3-(3-((7’-chloro-1’,1’-dioxido-2,3,5,6-tetrahydrospiro pyran- 4,4’-pyrido[2,3-b][1,4,5]oxathiazepin]-2’(3’H)-yl)meth yl)-4-methylphenyl)-2,2-dimethyl-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoate.

The title compound (760 mg, 73%) was prepared using analogous conditions as described in Example 11 where methyl 3-(3-(hydroxy methyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl- 3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)prop anoate (Intermediate 48) was used instead of ethyl 3-(1-(cyclopropylmethyl)-4-methyl-1H-benzo[d][1,2,3]triazol- 5-yl)-3-(3- hydroxymethyl)-4-methylphenyl)propanoate (Example 11, step A) and 7’-chloro-2,2’,3,3’,5,6- hexahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin e] 1’,1’-dioxide (Intermediate 68) was used instead of (*S)-7a-methyl-6,7,7a,8,9,19-hexahydropyrido[2,3-f]pyrollo[2 ,1- d][1,2,5]thiadiazepine 5,5-dioxide (Intermediate 39) in step B. MS (ESI): mass calcd. for C33H35ClF3N5O6S, 721.2; m/z found, 722.1 [M+H] + . 1 H NMR (400 MHz, CDCl3) d 8.05 (d, J = 8.0 Hz, 1H), 7.96 (d, J = 7.3 Hz, 1H), 7.17 - 7.10 (m, 2H), 7.03 (d, J = 1.2 Hz, 2H), 4.72 (s, 1H), 4.47 - 4.33 (m, 2H), 3.98 - 3.90 (m, 2H), 3.60 - 3.45 (m, 6H), 3.38 - 3.32 (m, 1H), 2.71 (s, 3H), 2.16 (s, 3H), 1.71 - 1.57 (m, 2H), 1.49 - 1.37 (m, 2H), 1.35 (s, 3H), 1.29 (s, 3H). Intermediate 71: Benzyl (*S)-3-(3-hydroxymethyl)-4-methylphenyl)-2,2-dimethyl)-3-(8- methyl-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7- yl)propanoate.

Step A: (*S)-3-(3-hydroxymethyl)-4-methylphenyl)-2,2-dimethyl)-3-(8- methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propan oic acid. To a solution of methyl (*S)-3-(3-hydroxymethyl)-4-methylphenyl)-2,2-dimethyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoate (Intermediate 145, 2.64 g, 5.9 mmol) in a 1:1 mixture of methanol (24 mL) and THF (24 mL) was added a 1M solution of LiOH in water (42 mL). The mixture was heated at 60 ^C for 18 h, cooled, and the pH adjusted to ~5 with 1M HCl. The resulting precipitate was collected and washed with water. The aqeous filtrate was extracted with ethyl acetate (4X) resulting in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure. The precipitate and the residue from extraction were combined to afford the title compound (2.48 g, 99%). MS (ESI): mass calcd. for C 21 H 22 F 3 N 3 O 3 , 421.2; m/z found, 422.2 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 ) d 12.43 (s, 1H), 8.43 (d, J = 7.3 Hz, 1H), 7.35 - 7.25 (m, 2H), 7.15 (dd, J = 7.9, 2.1 Hz, 1H), 7.06 (d, J = 7.9 Hz, 1H), 5.02 (s, 1H), 4.79 (s, 1H), 4.43 (s, 2H), 2.67 (s, 3H), 2.18 (s, 3H), 1.32 - 1.24 (m, 6H).

Step B: benzyl (*S)-3-(3-hydroxymethyl)-4-methylphenyl)-2,2-dimethyl)-3-(8- methyl-3- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-yl)propan oate. To a flask under N2 was added (*S)-3-(3-hydroxymethyl)-4-methylphenyl)-2,2-dimethyl)-3-(8- methyl-3-(trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridine-7-yl)propanoic acid (500 mg, 1.19 mmol), potassium carbonate (410 mg, 2.97 mmol) and acetonitrile (5.0 mL). After stirring for 5 minutes, benzyl bromide (0.17 mL, 1.43 mmol) was added to the mixture followed by stirring at r.t. for an additional 24 h. The reaction was poured into water and extracted with ethyl acetate (3X). These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: ethyl acetate/hexanes, 0:1 to 1:0, gradient elution) to afford the title compound (540 mg, 89%). MS (ESI): mass calcd. for C28H28F3N3O3, 511.2; m/z found, 512.3 [M+H] + . 1 H NMR (600 MHz, DMSO-d6) d 8.25 (d, J = 7.2 Hz, 1H), 7.28 - 7.22 (m, 2H), 7.10 - 7.00 (m, 7H), 5.09 - 5.00 (m, 2H), 4.87 (d, J = 12.1 Hz, 1H), 4.71 (s, 1H), 4.41 (d, J = 5.4 Hz, 2H), 2.54 (s, 3H), 2.16 (s, 3H), 1.35 (s, 3H), 1.29 (s, 3H). Intermediate 72: 8’-Methyl-7’-(2-(piperidin-1-yl)ethoxy)-2,2’,3,3’,5, 6- hexahydrospiro[pyran-4,4’-pyrido[2,3-b][1,4,5]oxathiazepin e]1’,1’-dioxide.

Step A: 6-Bromo-2-chloro-N-((4-hydroxytetrahydro-2H-pyran-4-yl)methy l)-5- methylpyridine-3-sulfonamide. A solution of 4-(aminomethyl)tetrahydro-2H-pyran-4-ol (14.0 g, 83.5 mmol) in THF:H 2 O (230 mL, 4:1) was cooled to 0 °C and K 2 CO 3 (26.2 g, 189 mmol) was added in portions to it. The resultant mixture was stirred for 5 min at 0 °C and then treated with 6-bromo-2-chloro-5-methylpyridine-3-sulfonyl chloride (23.1 g, 75.7 mmol). This mixture was stirred at room-temperature for 12 hours before pouring it into water (80 mL) and extracting with ethyl acetate (3X). These extractions resulted in several organic fractions which were combined, washed with brine (100 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness under reduced pressure to afford the title compound (27.8 g). MS (ESI): mass calcd. for

C12H16BrClN2O4S 399.7 m/z found 400.8 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) d 8.25 (m, 1H), 8.05 (m, 1H), 4.39 (s, 1H), 3.57 - 3.51 (m, 4H), 2.89 (d, J = 5.1 Hz, 2H), 2.40 (s, 3H), 1.55 - 1.45 (m, 2H), 1.33 (d, J = 13.0 Hz, 2H).

Step B: 7'-Bromo-8'-methyl-2,2',3,3',5,6-hexahydrospiro[pyran-4,4'-p yrido[2,3- b][1,4,5]oxathiazepine] 1',1'-dioxide. t-BuOK (7.91 g, 70.5 mmol) was added in portions to a solution of 6-bromo-2-chloro-N-((4-hydroxytetrahydro-2H-pyran-4-yl)methy l)pyridine-3- sulfonamide (14.1 g, 35.2 mmol) and DMSO (110 mL) at 0 °C. The resultant mixture was stirred at 100 °C for 2 hours before cooling to room-temperature and concentrating to dryness under reduced pressure. The residue was diluted with H2O (60 mL), the mixture acidified with 1 N HCl (100 mL) to pH = 6, and the suspension isolated via filtration. The filter cake was washed with petroleum ether (60 mL) before drying under reduced pressure to give the product (10.08 g, 79%). The product (8.28 g) was purified by preparative HPLC (stationary phase: YMC Triart C18, 250 mm x 50 mm x 7 mm column; eluent: 10% to 40% (v/v) CH3CN and H2O with 0.225% HCOOH) to afford the title compound (7.13 g, 56%). MS (ESI): mass calcd. for C 12 H 15 BrN 2 O 4 S 363.2 m/z found 363.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 ) d 8.50 (m, 1H), 8.09 (m, 1H), 3.79 - 3.70 (m, 2H), 3.61 (d, J = 11.2 Hz, 2H), 3.50 (s, 2H), 2.36 (s, 3 H), 1.69 - 1.55 (m, 4H).

Step C: 8'-Methyl-7'-(2-(piperidin-1-yl)ethoxy)-2,2',3,3',5,6-hexahy drospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepine] 1',1'-dioxide. Cs 2 CO 3 (6.72 g, 20.6 mmol) was added to a mixture of 7'-bromo-8'-methyl-2,2',3,3',5,6-hexahydrospiro[pyran-4,4'-p yrido[2,3- b][1,4,5]oxathiazepine] 1',1'-dioxide (2.5 g, 6.9 mmol), 2-(pyrrolidin-1-yl)ethanol (2.67 g, 20.7 mmol), JosiPhos pre-catalyst G3 (0.64 g, 0.70 mmol), and DMA (30 mL) under N 2 . The resultant mixture was stirred at 95 °C for 16 hours before quenching with H 2 O and extracting with ethyl acetate (2X). These extractions resulted in several fractions which were combined dried over anhydrous Na 2 SO 4 , filtered, and concentrated to dryness under reduced pressure. The residue was purified by flash chromatography (eluent: petroleum ether/ethyl acetate; 1:0 to 0:1, gradient) to afford the title compound (2.1 g, 69.5%). MS (ESI): mass calcd. for C19H29N3O5S 411.5 m/z found 412.2 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 ) d 8.15 (m, 1H), 7.83 (m, 1H), 4.39 (t, J = 6.1 Hz, 2H), 3.87 - 3.76 (m, 2H), 3.62 (d, J = 11.0 Hz, 2H), 3.43 (s, 2H), 2.66 (t, J = 6.1 Hz, 2H), 2.44 (s, 4H), 2.12 (s, 3H), 1.60 (s, 4H), 1.51 - 1.45 (m, 4H), 1.40 - 1.33 (m, 2H).

Intermediate 73: 7’-(2-(Piperidin-1-yl)ethoxy)-2,2’,3,3’,5,6-hexahydros piro[pyran-4,4’- pyrido[2,3-b][1,4,5]oxathiazepine]1’,1’-dioxide.

To a solution of 2-piperidin-1-yl)ethan-1-ol (2.00 mL, 14.9 mmol) in DMSO (20 mL),which had been cooled to 0 ^C, was added NaH (558 mg, 13.9 mmol). The mixture was stirred at 0 ^C for 2 minutes then allowed to warm to room temperature and stirred for an additional 45 minutes.7’-chloro-2,2’,3,3’,5,6-hexahydrospiro[pyran-4 ,4’-pyrido[2,3- b][1,4,5]oxathiazepine] 1’,1’-dioxide (1.00 g, 3.28 mmol, Intermediate 68) was then added as a solid in one portion and the reaction was stirred for an additional 15 h. The reaction was then quenched with saturated NH4Cl and the pH adjusted to about 7 with 1M aqueous HCl solution. The aqueous layer was extracted with ethyl acetate (5X) resulting in several organic fractions that were combined, washed with brine (1X), dried over MgSO 4 and concentrated to dryness under reduced pressure. The residue was purified by flash chromatography (eluent: ethyl acetate/methanol; 1:0 to 9:1, gradient elution) to afford the title compound (1.00 g, 77%). MS (ESI): mass calcd. for C 18 H 27 N 3 O 5 S 397.2 m/z found 398.2 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) d 8.18 (s, 1H), 7.98 (d, J = 8.4 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 4.38 (t, J = 6.0 Hz, 2H), 3.85 -3.78 (m, 2H), 3.67 - 3.60 (m, 2H), 3.47 (s, 2H), 2.65 (t, J = 6.0 Hz, 2H), 2.45 - 2.38 (m, 4H), 1.69 - 1.58 (m, 4H), 1.52 - 1.45 (m, 4H), 1.41 - 1.33 (m, 2H). Intermediate 74: (*R)-Methyl 3-(3-((7'-(3-(tert-butoxy)-3-oxopropyl)-1',1'-dioxido- 2,3,5,6-tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxath iazepin]-2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoate.

Step A: (E)-tert-Butyl 3-(1',1'-dioxido-2,2',3,3',5,6-hexahydrospiro[pyran-4,4'-pyr ido[2,3- b][1,4,5]oxathiazepin]-7'-yl)acrylate. tert-Butyl acrylate (477 mg, 3.72 mmol), Pd(OAc)2 (32.1 mg, 0.143 mmol), 2-(di-tert-butylphosphino)biphenyl (85.5 mg, 0.287 mmol), and Et3N (580 mg, 5.73 mmol) were added to a solution of 7'-bromo-2,2',3,3',5,6-hexahydrospiro[pyran-4,4'- pyrido[2,3-b][1,4,5]oxathiazepine] 1',1'-dioxide (1.00 g, 2.86 mmol) and DMF (18 mL). The resultant mixture was sparged with N2 for 5 minutes and then stirred while heating at 120 °C for 3 hours before cooling to room-temperature and concentrating to dryness under reduced pressure. The residue was diluted with sat. NH 4 Cl (7 mL) and the resultant mixture was extracted with ethyl acetate (2X). These extractions resulted in several fractions which were combined, dried over sodium sulfate and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 10: 1 to 1: 5, gradient elution) to afford the title compound (805 mg, 71%). MS (ESI): mass calcd. for

C18H24N2O6S 396.1 m/z found 396.9 [M+H] + .

Step B: tert-Butyl 3-(1',1'-dioxido-2,2',3,3',5,6-hexahydrospiro[pyran-4,4'-pyr ido[2,3- b][1,4,5]oxathiazepin]-7'-yl)propanoate. (E)-tert-Butyl 3-(1',1'-dioxido-2,2',3,3',5,6- hexahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin]- 7'-yl)acrylate (805 mg, 2.03 mmol), MeOH (10 mL), and dry Pd/C (200 mg, 10 wt.%, 0.189 mmol) were added to a 75 mL hydrogenation bottle. The resultant mixture was stirred at room-temperature for 16 hours under H2 (50 psi). The suspension was filtered through a pad of diatomaceous earth and the pad washed with MeOH (20 mL). The filtrate was concentrated to dryness under reduced pressure to give the product, which was purified by flash column chromatography (eluent: petroleum ether/ ethyl acetate, 10:1 to 1:5, gradient elution) to afford the title compound (780.5 mg). MS (ESI): mass calcd. for C 18 H 26 N 2 O 6 S 398.1 m/z found 399.2 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 ) d 8.60 - 8.10 (m, 1H), 8.02 (d, J = 7.83 Hz, 1H), 7.24 (d, J = 7.83 Hz, 1H), 3.81 (t, J = 9.78 Hz, 2H), 3.57 (d, J = 10.76 Hz, 2H), 3.47 (s, 2H), 2.97 (t, J = 6.97 Hz, 2H), 2.64 (t, J = 6.97 Hz, 2H), 1.72 - 1.46 (m, 4H), 1.34 (s, 9H).

Step C: (*R)-Methyl 3-(3-((7'-(3-(tert-butoxy)-3-oxopropyl)-1',1'-dioxido-2,3,5, 6- tetrahydrospiro[pyran-4,4'-pyrido[2,3-b][1,4,5]oxathiazepin] -2'(3'H)-yl)methyl)-4- methylphenyl)-2,2-dimethyl-3-(8-methyl-3-(trifluoromethyl)-[ 1,2,4]triazolo[4,3-a]pyridin-7- yl)propanoate. DIAD (2.33 g, 11.5 mmol) was added to a solution of (*R)-methyl 3-(3- (hydroxymethyl)-4-methylphenyl)-2,2-dimethyl-3-(8-methyl-3-( trifluoromethyl)- [1,2,4]triazolo[4,3-a]pyridin-7-yl)propanoate (Intermediate 141, 2.5 g, 5.7 mmol), tert-butyl 3- (1',1'-dioxido-2,2',3,3',5,6-hexahydrospiro[pyran-4,4'-pyrid o[2,3-b][1,4,5]oxathiazepin]-7'- yl)propanoate (2.75 g, 6.90 mmol), PPh3 (3.02 g, 11.5 mmol), and THF (30 mL). The resultant mixture was stirred at room temperature for 3 hours before concentrating to dryness under reduced pressure to give the product, which was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate, 10:1 to 1:3, gradient elution) to afford the title compound (6.1 g, 47%). MS (ESI): mass calcd. for C40H48F3N5O8S 815.32 m/z found 816.3 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 ) d 8.41 (d, J = 7.09 Hz, 1H), 8.05 (d, J = 7.83 Hz, 1H), 7.29 (d, J = 7.83 Hz, 1H), 7.25 - 7.16 (m, H), 7.16 - 7.09 (m, 1H), 4.80 (s, 1H), 4.54 - 4.24 (m, 2H), 3.76 (d, J = 9.05 Hz, 2H), 3.55 - 3.40 (m, 6H), 2.99 (t, J = 6.85 Hz, 2H), 2.76 - 2.59 (m, 5H), 2.15 (s, 3H), 2.07 (s, 1H), 1.52 - 1.40 (m, 4H), 1.36 (s, 12H), 1.29 (s, 3H). Intermediate 75: (S)-6,7,7a,8,9,10-Hexahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepine 5,5-dioxide.

The title compound (4.3 g) was prepared using analogous conditions as described in Intermediate 4 using tert-butyl (S)-2-(aminomethyl)pyrrolidine-1-carboxylate instead of tert- butyl (R)-2-(aminomethyl)pyrrolidine-1-carboxylate in Step A. MS (ESI): mass calcd. for C10H13N3O2S, 239.1; m/z found, 240.1 [M+H] + . Intermediate 76: (*S)-7,7a,8,9,10,11-Hexahydro-6H-benzo[f]pyrido[2,1- d][1,2,5]thiadiazepine 5,5-dioxide.

Step A: tert-Butyl 2-(((2-fluorophenyl)sulfonamido)methyl)piperidine-1-carboxyl ate. 2- Fluorobenzene-1-sulfonyl chloride (15 g, 77 mmol) was added in portions to a mixture of tert- butyl 2-(aminomethyl)piperidine-1-carboxylate (17 g, 81 mmol) and potassium carbonate (13 g, 93 mmol) in THF (150 mL) and water (38 mL). After 16 hours, sodium sulfate was added and the suspension was filtered through diatomaceous earth. The filtrate was concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (petroleum ether-ethyl acetate) to provide the title compound as a yellow oil (28 g, 93%). 1 H NMR (400 MHz, CDCl3) d 7.89 (dt, J = 7.5, 1.8 Hz, 1H), 7.61–7.53 (m, 1H), 7.30–7.25 (m, 1H), 7.21 (t, J = 9.5 Hz, 1H), 5.14 (br s, 1H), 4.33 (br s, 1H), 3.88 (br d, J = 12.6 Hz, 1H), 3.34 (br s, 1H), 2.59 (br s, 1H), 1.69–1.52 (m, 5H), 1.47 (s, 9H), 1.41–1.33 (m, 2H).

Step B: 2-Fluoro-N-(piperidin-2-ylmethyl)benzenesulfonamide hydrochloride. tert- Butyl 2-(((2-fluorophenyl)sulfonamido)methyl)piperidine-1-carboxyl ate (24 g, 64 mmol) was dissolved in a mixture of 4 M HCl in methanol (81 mL, 320 mmol). After 2 hours, the mixture was concentrated to dryness under reduced pressure to afford the title compound as a white solid which was used in the next step without further purification (19.9 g). 1 H NMR (400 MHz, DMSO-d 6 ) d 9.26–9.05 (m, 2H), 8.38 (br t, J = 5.7 Hz, 1H), 7.82 (dt, J = 7.6, 1.5 Hz, 1H), 7.77– 7.70 (m, 1H), 7.51–7.38 (m, 2H), 3.24–3.16 (m, 2H), 3.10–2.98 (m, 2H), 2.87–2.73 (m, 1H), 1.88–1.56 (m, 4H), 1.40 (br s, 2H).

Step C: (*S)-7,7a,8,9,10,11-Hexahydro-6H-benzo[f]pyrido[2,1-d][1,2,5 ]thiadiazepine 5,5-dioxide. The below reaction was run three times on 2 different scale: twice using 5 g of 2- fluoro-N-(piperidin-2-ylmethyl)benzenesulfonamide hydrochloride and once using 13.2 g. The 13.2 g scale reaction details are provided. A solution containing 2-fluoro-N-(piperidin-2- ylmethyl)benzenesulfonamide hydrochloride (13.2 g, 42.7 mmol), DIPEA (27.6 g, 214 mmol) and DMSO (240 mL) was degassed by bubbling nitrogen through the solution for 5 minutes. The mixture was warmed to 160 °C. After 6 hours, the solution was cooled to room temperature. At this point, the cooled reaction mixture was combined with the two additional reaction mixtures referred to above for further processing. The combined mixture was concentrated to dryness under reduced pressure. The residue was dissolved in ethyl acetate and washed with water. The organics extracts were dried over sodium sulfate, filtered and concentrated to dryness under reduced pressure. The residue was triturated with a mixture of petroleum ether and ethyl acetate (4:1, 40 mL) to afford a suspension. The solids were isolated by filtration and then dried to provide the title compound as a mixture of enantiomers (5.73 g). The mixture of isomers was separated by chiral SFC (stationary phase: Chiralcel OD-H 5 µm 3 x 25 cm; mobile phase: 25% methanol, 75% CO2 with 0.3% iPrNH2) to afford two enantiomers. The first eluting isomer (2.16 g) was designated (*S): 1 H NMR (400 MHz, DMSO-d6) d 7.79–7.69 (m, 1H), 7.61–7.56 (m, 1H), 7.42–7.35 (m, 1H), 7.19–7.14 (m, 1H), 7.03–6.96 (m, 1H), 3.73 (s, 1H), 3.52–3.33 (m, 3H), 3.10–2.98 (m, 1H), 1.74–1.51 (m, 6H). Intermediate 77: (*S)-3-Methyl-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2', 3'- f][1,2,5]thiadiazepine 5,5-dioxide.

Step A: 2-Chloro-5-methylpyridine-3-sulfonyl chloride. HBF4 (7.6 mL, 48 mmol) was added dropwise to a solution of 2-chloro-5-methylpyridin-3-amine (5.0 g, 35 mmol) in acetonitrile (30 mL) at 0 °C. After 10 minutes, tert-butyl nitrite (6.3 mL, 53 mmol) was added dropwise. After 1 hour, this solution was added to mixture of copper chloride (5.5 g, 56 mmol) and acetic acid (50 mL) that had been degassed by bubbling SO 2 through it for 1 hour at 0 °C. After 4 hours, the mixture was warmed to room temperature, and then saturated aqueous sodium bicarbonate solution was added. After 20 minutes, the aqueous portion was extracted with ethyl acetate and these extractions resulted in several organic fractions which were combined, washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (petroleum ether-ethyl acetate) to provide the title compound as a yellow oil (3 g, 38%). 1 H NMR (400 MHz, CDCl3) d 8.51 (s, 1H), 8.27‒ 8.19 (m, 1H), 2.46 (s, 3H).

Step B: 3-Methyl-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepine 5,5-dioxide. The title compound (1.6 g) was prepared using analogous conditions as described the preparation of in Intermediate 76 using 2-chloro-5-methylpyridine-3- sulfonyl chloride instead of 2-fluorobenzene-1-sulfonyl chloride in Step A and TFA in dichloromethane instead of 4 M HCl in methanol in Step B. MS (ESI): mass calcd. for

C12H17N3O2S, 267.1; m/z found, 267.9 [M+H]+.

Step C: (*S)-3-Methyl-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2', 3'- f][1,2,5]thiadiazepine 5,5-dioxide. The mixture of 3-methyl-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepine 5,5-dioxide isomers from Step B were separated by chiral SFC (stationary phase: Chiralpak AD 10 µm 5 x 25 cm; mobile phase: 40% ethanol, 60% CO 2 with 0.1% NH 3 ) to afford two enantiomers. The first eluting isomer (370 mg) was designated (*S): MS (ESI): mass calcd. for C 12 H 17 N 3 O 2 S, 267.1; m/z found, 268.0 [M+H]+. 1 H NMR (400 MHz, DMSO-d6) d 8.11–8.07 (m, 1H), 8.05–7.99 (m, 1H), 7.72–7.66 (m, 1H), 4.19– 4.06 (m, 2H), 3.47–3.38 (m, 1H), 3.32–3.24 (m, 1H), 3.19–3.10 (m, 1H), 2.18 (s, 3H), 1.72–1.49 (m, 6H). Intermediate 78: (*S)-3-Fluoro-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2', 3'- f][1,2,5]thiadiazepine 5,5-dioxide.

Step A: 2-Chloro-5-fluoropyridin-3-amine. Iron (15 g, 270 mmol) was added in portions to a solution of 2-chloro-5-fluoro-3-nitropyridine (12 g, 68 mmol) and acetic acid (200 mL). The mixture was warmed to 80 °C. After 30 minutes, the mixture was cooled to room temperature and concentrated to dryness under reduced pressure. The residue was suspended in ethyl acetate and the suspension filtered through a pad of diatomaceous earth. The filtrate was brought to neutral pH by the addition of saturated aqueous sodium bicarbonate solution. The aqueous layer was extracted with ethyl acetate and these extractions resulted in several organic fractions which were combined, dried over anhydrous Na2SO4, filtered, and concentrated to dryness under reduced pressure to afford the title compound as a white solid which was used in the next step without further purification (11 g). MS (ESI): mass calcd. for C 5 H 4 ClFN 2 , 146.0; m/z found, 146.8 [M+H] + .

Step B: 3-Fluoro-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2',3'- f][1,2,5]thiadiazepine 5,5-dioxide. The title compound (11 g) was prepared using analogous conditions as described in Intermediate 77 using 2-chloro-5-fluoropyridin-3-amine instead of 2- chloro-5-methylpyridin-3-amine in Step A. MS (ESI): mass calcd. for C11H14FN3O2S, 271.1; m/z found, 271.9 [M+H] + .

Step C: (*S)-3-Fluoro-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2', 3'- f][1,2,5]thiadiazepine 5,5-dioxide. The mixture of 3-fluoro-7,7a,8,9,10,11-hexahydro-6H- dipyrido[2,1-d:2',3'-f][1,2,5]thiadiazepine 5,5-dioxide isomers prepared in Step B were separated by chiral SFC (stationary phase: Chiralpak AS 10 µm 5 x 25 cm; mobile phase: 30% ethanol, 70% CO 2 with 0.1% NH 3 ) to afford two enantiomers. The first eluting isomer (5.22 g) was designated (*S): MS (ESI): mass calcd. for C11H14FN3O2S, 271.1; m/z found, 272.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 ) d 8.29 (d, J = 3.2 Hz, 1H), 8.22 (br s, 1H), 7.86–7.74 (m, 1H), 4.20–4.08 (m, 2H), 3.47 (t, J = 12.8 Hz, 1H), 3.30–3.22 (m, 1H), 3.21–3.11 (m, 1H), 1.71–1.48 (m, 6H). Intermediate 79: (*R)-3-Fluoro-7,7a,8,9,10,11-hexahydro-6H-dipyrido[2,1-d:2', 3'- f][1,2,5]thiadiazepine 5,5-dioxide.

The second eluting isomer (4.95 g) from the separation of isomers by chiral SFC described in Intermediate 78 was designated (*R): MS (ESI): mass calcd. for C 11 H 14 FN 3 O 2 S, 271.1; m/z found, 272.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) d 8.29 (d, J = 2.8 Hz, 1H), 8.26–8.19 (m, 1H), 7.85–7.78 (m, 1H), 4.22–4.07 (m, 2H), 3.53–3.42 (m, 1H), 3.31–3.23 (m, 1H), 3.22–3.12 (m, 1H), 1.72–1.49 (m, 6H). Intermediate 80: 8'-Fluoro-2',3'-dihydrospiro[cyclopropane-1,4'-pyrido[2,3- b][1,4,5]oxathiazepine] 1',1'-dioxide.

The title compound (2.2 g) was prepared using analogous conditions as described in Intermediate 78 using 1-(aminomethyl)cyclopropan-1-ol instead of tert-butyl 2- (aminomethyl)piperidine-1-carboxylate in Step B. MS (ESI): mass calcd. for C9H9FN2O3S, 244.0; m/z found, 245.0 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) d 8.24 (d, J = 3.0 Hz, 1H), 7.99– 7.95 (m, 1H), 5.02–4.87 (m, 1H), 3.70 (d, J = 7.0 Hz, 2H), 1.29–1.17 (m, 2H), 0.82–0.67 (m, 2H). Intermediate 81: 4,4-Dimethyl-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide.

The title compound (238 mg) was prepared using analogous conditions as described in Intermediate 7 using 1-amino-2-methylpropan-2-ol instead of 3-(aminomethyl)oxetan-3-ol in Step A. MS (ESI): mass calcd. for C 10 H 13 NO 3 S, 227.1; m/z found, 228.1 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) d 7.80 (dd, J = 7.8, 1.7 Hz, 1H), 7.45 (td, J = 7.8, 1.7 Hz, 1H), 7.20 (td, J = 7.7, 1.2 Hz, 1H), 7.09 (dd, J = 8.0, 1.2 Hz, 1H), 4.85– 4.74 (m, 1H), 3.61– 3.40 (m, 2H), 1.29 (s, 6H). Intermediate 82: 4,4-Dimethyl-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin e 1,1-dioxide.

The title compound (139 mg) was prepared using analogous conditions as described in Intermediate 5 using 1-amino-2-methylpropan-2-ol instead of 1-(aminomethyl)cyclopropanol in Step A. MS (ESI): mass calcd. for C 9 H 12 N 2 O 3 S, 228.1; m/z found, 229.1 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) d 8.45 (dd, J = 4.9, 2.0 Hz, 1H), 8.30 (s, 1H), 8.11 (dd, J = 7.6, 2.0 Hz, 1H), 7.36 (dd, J = 7.6, 4.8 Hz, 1H), 3.43 (s, 2H), 1.21 (s, 6H). Intermediate 83: (R)-6,7,7a,8,9,10-Hexahydrobenzo[f]pyrrolo[2,1-d][1,2,5]thia diazepine 5,5-dioxide.

Step A: (R)-2-Fluoro-N-(pyrrolidin-2-ylmethyl)benzenesulfonamide. A mixture of 2- fluorobenzenesulfonamide (11.2 g, 64.2 mmol), (R)-pyrrolidin-2-ylmethanol (19 g, 188 mmol) in DMSO (33 mL) was warmed to 150 °C. After 2.5 hours, the mixture was cooled to room temperature and then ethyl acetate was added. The organic layer was washed with saturated aqueous sodium bicarbonate solution and then with saturated sodium chloride solution. The organic layers were dried over anhydrous sodium sulfate, filtered, and then concentrated under reduced pressure. The residue was purified by flash column chromatography (dichloromethane- ethyl acetate) to provide the title compound (5.5 g, 33%). Impure product fractions were concentrated, triturated with dichloromethane, filtered, and the solids collected to obtain an additional portion of the title compound (5.4 g, 33%). MS (ESI): mass calcd. for C 11 H 16 N 2 O 3 S, 256.1; m/z found, 257.1 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) d 8.08– 7.99 (m, 1H), 7.60 (t, J = 7.7 Hz, 1H), 7.44 (d, J = 8.1 Hz, 1H), 7.37– 7.27 (m, 1H), 5.96 (s, 2H), 3.78– 3.51 (m, 4H), 2.88 (s, 1H), 2.66 (s, 1H), 2.19‒1.91 (m, 4H).

Step B: (R)-6,7,7a,8,9,10-Hexahydrobenzo[f]pyrrolo[2,1-d][1,2,5]thia diazepine 5,5- dioxide. Di-tert-butyl azodicarboxylate (5.6 g, 24 mmol) was added to a stirring slurry of (R)-2- fluoro-N-(pyrrolidin-2-ylmethyl)benzenesulfonamide (5.2 g, 20 mmol) and triphenylphosphine (8 g, 30 mmol) in dichloromethane (104 mL). After 30 minutes, the mixture was concentrated under reduced pressure and the residue was purified by flash column chromatography

(dichloromethane-ethyl acetate) to provide the title compound (1.5 g, 31%). MS (ESI): mass calcd. for C11H14N2O2S, 238.1; m/z found, 238.9 [M+H] + . 1 H NMR (400 MHz, CDCl3) d 7.90 (dd, J = 8.0, 1.7 Hz, 1H), 7.40 (ddd, J = 8.6, 7.1, 1.6 Hz, 1H), 7.00– 6.90 (m, 2H), 4.84 (s, 1H), 4.16 (s, 1H), 3.55– 3.35 (m, 3H), 3.18– 3.02 (m, 1H), 2.21– 1.99 (m, 3H), 1.83– 1.73 (m, 1H). Intermediate 84: (S)-6,7,7a,8,9,10-Hexahydrobenzo[f]pyrrolo[2,1-d][1,2,5]thia diazepine 5,5-dioxide.

The title compound (1.7 g) was prepared using analogous conditions as described in Intermediate 83 using (S)-pyrrolidin-2-ylmethanol instead of (R)-pyrrolidin-2-ylmethanol in Step A. MS (ESI): mass calcd. for C11H14N2O2S, 238.1; m/z found, 239.1 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 ) d 7.79– 7.71 (m, 1H), 7.67 (dd, J = 7.9, 1.6 Hz, 1H), 7.38 (ddd, J = 8.6, 7.1, 1.7 Hz, 1H), 7.00– 6.94 (m, 1H), 6.90 (ddd, J = 8.0, 7.1, 1.1 Hz, 1H), 3.86– 3.74 (m, 1H), 3.37 – 3.24 (m, 2H), 3.17 (ddd, J = 13.4, 4.7, 3.3 Hz, 1H), 2.95 (ddd, J = 13.3, 11.6, 7.8 Hz, 1H), 2.12 – 1.82 (m, 3H), 1.67 (ddt, J = 12.2, 6.0, 1.8 Hz, 1H). Intermediate 85: (*S)-9-Methyl-7,7a,8,9,10,11-hexahydro-6H-pyrazino[2,1- ]thiadiazepine 5,5-dioxide.

Step A: 4-Benzyl 1-(tert-butyl) 2-carbamoylpiperazine-1,4-dicarboxylate. NH4HCO3 (9 g, 114 mmol) was added to a solution of 4-((benzyloxy)carbonyl)-1-(tert- butoxycarbonyl)piperazine-2-carboxylic acid (33 g, 91 mmol), Boc2O (25.7 g, 118 mmol), pyridine (4.3 g, 54 mmol), and 1,4-dioxane (462 mL). After 14 hours, the mixture was concentrated under reduced pressure. The residue was dissolved in ethyl acetate (300 mL) and the solution was washed with brine. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford the title compound (36 g). This material was used in the next step without further purification. MS (ESI): mass calcd. for C 18 H 25 N 3 O 5 , 363.2; m/z found, 386.0 [M+Na] + .

Step B: 4-Benzyl 1-(tert-butyl) 2-cyanopiperazine-1,4-dicarboxylate. The below reaction was run twice on 2 different scales: once using 10 g of 4-benzyl 1-tert-butyl 2- carbamoylpiperazine-1,4-dicarboxylate and once using 26 g. The 26 g scale reaction details are provided. TFAA (19.5 g, 93.0 mmol) was added to an ice‒water cooled solution of 4-benzyl 1- tert-butyl 2-carbamoylpiperazine-1,4-dicarboxylate (26 g, 72 mmol), Et3N (23 g, 230 mmol), and THF (260 mL). The resulting mixture was stirred for 2 hours with gradual warming to room- temperature and then combined with a similar reaction mixture as described above starting with 10 g of 4-benzyl 1-tert-butyl 2-carbamoylpiperazine-1,4-dicarboxylate. The combined mixture was concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether‒ethyl acetate, 10:1 to 2:1, gradient elution) to afford the title compound (26 g) as a light yellow oil. MS (ESI): mass calcd. for C18H23N3O4, 345.2; m/z found, 345.9 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) d 7.42–7.29 (m, 5H), 5.24–4.98 (m, 3H), 4.54–4.16 (m, 2H), 3.95 (br s, 1H), 3.24–3.01 (m, 2H), 2.88 (br s, 1H), 1.49 (s, 9H).

Step C: 4-Benzyl 1-(tert-butyl) 2-(aminomethyl)piperazine-1,4-dicarboxylate. The below reaction was run twice on 2 different scales: 4-benzyl 1-tert-butyl 2-cyanopiperazine-1,4- dicarboxylate and a second using 16 g of 4-benzyl 1-tert-butyl 2-cyanopiperazine-1,4- dicarboxylate. The details for the 16 g reaction are shown below. NaBH4 (17.5 g, 463 mmol) was added in portions to an ice‒water cooled solution of 4-benzyl 1-tert-butyl 2- cyanopiperazine-1,4-dicarboxylate (16 g, 46 mmol) and CoCl 2 (22 g, 93 mmol), and MeOH (347 mL). The mixture was allowed to warm to room temperature. After 2 hours, the mixture was combined with the reaction mixture as described above starting with 10 g of 4-benzyl 1-tert- butyl 2-cyanopiperazine-1,4-dicarboxylate. The mixture was diluted with ethyl acetate (300 mL) and the suspension filtered through a pad of diatomaceous earth. The filtrate was concentrated under reduced pressure and water was added to the residue. The mixture was extracted with dichloromethane which resulted in several organic fractions. These fractions were combined, dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure to afford the title compound (21 g) as a dark yellow oil, which was used in the next step without further purification. MS (ESI): mass calcd. for C18H27N3O4, 349.2; m/z found, 350.0 [M+H] + .

Step D: 4-Benzyl 1-(tert-butyl) 2-(((2-chloropyridine)-3-sulfonamido)methyl)piperazine- 1,4-dicarboxylate. K 2 CO 3 (5.44 g, 39.4 mmol) was added to a mixture of 4-benzyl 1-tert-butyl 2-(aminomethyl)piperazine-1,4-dicarboxylate (11.5 g), THF (124 mL), and H2O (31 mL). After 5 minutes, 2-chloropyridine-3-sulfonyl chloride (6.96 g, 32.8 mmol) was added in portions. After 2 hours, the mixture was extracted with ethyl acetate which resulted in numerous organic fractions. These fractions were combined, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford the title compound (18 g) which was used in the next step without further purification. MS (ESI): mass calcd. for C 23 H 29 ClN 4 O 6 S, 524.2; m/z found, 547.0 [M+Na] + .

Step E: Benzyl 3-(((2-chloropyridine)-3-sulfonamido)methyl)piperazine-1-car boxylate 2,2,2-trifluoroacetate. TFA (20.0 mL, 269 mmol) was added to a solution of 4-benzyl 1-tert- butyl 2-((2-chloropyridine-3-sulfonamido)methyl)piperazine-1,4-dic arboxylate (13.0 g, 24.8 mmol) and methylene chloride (100 mL). After 2 hours, the mixture was concentrated under reduced pressure to afford the title compound (14.5 g) as a yellow oil, which was used in the next step without further purification. MS (ESI): mass calcd. for C 18 H 21 ClN 4 O 4 S, 424.1; m/z found, 425.0 [M+H] + .

Step F: Benzyl 6,7,7a,8,10,11-hexahydro-9H-pyrazino[2,1-d]pyrido[2,3- f][1,2,5]thiadiazepine-9-carboxylate 5,5-dioxide. Cs 2 CO 3 (43.8 g, 134 mmol) was added to a solution of benzyl 3-((2-chloropyridine-3-sulfonamido)methyl)piperazine-1-carbo xylate 2,2,2- trifluoroacetate (14.5 g, ) and DMSO (250 mL).The mixture was warmed to 160 °C. After 6 hours, the mixture was cooled to room temperature and then concentrated under reduced pressure. The residue was dissolved in ethyl acetate (350 mL) and washed with water. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether:ethyl acetate = 10:1 to 2:1, gradient elution) to afford the title compound (4.5 g, 43%) as a yellow oil. MS (ESI): mass calcd. for C18H20N4O4S, 388.1; m/z found, 389.0 [M+H] + .

Step G: 7,7a,8,9,10,11-Hexahydro-6H-pyrazino[2,1-d]pyrido[2,3-f][1,2 ,5]thiadiazepine 5,5-dioxide. Benzyl 6,7,7a,8,10,11-hexahydro-9H-pyrazino[2,1-d]pyrido[2,3- f][1,2,5]thiadiazepine-9-carboxylate 5,5-dioxide (4.0 g, 10 mmol), MeOH (200 mL), and Pd(OH) 2 on carbon (2.0 g, 10 wt.%, 1.4 mmol) were added to a 500-mL round-bottomed flask. The mixture was stirred under a H 2 atmosphere (15 psi) at room temperature. After 1 hour, the suspension was filtered through a pad of diatomaceous earth and the pad washed with MeOH. The filtrate was concentrated under reduced pressure to afford the title compound (2.5 g) as a white solid, which was used in the next step without further purification. MS (ESI): mass calcd. for C10H14N4O2S, 254.1; m/z found, 255.1 [M+H] + .

Step H: (*S)-9-Methyl-7,7a,8,9,10,11-hexahydro-6H-pyrazino[2,1-d]pyr ido[2,3- f][1,2,5]thiadiazepine 5,5-dioxide. NaBH 3 CN (3.7 g, 59 mmol) was added in portions to an ice‒water cooled solution of 7,7a,8,9,10,11-Hexahydro-6H-pyrazino[2,1-d]pyrido[2,3- f][1,2,5]thiadiazepine 5,5-dioxide (2.5 g), 37% aqueous formaldehyde (16 g, 197 mmol), MeOH (100 mL), and dichloromethane (50 mL). The mixture was allowed to warm to room

temperature. After 1 hour, the mixture was concentrated under reduced pressure. Water was added to the residue and the aqueous layer was extracted with ethyl acetate. This resulted in several organic fractions which were combined, washed with brine, dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure. The residue was purified by preparative HPLC (Waters Xbridge Prep OBD C18250 x 50 mm x 10 mm column, eluent: 5% to 25% (v/v) CH 3 CN in H 2 O with 0.05% NH 3 ) to afford the title compound as a racemic mixture as a pink solid (900 mg, 33%). This was combined with an additional 750 mg of the racemic mixture (1.6 g total). A second purification was performed by preparative liquid

chromatography (irregular bare silica, 5% methanol in dichloromethane with 0.5% NH4OH) to provide the title compound (1.4 g) as the racemic mixture. The isomers were separated by chiral SFC (stationary phase: Chiralcel OD-H 5 µm 250 x 30 mm, mobile phase: 80% CO2 and 20% ethanol) to afford two enantiomers. The first eluting enantiomer (625 mg) was designated (*S). MS (ESI): mass calcd. for C 11 H 16 N 4 O 2 S, 268.1; m/z found, 268.9 [M+H] + . Intermediate 86: (*R)-9-Methyl-7,7a,8,9,10,11-hexahydro-6H-pyrazino[2,1- ]thiadiazepine 5,5-dioxide.

The second eluting isomer (650 mg) from the separation of isomers by chiral SFC described in Intermediate 85 was designated (*R). MS (ESI): mass calcd. for C11H16N4O2S, 268.1; m/z found, 268.9 [M+H] + . Intermediate 87: (R)-6,7,7a,8,9,10-hexahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepine-3-carbonitrile 5,5-dioxide.

Step A: tert-Butyl (R)-2-(((2,5-dichloropyridine)-3-sulfonamido)methyl)pyrrolid ine-1- carboxylate. tert-Butyl (R)-2-(aminomethyl)pyrrolidine-1-carboxylate (2.44 g, 12.2 mmol) was added to a suspension consisting of K 2 CO 3 (1.18 g, 8.52 mmol), THF (27 mL), and H 2 O (5.5 mL) at 0 °C. The reaction mixture was stirred for 10 minutes at 0 °C and then treated with 2,5- dichloropyridine-3-sulfonyl chloride (2.0 g, 8.1 mmol). The resulting mixture was stirred at room temperature for 6.5 hours and concentrated to dryness under reduced pressure. The residue was dissolved in water (20 mL) and the aqueous layer was extracted with ethyl acetate (20 mL x 3). These extractions resulted in several organic solvent fractions which were combined, washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: 0-100% ethyl acetate/hexanes, gradient elution) to afford the title compound (3.0 g, 90%) as a yellow solid. MS (ESI): mass calcd. for C15H21Cl2N3O4S, 409.1; m/z found, 310.1 [M-100] + . 1 H NMR (500 MHz, CDCl 3 ) d 8.47 (d, J = 2.5 Hz, 1H), 8.33 (d, J = 2.6 Hz, 1H), 7.51 (s, 1H), 4.09 (q, J = 7.1 Hz, 1H), 4.01 - 3.95 (m, 1H), 3.42 - 3.33 (m, 1H), 3.25 (dt, J = 11.5, 6.3 Hz, 1H), 3.20 - 3.12 (m, 1H), 2.94 - 2.85 (m, 1H), 2.08 - 1.96 (m, 2H), 1.85 - 1.72 (m, 1H), 1.43 (s, 9H).

Step B: (R)-3-Chloro-6,7,7a,8,9,10-hexahydropyrido[2,3-f]pyrrolo[2,1 - d][1,2,5]thiadiazepine 5,5-dioxide. TFA (5 mL) was added dropwise to a solution of tert-butyl (R)-2-(((2,5-dichloropyridine)-3-sulfonamido)methyl)pyrrolid ine-1-carboxylate (3.0 g,7.3 mmol) and dichloromethane (20 mL) at 0 °C. The resulting mixture was stirred for 16 hours with gradual warming to room temperature. It was then concentrated to dryness under reduced pressure. TEA (6.2 mL, 44 mol) was added to the residue in toluene (33 mL). The resulting solution was stirred at refluxing temperature for 16 hours before cooling to room-temperature and concentrating to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: 0-100% ethyl acetate/hexanes, gradient elution) to afford the title compound (2.0 g, 99%) as a yellow solid. MS (ESI): mass calcd. for C10H12ClN3O2S, 273.0; m/z found, 274.1 [M+H] + . 1 H NMR (500 MHz, CDCl 3 ) d 8.16 - 8.09 (m, 1H), 7.83 (dd, J = 5.3, 2.5 Hz, 1H), 5.84 (d, J = 11.6 Hz, 1H), 4.46 - 4.35 (m, 1H), 4.15 - 4.00 (m, 2H), 3.61 (p, J = 4.8 Hz, 2H), 3.49 - 3.39 (m, 1H), 3.17 - 3.03 (m, 1H), 2.15– 2.05 (m, 1H), 1.76– 1.68 (m, 1H).

Step C: (R)-6,7,7a,8,9,10-Hexahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5 ]thiadiazepine-3- carbonitrile 5,5-dioxide. Zn(CN) 2 (1.47 g, 12.5 mmol) was added to a mixture of (R)-3-chloro- 6,7,7a,8,9,10-hexahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thi adiazepine 5,5-dioxide (2.0 g, 7.3 mmol), Zn (185 mg, 2.83 mmol), and DMA (42 mL). The mixture was sparged with Ar for 5 minutes and then treated with Pd(dppf)Cl 2 (631 mg, 0.69 mmol) and X-Phos (526 mg, 1.10 mmol). The resultant mixture was sparged with Ar for another 5 minutes and then stirred at 110 °C for 18 hours before cooling to room temperatrue. The reaction mixture was filtered and the solid was rinsed with ethyl acetate (10 mL x 2). The filtrate was concentrated to dryness under reduced pressure and purified by flash column chromatography (eluent: 0-100% ethyl acetate/hexanes, gradient elution) to afford the title compound (1.7 g, 88%) as a brown solid. MS (ESI): mass calcd. for C 11 H 12 N 4 O 2 S, 264.1; m/z found, 264.9 [M+H] + . 1 H NMR (500 MHz, CDCl3) d 8.39 (d, J = 2.2 Hz, 1H), 8.06 (d, J = 2.1 Hz, 1H), 5.65 (dd, J = 6.6, 3.8 Hz, 1H), 4.85– 4.75 m, 1H), 3.86 - 3.65 (m, 2H), 3.56 (dt, J = 12.9, 3.7 Hz, 1H), 3.20 (td, J = 12.6, 6.5 Hz, 1H), 2.11 - 1.94 (m, 3H), 1.84 - 1.74 (m, 1H). Intermediate 88: (S)-6,7,7a,8,9,10-Hexahydropyrido[2,3-f]pyrrolo[2,1- d][1,2,5]thiadiazepine-3-carbonitrile 5,5-dioxide.

Step A: tert-Butyl (S)-2-(((2,5-dichloropyridine)-3-sulfonamido)methyl)pyrrolid ine-1- carboxylate. tert-Butyl (S)-2-(aminomethyl)pyrrolidine-1-carboxylate (2.44 g, 12.2 mmol) was added to a suspension consisting of K2CO3 (1.18 g, 8.52 mmol), THF (27 mL), and H2O (5.5 mL) at 0 °C. The reaction mixture was stirred for 10 minutes at 0 °C and then treated with 2,5- dichloropyridine-3-sulfonyl chloride (2.0 g, 8.1 mmol). The resulting mixture was stirred at room temperature for 6.5 hours and concentrated to dryness under reduced pressure. The residue was dissolved in water (20 mL) and the aqueous layer was extracted with ethyl acetate (20 mL x 3). These extractions resulted in several organic solvent fractions which were combined, washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: 0-100% ethyl acetate/hexanes, gradient elution) to afford the title compound (3.0 g, 90%) as a yellow solid. MS (ESI): mass calcd. for C15H21Cl2N3O4S, 409.1; m/z found, 310.1 [M-100] + . 1 H NMR (500 MHz, CDCl3) d 8.44 (d, J = 2.5 Hz, 1H), 8.29 (d, J = 2.5 Hz, 1H), 7.49 (dd, J = 6.4, 3.1 Hz, 1H), 3.93 (tt, J = 8.4, 4.1 Hz, 1H), 3.33 (dt, J = 10.9, 7.5 Hz, 1H), 3.22 (dt, J = 11.6, 6.3 Hz, 1H), 3.15 - 3.07 (m, 1H), 2.92 - 2.83 (m, 1H), 2.04 - 1.91 (m, 2H), 1.83 - 1.69 (m, 2H), 1.39 (s, 9H).

Step B: (S)-3-Chloro-6,7,7a,8,9,10-hexahydropyrido[2,3-f]pyrrolo[2,1 - d][1,2,5]thiadiazepine 5,5-dioxide. TFA (5 mL) was added dropwise to a solution of tert-butyl (S)-2-(((2,5-dichloropyridine)-3-sulfonamido)methyl)pyrrolid ine-1-carboxylate (3.0 g,7.3 mmol) and dichloromethane (20 mL) at 0 °C. The resulting mixture was stirred for 16 hours with gradual warming to room temperature. It was then concentrated to dryness under reduced pressure. TEA (6.2 mL, 44 mol) was added to the residue in toluene (33 mL). The resulting solution was stirred at 130 °C for 16 hours before cooling to room-temperature and concentrating to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: 0-100% ethyl acetate/hexanes, gradient elution) to afford the title compound (2.0 g, 99%) as a yellow solid. MS (ESI): mass calcd. for C10H12ClN3O2S, 273.0; m/z found, 273.9 [M+H] + . 1 H NMR (500 MHz, CDCl3) d 8.12 (d, J = 2.5 Hz, 1H), 7.80 (d, J = 2.5 Hz, 1H), 6.00 (s, 1H), 4.44 - 4.35 (m, 1H), 3.68 - 3.53 (m, 2H), 3.43 (dd, J = 13.1, 3.6 Hz, 1H), 3.10 (dd, J = 13.1, 12.1 Hz, 1H), 2.03 - 1.88 (m, 3H), 1.76 - 1.67 (m, 1H).

Step C: (S)-6,7,7a,8,9,10-Hexahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5 ]thiadiazepine-3- carbonitrile 5,5-dioxide. Zn(CN)2 (1.47 g, 12.5 mmol) was added to a mixture of (R)-3-chloro- 6,7,7a,8,9,10-hexahydropyrido[2,3-f]pyrrolo[2,1-d][1,2,5]thi adiazepine 5,5-dioxide (2.0 g, 7.3 mmol), Zn (185 mg, 2.83 mmol), and DMA (42 mL). The mixture was sparged with Ar for 5 minutes and then treated with Pd(dppf)Cl2 (631 mg, 0.69 mmol) and X-Phos (526 mg, 1.10 mmol). The resultant mixture was sparged with Ar for another 5 minutes and then stirred at 110 °C for 18 hours before cooling to room temperatrue. The reaction mixture was filtered and the solid was rinsed with ethyl acetate (10 mL x 2). The filtrate was concentrated to dryness under reduced pressure and purified by flash column chromatography (eluent: 0-100% ethyl acetate/hexanes, gradient elution) to afford the title compound (1.7 g, 87%) as a brown solid. MS (ESI): mass calcd. for C11H12N4O2S, 264.1; m/z found, 264.9 [M+H] + . 1 H NMR (500 MHz, CDCl3) d 8.42 (d, J = 2.1 Hz, 1H), 8.09 (d, J = 2.2 Hz, 1H), 5.50 (s, 1H), 4.87– 4.75 (m, 1H), 3.86 - 3.64 (m, 2H), 3.58 (dt, J = 12.9, 3.5 Hz, 1H), 3.20 (td, J = 12.5, 6.2 Hz, 1H), 2.25– 2.15 (m, J = 12.7, 11.4, 8.6, 6.7 Hz, 1H), 2.12 - 1.93 (m, 2H), 1.84 - 1.75 (m, 1H). Intermediate 89: (*S)-3-Chloro-6,7,7a,8,10,11-hexahydro-[1,4]oxazino[3,4-d]py rido[2,3- f][1,2,5]thiadiazepine 5,5-dioxide.

(*S)-6,7,7a,8,10,11-hexahydro-[1,4]oxazino[3,4-d]pyrido[2,3- f][1,2,5]thiadiazepine 5,5- dioxide (Intermediate 13, 300 mg, 1.18 mmol) was dissolved in DCM (24 mL). At room temperature, N-chlorosuccinimide (314 mg, 2.35 mmol) was added. The resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was dissolved in water (10 mL) and the aqueous layer was extracted with ethyl acetate (10 mL x 3). These extractions resulted in several organic solvent fractions which were combined, washed with brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (eluent: 0-100% ethyl acetate/hexanes) to afford the title compound (200 mg, 59%) as a yellow solid. MS (ESI): mass calcd. for C 10 H 12 ClN 3 O 3 S, 289.0; m/z found, 290.0 [M+1] + . 1 H NMR (600 MHz, CDCl3) d 8.14 (d, J = 2.5 Hz, 1H), 7.77 (d, J = 2.5 Hz, 1H), 5.88 - 5.83 (m, 1H), 4.37 - 4.28 (m, 2H), 4.10 - 4.00 (m, 1H), 3.84 (td, J = 13.0, 6.4 Hz, 1H), 3.79 - 3.71 (m, 2H), 3.70 (dd, J = 12.2, 2.0 Hz, 1H), 3.55– 3.47 (m, 1H), 3.42 (dt, J = 13.4, 4.5 Hz, 1H). Intermediate 90: Ethyl 3-(6-(acetoxymethyl)-5-methylpyridin-2-yl)-3-(1-cyclopropyl- 4- methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoate.

Step A: 1-Cyclopropyl-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxabor olan-2-yl)-1H- benzo[d][1,2,3]triazole. A mixture of 5-bromo-1-cyclopropyl-4-methyl-1H- benzo[d][1,2,3]triazole (Intermediate 29, 135 mg, 0.54 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'- bi(1,3,2-dioxaborolane) (166 mg, 0.64 mmol), KOAc (158 mg, 1.61 mmol), and dioxane (15 mL) was sparged with N2 for 5 minutes and then treated with Pd(dppf)Cl2 (12 mg, 0.02 mmol). The mixture was sparged with N 2 for another 5 minutes and then stirred at 90 °C for 4 hours. After cooling to room temperature, the suspension was filtered through diatamaceous earth and washed with ethyl acetate (10 mL). The filtrate was concentrated to dryness under reduced pressure and the residue was purified by flash column chromatography (eluent: 0-100% ethyl acetate/hexanes, gradient elution) to afford the title compound (150 mg, 94%) as a white solid. MS (ESI): mass calcd. for C16H22BN3O2, 299.2; m/z found, 299.0 [M] + .

Step B: Ethyl 3-(6-(acetoxymethyl)-5-methylpyridin-2-yl)-3-(1-cyclopropyl- 4-methyl- 1H-benzo[d][1,2,3]triazol-5-yl)propanoate. 1-Cyclopropyl-4-methyl-5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1H-benzo[d][1,2,3]triazole (258 mg, 0.86 mmol), triethylamine (0.12 mL, 0.86 mmol), and [Rh(COD)Cl]2 (14 mg, 0.03 mmol) were added to a solution of ethyl (E)-3- (6-(acetoxymethyl)-5-methylpyridin-2-yl)acrylate (Intermediate 15, 150 mg, 0.57 mmol) in 1,4- dioxane (4 mL) and water (2 mL). The reaction mixture was stirred at 95 °C for 2 hours.

After this time, the reaction was cooled to room temperature, then diluted with water and ethyl acetate. The resulting biphasic mixture was separated and the aqueous layer was extracted with ethyl acetate. These extractions resulted in several organic solvent fractions which were combined, dried over MgSO 4 , filtered, and concentrated to dryness under reduced pressure. The material was purified by flash column chromatography (eluent: 0-20% ethyl acetate/hexanes) to afford the title compound (50 mg, 20 % yield). MS (ESI): mass calcd. for C 24 H 28 N 4 O 4 , 436.2; m/z found, 437.0 [M+H] + . Intermediate 91: (R)-4-Ethyl-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepine 1,1-dioxide.

Step A: (R)-1-Aminobutan-2-ol. (R)-2-Ethyloxirane (6.0 g, 83 mmol) and 28% aqueous NH 3 (100 mL, 727 mmol) were added to a 250 mL three-necked round-bottomed flask.

The mixture was stirred at room temperature for 18 hours before concentrating to dryness under reduced pressure to afford the title compound (8 g) as a yellow oil, which was used in the next step without purification. 1 H NMR (400 MHz, CDCl 3 ) ^ 3.47 - 3.38 (m, 1H), 2.85 - 2.74 (m, 1H), 2.57 - 2.48 (m, 4H), 1.50 - 1.35 (m, 2H), 0.93 (t, J = 7.6 Hz, 3H).

Step B: (R)-2-Chloro-N-(2-hydroxybutyl) pyridine-3-sulfonamide. A solution of 2- chloropyridine-3-sulfonyl (20 g, 94 mmol) and THF (80 mL) was added dropwise to a 0 °C mixture of (R)-1-aminobutan-2-ol ( 8.0 g, ), K2CO3 (24.0 g, 173 mmol), THF (80 mL), and H2O (40 mL). The mixture was stirred at room temperature for 12 hours, then concentrated to dryness under reduced pressure. The residue was diluted with water (150 mL) and the resultant mixture extracted with ethyl acetate (100 mL x 3). These extractions resulted in several organic solvent fractions which were combined, dried over anhydrous Na 2 SO 4 , filtered, and concentrated to dryness under reduced pressure to afford the title compound (20 g) as a yellow oil, which was used in the next step without further purification. MS (ESI): mass calcd.

C9H13ClN2O3S 264.03 m/z, found 264.8 [M+H] + .

Step C: (R)-4-Ethyl-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepine 1,1-dioxide. t- BuOK (25.0 g, 223 mmol) was added in portions to a 0 °C solution of (R)-2-chloro-N-(2- hydroxybutyl)pyridine-3-sulfonamide (20 g) and DMSO (100 ml). The mixture was heated at 80 °C for 12 hours before cooling to room temperature and concentrating to dryness under reduced pressure. The residue was diluted with H 2 O (200 mL), and the resultant mixture acidified to pH 6 with 1 N HCl, and extracted with ethyl acetate (100 mL x 3). These extractions resulted in several organic solvent fractions which were combined, dried over anhydrous Na 2 SO 4 , filtered, and concentrated to dryness under reduced pressure. The material was purified by preparative acidic HPLC using a Xtimate C18, 150 x 25 mm x 5 mm column (eluent: 5% to 35%

(v/v) CH3CN and H2O with 0.225% HCOOH) to afford the title compound (6 g). The product contained impurities and was triturated with petroleum ether: ethyl acetate (30:1, 100 mL) and the suspension isolated via filtration. The filter cake was washed with petroleum ether (50 mL) before drying under reduced pressure to afford the title compound (5.67 g) as a white solid. MS (ESI): mass calcd. for C 9 H 12 N 2 O 3 S 228.06 m/z, found 229.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 ) d 9.04 (s, 1H), 8.85 (d, J = 5.2 Hz, 1H), 7.72 - 7.67 (m, 2H), 6.76 - 6.70 (m, 1H), 6.68 - 6.65 (m, 1H), 5.40 (s, 2H), 4.49 (t, J = 6.4 Hz, 2H), 2.69 (t, J = 6.4 Hz, 2H). Intermediate 92: Ethyl 3-(3-(chloromethyl)-4-methylphenyl)-3-(1-(cyclopropylmethyl) -4- (difluoromethyl)-1H-benzo[d][1,2,3]triazol-5-yl)propanoate.

Step A: 1-Chloro-3-(difluoromethyl)-2-nitrobenzene. Diethylamino sulfurtrifluoride (32.6 g, 202 mmol) was added to a 0 °C solution of 3-chloro-2-nitrobenzaldehyde (15 g, 81 mmol) and dichloromethane (200 mL). The mixture was stirred for 3 hours with gradual warming to room temperature before quenching with H2O (200 mL) and extracting with dichloromethane (100 mL x 3). These extractions resulted in several organic solvent fractions which were combined, dried over anhydrous Na 2 SO 4 , filtered, and concentrated to dryness under reduced pressure. The material was purified by FCC (petroleum ether:ethyl acetate = 1:0 to 20:1, gradient elution) to provide the title compound (12 g, 64%) as a yellow oil. 1 H NMR (400 MHz, DMSO-d 6 ) d 8.06 - 7.95 (m, 1H), 7.86 - 7.77 (m, 2H), 7.42 - 7.11 (m, 1H).

Step B: N-(Cyclopropylmethyl)-3-(difluoromethyl)-2-nitroaniline.1-Ch loro-3- (difluoromethyl)-2-nitrobenzene (2.0 g, 9.6 mmol) and cyclopropylmethanamine (10 mL) were added to a 20 mL sealed tube. The mixture was stirred at 80 °C for 16 hours before cooling to room temperature. At that time the reaction mixture was quenched with water (60 mL), and extracted with ethyl acetate (50 mL x 3). These extractions resulted in several organic solvent fractions which were combined, dried over anhydrous Na2SO4, filtered, and concentrated to dryness under reduced pressure. The material was purified by FCC (petroleum ether:ethyl acetate, 1:0 to 5:1, gradient elution) to give the title compound (2.1 g, 90%) as a red solid.

Step C: 4-Bromo-N-(cyclopropylmethyl)-3-(difluoromethyl)-2-nitroanil ine. N- (Cyclopropylmethyl)-3-(difluoromethyl)-2-nitroaniline (2.1 g, 8.7 mmol), NBS (1.54 g, 8.65 mmol), and DMF (10 mL) were added to a 50 mL round-bottomed flask. The mixture was stirred at room temperature for 4 hours before quenching with water (50 mL) and extracting with ethyl acetate (30 mL x 3). These extractions resulted in several organic solvent fractions which were combined, dried over anhydrous Na 2 SO 4 , filtered, and concentrated to dryness under reduced pressure. The material was purified by FCC (petroleum ether:ethyl acetate,1:0 to 5:1, gradient elution) to give the title compound (2.1 g, 68%) as yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) d 7.47 (d, J = 9.0 Hz, 1H), 7.09 - 6.79 (m, 2H), 6.22 (t, J = 5.6 Hz, 1H), 2.86 (t, J = 6.2 Hz, 2H), 0.91 - 0.79 (m, 1H), 0.28 - 0.18 (m, 2H), 0.05 -0.04 (m, 2H).

Step D: 4-Bromo-N 1 -(cyclopropylmethyl)-3-(difluoromethyl)benzene-1,2-dia mine. Zn (3.4 g, 52 mmol) was added to a solution of 4-bromo-N-(cyclopropylmethyl)-3-(difluoromethyl)- 2-nitroaniline (2.1 g, 6.5 mmol), NH4Cl (5.60 g, 105 mmol), and THF (20 mL). The resultant mixture was stirred at room temperature for 16 hours. The suspension was filtered through a pad of diatomaceous earth and the pad was washed with ethyl acetate (60 mL). The filtrate was concentrated to dryness under reduced pressure to afford the title product (1.8 g, 95%) as a yellow solid. MS (ESI): mass calcd. for C11H13BrF2N2290.02, m/z found 292.8 [M+H] + .

Step E: 5-Bromo-1-(cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d] [1,2,3]triazole. A solution of NaNO2 (5.7 g, 83 mmol) and H2O (10 mL) were added to a 0 °C mixture of 4- bromo-N 1 -(cyclopropylmethyl)-3-(difluoromethyl)benzene-1,2-dia mine (8.0 g, 27 mmol), 4- methylbenzenesulfonic acid hydrate (18.3 g, 96.2 mmol), and CH 3 CN (100 mL). The resultant mixture was stirred at 0 °C for 3 hours before quenching with aq. NaHCO 3 (300 mL) and extracting with ethyl acetate (100 mL x 3). These extractions resulted in several organic solvent fractions which were combined, dried over anhydrous Na 2 SO 4 , filtered, and concentrated to dryness under reduced pressure. The material was purified by FCC (petroleum ether:ethyl acetate, 1:0 to 5:1, gradient elution) to give the title compound (6.2 g, 75%) as a brown solid.

Step F: (E)-Ethyl 3-(1-(cyclopropylmethyl)-4-(difluoromethyl)-1H- benzo[d][1,2,3]triazol-5-yl)acrylate.5-Bromo-1-(cyclopropylm ethyl)-4-(difluoromethyl)-1H- benzo[d][1,2,3]triazole ( 2.0 g, 6.6 mmol), (E)-ethyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)acrylate (3.0 g, 13 mmol), and Na2CO3 (1.4 g, 13 mmol) were added to a 100 mL three- necked round-bottomed flask and the mixture dissolved in 1,4-dioxane (30 mL) and H 2 O (6 mL). The mixture was sparged with N 2 for 5 minutes and then treated with Pd(dppf)Cl 2 (484 mg, 0.661 mmol). The mixture was sparged with N2 for another 5 minutes and then stirred and heated at 100 °C for 16 hours before cooling to room temperature, quenching with water (60 mL) and extracting with ethyl acetate (40 mL x 3). These extractions resulted in several organic solvent fractions which were combined, dried over anhydrous Na2SO4, filtered, and concentrated to dryness under reduced pressure. The material was purified by FCC (petroleum ether:ethyl acetate, 20:1 to 5:1, gradient elution) to give the title compound (2.0 g, 80%) as a black solid. MS (ESI): mass calcd. for C16H17F2N3O2321.13, m/z found 321.9 [M+H] + .

Step G: Ethyl 3-(1-(cyclopropylmethyl)-4-(difluoromethyl)-1H-benzo[d][1,2, 3]triazol-5- yl)-3-(3-(hydroxymethyl)-4-methylphenyl)propanoate. (E)-Ethyl 3-(1-(cyclopropylmethyl)-4- (difluoromethyl)-1H-benzo[d][1,2,3]triazol-5-yl)acrylate (1.5 g, 4.7 mmol), (3-(hydroxymethyl)- 4-methylphenyl)boronic acid (2.3 g, 14 mmol), aq. KOH (5.6 mL, 1.0 M, 5.6 mmol), and 1,4- dioxane (20 mL) were added to a 100 mL round-bottomed flask. The mixture was sparged with N 2 for 5 minutes and then treated with chloro(1,5-cyclooctadiene)rhodium(I) dimer (230 mg, 0.466 mmol). The reaction mixture was stirred at room temperature for 16 hours before quenching with H2O (60 mL) and extracting with ethyl acetate (50 mL x 3). These extractions resulted in several organic solvent fractions which were combined, dried over anhydrous Na2SO4, filtered, and concentrated to dryness under reduced pressure. The material was purified by preparative basic HPLC using a Phenomenex Gemini C18250 mm x 50 mm, 10 mm column (eluent: 30% to 70% (v/v) CH 3 CN and H 2 O with 0.05% NH 3 ) to afford the title compound. MS (ESI): mass calcd. for C 24 H 27 F 2 N 3 O 3 443.20, m/z found 444.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) d 8.07 - 7.75 (m, 2H), 7.57 (d, J = 8.8 Hz, 1H), 7.31 (s, 1H), 7.18 - 7.12 (m, 1H), 7.07 - 7.01 (m, 1H), 5.17 - 5.07 (m, 1H), 5.01 (t, J = 5.3 Hz, 1H), 4.58 (d, J = 7.3 Hz, 2H), 4.43 - 4.35 (m, 2H), 3.97 - 3.88 (m, 2H), 3.28 - 3.19 (m, 1H), 3.14 - 3.05 (m, 1H), 2.14 (s, 3H), 1.38 - 1.26 (m, 1H), 1.01 (t, J = 7.2 Hz, 3H), 0.55 - 0.39 (m, 4H).

Step H: Ethyl 3-(3-(chloromethyl)-4-methylphenyl)-3-(1-(cyclopropylmethyl) -4- (difluoromethyl)-1H-benzo[d][1,2,3]triazol-5-yl)propanoate. Thionyl chloride (0.16 mL, 2.2 mmol) was added to a solution of ethyl 3-(1-(cyclopropylmethyl)-4-(difluoromethyl)-1H- benzo[d][1,2,3]triazol-5-yl)-3-(3-(hydroxymethyl)-4-methylph enyl)propanoate. (5 mg, 1.1 mmol) in DCM (5.5 mL) and 2 drops of DMF. The reaction was stirred at room temperature for 5 minutes. The reaction was quenched with saturated aqueous NaHCO 3 , then extracted with DCM. These extractions resulted in several organic solvent fractions which were combined, dried over MgSO 4 , filtered, and concentrated to dryness under reduced pressure, to provide the title compound which was used without further purification. MS (ESI): mass calcd. for

C24H26ClF2N3O2, 461.9; m/z found, 462.3 [M+H] + . Intermediate 93: 5'-Methyl-2',3'-dihydro-5'H-spiro[cyclopropane-1,4'-pyrido[2 ,3- f][1,2,5]thiadiazepine] 1',1'-dioxide.

Step A: tert-Butyl (1-carbamoylcyclopropyl)carbamate. Pyridine(11.8 g,149 mmol) was added drop-wise to a mixture consisting of 1-((tert- butoxycarbonyl)amino)cyclopropanecarboxylic acid (50.0 g, 248 mmol), Boc 2 O (70.5 g, 323 mmol), NH4HCO3 (24.6 g, 311 mmol), and MeCN (500 mL) over a period of 10 minutes. The resultant mixture was stirred at room temperature for 16 hours before concentrating to dryness under reduced pressure. The residue was diluted with H 2 O (100 mL), adjusted to pH 7 with 1 N HCl, and then the resultant mixture was extracted with ethyl acetate (300 mL x 3). These extractions resulted in several organic solvent fractions which were combined, dried over MgSO 4 , filtered, and concentrated to dryness under reduced pressure, to provide the title compound (40.1 g, 80 %) as a white solid, which was used in the next step without further purification. 1 H NMR (400 MHz, DMSO-d6) d 6.42 (br. s, 1 H), 5.71 (br. s, 1 H), 5.18 (br. s, 1 H), 1.61 - 1.56 (m, 2 H), 1.46 - 1.45 (m, 9 H), 1.09 - 0.98 (m, 2 H).

Step B: tert-Butyl (1-cyanocyclopropyl)carbamate. TFAA (47.3 g, 225 mmol) was added drop-wise to solution consisting of tert-butyl (1-carbamoylcyclopropyl)carbamate (30.0 g, 150 mmol), triethylamine (62.7 g, 450 mmol), and dichloromethane (180 mL) over a period of 1 hour. The resultant mixture was stirred at room temperature for 4 hours before concentrating to dryness under reduced pressure to give the title compound, which was purified by FCC

(petroleum ether:ethyl acetate, 1:0 to 5:1, gradient elution) to afford the title compound (22.5 g, 82.3%) as a light yellow solid. 1 H NMR (400 MHz, CDCl 3 ) d 6.60 (br s, 1 H), 2.63 (s, 9 H), 1.28 (s, 2 H), 1.24 - 1.20 (m, 1 H), 1.07 - 1.01 (m, 1 H).

Step C: tert-Butyl (1-cyanocyclopropyl)(methyl)carbamate. Sodium hydride in mineral oil (15.0 g, 60% purity, 375 mmol) was added in portions to a 0 °C solution of tert-butyl (1- cyanocyclopropyl)carbamate (22.5 g, 123mmol) and THF (150 mL). The resultant mixture was treated with iodomethane (34.7 g, 244 mmol) by dropwise addition at 0 °C and then stirred for 12 hours with gradual warming to room temperature before quenching with saturated aqueous NH 4 Cl (100 mL) and extracting with ethyl acetate (150 mL x 3). These extractions resulted in several organic solvent fractions which were combined, washed with brine (100 mL), dried over MgSO4, filtered, and concentrated to dryness under reduced pressure, to provide the title compound (23.0 g), which was used in the next step without further purification. 1 H NMR (400 MHz, CDCl3) d 2.90 (s, 3H), 1.48 (s, 9H), 1.27 - 1.26 (m, 2H), 0.86 - 0.82 (m, 2H).

Step D: tert-Butyl (1-(aminomethyl)cyclopropyl)(methyl)carbamate. Raney Ni (2 g) was added to a 1 L round-bottomed flask containing a mixture of tert-butyl (1- cyanocyclopropyl)(methyl)carbamate (23 g, ), methanol (200 mL), and 25% aqueous NH 3 (5 mL) which had been degassed with argon. The mixture was stirred under an atmosphere of H2 (15 psi) at room temperature for 15 hours. The suspension was filtered through a pad of diatomaceous earth and the pad was washed with ethyl acetate (150 mL). The filtrate was concentrated to dryness under reduced pressure to afford the title product (25 g), which was used in the next step without further purification. 1 H NMR (400 MHz, CDCl3) d 2.86 (br s, 3H), 1.84 - 1.80 (m, 2H), 1.44 (br. s, 9H), 1.23 - 1.22 (m, 2H), 0.85 - 0.81 (m, 2H).

Step E: tert-Butyl (1-((2-chloropyridine-3- sulfonamido)methyl)cyclopropyl)(methyl)carbamate. A solution consisting of 2-chloropyridine- 3-sulfonyl chloride (20 g, 94 mmol) and THF (50 mL) was added dropwise to a mixture of tert- butyl (1-(aminomethyl)cyclopropyl)(methyl)carbamate (20 g, ), K 2 CO 3 (20.0 g, 145 mmol), THF (150 mL), and H2O (40 mL) which had been cooled to 0 °C. The resultant mixture was stirred for 12 hours with gradual warming to room temperature before concentrating to dryness under reduced pressure. The residue was diluted with water (100 mL) and extracted with ethyl acetate (200 mL x 2). These extractions